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Early life programming of adult Leydig cell function 
There is increasing evidence to suggest that fetal events can predetermine 
reproductive health and general wellbeing in adulthood, a process termed 'fetal 
programming'. This refers to the association between altered fetal 
growth/development and health disorders in adulthood e.g. the metabolic 
syndrome, which is linked to low male testosterone levels. Studies from both 
Europe and the USA have shown that adult male testosterone levels have been 
declining, independent of age. As low testosterone levels in aging men are 
associated with increased morbidity and mortality, this highlights the 
importance of investigating how testosterone levels are determined or 
potentially ‘programmed’ during fetal development.  
Evidence from human and rodent studies have shown that reduced fetal 
androgen exposure results in lower adult testosterone levels, although the 
mechanism(s) is unknown, to date. One way to explain how a fetal insult (e.g. 
androgen deficiency) could affect (testosterone producing) adult Leydig cells in 
adulthood, is if their progenitor cells were present during fetal life and were 
thus affected by such an insult. This hypothesis has been unexplored to date, 
due to the lack of a unifying/defining marker for adult Leydig progenitor cells. 
An earlier study promoted the hypothesis for the studies in this thesis, namely 
that chicken ovalbumin upstream promoter transcription factor-II (COUP-TFII) 
might constitute such a marker, as inducible knockout of COUP-TFII in pre-
pubertal male mice results in failure of adult Leydig cells to develop. Therefore, 
the hypothesis which was explored in this thesis was that 'fetal programming' of 
COUP-TFII+ adult Leydig progenitor cells prior to their differentiation into adult 
Leydig cells, would explain how fetal events could predetermine adult 
testosterone levels. 
To investigate whether adult Leydig cells (ALC) develop from COUP-TFII+ 
interstitial cells, firstly an adult Leydig cell ablation/regeneration model was 
used, which involved a single injection of ethane dimethane sulphonate (EDS). 
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This identified that in rats, ALC derive from COUP-TFII+ interstitial cells which 
do not express any other phenotypical adult Leydig or interstitial cell markers 
prior to differentiation. Secondly, COUP-TFII+ adult Leydig progenitor cells are 
abundant in the fetal testis and conserved across species, including man. 
Thirdly, fetal interstitial cells which differentiated into ALC, as evident from an 
ALC lineage tracer model, also expressed COUP-TFII. Overall, these findings 
suggest that the COUP-TFII+ interstitial cells which differentiate into ALC are 
'adult Leydig progenitor cells'. 
The findings from this thesis also show that the identified adult Leydig 
progenitor cells express the androgen receptor (AR) in fetal life. Furthermore, 
experimental reduction of androgen action in fetal life in transgenic mice (AR 
knockout) or chemical manipulations to reduce fetal testosterone levels (di (n-
butyl) phthalate; DBP exposure) resulted in a similar reduction (~40%) in 
progenitor cell numbers from birth through to adulthood. A parallel reduction 
of adult Leydig cell numbers across postnatal development was found in mice, 
but not rats, but as a result of altered fetal androgen action, both models showed 
evidence for compensated adult Leydig cell failure. This is defined as 
normal/low testosterone and elevated luteinising hormone (LH) levels. Cell-
selective knockout of AR in peritubular myoid (PTM) cells (PTM-ARKO) or 
Sertoli cells (SC-ARKO) did not affect the numerical development of adult Leydig 
progenitor cells. To manipulate testicular testosterone action in postnatal life, 
rats were exposed to a potent AR antagonist, flutamide, which reduced the 
number of adult Leydig progenitor cells but did not affect ALC number/function. 
However, the combination of fetal DBP+postnatal flutamide exposure reduced 
adult Leydig progenitor cells and resulted in compensated ALC failure. Overall, 
these studies highlight the importance of fetal androgens for the normal 
development of adult Leydig progenitor cells and for the subsequent 
development of normally functioning adult Leydig cells.  
As fetal deficits in androgen exposure resulted in adult Leydig cell dysfunction, 
this thesis also investigated three separate models to determine whether 
increased fetal androgen exposure could increase/enhance adult Leydig 
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progenitor cell development, resulting in a 'gain of adult Leydig cell function'. In 
the first model to increase fetal androgen exposure, pregnant dams injected 
with testosterone propionate (TP; 20mg/kg/day e14-21.5) were discarded, due 
to confounding factors including fetal growth restriction and aromatisation of 
TP. The second model utilised dihydrotestosterone (DHT; 10mg/kg/day), 
administered to pregnant dams, but there were no effects found in adulthood to 
male offspring. It was concluded that the administered dose was not sufficient 
to increase intratesticular testosterone levels in the fetus. The third model 
utilised an inducible nitric oxide synthase knockout (iNOS-/-) mouse model, for 
which previous evidence showed increased testis weight, Leydig and Sertoli cell 
number (~50%), and normal testosterone but low LH levels in adulthood. 
Stereological quantification showed an increase in the number of adult Leydig 
progenitor cells in postnatal, but not fetal life, which resulted in the conclusion 
that the observed changes were a consequence of postnatal effects. 
Finally, a potential mechanism to explain how DBP-induced androgen deficiency 
in fetal life, could result in adult Leydig cell dysfunction in adulthood was 
investigated. Analysis of testicular genes in adulthood, involved in the 
steroidogenic pathway, showed a reduction in 3b-hsd and StAR. The reduced 
StAR expression was associated with increased repressive histone methylation 
(H3K27me3) in its proximal promoter region, as demonstrated by a chromatin 
immunoprecipitation (ChIP) assay, qPCR, and densitometrical analysis. 
Accordingly, adult Leydig cells were shown to express increased H3K27me3 by 
immunohistochemistry, a change also evident in adult Leydig progenitor cells in 
the fetal testis. This would provide a potential mechanism to explain how fetal 
events can 'programme' adult Leydig cell testosterone production, namely via 
an epigenetic change to adult Leydig progenitor cells. In summary, the results in 
this thesis show how fetal events, including androgen action on progenitor cells, 
can potentially programme adult Leydig cell function and thus determine 
testosterone levels. As testosterone is crucial to man, the findings reported in 
this thesis may have important implications for the general health and longevity 
of man. 
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Chapter 1 Literature Review 
Normal testosterone level/function is fundamental for man, firstly during fetal 
life to become male and secondly during adult life for reproductive function and 
overall health (Verhoeven et al 2010). Perturbations to fetal androgen 
level/function can cause a variety of disorders, which can manifest at birth e.g. 
cryptorchidism and/or hypospadias, or in young adulthood e.g. testicular cancer 
and low sperm counts, all of which are thought to be consequences of abnormal 
fetal testicular somatic cell function. These disorders, which are believed to 
originate in fetal life comprise a 'testicular dysgenesis syndrome' (TDS) (Sharpe 
& Skakkebaek 2001, 2003, 2008). This proposes that abnormal development of 
the testis results in malfunctioning testicular cells, thus increasing the risk of 
reproductive disorders or TDS. The precise mechanisms behind abnormal 
testicular fetal development of individuals with TDS remain to be identified.   
1.1 Testicular dysgenesis syndrome 
Investigating how fetal events i.e. abnormal androgen level/action 
predetermines adult reproductive function would ideally be carried out in the 
human male. However, as there is limited access to fetal testes or to fetal blood 
to measure testosterone levels, the evaluation of normal/abnormal testis 
development in humans is difficult. In order to examine the effects of altering 
fetal androgen action/levels on male reproductive development, rodents 
provide a very useful model. In line with this, fetal di-n-butyl-phthalate (DBP) 
exposure in rats induces a TDS like syndrome in male offspring, resulting in 
cryptorchidism, hypospadias, impaired spermatogenesis, altered hormone 
levels, focal areas of dysgenesis and Leydig cell aggregation and dysfunction 
(Mylchreest et al 2000, Fisher et al 2003, van den Driesche et al 2012). These 
disorders, which are comparable to the human TDS phenotype, may arise as a 
result of androgen insufficiency during the critical masculinisation period 
(Welsh et al 2008, Wohlfahrt-Veje et al 2009). The rodent model for human TDS 
provides a useful model for investigating potential mechanisms behind 'fetal 
programming' of adult male reproductive function and disease risk.  





TDS is believed to have a foetal origin as a result of genetic, environmental, 
lifestyle factors or a combination of all three (Skakkebaek et al 2001, Sharpe and 
Skakkebaek, 2008). Cryptorchidism may serve as a marker for TDS or a risk 
factor for infertility (Toppari et al 2010), and its incidence appears to be 
increasing both in the UK (Acerini et al 2009) and Europe (Main et al 2010). 
From the mid 1900's to the present date, studies have reported an increasing 
secular trend in reproductive abnormalities e.g. hypospadias and/or 
cryptorchidism, decreased spermatogenesis (Giwercman, 1995, Paulozzi et al 
1999, Skakkebaek et al 2001, Acerini et al 2009, Main et al 2010, Toppari et al 
2010) and an increase in testicular cancer in Europe (Richiardi et al 2004, Bray 
et al 2006) and the USA (Shah et al 2007). Furthermore, there is evidence for 
declining semen quality (Andersen et al 2000, Jorgensen et al 2002, 2006, 
Nordkap et al 2012) and sperm quality (Jorgensen 2002, 2006, Aitken, 2013). 
An indication/read-out of fetal androgen exposure is provided by the anogenital 
distance (AGD) (Eisenberg et al 2012, Dean & Sharpe 2013). Semen quality and 
infertility were shown to be associated with reduced AGD (reduced fetal 
androgen exposure) (Mendiola et al 2011, Eisenberg et al 2011). Overall, there 
appears to be an international increase in the prevalence of male reproductive 
disorders (Serrano et al 2013). Recent studies from the US (Travison et al 2007) 
and Europe (Andersson et al 2007, Perheentupa et al 2013) have also shown 
that adult male testosterone levels are gradually declining, independent of age. 
One proposed hypothesis for declining testosterone levels is 'fetal 
programming' i.e. fundamental events during fetal development are pre-
determining testosterone levels in adult life (Vanbillemont et al 2010, Traish et 
al 2011). The importance of investigating this phenomenon is highlighted by the 
association between low adult testosterone and increased risk of the metabolic 
syndrome i.e. hypertension, cardiovascular diseases, type 2 diabetes 
(Muraleedharan et al 2010, Traish et al 2011, Tsujimura et al 2013) and 
mortality (Laughlin et al 2008, Tivesten et al 2009). 





1.2 Abnormal androgen action or levels in fetal life 
Abnormal androgen action during fetal life can result in male infertility, as 
evident from patients with complete or partial androgen insensitivity 
syndromes (CAIS and PAIS) (Hughes et al 2012). This manifests as under-
masculinisation of the external genitalia e.g. hypospadias and/or 
cryptorchidism and are the most common congenital disorders in humans 
(Boisen et al 2004, 2005). AGD is reduced in boys presenting with 
cryptorchidism or hypospadias (Thankamony et al 2013), thus highlighting 
androgen insufficiency as one of the primary causes. Complete and partial AIS 
most frequently occur due to mutations in the androgen receptor gene or due to 
a deficit in androgen production or exposure. CAIS individuals are genetically 
male (XY) but present with a female phenotype and often with cryptorchidism 
(Hughes et al 2012). Rodent models are extremely useful to investigate human 
CAIS or PAIS and include transgenic mice (Cre/loxP technology) with mutation 
in the AR gene, essentially rendering the model insensitive to androgens e.g. the 
ubiquitous androgen receptor knockout (ARKO) mouse model or cell-specific 
ARKO (De-Gendt et al 2005, Verhoeven et al 2010) and will be discussed later in 
this review. Abnormal fetal testosterone production, either as a result of genetic 
mutations (as above) or environmental e.g. exposure to phthalates (e.g. DBP) 
can affect adult reproductive function (Jensen et al 2004, Kristensen et al 2011, 
Toppari et al 2010).  
1.3 Clinical studies of compensated Leydig cell failure 
A large study that investigated serum hormone levels in 318 fertile and 357 
infertile men, demonstrated that on average, the 'infertile group' exhibited a 
19% increase in luteinising hormone (LH) and an 18% reduction in testosterone 
serum level, in comparison to the 'fertile' group of men. This is indicative of 
compensated adult Leydig cell failure whereby increased LH is necessary to 
maintain a low-normal testosterone level (Andersson et al 2004). Patients with 
TDS commonly display abnormal/compensated adult Leydig cell failure, as 
evident from increased LH and decreased testosterone (Joensen et al 2008, 





Lardone et al 2012). In long-term follow up studies of males with disorders of 
sexual development (DSD), analysis of their serum hormone levels 
demonstrated an increase in LH and FSH with low-normal testosterone, 
indicative of compensated adult Leydig cell failure (Kojima et al 2009, van der 
Zwan et al 2013). This phenotype is comparable to the ARKO murine model 
which also demonstrates compensated adult Leydig cell failure (Yeh et al 2002, 
DeGendt et al 2005), thus providing a useful model to investigate the 
mechanisms involved in abnormal adult Leydig cell function. Understanding the 
mechanisms via which genetic or lifestyle/environmental exposures lead to TDS 
or CAIS e.g. by affecting Leydig cells is pivotal to our understanding of testicular 
disorders. 
In order to investigate whether fetal events, namely androgen action/level, 
contribute to testicular cell dysgenesis and thus determine adult Leydig cell 
function, it is firstly important to consider how the testis forms during fetal life, 
the organisation of testicular cells and factors which may be involved in adult 
Leydig cell development.  
1.4 The bipotential gonad 
The bipotential gonads develop from within the urogenital system of the 
developing embryo, comprising of separate regions; pronephros, mesonephros 
and metanephros. The kidneys arise from the metanephros while the gonads 
develop from the medial side of the mesonephros (Byskov, 1986). As a result of 
proliferation of the coelomic epithelium which overlies the mesonephroi, an 
'outgrowth' is formed, termed the 'genital ridge' and is first evident in mice at 
embryonic day (e) 10.5 (Merchant, 1975, Schmahl et al 2000). There is no 
difference in the morphology between XX and XY genital ridges and at this point, 
the genital ridges can develop into either testis or ovary, depending on the 
specific genes and cellular activity (Sekido and Lovell-Badge 2013).  
 





1.4.1 Sex determination 
Sex determination of the embryo is generally known to be controlled by the 
presence or absence of the 'Y' chromosome in mammals. As most studies 
involving gonadal development and regulation have been undertaken in the 
rodent, due to its accessibility and the generation of knockout models for 
investigation of specific genes, the rodent model will be referred to most 
frequently in this review. The expression of the Y-linked gene, Sry, initiates male 
(XY) development and was coined  the "testis-determining" gene (Gubbay et al 
1990, Sinclair et al 1990, Berta et al 1990, Koopman et al 1991, Basciani et al 
2010). In the absence of the testis-determining gene, Sry, the gonad develops 
into an ovary, evident from deletion/mutation of Sry (Gubbay et al 1992, 
Hawkins et al 1992) leading to the original assumption that the female pathway 
was simply the "default". In the presence of Sry and/or Sox9, female (XX) 
gonads, can be induced to develop as testes, while gonads in Sox9-/- XY males 
develop as females (Koopman et al 1991, Vidal et al 2001, Sekido and Lovell-
Badge 2013). Heterozygous mutations in Sox9 in the human have been 
associated with XY male sex reversal (Gordon et al 2009). 
However, rather than the simplistic view of the female XX pathway of 
development being the 'default', it is now clear that in females, male sex 
development is actively repressed by female factors, namely Foxl2, which 
encodes a forkhead transcription factor. Conditional deletion of this factor in 
adult mouse ovaries, leads to gonadal sex reversal, specifically ovarian 
granulosa and theca cells change their cell fate into Sertoli and Leydig cells 
respectively. Moreover, testosterone levels in XX female adult Foxl2-/- mice were 
similar to adult control XY mice (Uhlenhaut et al 2009). The granulosa cells also 
expressed Sox9 which highlights the opposing roles of Sox9 and Foxl2. Wingless 
type MMTV integration site family, member 4 (Wnt4), is regulated by R-spondin 
1 (RSPO1) which suppresses male sexual differentiation and promotes 
Müllerian duct differentiation in the female. Loss of both Wnt4 and Foxl2 leads 
to XX-XY sex reversal (Ottolenghi et al 2007). Although development and 
regulation of female gonadogenesis is out of the scope of this review, it is 





important to note that sex determination is now viewed as an active process, 
involving several supporting and opposing regulatory genes from both XX and 
XY gonads (Piprek et al 2010). The development of the testis and the timing of 
differentiation of its comprising cells are described below and summarised in 
Figure 1.1 (page 10). 
1.5 Male Reproductive Development 
1.5.1  Testis formation and development 
The adult testis is the site of spermatogenesis and steroidogenesis and thus its 
formation and organisation is essential for normal male functioning. This 
organised structure is a source of testosterone producing interstitial Leydig 
cells which this review will focus on. Sertoli and germ cells are contained within 
seminiferous cords and enveloped by peritubular myoid cells. The testis first 
begins to form when germ cells migrate from the yolk sac into the 
undifferentiated/bipotential gonad, which causes the coelomic epithelial cells to 
proliferate. The increased proliferation is evident from the increase in gonad 
size which is indicative of a 'masculinised' or male gonad (Schmahl et al 2000). 
The testis structure is in place at approximately e13 in the mouse and 6 weeks 
in the human (O'Shaughnessy et al 2011). 
 
1.5.2 Coelomic epithelium  
The coelomic epithelium describes the layer of coelomic epithelial cells which 
form in both XY and XX genital ridges and which encapsulate the gonad 
(Bullejos and Koopman 2001, Rey and Grinspon 2011). These cells proliferate 
and increase the size of the XY gonad at e11.2 in the mouse in response to the 
male specific fibroblast growth factor 9 (FGF9) (Schmahl et al 2000, 2003) as a 
result of Sry expression. Coelomic epithelial cells which express steroidogenic 
factor-1 (SF1+) give rise to the Sertoli (Schmahl et al 2000) and fetal Leydig cells 
(Defalco et al 2011). 






The gonad develops on the medial surface of the mesonephros. Following Sry 
expression, migrating cells from the mesonephros lead to the formation of testis 
cords (Buehr et al 1993, Tilmann and Capel 1999). It has been suggested that 
the migrating mesonephric cells can give rise to interstitial cells (Buehr et al 
1993, Merchant-Larios et al 1993) and specifically Leydig cells (Merchant-
Larios and Moreno-Mendoza 1998, Nishino et al 2001, Val et al 2006). The 
mesonephroi also contain a sex-specific ductal system, the mesonephric 
Wolffian ducts and the paramesonephric Müllerian ducts in males and females 
respectively. In males, the Wolffian ducts develop into the epididymis, seminal 
vesicles and vas deferens. Anti-müllerian hormone (AMH) acts to regress the 
female ductal system in males, which is discussed later in this review.  
 
1.5.4 Primordial germ cells 
Primordial germ cells are first evident in the genital ridges at e11 in the mouse 
and 4 weeks' gestation in humans (Culty et al 2009). Unlike the other testicular 
cells, as described above, which migrate from the mesonephros or coelomic 
epithelium, the primordial germ cells proliferate during and after migration 
from the hindgut into the genital ridge (McLaren, 1991). Once present in the 
genital ridge, the primordial germ cells mature into fetal germ cells and 
continue to proliferate until e15.5-e16.5 in the mouse or e17.5-e18.5 in the rat 
and then enter quiescence (Culty et al 2009). The germ cells become mitotic 
again between postnatal (pnd) 1-4 in the mouse and pnd 4-6 in the rat (Ferrara 
et al 2006) and migrate toward the basement membrane of the seminiferous 
cords and differentiate into spermatogonial stem cells (Boulogne et al 1999, 
Culty et al 2009). Spermatogenesis describes the postpubertal progression of 
germ cells from spermatogonia, to spermatocytes, to spermatids and is 
maintained by testosterone stimulation from Leydig cells acting via Sertoli cells 
(Svingen and Koopman 2013).  





1.5.5 Sertoli cells 
Following Sry expression at e10.5 in the mouse gonad, gonadal somatic cells 
begin to differentiate into Sertoli cells, arising from the coelomic epithelium 
(Cool et al 2008), which serve three significant fetal functions. Firstly, Sertoli 
cells aggregate in a layer around germ cells, thus forming seminiferous cords, 
where they continue to proliferate and elongate the seminiferous cords (Nel-
Themaat et al 2011). It is unlikely that germ cells are the focal point for Sertoli 
cell aggregation into seminiferous cords, as in XY gonads where germ cells are 
absent, seminiferous cords are formed nonetheless (Escalante-Alcalde and 
Merchant-Larios 1992). Secondly, Sertoli cells also produce and secrete Desert 
hedgehog (Dhh) (Pierucci-Alves et al 2001) (detailed in section 1.7.9) which 
induces fetal Leydig cell differentiation (Bitgood et al 1996, Yao et al 2002, 
Griswold and Behringer 2009). Thirdly, Sertoli cells also function to secrete 
AMH (detailed in section 1.5.8.1) which is necessary for regression of the 
Müllerian ducts. Sertoli cells do not express AR during fetal life (Majdic et al 
1995, Williams et al 2001, Sharpe et al 2003) but during postnatal life, androgen 
signalling via the Sertoli cells is essential for spermatogenesis (De Gendt et al 
2004). Each adult Sertoli cell supports a fixed number of germ cells and this 
number is reached post-puberty when Sertoli cells are no longer mitotic 
(Sharpe et al 2003). Specialised tight junctions between each Sertoli cell, forms 
the "blood-testis-barrier" at puberty (Cheng and Mruk 2010). 
 
1.5.6 Seminiferous cord formation 
The formation of seminiferous cords is a crucial event, marking testis 
differentiation (Svingen and Koopman 2013). Testis cords separate Sertoli cells 
and gonocytes from the interstitium to create a separate environment for 
spermatogenesis, which occurs from puberty onwards. Seminiferous cords are 
first evident in the mouse at e12 (Combes et al 2009). Vascular endothelial cells 
have been shown to play a role in testis cord formation as interstitial cells 
respond to vascular endothelial growth factor, (VEGF), signalling from 
migrating cells and proliferate forming testis cords (Cool et al 2011). Together 





with vascular endothelial cells, migrating endothelial cells from the 
mesonephros are also involved in cord formation, as evident from the 
abnormal/disrupted cord formation following blockage of cell migration and 
vascular formation via VE-cadherin (Combes et al 2009).  
 
1.5.7 Peritubular myoid cells 
At e13 in the mouse, a single layer of spindle shaped elongated cells, termed 
peritubular myoid (PTM) cells, form around the layer of Sertoli cells (Skinner et 
al 1985). Earlier studies suggested that PTM cells arose from the mesonephric 
layer (Merchant-Larios et al 1993, Martineau et al 1997), however more recent 
studies demonstrate that migrating mesonephric cells contribute rather to the 
endothelial cell population and testis vasculature, than to the PTM cells (Cool et 
al 2008, Combes et al 2009). The precise ontogeny of PTM cells remains 
unknown although some authors (Combes et al 2009) propose the coelomic 
epithelium is a likely origin whereby PTM cells arise by "epithelial-to-
mesenchymal" transformation. PTM cells express AR during fetal and postnatal 
life (You and Sar 1998, Welsh et al 2009, 2012) and in relation to Leydig cells, 
specific AR knockout in PTM cells results in altered adult Leydig cell function, 
although their numbers were unchanged (Welsh et al 2012). This suggests a 
role for PTM cells in regulating normal adult Leydig cell function via androgen 
signalling.  






Figure 1.1 Timing of reproductive development in rodents and man  
(Adapted from Wilhelm and Koopman 2006). 
 
1.5.8 Masculinisation 
Masculinisation of the fetus is an androgen-dependent process (Zirkin, 2010, 
Swrdloff et al 2010, Svechikov et al 2014) and occurs from e15.5-17.5 in the rat 
and during weeks 8-12 in the human during a critical period termed the 
'masculinisation programming window' (MPW) (Welsh et al 2008, Scott et al 
2009). This involves differentiation and development of the internal 
(epididymis, vas deferens, seminal vesicles and prostate) and external (penis, 
scrotum and perineum) genitalia (Svechikov et al 2014). Fetal masculinisation is 
driven by three crucial hormones, AMH, Insl3 and testosterone (Rey et al 2012), 
which are described in more detail in the following sections.  
 
1.5.8.1  Anti-Müllerian hormone 
Anti-müllerian hormone (AMH) or müllerian inhibitory substance (MIS) is 
secreted by fetal Sertoli cells as a 140kDA glycoprotein to cause regression of 
female müllerian reproductive derivatives (Ingraham et al 2000). This occurs 
between e14-17 in the rat whereby AMH binds to its receptor AMHR2 on 





mesenchymal cells of the müllerian duct to induce their apoptosis (Mishina et al 
1996). Its potential role during adult Leydig cell differentiation will be discussed 
later (Section 1.7.4). 
1.5.8.2  Insulin-like factor 3 
Insulin-like factor 3 (Insl3 or relaxin-like factor, (RLF)) is produced by fetal 
Leydig cells (Ivell and Bathgate 2002, Foresta et al 2008) and is involved in the 
first (trans-abdominal) phase of  testis descent. This occurs when Insl3 binds to 
its receptor (G-protein-coupled receptor affecting testis descent, GREAT) 
present on the gubernacular ligaments, which links the testis to the inguinal 
region of the abdominal cavity (Ivell and Hartung 2003, Park et al 2008). 
Testosterone induces the regression of the cranio-suspensory ligament, which is 
required to release the testis from the abdominal wall for descent into the 
inguinal region. Without functional Insl3, as evident from the disruption of Insl3 
in transgenic mice, testes remain intra-abdominal (Figure 1.2) (Zimmermann et 
al 1999, Ivell et al 2009). The second phase of testicular descent (inguino-
scrotal) is predominantly androgen-dependent and occurs due to shortening of 
the gubernaculum cord which pulls the testis through the inguinal canal and 
into the scrotum (Hughes and Acerini 2008). This occurs between pnd 10-14  in 
the rat completing testis descent (Amann and Veeramachaneni, 2007). In 
humans, the process of testis descent is normally completed prior to birth 
(Hutson et al 2013). However, incomplete descent is a common finding in boys 
at birth, although the incidence varies between countries, it has generally been 
shown to occur in 2-9% of boys at birth and the majority of cases result from a 
failure of the inguino-scrotal phase of descent (Foresta et al 2008). In contrast, 
incomplete testis descent in rats and mice is extremely rare (<0.5%) (Amann 
and Veeramachaneni 2007). Patients with AIS commonly display undescended 
testes due to lack of androgen-induced inguino-scrotal descent (Hughes and 
Acini 2008). Fetal rats exposed to DBP during the masculinisation programming 
window, demonstrate a significant reduction in the production of Insl3 and 
testosterone by fetal Leydig cells, which results in cryptorchidism (Mylchreest 
et al 2000, Foster et al 2001, van den Driesche et al 2012).  







Figure 1.2 Testis Descent. The schematic depicts testis descent and the role of Insl3 
and androgens in this process. (Adapted from Nef and Parada et al 2000). 
 
1.5.8.3  Testosterone and fetal masculinisation 
Testosterone produced by fetal Leydig cells is crucial for the differentiation of 
the internal reproductive organs (epididymis, vas deferens, seminal vesicles, 
prostate) and the external genitalia (penis, scrotum) and perineum (anogenital 
distance) (Imperato-McGinley et al 2002, Welsh et al 2008, Murashima et al 
2011). Testosterone is converted into dihydrotestosterone (DHT) by 5α-
reductase and signals through the androgen receptor in peripheral target 
tissues, as mentioned above, to masculinise the external genitalia and the 
prostate (Svechnikov et al 2014). Testosterone is also important in testis 
descent, as mentioned above.  





Anogenital distance (AGD) is twice the length in males compared to females in 
humans (Salazar-Martinez et al 2004, Swan et al 2005, 2008, Thankamony et al 
2009, Sathyanarayan et al 2010, Eisenberg, 2011) and in rats (McIntyre et al 
2001, Zhang et al 2004, Welsh et al 2008), and provides a permanent read out of 
androgen exposure during fetal life (Welsh et al 2008, MacLeod et al 2010, Dean 
and Sharpe 2013). AGD is decreased following fetal exposure to DBP in male 
rats, as a result of decreased androgen exposure (Foster et al 2000, Mylchreest 
et al 2000, Barlow and Foster 2003, van den Driesche et al 2012). 
1.6 Identification of Leydig cells 
Interstitial cells of the testis were coined 'Leydig cells' following their discovery 
in 1850 by Franz von Leydig, however it was not until the 1880's and early 
1900's that researchers began to realise the endocrine function of Leydig cells. 
The potential for endocrine factors in the testis was introduced in 1849 with 
Arnold Berthold's experimental transplantation of testes into castrated 
roosters, which resulted in the roosters exhibiting male sexual characteristics. 
This suggested that a hormone from the blood circulation was causing the 'male 
traits' as the nerve supply to the testis was severed. Berthold's study, a year 
prior to the identification of Leydig cells, has been widely accepted as the start 
of endocrinology. The controversial studies of Brown-Séquard in 1889 who 
claimed a 'beneficial effect' from self-injection with animal testes extracts, 
further highlighted a role for the testis as an endocrine gland.  The hypothesis 
that it was in fact the Leydig cells which had an endocrine function, was shown 
by Bouin & Ancel in 1903-1905. Finally in 1958, the first direct evidence that 
Leydig cells were steroidogenic and could produce testosterone came from an 
enzymatic activity experiment demonstrating the expression of the 
steroidogenic enzyme 3β-HSD in Leydig cells (Wattenberg, 1958).  
 





1.6.1 Separate Leydig cell lineages 
As previously described, Leydig cells are essential testicular cells for endocrine 
function, producing the steroid hormone testosterone. Leydig cell development 
in the human is considered a 'triphasic event', evident with separate lineages of 
Leydig cells developing during fetal, neonatal and pubertal periods (Prince 
2001). The developmental timing of testosterone production in the rodent is 
substantially faster than the human, with only two separate lineages of Leydig 
cells, 'fetal' and 'adult', evident during fetal and postnatal life respectively 
(Rosen-Runge and Anderson 1959, Lording and De Kretser 1972, Ariyaratne 
and Mendis-Handagama 2000, Habert et al 2001, O'Shaughnessy et al 2002, 
Chen et al 2009). 'Fetal Leydig cells' are required for masculinisation of the fetus 
whereas 'adult Leydig cells' are essential from puberty onwards for 
spermatogenesis, sex drive and overall male health. There is continuing debate 
over Leydig cell origin, and various hypotheses have been proposed e.g. that 
both fetal and adult Leydig cell populations arise from a common precursor cell, 
fetal Leydig cells then regress after birth and adult Leydig cells differentiate 
from the common precursor which lies dormant until puberty (Barsoum et al 
2013, Svingen and Koopman 2013). Both generations will be discussed in this 
review. 
 
1.6.2 Fetal Leydig cells 
The first population of Leydig cells, the fetal generation, are evident at e12.5 in 
the mouse (Baker et al 1999), and 7-8 weeks in human, having differentiated 
from 'mesenchymal-like stem cells (Byskov, 1986, O'Shaughnessy et al 2006, 
Ostrer et al 2007). The fetal Leydig cells have also been postulated to arise from 
the adrenogenital primordium, which gives rise to steroidogenic cells in the 
adrenal and gonads (Hatano et al 1996), with some gonad steroidogenic cells 
retaining "adrenal-like" properties (Val et al 2006). More recent studies 
describe two origins for fetal Leydig cells, namely the coelomic epithelium and 
the gonad-mesonephric border (DeFalco et al 2011). As steroidogenesis 
requires cholesterol as a substrate and cholesterol is not evident in the testis 





prior to testosterone production (Budefeld et al 2009), it suggests that 
cholesterol might be exogenously derived during this period, likely from the 
coelomic blood vessel or vascular plexus near the gonad-mesonephric border.   
The expression of steroidogenic factor 1 (SF1) (as a result of Sry) increases in 
differentiating Leydig cells which initiates Leydig cell steroidogenesis (Barsoum 
et al 2013), evident by testosterone production at e13 in the mouse 
(O'Shaughnessy and Fowler 2011) and 7 weeks of gestation in the human 
(O'Shaughnessy et al 2007, Scott et al 2009). The fetal population of Leydig cells 
regress after birth or are superseded by adult Leydig cells (Baker et al 1999, 
Chen et al 2009, Scott et al 2009, O’Shaughnessy and Fowler 2011). Both cell 
generations differ in their morphology, function and regulation (O'Shaughnessy 
et al 2002, Dong et al 2007, Scott et al 2009, Pinto et al 2010, Kotula-Balak et al 
2012) and will be discussed in this review. 
 
1.6.3  Function and regulation of fetal Leydig cells 
In the rat, morphological (Jost et al 1981) and functional differentiation of 
Leydig cells occurs at e15.5, coincident with testosterone production (Warren et 
al 1973, Habert & Picon 1984). Fetal Leydig cells produce androgens which 
induce the formation of the epididymis, vas deferens and seminal vesicles from 
the Wolffian ducts, and development of the penis and scrotum (Scott et al 2009) 
along with the production of Insl3, which is crucial for testis descent (Ivell et al 
2009). Testosterone produced by fetal Leydig cells is converted by 5α-reductase 
into dihydrotestosterone (DHT) in certain target peripheral tissues such as the 
external genitalia, which virilises these tissues. 
Fetal Leydig cell development and initial steroidogenesis occurs in a 
gonadotrophin-independent manner (Habert and Picon 1982, O' Shaughnessy et 
al 1998, 2002, Baker et al 2001, Migrenne et al 2001), as evident from their 
ability to produce androgens required for fetal masculinisation prior to the 
establishment of the hypothalamic-pituitary-gonadal (HPG) signalling axis 





(Huhtaniemi 1989, O'Shaughnessy and Fowler 2011). There is some evidence to 
suggest that factors secreted by Sertoli cells including Dhh (Byskov 1986, 
Koopman 2001, Pierucci-Alves et al 2001, Yao et al 2002) and/or the 
extracellular matrix (Jost et al 1988) may be involved in this process. Other 
paracrine factors in the testis e.g. vasoactive intestinal peptide (VIP) and 
pituitary adenylate cyclase-activating polypeptide (PACAP-27) have also been 
shown to stimulate fetal, but not adult Leydig cell steroidogenesis (El-Genahi et 
al 1998).  Natriuretic peptides (NP) e.g. brain and C-type (BNP and CNP) have 
also been shown to stimulate steroidogenesis in the fetal rat testis (El-Genahi et 
al 2001) and adult mouse testis (Khurana and Pandey 1993). 
Chicken ovalbumin upstream promoter transcription factor II has been recently 
identified as a molecular target for DBP-induced testicular dysgenesis (van den 
Driesche et al 2012). This study demonstrated the abundant expression of 
COUP-TFII in fetal Leydig cells, interstitial, and PTM cells. In control animals, 
COUP-TFII is down-regulated in fetal Leydig cells during differentiation. 
However in DBP-exposed animals, COUP-TFII expression is maintained in the 
fetal Leydig cells which results in decreased fetal Leydig cell maturation and a 
70% reduction in testosterone production (van den Driesche et al 2012). This 
study proposed that down-regulation of COUP-TFII in fetal Leydig cells may be 
an important regulatory mechanism to promote testosterone production. The 
role of COUP-TFII in adult Leydig cell differentiation is described later in this 
review. 
 
1.6.4 Adult Leydig cells 
Adult Leydig cells gradually decline in number and function with increasing age 
in the human testis (Neaves et al 1984, 1985, Zirkin and Tenover 2012). In 
ageing rodents, adult Leydig cells become less responsive to LH and thus 
produce less testosterone with increasing age (Chen et al 2009). Adult Leydig 
cells have been proposed to arise from a multitude of sources; interstitial 
mesenchymal stem cells located in close proximity to peritubular cells (Mendis-





Handagama and Ariyaratne 2001, Ge and Hardy 2007), pericytes in the 
vasculature (Davidoff et al 2004) or peritubular myoid cells (Landreh et al 
2013), which supports the notion of a multifocal origin of adult Leydig cells 
(Haider, 2004, Habert et al 2001).  
Four stages of adult Leydig cell development have been identified in the rat; 
stem, progenitor, immature and adult (Hu et al 2009, Chen et al 2010) (Figure 
1.3) with similar stages evident in humans, over an extended time frame (Prince 
et al 2001). The adult Leydig 'progenitor' cell is the first evidence of a 
committed interstitial cell to the adult Leydig cell lineage, found in the rat testis 
between pnd 10-14 and the mouse at pnd 7-10 (Wu et al 2010). Progenitor 
Leydig cells express 3β-HSD and CYP11A1 and mainly produce androsterone 
and androstenedione (Haider et al 1986, Shan et al 1993, Ge et al 1998, 
O'Shaughnessy et al 2000, Chen et al 2009, Stanley et al 2011). Progenitor cells 
also express a truncated form of the LH receptor (Hu et al 2010). Progenitor 
Leydig cells continue to proliferate and their cytoplasm enlarges, and becomes 
rounded in shape, which marks their differentiation into immature Leydig cells, 
evident at pnd 28-56 in the rat (Ge et al 1998, Stanley et al 2011).  Immature 
adult Leydig cells have a high lipid content and high expression of androgen-
metabolising enzymes, namely 3α-HSD and 5α-reductase, which causes 
androstanediol to be the most abundant androgen at this stage of Leydig cell 
development (Chen et al 2009, Wu et al 2010). The immature adult Leydig cells 
differentiate into large rounded cells with abundant smooth endoplasmic 
reticulum, few lipid droplets and high steroidogenic enzyme expression to 
produce testosterone (Chen et al 2009, Stanley et al 2011). This final 
differentiation of immature cells (between pnd 28-56) results in the 
testosterone producing, adult Leydig cell population (Stanley et al 2011). 
It has long been a question of debate as to whether or not progenitor Leydig 
cells differentiate from a pool of undifferentiated self-renewing 'stem Leydig 
cells', which has largely remained unanswered due to the lack of a unifying 
specific marker. It is widely accepted that stem cells are capable of self renewal, 





commitment, amplification and differentiation. If there are adult Leydig stem 
cells, these would be present in the fetal and postnatal testis and their numbers 
would be maintained by cell renewal divisions throughout postnatal life. One or 
both of the adult Leydig stem cell progeny would be expected to commit to the 
Leydig cell lineage, resulting in an increase through amplification of cell 
divisions, thus giving rise to progenitor Leydig cells (Zirkin et al 2009). Prior to 
the appearance of progenitor Leydig cells (3β-HSD+), undifferentiated (3β-HSD- 
and LHR-) spindle shaped interstitial 'stem Leydig cells' are found at pnd 7 in 
the rat (Ge et al 2006). Isolation of these stem cells, which express PDGFRα, 
GATA4, c-kit and LIFR (3β-HSD or LHR negative) followed by cell culture in 
expansion medium, demonstrated the identified interstitial cells were capable 
of maintaining a stable phenotype for 6 months (Ge et al 2006). If these cells 
were further cultured in medium containing thyroid hormone, IGF1 and LH, 
40% of the cells expressed steroidogenic enzymes CYP11A1, 3β-HSD, CYP17A1, 
LHR, and STAR and were capable of producing testosterone. In line with this, 
the isolated stem cells were also capable of differentiating into 3β-HSD+ adult 
Leydig cells in an ALC ablation/regeneration rat model (Ge et al 2006). 






Figure 1.3 Development of adult Leydig cells The development of adult Leydig cells 
occurs in four stages consisting of stem, progenitor, immature and adult Leydig cells 
(Chen et al 2009). 
 
1.7 Factors involved in adult Leydig cell differentiation 
There are several factors implicated in adult Leydig cell differentiation, 
including endocrine hormones and paracrine factors produced locally in the 
testis. Some of the key hormones and factors involved in adult Leydig cell 
development are described below. 
 
 





1.7.1 Luteinising hormone 
Luteinising hormone (LH) is a key regulator of male reproductive function, 
specifically the production of testosterone by Leydig cells (Rey and Grinspon 
2011). LH is a gonadotrophin which is released from the anterior pituitary gland 
in response to the hypothalamic hormone GnRH (gonadotrophin releasing 
hormone) secreted from the hypothalamus. LH is a glycoprotein hormone, 
composed of an alpha and a beta subunit, which binds to its protein receptor, 
the LHR (McFarland et al 1989). Due to its protein structure, it is unable to 
diffuse through the membrane and instead binds to LHR on the cell membrane 
of Leydig cells, and thus initiates the intracellular signalling pathway for 
steroidogenesis (Huhtaniemi 1996). Once bound, the LH receptors stimulate a 
signalling cascade involving an increase in adenylyl cyclase activity via GTP 
binding proteins which results in the production of cAMP (Cooke 1996) and also 
increased cytoplasmic Ca2+ release following LH stimulation (Abdou et al 2013). 
Other second messengers include phospholipids and arachidonic acid which are 
activated in Leydig cells following LH stimulation (Wang et al 2000). Although 
LH is the natural ligand for the LHR in most adult mammals, hCG produced by 
the primate placenta can also bind to and activate the LHR (Rey and Grinspon 
2011).  
LH stimulation is critical for the functional development of adult Leydig cells, as 
demonstrated in mice lacking circulating LH, in which the number of adult 
Leydig cells only reached 10% of that in control mice (Baker and O'Shaughnessy 
2001). This is also evident in transgenic mice with a mutated LH receptor 
(LuRKO) which, at birth, resulted in normal testis development and androgen 
levels but during postnatal life resulted in hypogonadism, blocked development 
of sex accessory organs, and an arrest in spermatogenesis (Zhang et al 2001). In 
relation to adult Leydig cells, LHR knockout resulted in a reduction in the size 
and number of adult Leydig cells (Zhang et 2001, 2004, Ma et al 2004) which 
was not restored by testosterone administration (Lei et al 2004). Conversely, 
fetal Leydig cell number and testosterone levels were normal in the 
aforementioned studies, highlighting the gonadotrophin-independent 





development of the fetal Leydig cell lineage in the mouse (O'Shaughnessy et al 
1998, Baker et al 2001). However, while LH is crucial for their functional 
maturation, it does not appear to be involved in the onset of adult Leydig cell 
differentiation, as adult Leydig cells in rats express steroidogenic enzymes prior 
to any LHR expression (Ariyaratne et al 2000). This demonstrates the ability of 
adult Leydig cells to differentiate without initial LH stimulation. Human males 
with inactivating mutations in the LHCGR gene have lower testosterone levels, 
with elevated LH and mature adult Leydig cells are absent or scarce (Latronico 
and Arnhold 2012, 2013). Earlier studies of severe inactivating LHR mutations 
in XY humans resulted in a female phenotype (female external genitalia) and 
Leydig cell hypoplasia. Milder LHR mutations resulted in micropenis and 
hypospadias (Themmen, 2005). Conversely, activating mutations in LHR in 
humans leads to precocious puberty and Leydig cell hyperplasia (McGee and 
Narayan 2013). While LuRKO mouse models have proved useful for 
investigating the effects of inactivating LHR mutations on Leydig cell 
development in humans, transgenic mouse models for activating LHR mutations 
are not as well developed. One potentially useful mouse model with an 
activating LHR mutation has been described recently, which displays a similar 
phenotype to humans with this condition e.g. precocious puberty, increased 
testosterone and hyperplasia of adult Leydig cells (McGee and Narayan 2013).  
 
1.7.2 Follicle stimulating hormone 
Follicle-stimulating hormone (FSH) is one of the gonadotrophins released from 
the pituitary in response to hypothalamic stimulation by gonadotropin-
releasing hormone (GnRH). FSH binds to its receptor (FSHR) in Sertoli cells pre-
pubertally, to stimulate Sertoli cell proliferation. In adults, the binding of FSH 
and testosterone production maintain spermatogenesis (Rey and Grinspon 
2011). The product 'inhibin' produced by Sertoli cells is involved in negative 
feedback regulation of the HPG axis, specifically of FSH (Themmen and 
Huhtaniemi 2000). FSHRs are first evident in the mouse testis at e16.5 





(Rannikki et al 1995), before development of the HPG axis, thus indicating 
Sertoli cell function, prior to establishment of the HPG axis in mice, is FSH-
independent (O'Shaughnessy and Fowler 2011). In line with this, FSHR 
knockout (FSHRKO) mice did not display any altered Sertoli number or protein 
expression markers (e.g. Dhh, AMH, PDGFα) from birth to pnd 5 (Johnston et al 
2004). In postnatal life, testosterone or DHT act alongside FSH via Sertoli cells 
to stimulate and maintain spermatogenesis (O'Shaughnessy et al 2012).  
An important role for FSH in stimulating Leydig cell development has been 
shown from FSHRKO-/- mice. The FSHRKO mouse was first reported by Dierich 
et al 1998, which resulted in oligospermia, reduced fertility, normal LH but a 3-
fold increase in serum FSH with decreased testosterone. A later study 
demonstrated that FSHRKO-/- male mice were fertile although displayed 
increased serum LH and FSH levels (Abel et al 2000). There is a failure of 
normal adult Leydig cell development in FSHRKO-/- mice with evidence for 
compensated Leydig cell failure, evident from increased LH (Abel et al 2008) 
and decreased testosterone (one third of the wild-type control value) in adult 
FSHRKO-/- mice (Baker et al 2003). In a more recent FSHRKO-/- study, the 
number of adult Leydig cells was significantly reduced at pnd 20 and in 
adulthood (O'Shaughnessy et al 2012), which was exacerbated in a double 
knockout of FSHRKO-ARKO (O'Shaughnessy et al 2012). To date, there have 
only been 5 cases of human FSHR mutations reported (Siegel et al 2013). The 
FSHR gene mutation was reported in five Finnish men who presented with 
normal-small testis size, abnormal sperm parameters, normal-elevated FSH and 
LH, with normal testosterone levels (Tapanainen et al 1997), which seems 
similar to the phenotype of the FSHRKO-/- mouse, making this a useful model. 
 
1.7.3 Insulin-like Growth Factor 1 
Insulin-like growth factor 1 (IGF1) and its receptor are expressed in progenitor 
and immature Leydig cells (Hu et al 2010). IGF-1 has been shown to stimulate 
steroidogenesis and increase StAR expression at both the mRNA and protein 





level in adult Leydig cells via hCG stimulation (Lin et al 1998). IGF-1 treatment 
of cultured rat Leydig cells in vitro from pubertal and adult animals 
demonstrated an increase in intracellular steroidogenesis and testosterone 
production, with a greater response from the pubertal cells than adult, 
suggesting a role for IGF-1 in Leydig cell maturation (Gelber et al 1992). IGF-null 
mice have a significant reduction in body weight, adult Leydig cell number and 
an 80% reduction in serum testosterone levels, compared to wild-type (Baker et 
al 1996, Wang et al 2003, Hu et al 2010), implicating a role for IGF-1 in adult 
Leydig cell development and function. IGF-1-null mice express higher levels of 
5α-reductase-1 in adulthood and as a result, testosterone is reduced. 
Furthermore, mRNA levels of StAR, CYP11A1 and CYP17a1 are also reduced, 
which suggests that the developing adult Leydig cells are arrested at the 
immature stage (Wang et al 2003). In a recent study of IGF-1 null mice, the 
proliferative index of progenitor and immature adult Leydig cells was reduced 
in Igf1-/- mice, and this deficit could be rescued by recombinant IGF-1 (Hu et al 
2010). Interestingly, this deficit in proliferative capacity was not evident in 
'stem' Leydig cells, in which proliferation was comparable to wild-type controls. 
Overall, this suggests IGF-1 is involved in the proliferation and differentiation of 
adult Leydig progenitor cells, at least at pnd 14, in the rat (Hu et al 2010). 
 
1.7.4 Anti-Müllerian Hormone 
Anti-Mullerian hormone (AMH) is expressed at high levels pre-pubertally in 
males (Grinspon and Rey 2010) and its receptor, AMHR2, is found on adult 
Leydig cells (Lee et al 1999, Fynn-Thompson et al 2003). AMH expression 
decreases during puberty, coincident with the increasing intratesticular 
testosterone concentration at this time (Lukas-Croisier et al 2003). This inverse 
relationship occurs in central precocious puberty and gonadotrophin-
independent precocious puberty (Lukas-Croisier et al 2003), demonstrating 
androgens down-regulate AMH, independent of age and gonadotrophin levels. 
As testosterone increases at puberty, AMH decreases, which is coincident with 





adult Leydig cell differentiation (Grinspon and Rey 2010). A failure for 
androgens to stimulate the normal reduction in AMH levels at puberty results in 
hypogonadotrophic hypogonadism, in which patients present with increased 
AMH and low testosterone levels (Young et al 1999). Furthermore, patients with 
AIS have high levels of AMH (Rey et al 1994). In rodents, binding of AMH to its 
receptor on Leydig cells, can inhibit the proliferation of adult Leydig progenitor 
cells pre-pubertally, and reduces steroidogenesis, potentially via down-
regulation of Cyp17a1 (Racine et al 1998, Trbovich et al 2001). This 'repression' 
is lifted during puberty with increasing testosterone levels (Grinspon and Rey 
2011). Overexpression of AMH in a mouse model, resulted in blockage of adult 
Leydig cell differentiation at the progenitor stage (Racine et al 1998). This was 
shown to occur via its receptor (AMHR2), on adult Leydig progenitor cells in 
both rats and mice (Lee et al 1999).  
 
1.7.5 Oestrogens 
Oestrogens are highly expressed within the testis and are produced from the 
aromatisation of testosterone via P450aromatase/CYP19 (de Ronde et al 2003). 
Mature adult Leydig cells produce oestrogen and express oestrogen receptors 
(ER-α and β), as evident in the mouse and rat (Saunders et al 1998, Zhou et al 
2002) with mainly ERβ expression in human adult Leydig cells (Saunders et al 
2001). ERβ knockout mice have increased adult Leydig cell numbers but not 
cytoplasmic volume, with comparable testosterone levels to wild-type (Gould et 
al 2007). In ERα knockout mice, the number of adult Leydig cells is unchanged, 
however there is an increase in adult Leydig cell volume, testosterone levels and 
steroidogenic gene expression e.g. Star and Cyp11a1 (Gould et al 2007). A study 
investigating oestrogen-mediated fetal testis dysgenesis in the rat, via 
administration of oestradiol and diethylstilboestrol (DES) during fetal life, 
showed significant reductions in mRNA levels of StAR, Insl3, Cyp17A1. This 
oestrogenic response was found to be mediated via ERα, as evident in ERα 
knockout mice, which displayed comparable mRNA levels of genes encoding 





steroidogenic enzymes, compared to wild-type control (Cederroth et al 2007). 
In a more recent study, transgenic male mice expressing aromatase (Arom+ 
mice) crossed with ERα knockout mice showed a reduction in steroidogenic 
gene expression (StAR and Cyp17a1) and abnormal adult Leydig cell protein 
expression e.g. StAR, Insl3 (Strauss et al 2009). This suggests that the imbalance 
of oestrogens to androgens (high oestrogen, low androgen) affects adult Leydig 
cell development. There appears to be species and age differences in oestrogen 
receptor expression within the human testis, as there is inconsistency in the 
literature regarding the localisation of ERα and β. One study reported ERα in 
fetal Leydig cells of the human testis (Shapiro et al 2005) while most report it is 
absent (Boukari et al 2007, Mitchell et al 2013, Svechnikov et al 2014).  ERβ 
expression was reported in human fetal Leydig cells (Shapiro et al 2005) and 
human adult Leydig cells (Cavaco et al 2009). Aromatase is expressed in various 
cell types in the human including adipose tissue, the brain and adult Leydig cells 
(Simpson et al 2002). There have been very few reports of aromatase 
deficiency; those reported relate to seven men in whom aromatase is non-
functional due to a mutation in the CYP19a1 gene, encoding aromatase (Jones et 
al 2006). This results in the absence of oestrogen, normal-high testosterone 
levels and gonadotrophins, tall stature, osteoporosis and impaired reproductive 
function (Jones et al 2006).  The aromatase knockout (ArKO) mouse is a very 
useful model as it displays a similar phenotype to that reported in the human. 
Male mice deficient in aromatase display elevated testosterone, DHT and LH 
serum levels, while FSH levels were unchanged (Fisher et al 1998, Robertson et 
al 1999). While the aromatase deficient mouse model (ArKO) is useful to 
explore the role of aromatase and oestrogens, the balance between androgen 
and oestrogens may be more important than just the level of oestrogens per se 
(Seralini and Moselemi 2001). 
 





1.7.6 Thyroid hormone (Thyrotrophin) 
Thyroxine (T4), a thyroid hormone, can be deionised to 3,5,3-triiodo-L-
thyronine (T3), the bioactive thyroid hormone, where it binds to its receptors 
TRα and TRβ in target tissues (Mendis-Handagama and Ariyaratne 2004, 2005, 
Martin and Tremblay 2010), including the human and rat testes (Jannini et al 
2000, Buzzard et al 2000). Thyroid hormones stimulate and maintain mouse 
Leydig cell function via stimulation of StAR and intracellular steroidogenesis in 
adult Leydig cells (Manna et al 2001, Mendis-Handagama and Ariyaratne 2005). 
Thyrotrophin stimulates thyroid stimulating hormone (TSH) release and 
receptors for TSH are present in interstitial cells, PTM and germ cells across 
development (Buzzard et al 2000). Thyrotrophin mRNA levels, protein 
expression and its receptor localisation are all found specifically in adult Leydig 
cells (Mendis-handagama and Ariyaratne 2005). In pre-pubertal hypothyroid 
rats, intratesticular testosterone and Leydig cell activity, as measured by 3β-
HSD and 17β-HSD enzyme expression, were reduced both in vivo and vitro. The 
abnormal adult Leydig cell function could be reversed by thyroxine (T4) 
supplementation (Antony et al 1995). Acute stimulation of Leydig cells in 
culture with thyronine (T3) resulted in an increase in testosterone production 
(Maran et al 2000). The same authors later investigated neonatal onset 
hypothyroidism which resulted in altered Leydig cell development, reduced 
steroidogenesis and compensated adult Leydig cell failure, evident by increased 
LH and decreased testosterone (Maran et al 2001). The role of thyroid hormone 
in developing adult Leydig cells (during puberty) and regenerating adult Leydig 
cells (post-EDS injection), was investigated in rats via dietary induced 
hypothyroidism. This resulted in a delay in the development of adult Leydig 
cells in the two experimental hypothyroid rat groups, at puberty and during 
adult Leydig cell regeneration post-EDS (Rijntjes et al 2009, 2010). Overall, 
thyroid hormone appears to play a role in adult Leydig cell differentiation. 
Interestingly in relation to potential adult Leydig stem/progenitor cells, an 
isoform of the thyroid hormone receptors, (TRα1) was found abundantly 
expressed in unidentified spindle shaped interstitial cells in the developing 





mouse testis (Pnd 0-5) and in adult testis (Pnd 63) (Buzzard et al 2000). Young 
boys with hypothyroidism have elevated serum FSH, but normal LH and 
testosterone levels (Castro-Magana et al 1988, Mendis-Handagama et al 2005), 
which suggests normal Leydig cell function. However, adult men with 
hypothyroidism display reduced serum testosterone concentrations and a 
reduced number of adult Leydig cells (Wortsman et al 1987, Mendis-
Handagama et al 2005), which is a similar phenotype to hypothyroid rats, as 
described above. 
 
1.7.7 Platelet Derived Growth Factor Receptor Α 
Platelet derived growth factors comprise of four ligands, PDGF-α, β, C and Δ 
(Ding et al 2000, Basciani et al 2010) and their receptors display conserved 
signalling, with the PDGF-C ligand capable of binding to PDGFα receptors (Li et 
al 2000). In relation to humans, fetal Leydig cells express significant levels of 
platelet-derived growth factor (PDGF) isoforms α and β, and their respective 
receptors (Basciani et al 2002, 2010). PDGFα is expressed in adult Leydig cells 
(Mariani et al 2002) along with its receptor, PDGFRα in the human (Basciani et 
al 2002). The importance of platelet derived growth factor receptor α (PDGFRα) 
in the development of fetal Leydig cells in the rodent was demonstrated in 
earlier studies in which deletion/disruption of PDGFRα impaired fetal Leydig 
cell differentiation, potentially due to a failure in progenitor cell proliferation 
(Brennan et al 2003, Schmahl et al 2008, Griswold and Behringer 2009). 
PDGFRα is expressed in the interstitium and PTM cells of fetal rodent testes at 
e12.5-e13.5 (Brennan et al 2003, Ricci et al 2004, Basciani et al 2010), 
interstitial and PTM cells of the neonate (Gnessi et al 1995, Thuillier et al 2003) 
and in adult Leydig cells (Ge et al 2005). PDGFα has been shown to be expressed 
in 3β-HSD+ adult Leydig progenitor cells in the rat at pnd 10 (Fecteau et al 
2006). It has been suggested to play in role in adult Leydig cell differentiation, 
as adult Leydig cells are absent in PDGFα-deficient mice (Gnessi et al 2000). 
Isolated putative non-steroidogenic Leydig stem cells, from rat testes at pnd 7 





which expressed PDGFRα, LIFR and c-kit were shown to proliferate in vitro and 
express Leydig cell specific genes once stimulated by PDGFα and other factors in 
differentiation-inducing medium (Ge et al 2006). In line with this, mRNA levels 
of pdgfrα increases dramatically and transiently one day post-EDS i.e. adult 
Leydig cell ablation (O'Shaughnessy et al 2008), which may suggest a role for 
PDGFRα in adult Leydig stem cell differentiation. A recent study demonstrated 
that PDGFRα+ cells isolated from pnd 8 rat testis belong to the peritubular 
myoid cell (PTC) lineage, evident from their expression of PTC-specific genes, 
pluripotency markers and the expression of genes encoding steroidogenic 
enzymes (Landreh et al 2013). This suggests neonatal PDGFRα+ PTM cells might 
give rise to adult Leydig cells, in agreement with the hypothesis of a multifocal 
adult Leydig cell origin (Habert et al 2001, Haider, 2004).  
Conditional deletion of pdgfrα in steroidogenic cells driven by the Sf1-Cre 
promoter (Sf1-Cre;PDGFRα-/-) in early adulthood resulted in significantly 
smaller testes, reduced sperm count, reduced adult Leydig cell number which 
coincided with reduced Cyp11a1 expression, in comparison to wild-type mice 
(Schmahl et al 2008, Basciani et al 2010). Interestingly, the mutant mice become 
fertile between 3-6 months of age, which is coincident with increased 
expression of PDGFRβ in the Sf1-Cre;PDGFRα-/- mouse line (Schmahl et al 2008, 
Basciani et al 2010). This could suggest a compensatory mechanism by PDGFRβ 
as PDGFRs maintain conserved cell signalling, despite different functions (Li et 
al 2000, Klinghoffer et al 2001). An earlier study that investigated adult Leydig 
cell development in an adult Leydig cell ablation/regeneration model (EDS) 
showed the adult Leydig population arises from vasculature pericytes which 
expressed PDGFRβ (Davidoff et al 2004). Overall, the involvement of PDGFs in 
adult Leydig cell development is complex and further investigations are 
necessary to fully elucidate their role in this process. 
 





1.7.8 Leukemia Inhibitory Factor 
Leukemia inhibitory factor (LIF) is a highly pleiotrophic cytokine (Hilton, 1992, 
Ge et al 2005). LIF has previously been shown to promote proliferation of 
murine embryonic stem cells whilst maintaining these cells in an 
undifferentiated totipotent state (Smith et al 1988, Ge et al 2005). It is a 
member of the IL-6 cytokine family and is required for neural stem cell self 
renewal, as shown in vitro (Wright et al 2003), and is also expressed in PTM 
cells in rat testes from e13.5 onwards (Piquet-Pellorce et al 2000). In a recent 
study that investigated putative adult Leydig 'stem cells', isolated interstitial 
cells from rat testes at pnd 7, which expressed LIFR (and PDGFRα), were shown 
to proliferate upon stimulation with differentiation-inducing medium 
containing LIF in vitro (Ge et al 2006). These cells were capable of 
differentiating into 3β-HSD+ adult Leydig cells which could produce 
testosterone (Ge et al 2006), thus suggesting a key role for LIF in adult Leydig 
cell development. Withdrawal of LIF has also been shown to stimulate 
differentiation in mouse embryonic stem cells (Ward et al 2004). This is also 
evident in a more recent study that investigated adult Leydig cell regeneration, 
post-EDS treatment. In this study, mRNA levels of Lif increased significantly 
following adult Leydig cell ablation (24 hours post-EDS) and decreased to basal 
levels between 3-5 days at the point where newly developing adult Leydig cells 
are differentiating (O'Shaughnessy et al 2008). Overall, this suggests a role for 
LIF in adult Leydig stem cell proliferation and differentiation.  
 
1.7.9 Desert hedgehog 
Desert hedgehog (Dhh) is a member of the hedgehog family of genes and apart 
from the gonads, Dhh can also play a role in other organs including pancreas 
and adipocytes (King et al 2008). In the testis, it is secreted by Sertoli cells and 
its receptor, Patched 1 (PTCH1), is located on Leydig and peritubular myoid 
cells in mice (Clark et al 2000, Yao et al 2002). Dhh is known to play a role in 
Leydig and peritubular myoid cell differentiation (Yao et al 2002), as evident 
from mice in which the absence of a functional Dhh in male gonads, results in 





undescended small testes, failure of Leydig cells to complete differentiation and 
abnormal seminiferous cord formation (Clark et al 2000, Yao et al 2002, Park et 
al 2007). The majority of Dhh null mice develop into pseudohermaphrodites 
(Clark et al 2000). In human, mutations in Dhh are associated with 46, XY 
individuals who present with partial/complete gonadal dysgenesis (Umehara et 
al 2000, Canto et al 2004). The role of Dhh in fetal Leydig cell differentiation is 
highlighted by studies in which Dhh was induced in fetal mouse ovaries, 
resulting in fetal Leydig cell differentiation from SF1+ cells, as evident from their 
production of androgens and Insl3 (Barsoum et al 2009).  
 
1.7.10 GATA4 
GATA4 is the only one of six family members to be expressed in somatic cells, as 
opposed to germ cells, in the bipotential gonad (Eggers et al 2012). Expression 
of the transcription factor (GATA4) becomes sexually dimorphic at e13.5 
(Eggers et al 2012), and in human fetal Leydig cells, this expression peaks 
around 15 weeks of gestation, coincident with a peak in testosterone levels and 
the exponential rise in fetal Leydig cell number (O'Shaughnessy et al 2007, 
Ketola et al 2000, Svechnikov et al 2010). Gata4 is evident in fetal Leydig cells, 
interstitial cells and PTM cells at e13.5 and e17.5 (Bielinska et al 2007) and is 
expressed in Sertoli and adult Leydig cells of the mouse testis (Ketola et al 2000, 
Bielinska et al 2007). Isolated putative 'adult Leydig stem' cells from rat testes 
at pnd 7 which were PDGFRα+, expressed c-Kit, LIF and GATA4, were shown to 
be capable of differentiating into adult Leydig cells in vitro (Ge et al 2006). 
Furthermore, in an adult Leydig cell ablation/regeneration model via EDS, the 
isolated GATA4+ Leydig 'stem cells' were also capable of developing into adult 
Leydig cells (Ge et al 2006). This highlights a role for GATA4 in adult Leydig 
stem/progenitor cell development. GATA4 is present in Sertoli and adult Leydig 
cells throughout postnatal mouse and human testis development (Ketola et al 
1999, 2000). During puberty in the human testis, GATA4 expression was more 
intense in developing Leydig cells, which decreased with age (Ketola et al 2000). 





Taken together, this suggests GATA4 could provide a useful marker for newly 
differentiating adult Leydig progenitor cells. 
1.7.11 COUP-TFII  
Chicken ovalbumin upstream promoter-transcription factor (COUP-TF) derived 
its title from its ability to regulate expression of the chicken ovalbumin gene 
(Wang et al 1989). There are two COUP-TF nuclear receptors (I and II), which 
are ligand-inducible, highly conserved transcription factors, containing identical 
ligand-binding-domains (LBD) across species (Tsai and Tsai 1997, Kruse et al 
2008). COUP-TFs are termed 'orphan' nuclear receptors as their ligand has not 
yet been identified (Martin and Tremblay 2010). COUP-TFI is expressed in the 
neural system (Tang et al 2006) whereas COUP-TFII is expressed in the 
mesenchyme of developing organs. This review will focus on COUP-TFII, as it is 
involved in male (Qin et al 2008) and female reproduction (Takamoto et al 
2005). COUP-TFII has also been reported to play a role in venous identify (You 
et al 2005), cell fate determination (endothelial lymphatic cells; Yamazaki et al 
2009, neural progenitor cells during eye development; Tang et al 2010), 
organogenesis, angiogenesis (Qin et al 2010), cerebellum development (Kim et 
al 2009) and metabolic homeostasis (Kruse et al 2008, Li et al 2009, Lin et al 
2011).  
COUP-TFII is first detected in the visceral mesoderm and myocardium and 
umbilical veins at e8.5 in the mouse (Pereira et al 1999). COUP-TFII-/- mutant 
mice were embryonic lethal, due to angiogenesis and cardiovascular defects 
(Periera et al 1999). This was confirmed by specific deletion of COUP-TFII in the 
endothelium via Tie2-Cre recombinase, which resulted in death due to vascular 
defects. Ectopic expression of COUP-TFII in the endothelium of transgenic mice 
resulted in down regulation of arterial markers e.g. Jag1, and up-regulation of 
venous markers, EphB4. This demonstrates a key role for COUP-TFII in the 
regulation of vein identity (You et al 2005). 
Regarding the female reproductive system, COUP-TFII is predominantly 
expressed in steroidogenic theca cells surrounding ovarian follicles (Takamoto 





et al 2005), suggesting potential involvement in the steroidogenic pathway. 
Following LH stimulation in wild-type female mice, theca cells synthesize 
precursor C19 steroids in the pre-ovulatory follicle (Chaffin and Vandevoort 
2013). The ablation of one allele (haploinsufficiency) of COUP-TFII+/- in female 
mice, resulted in reduced responsiveness to gonadotrophins and therefore 
reduced progesterone levels. COUP-TFII+/- mice had a 70% reduction in 
steroidogenic enzyme expression of CYP11A1, StAR and 3β-HSD1 which could 
explain the reduced ability to synthesise progesterone (Takamoto et al 2005). 
In relation to the male reproductive system, COUP-TFII has been shown to be 
involved in adult Leydig cell development, specifically the differentiation but not 
maintenance of adult Leydig cells (Qin et al 2008). In this study, the embryonic 
lethality of COUP-TFII null mice was circumvented using a tamoxifen inducible 
Cre to inactivate COUP-TFII in a time specific manner in a mouse model. 
Postnatal inactivation of COUP-TFII pre-puberty resulted in infertility, 
spermatogenic arrest and hypogonadism, presumably as a result of the arrested 
differentiation of adult Leydig progenitor cells (Qin et al 2008). COUP-TFII does 
not seem to be required for the maintenance of adult Leydig cells as post-
pubertal deletion of COUP-TFII resulted in normal male reproduction and 
Leydig cell function. 
The precise structure or ligand regulation of COUP-TFII has not yet been 
elucidated. A previous study investigated the conformational status of COUP-
TFII and described it as having an 'autorepressed conformation', as the 
activation binding sites are inaccessible due to its folded conformation (Kruse et 
al 2008). Retinoic acid, a vitamin A metabolite, can alter this conformational 
state thus promoting COUP-TFII to recruit co- activators and increase its 
transcriptional activity (Kruse et al 2008). An earlier study reported that 
retinoic acid can regulate steroidogenesis in rodents, as evident by reduced 
testosterone production in male fetuses of pregnant dams who were fed a 
vitamin A deficient diet (Livera et al 2004). During fetal Leydig cell 
differentiation, retinoic acid is reported to negatively regulate steroidogenesis, 





potentially via down regulation of Cyp17a1, as demonstrated in cultured cells 
from rat testes (Livera et al 2004). There are six receptors via which retinoic 
acid mediates its effects (NR1B;1,2,3 and NR2B;1,2,3), with NR2B1 in particular 
expressed in adult Leydig cells (Boulogne et al 1999). Interestingly, Nr2b1-
deficient mice die during fetal life due to cardiac defects (Sucov et al 1994) thus 
its role in adult Leydig cell development remains to be elucidated. The role for 
retinoic acid in negatively regulating steroidogenesis during fetal Leydig cell 
differentiation (Livera et al 2004) appears somewhat similar to COUP-TFII, 
which has also been proposed to negatively regulate steroidogenesis in 
differentiating fetal Leydig cells (van den Driesche et al 2012). However, the 
precise role and interplay between these factors postnatally, in the potential 
development/regulation of adult Leydig cells, remains to be elucidated. 
 
1.7.12 Macrophages 
Macrophages lie in close proximity to Leydig cells and are believed to play a role 
in adult Leydig cell function. They constitute 25% of the total interstitial cell 
population in adult rodents (Giannessi et al 2005) but have been shown to first 
appear in the fetal testis in rats at e16 (Livera et al 2006). In the absence of 
macrophages, adult Leydig cells demonstrate abnormal development (Hales, 
2002). Macrophages produce several factors which can influence Leydig cell 
steroidogenesis including macrophage derived factor (MDF) (Lukyanenko et al 
2000), interleukin-1 (IL-1) (Verhoeven et al 1988), tumor necrosis factor alpha 
(TNFα), and reactive oxygen species (ROS). Cultured immature Leydig cells 
from rats treated with IL-1 resulted in stimulation of steroid production 
(Verhoeven et al 1988). MDF, or its more recent identification as 25-
hydroxycholesterol (HC), is secreted by macrophages and was shown to 
increase 3β-HSD activity in developing Leydig cells and to stimulate 
testosterone production (Nes et al 2000, Chen et al 2002). Testosterone can also 
regulate 25-HC production in a paracrine fashion via a negative-feedback loop 
(Lukyanenko et al 2002). The importance of macrophages in Leydig cell 





development is evident from adult Leydig cell ablation/regeneration studies, in 
which macrophages were depleted from one testis prior to EDS-induced adult 
Leydig cell ablation/regeneration. Adult Leydig cells failed to regenerate in the 
absence of testicular macrophages, whereas in the contralateral testis (control 
vehicle only), adult Leydig cells regenerated normally (Gaytan et al 1994). 
Overall, this suggests macrophages play a key role in adult Leydig cell 
development.  
1.8 Steroidogenesis 
Steroidogenesis refers to the synthesis of steroid hormones, which occurs in 
steroidogenic cells of the testis, ovary, adrenal, placenta and brain (Baulieu 
1997, King et al 2002, Papadopoulos and Miller 2012). Steroid hormones are 
essential for reproductive function and homeostasis. As 95% of testosterone in 
human males is synthesised within the testis, intratesticular testosterone levels 
are ~250 times higher than in blood serum with approximately 6-7mg 
testosterone produced per day (Coffey 1988, Maddocks et al 1993). Steroid 
concentration in target tissues and body fluids is dependent on binding proteins 
e.g. sex hormone binding globulin (SHBG) and albumin. Approximately 98% of 
circulating testosterone is present in bound form, with 2% free, which 
eventually is metabolised in the liver or converted into dihydrotestosterone 
(Miller and Bose 2011). The rate of androgen production in adult Leydig cells 
must be maintained to produce the high levels of testosterone necessary for 
spermatogenesis and male health. The biosynthesis of testosterone is discussed 
in detail below, beginning with its substrate, cholesterol. 
 
1.8.1 Cholesterol transport 
The transfer of cholesterol to the outer mitochondrial membrane involves high-
affinity cholesterol binding proteins. Sterol carrier protein-2 (SCP2) was 
originally believed to be involved in this trafficking (Vahouny et al 1983, van 
Noort et al 1988), however a later study that investigated SCP2 expression in 





Leydig cells described it as membrane-bound (van Haren et al 1992) and not 
abundantly present in the cytosol as previously thought. Furthermore, SCP2 was 
recently described as having a low affinity for cholesterol (Gallegos et al 2001) 
so its role in cholesterol trafficking may not be important. The most important 
event in the transfer of cholesterol occurs between the outer and inner 
mitochondrial membranes in order to initiate steroidogenesis. A crucial player 
in this critical step is steroid acute regulatory protein, StAR (Payne and Hales 
2004, Manna et al 2009, Papadopoulos and Miller 2012) and will be described in 
the next section. Several other factors have also been described for cholesterol 
trafficking, which facilitates steroidogenesis, including peripheral 
benzodiazepine receptor (PBR) or the mitochondrial transporter protein 
(TSPO) (Fan and Papadopoulos 2013). PBR/TSPO is an 18kDA protein which 
acts on the outer mitochondrial membrane downstream from StAR, to transfer 
cholesterol into the inner mitochondrial membrane (Papadopoulos 1993, Liu et 
al 2006). Targeted deletion of PBR/TSPO in a Leydig cell mouse line resulted in 
the blockage of cholesterol transport and reduced/disrupted steroidogenesis, 
which was restored following PBR/TSPO replacement (Li et al 2001).  
 
1.8.2 Steroid Acute Regulatory protein (StAR) 
StAR plays a crucial step for the regulated delivery of cholesterol to the inner 
mitochondrial membrane for steroidogenesis (Clark et al 1994, Bose et al 1996, 
Miller et al 1999, Stocco 2001, Bose et al 2002, Stocco and Clark 2006,). During 
embryonic development, StAR transcription in fetal Leydig cells is regulated by 
SF-1 (Clark et al 1995). The proximal promoter of StAR is important for 
regulation of StAR transcription and this region is highly conserved across 
species (Manna et al 2009). The rate of transcription of StAR in adult Leydig 
cells is regulated by LH, which under normal conditions stimulates the 
production of a 37kDA protein, StAR (Stocco and Sodeman 1991, Clark et al 
1994, 1995, Manna et al 2009, Lee et al 2013). More recently, histone 
modifications in the proximal promoter region of StAR have been shown to play 





a key role in StAR transcription (Silverman et al 1999, LaVoie et al 2005, Lee et 
al 2013) and will be discussed later in this review.  
StAR creates a link bridge or a hydrophobic tunnel on the outer mitochondrial 
membrane allowing for cholesterol transfer from its sterol-binding pocket into 
the inner mitochondrial membrane (Tsujishita and Hurley 2000). Continuous 
StAR synthesis is required to maintain the high levels of steroid production in 
the testis. LH stimulation induces the phosphorylation of StAR on Ser 195 by 
protein kinase A, which doubles its activity and is essential for optimal 
steroidogenesis (Arakane et al 1997, Papadopoulos and Miller 2012). The 
activity of StAR in promoting steroidogenesis is proportional to the length of 
time spent on the outer mitochondrial membrane (Bose et al 2002). 
The indispensable role for StAR is clearly evident from earlier clinical and 
rodent studies (Lin et al 1995, Bose et al 1996, Caron et al 1997, Hasegawa et al 
2000). In mice with mutated/deleted StAR, an accumulation of cholesterol in 
steroidogenic Leydig and adrenal cells, combined with a failure of steroid 
production was evident, which is identical to the human condition of lipoid 
congenital adrenal hyperplasia (CAH). Thus, lipoid CAH was shown to be caused 
by mutation/inactivation of the StAR gene (Lin et al 1995, Miller, 1997, Caron et 
al 1997, Stocco 2002). As previously mentioned, other proteins apart from StAR 
are also involved in cholesterol transfer e.g. those encompassing a 
"transduceosome" (Papadopoulos and Miller 2012, Fan and Papadopoulos 
2013). PBR/TSPO is suggested to interact with StAR for normal cholesterol 
transfer (Hauet et al 2005), however the significance of the interplay between 
this protein and others to StAR, is not yet conclusive. Although PBR/TSPO is 
present and functions normally in StAR mutant mice, its function appears 
insufficient to support the rapid level of cholesterol transport needed for 
androgen production. Thus, the external genitalia were not virilised in Star 
mutant mice and adrenal steroidogenesis was absent, which resulted in death 
(Lin et al 1995, Caron et al 1997). To circumvent the previous lethality, StAR 
knockout mice were kept alive by corticosteroid replacement and analysis of the 





Leydig cells revealed limited androgen production (Hasegawa et al 2000). 
Although StAR is crucial for the acute steroidogenic responses, in its absence, 
steroidogenesis continues at about 14% of its previous rate (Lin et al 1995). 
Overall, it highlights that StAR is crucial for the "rapid" transport of cholesterol 
which is essential for the acute regulation of steroid synthesis, as described in 
the next section.  
 
1.8.3 Testicular testosterone biosynthesis 
Following hormonal stimulation by LH in adult Leydig cells (Section 1.7.1), 
steroidogenesis is regulated by either a chronic or acute response. The chronic 
or long term response refers to an increase in transcription of steroidogenic 
genes encoding enzymes involved in the steroidogenic pathway, mainly 
CYP11a1/P450scc (Simpson and Waterman 1988). The acute response is an 
essential one, due to the limited steroid storage by steroidogenic cells (Miller 
and Auchus 2011). Acute or short term steroid production requires the rapidly 
synthesized protein StAR, to perform a vital step in steroidogenesis, namely to 
transfer cholesterol from the outer to the inner mitochondrial membrane, as 
previously described. Steroidogenesis commences with mobilisation and 
delivery of the steroid hormone substrate, cholesterol (C27). Cholesterol is either 
1) synthesised de novo from acetate in the endoplasmic reticulum (Ferguson 
1963) which is coordinated by sterol regulatory element binding proteins 
(SREBPs), 2) taken up from plasma lipoprotein stores (high density lipoprotein 
(HDL) or low (L)DL) or 3) taken up from intracellular lipid droplets containing 
cholesterol esters (Miller and Bose 2011). Rodents use cholesterol from 
circulating HDL, while humans use LDL, as their principal source of cholesterol. 
Active or free cholesterol is able to move from the plasma membrane to the 
intracellular membranes (Miller and Auchus 2011), as cholesterol is insoluble in 
water (Haberland and Reynolds 1973).  
Steroidogenic enzymes can be subdivided into two groups; cytochrome P450 
enzymes, a term encompassing the oxidative enzymes (CYP11A1/P450scc, 





CYP17A1/P450c17, CYP19A1/P450arom) and hydroxysteroid dehydrogenase 
enzymes (3β-HSD and 17β-HSD). The P450 enzymes were named from their 
yellow pigmentation in solution due to maximal light absorption at 450nm 
(Miller and Bose 2011). P450 genes are now formally termed CYP genes (Miller 
and Auchus, 2011). P450 and the HSD enzymes receive electrons from 
nicotinamide adenine dinucleotide phosphate (NADPH) to catalyze 
hydroxylation and cleavage of their substrate (Sherbet et al 2007). 
Once StAR has promoted the movement of the insoluble steroid substrate 
cholesterol into the inner mitochondrial membrane, steroidogenesis begins 
when CYP11A1 cleaves the side chain of cholesterol, forming soluble 
pregnenolone (C21) (Koritz, 1970, Simpson, 1979). Soluble pregnenolone can 
then either be converted to progesterone via 3β-hsd, or converted to 17α-
hydoxypregnenalone by CYP17A1 (Zuber et al 1986). The formation of 
androstenedione by CPY17A1 occurs within the endoplasmic reticulum (Zirkin 
and Chen 2000). The enzyme 3β-HSD can convert pregnenolone into 
progesterone and dehydroepiandrosterone to androstenedione, and the 
preference of either of these pathways (Δ5 to Δ4) is species-dependent.  
The preferred route of testosterone synthesis differs between species, i.e. 
CYP17A1 will use the Δ5 pathway for 17a-hydroxypregnenolone as a substrate 
in human and bovine (Fluck et al 2003, Rey and Grinspon 2011), whereas in 
rodents, CYP17A1 will use the Δ4 pathway for 17a-hydroxyprogesterone as a 
substrate (Brock and Waterman 1999). There are several isoforms of 17β-HSD 
with type 3 (17β-HSD) found in adult Leydig cells (Miller and Bose et al 2011) 
but located within the seminiferous cords in fetal mouse testis (O'Shaughnessy 
et al 2000). The expression of 17β-HSD3 within fetal seminiferous cords, has so 
far, not been shown in any other species, so its wider significance is unknown. 
In adulthood, the enzyme 17β-HSD3 marks the final step in steroidogenesis by 
which androstenedione is converted to testosterone. Deficiency in 17β-HSD3 
represents one cause of 46,XY disorders of sex development (DSD) in humans 
(Werner et al 2012). Presently, there are 27 known mutations in the 17β-HSD3 





gene, which result in severe under-masculinisation (Galdiero et al 2013). 
Defects in 17β-HSD3 in humans is the most common androgen synthesis 
disorder and cases are reported world-wide (Mendonca et al 2010). Patients 
present with ambiguous or female-like genitalia and intra abdominal/inguinal 
testes (Mendonca et al 2010).  
Testosterone can be metabolised into either dihydrotestosterone (DHT) by 5α-
reductase or oestradiol by CYP19A1 (Normington and Russell 1992, 
Papadopoulos and Miller 2012). A schematic of testosterone biosynthesis is 
shown in Figure 1.4 below. 
 
Figure 1.4 Testosterone biosynthesis in the Leydig cell. Following the transport of 
cholesterol by StAR, CYP11A1 metabolises cholesterol into pregnenolone which is 
then subjected to degradation by either of two categories of enzymes; Cytochrome 
450 (depicted in blue) and the hydroxydehydrogenase enzymes (depicted in green). 
The action by 17β-HSD3 is the final step in steroidogenesis, forming the end product 
testosterone. Testosterone can be metabolised into DHT or oestradiol. 





1.9 Regulation of steroidogenesis 
Steroidogenesis in Leydig cells occurs if the following criteria are met; 1) 
integrity of the LHR in order to initiate the signalling pathway 2) availability of 
the steroid hormone precursor cholesterol 3) integrity of transporters of 
cholesterol from stores to mitochondria 4) integrity of mitochondrion 5) 
steroidogenic enzymes present at normal levels. Testosterone biosynthesis is 
regulated by the hypothalamic pituitary gonadal (HPG) axis, as described below. 
 
1.9.1 Hypothalamic Pituitary Gonadal axis 
The hypothalamic-pituitary-gonadal axis refers to a significant pathway for 
steroidogenesis and spermatogenesis. It is composed of three components; 
gonadotrophin releasing hormone (GnRH) neurons which project from the 
hypothalamus, the gonadotroph cells in the anterior pituitary and the testicular 
Sertoli and Leydig cells (Handa and Weiser 2013). The HPG axis controls the 
release of FSH, required for Sertoli cell proliferation and spermatogenesis and 
LH, which regulates steroidogenesis in adult Leydig cells. Gonadotrophin 
releasing hormone (GnRH) is transported from the hypothalamus to the 
pituitary via the hypothalamic-hypophyseal portal blood system and causes the 
release of FSH and LH from the gonadotroph cells (Matsumoto and Bremner 
1984). In terms of steroidogenesis, a negative feedback system regulates 
testosterone production either directly via testosterone or indirectly via its 
metabolites dihydrotestosterone and oestradiol, which act to inhibit the 
secretion of GnRH and thus the release of LH. In the case of high levels of 
testosterone, the normal response is low LH. Conversely, where low levels of 
testosterone occur, LH is usually elevated, a condition termed “primary 
hypogonadism” (Handa et al 1985, Rey et al 2013). 
 
1.9.2 Other mechanisms controlling Leydig cell function 
Several studies have described a pathway regulating steroidogenesis in Leydig 
cells, which is independent of the pituitary and occurs between the 





paraventricular nucleus and the testis. These studies identify a neural based 
regulatory pathway, which affects steroidogenesis via β-adrenergic receptor 
activation in the brain (Gerendai et al 1995, Turnbull and Rivier 1997, Ogilbe 
and Rivier 1998). Leydig cell responsiveness to gonadotrophins was rapidly 
inhibited following intracerebro-ventricular injection of IL-1β or corticotrophin 
releasing factor (CRF), which also occurred when LH release had been blocked, 
thus suggesting a pituitary-independent pathway (Ogilvie et al 1998, Selvage 
and Rivier 2003) in rats. This resulted in a blunted response of testosterone 
production to hCG stimulation. Furthermore, StAR protein expression was 
reduced in Leydig cells which might have contributed to the reduced 
steroidogenesis reported. This defect could be partially restored via 
administration of a water permeable cholesterol to bypass the requirement of 
StAR (Ogilvie et al 1999).  
A factor which has been shown to regulate the HPG axis and thus regulate adult 
Leydig cell function is 'kisspeptin', which itself is regulated by a steroid negative 
feedback pathway (Smith 2013). Kisspeptin acts via its receptor (Gpr54) in the 
arcuate nucleus and the anteroventral periventricular nucleus of the 
hypothalamus and stimulates GnRH release (Kirilov et al 2013).  This has 
previously been shown to increase levels of LH and testosterone in rats 
(Patterson et al 2006) and rhesus monkeys (Seminara et al 2006). Mutant mice 
with a neuron-specific deletion of Gpr54 are infertile with significantly smaller 
testes, as compared to wild-type (Kirilov et al 2013). Targeted insertion of 
Gpr54 into GnRH neurons of the mutant mice rescued the normal kisspeptin 
stimulatory action upon GnRH neurons (Kirilov et al 2013).  
Nitric oxide (NO) has also been reported to modulate testosterone production 
via paracrine signalling between adult Leydig cells and macrophages. NO is 
formed via the oxidation of L-arginine by nitric oxide synthase (NOS) (Laubach 
et al 1995). Isoforms of NOS are present in the testes of human (Davidoff et al 
1995), horse (Ha et al 2004), pig (Kim et al 2007) and rodents (O'Bryan et al 
2000, Jarazo-Dietrich et al 2012). One of the NOS isoforms, inducible nitric oxide 





synthase (iNOS), is expressed in testicular cells including adult Leydig cells 
under normal conditions (Davidoff et al 1995, O'Bryan et al 2000, Kon et al 
2002, Lee and Cheng 2004). It has been proposed that NO produced from iNOS 
activity, can modulate testosterone production in adult Leydig cells, by 
inhibiting steroidogenesis in the mouse (Adams et al 1994, Pomerantz & Pitelka 
1998, Weissman et al 2005). The latter study showed that the generation of NO 
specifically occurs in testicular macrophages, which then inhibits 
steroidogenesis in Leydig cells via a paracrine action (Weissman et al 2005). 
1.10 Androgen receptor expression in the testis 
In adult human males, intratesticular androgen levels range between 340-
2000nM compared to 8.75-35nM in serum (Walker 2011) with a similar 
elevation between intratesticular levels and serum evident in rodents 
(Maddocks et al 1993). Androgen receptor (AR; also called NR3CA) expression 
in fetal rat testis is evident in interstitial cells at e17 (Majdic et al 1995), 
although the identity of these AR+ non-steroidogenic interstitial cells is still 
unclear. At e19, e21.5 and pnd 5, AR expression is localised to PTM and non-
steroidogenic interstitial cells (Majdic et al 1995). The authors suggest these 
cells may represent adult Leydig progenitor cells, although extensive 
morphological and marker analysis is needed to investigate this further (Eacker 
and Braun 2007). 
Androgen signalling is mediated via the AR, which is present in specific 
testicular cells, including adult Leydig cells throughout their maturation, as 
previously described. Testosterone signalling via germ cells is not required for 
spermatogenesis, as a functional AR is absent from germ cells (Tsai et al 2006, 
Smith and Walker 2014). Testosterone supports spermatogenesis therefore via 
ARs present in other testicular cells. AR expression is localised to Sertoli cells 
(DeGendt et al 2004, Rey et al 2009, Willems et al 2010, O'Shaughnessy et al 
2010), peritubular myoid (PTM) cells, (Welsh et al 2009, 2012), arteriole 
smooth muscle (Bremner et al 1994, Welsh et al 2010), vascular endothelial 
cells (O'Hara and Smith 2012) and adult Leydig cells (Bremner et al 1994, You 





and Sar 1998, DeGendt et al 2005). The role of AR in adult Leydig cells will be 
discussed in the following sections.  
In postnatal life, androgens exert their largest effect on adult Leydig cell 
development through direct action on Leydig cells themselves (De Gendt et al 
2005). Isolated progenitor Leydig cells from rats at pnd 21, express mRNA for 
AR, and acquire increasing AR mRNA and protein expression during their 
differentiation into immature adult Leydig cells at pnd 35 (Shan et al 1992, 
1995). Once immature adult Leydig cells undergo a single division into mature 
adult Leydig cells, AR levels decline and both gene and protein expression levels 
in mature adult Leydig cells are lower than in progenitor or immature adult 
Leydig cells (Eacker and Braun 2007). To investigate the hormonal regulation of 
developing adult Leydig cells, isolated progenitor and immature adult Leydig 
cells were treated with a GnRH antagonist (NalGlu) which resulted in a 
reduction in mRNA levels and protein expression of AR. Administration of 
exogenous LH or testosterone following GnRH inhibition, caused an increase in 
AR protein expression in progenitor and immature, but not mature, adult Leydig 
cells (Shan et al 1995, 1997). Thus, the postnatal maturation of adult Leydig 
cells requires hormonal stimulation by testosterone. In order to alter gene 
expression in specific target cells, androgens bind to their receptors and elicit a 
signalling response, as described below. 
 
1.10.1 Androgen receptor gene 
The AR is encoded by a single gene on the X chromosome (Brown et al 1989), 
thus any mutation in AR affects males, whereas females transmit the AR 
mutation to the next generation. The AR gene is conserved across species (Tilley 
et al 1990, Lindzey et al 1993) and consists of four structurally and functionally 
distinct domains. These include; a highly conserved central DNA binding 
domain (DBD) encoded by exons 2 and 3, a hinge region which connects the 
DBD to a C-terminal ligand-binding domain (LBD) encoded by exons 4-8, and an 
N-terminal domain (NTD) encoded by exon 1 (Brinkmann et al 1989, McLachlan 





et al 2002, Smith and Walker 2014). There are two transcriptional activation 
domains (AF-1 and 2) (Matsumoto et al 2008). The interaction between the 
amino/carboxyl termini of the AR (N/C interaction) is essential for its 
stabilisation, as induced by testosterone. Disruption of the N/C interaction due 
to naturally occurring AR mutations, have been identified in patients with 
androgen insensitivity syndrome (AIS), highlighting its crucial role in normal 
androgen signalling (Thompson et al 2001, Ghali et al 2003, Jaaskelainen et al 
2006). Previous studies have shown that adult humans with a mutation in the 
AR gene have generally normal-high testosterone and elevated LH levels 
(Madden et al 1975, Eacker and Braun 2007). 
 
1.10.2 Androgen signalling pathways 
Steroids circulate in blood either freely or bound to steroid hormone binding 
globulin (SHBG) (or also called androgen binding protein (ABP)) or albumin. As 
androgens are small lipid soluble steroid hormones, they enter directly through 
the plasma membrane of target cells to reach the AR. Testosterone can be 
converted by 5α-reductase into DHT, as previously described, and its actions are 
also mediated by AR. Unliganded AR is located in the cytoplasm of cells bound to 
heat-shock chaperone proteins (HSP) e.g. HSP 70 and 90 (Pratt and Toft 1997, 
Tyagi et al 2000). These chaperones stabilise the conformation of the LBD and 
assist in the maintenance of a high affinity AR structure (Fang et al 1996), 
essential for an efficient response to androgens.  
 
1.10.3 Genomic androgen signalling pathway 
Once the androgen ligand has bound to AR, the complex undergoes a 
conformational change and releases itself from the attached heat-shock 
proteins. This change is essential to reveal the DBD region, necessary for 
interaction with AREs on target genes. AR translocates to the nucleus where it 
binds as a dimer (homodimerisation) to specific regions of the DNA promoter 
region (DBD) of AR target genes, termed androgen response elements (ARE) 





(Chang et al 1995, Kimura et al 2007). Thus, AR homodimerisation and binding 
to AREs promotes transcriptional activation or repression of specific target 
genes. The highly conserved DBD region contains two zinc finger domains 
(Schoenmakers et al 2000), of which the second zinc finger domain and the N/C 
interaction mediate homodimerisation of the AR. Androgen-dependent 
homodimerisation then recruits co-activator/repressor proteins and protein 
complexes which alter gene expression (Nemoto et al 1994, Smith and Walker 
2014). This pathway of action has been termed the "genomic or classical" 
pathway (Figure 1.5) and can take up to 60 minutes to modulate gene 
expression and produce proteins (Shang et al 2002). 
 
1.10.4 Non-genomic androgen signalling pathways 
Recently identified alternative "non-genomic" pathways of testosterone action 
have been identified. In Sertoli cells, this pathway involves testosterone binding 
to AR at the plasma membrane which results in rapid activation of Src tyrosine 
kinase (Cheng et al 2007), as shown in Figure 1.5. This then phosphorylates and 
stimulates the epidermal growth factor receptor (EGFR), followed by 
stimulation of the MAP kinase cascade, inducing cAMP response element-
binding protein (CREB) phosphorylation and transcription within one minute 
(Cheng et al 2007, Walker 2010). Furthermore, cells expressing AR and ER 
which are stimulated by either androgen or oestradiol can activate Src (via 
induction of an ERα/β-AR-Src ternary complex) which stimulates the Src/Raf-
1/Erks signalling pathway (Figure 1.5) and can result in cell proliferation, as 
shown in a prostate cancer cell line (Migliaccio et al 2000). Antagonists to either 
steroid hormone can inhibit this pathway. This in vitro study used co-
transfected cells with AR and ER, and showed that stimulation by either 
androgen or oestradiol resulted in more efficient/stronger Src activation, in 
comparison with cells transfected with only AR or ER alone. Src interacts with 
ERα/β through its SH2 domain, and AR through its SH3 domain (Migliaccio et al 
2000). Thus either steroid (androgen or oestradiol), in the presence of both AR 





and ERα/β, can enhance Src kinase activity via binding of AR to SH3 and ERα/β 
to SH2, of the 'inactive' Src. This induces a conformational change, resulting in 
an 'active' form of the Src complex which then stimulates the Src/Raf-1/Erks 
pathway, as mentioned above. This suggests that an important balance and 
crosstalk exists between AR and ER for non-genomic signalling. Whether this 
pathway is utilised in the fetal or adult testis has not been investigated. 
The second pathway of non-genomic testosterone action has been 
demonstrated in cultured Sertoli cells from pre-pubertal rats (Lyng et al 2000, 
Loss et al 2011). Testosterone can activate the hydrolysis of PIP2 by 
phospholipase C (PLC), which causes cell depolarisation and results in an influx 
of Ca2+ (Loss et al 2011), as depicted in Figure 1.5. It is not yet known whether 
AR or another receptor is required to activate these pathways which, unlike 
genomic androgen signalling, can occur within seconds (Smith and Walker 
2014). 
   
 
 






Figure 1.5 Androgen signalling pathways. Genomic androgen signalling is denoted 
in the blue arrows. Non genomic androgen signalling is shown in black arrows 
(Adapted from Walker 2011). 
1.11  Androgen deficiency 
Androgen production commences in the human fetal male between 7-8 weeks 
gestation, peaks between 12-14 weeks and then slowly declines (Prince 2001). 
In the rat, testosterone is first detected at e15.5 and peaks before birth at e18.5 
(MacLeod et al 2010). Androgen signalling in the MPW is pivotal for normal 
phenotypical male development (Welsh et al 2008). Insufficient fetal androgen 
production or exposure interferes with masculinisation and results in disorders 
of sex development (DSD), which at birth manifests as ambiguous genitalia (Rey 





and Grinspon, 2011, Rey et al 2012). Early fetal-onset hypogonadism results in 
'dysgenetic DSD' and affects both Leydig and Sertoli cells whereas 'non-
dysgenetic DSD' affects either Sertoli or Leydig cells (Josso et al 2012). In 
humans, insufficient androgen production as a result of fetal Leydig cell 
dysfunction (LH/hCG receptor mutations or defects in steroidogenic enzymes) 
results in undervirilization and cryptorchidism. Such patients have normal 
regression of Müllerian ducts due to normal functioning of Sertoli cells secreting 
AMH. During puberty, these patients display low-non detectable testosterone 
levels but LH is elevated (Mendonca et al 2010, Rey et al 2012). 
 
1.11.1 Androgen receptor mutations 
The term 'testicular feminisation syndrome' was put forward in the early 1950's 
to describe 46,XY patients who presented as females with bilaterally 
cryptorchid testes producing "oestrogen-like hormones" (Morris, 1953). This is 
now known as complete androgen insensitivity syndrome (cAIS) (Quigley et al 
1995, Hughes et al 2012). Mutations in the AR gene can prevent AR-mediated 
signalling which results in 'androgen insensitivity syndrome' (AIS). In humans, 
46,XY individuals with AIS present with female genitalia but incomplete testes 
descent and with normal and/or high testosterone production (MacLean et al 
1995, Quigley et al 1995, Hughes et al 2012). Complete (c)AIS individuals 
present with complete undermasculinisation of the external genitalia at birth, 
abnormal pubertal sexual development and infertility during adulthood 
(Gottlieb et al 2011). Analysis of hormone levels showed normal-elevated 
testicular testosterone and increased LH levels (Brinkmann, 2001). Partial 
(p)AIS results in varying degrees of masculinisation of the external genitalia e.g. 
micropenis, hypospadias or ambiguous genitalia, whereas mild (m)AIS 
individuals present with typical male external genitalia but gynaecomastia at 
puberty or infertility later in life (Gottlieb et al 2011, Hughes et al 2012). There 
are more than 800 X-linked AR gene mutations reported in AIS patients, with 
the majority affecting the ligand binding domain of the AR gene (Hughes et al 





2012). A recent study found a higher number of CAG repeat sequences in the AR 
gene was associated with increased risk of hypospadias (Adamovic et al 2012). 
High number of CAG repeat sequences is also indicative of Kennedy's disease in 
humans in which AIS is a common additional disorder  (Kerkhofs et al 2009). 
 
1.11.2 Tfm mouse model 
The first mouse model for human androgen insensitivity was described in 1970 
and was termed the 'testicular feminisation' (Tfm) mouse model (Lyon and 
Hawkes, 1970). Genetically XY male 'Tfm mice' are infertile, have smaller 
cryptorchid testes (in the inguinal region), and are phenotypically female as 
evident by the external genitalia, which depicts a similar phenotype to cAIS 
humans (Kerkhofs et al 2008). As cytosolic AR protein expression was absent, 
but DHT and testosterone concentrations could still be detected, this suggested 
that the resulting phenotype arose from a defect in AR, instead of a lack of 
androgen production (Gehring and Tomkins, 1974). More specifically, Tfm mice 
are characterised by a frameshift mutation in the AR gene resulting in non-
functioning AR. Results from Tfm mice show that, of the two generations of 
Leydig cells, (fetal and adult), it is the adult Leydig cell population which fails to 
differentiate (Murphy et al 1994, O’Shaughnessy et al 2002, Merlet et al 2007). 
 
1.11.3 Androgen Receptor Knock Out 
To investigate the role of androgens in testicular cells, the Cre-loxP system has 
been invaluable for assessing cell-specific function by targeting AR deletion in 
specific testicular cells via a specific promoter-driven Cre. This provides an 
excellent in vivo model to investigate human cAIS as both have an inactive AR, 
and present as phenotypically female but with cryptorchid testes (Verhoeven et 
al 2010). An advantage of using this over Tfm mice is that Cre/loxP technology 
inactivates the AR but keeps the reading frame intact so that the mutant AR can 
bind its ligand but not DNA, thus target gene transcription is not regulated.  To 
date, there have been five transgenic mouse models with ubiquitous knockout 





of AR (ARKO) generated, which differ by which exon is targeted or promoter 
utilised (Kerkhofs et al 2009, Verhoeven et al 2010, Smith et al 2014). The 
phenotype of the Tfm and ARKO mouse models are comparable, both having 
greatly reduced testis size, cryptorchidism, absence of Wolffian duct derived 
structures, a vaginal opening, and increased LH levels with normal/reduced 
testosterone levels (Kerkhofs et al 2009). Exon 3 encodes the second zinc finger 
of the DNA binding domain of the AR protein (Berg et al 1989). Using a murine 
model with deletion of exon 3 of the AR gene (Notini et al 2005) models a 
population of human CAIS patients who present with a deletion of the third 
exon of AR (Quigley et al 2002). Investigation of adult Leydig cell development 
and function in ARKO mice revealed a reduction in testosterone levels (Yeh et al 
2002) and increased LH (DeGendt et al 2005), as compared to wild-type. The 
number of adult Leydig cells was severely reduced (DeGendt et al 2005, 
O'Shaughnessy et al 2012), again implicating a role for androgen signalling in 
adult Leydig cell development. 
1.12 Adult Leydig cell specific ARKO  
Androgen signalling via the AR in adult Leydig cells regulates their development 
and maturation, final population number, and controls steroidogenic gene 
expression (De Gendt et al 2005, Eacker and Braun 2007). While the role of AR 
in Leydig cells has been derived from ARKO mouse models, this does not 
elucidate the specific role of AR signalling within Leydig cells, as AR is ablated in 
all cell types and results in potentially confounding changes such as 
cryptorchidism (Smith and Walker 2014). One relatively recent attempt to 
target AR in Leydig cells, used an anti-Müllerian hormone receptor 2 (AMHR2)-
Cre. Although spermatogenesis was blocked in these animals and Leydig cells 
had a reduced steroidogenic capacity and decreased testosterone production 
(Xu et al 2007), this model cannot be deemed 'specific to adult Leydig cells' due 
to the Cre-promoter used, which is also expressed in Sertoli cells (Verhoeven et 
al 2010, Smith and Walker 2014). Thus, the precise role for AR signalling in 
adult Leydig cells remains to be fully elucidated, but use of other AR knockout 





models (SCARKO, ARKO, PTM-ARKO) are useful tools to investigate adult Leydig 
cell development, and are described below. 
 
1.12.1 Sertoli cell specific androgen receptor knock out 
Sertoli cell-specific ARKO (SC-ARKO) male mice are generated by crossing exon 
2-floxed AR mice with an AMH/Mis promoter-driven Cre (specific for Sertoli 
cells) (De Gendt et al 2004). This method allows investigation of the cell specific 
role of AR in Sertoli cells and how this might affect adult Leydig cell 
development. Compared to ARKO and Tfm mice, SCARKO males have a normal 
external male phenotype, and internal male accessory sex organs (epididymis, 
vas deferens, seminal vesicles and the prostate). Unlike the undescended and 
smaller testes in cryptorchid ARKO and Tfm mice, testes from SCARKO mice are 
normally descended, but reduced in size. SCARKO males are infertile with 
arrested spermatogenesis at the pre-meiotic stage (De Gendt et al 2004, Tan et 
al 2005). This suggests a role for AR signalling in germ cell meiosis and 
spermatogenesis, and also maintenance of cell-cell interactions between Sertoli 
and germ cells (Denolet at al 2006). As the number of Sertoli cells is significantly 
decreased in Tfm and ARKO models (De Gendt et al 2004), this might suggest 
that AR signalling via Sertoli cells is important for determination of Sertoli cell 
number. However quantification of Sertoli cells in SCARKO mice, demonstrated 
AR signalling via Sertoli cells was dispensable for final Sertoli cell number and 
maturation (De Gendt et al 2004, Tan et al 2005, Lim et al 2009, O'Shaughnessy 
et al 2012). Thus, AR must signal via another testicular cell type to regulate the 
final number of Sertoli cells.  
In relation to adult Leydig cells, SCARKO mice have an approximate 40% 
reduction in adult Leydig cell number, evident from pnd 20 onwards, although 
their function was not impaired (De Gendt et al 2005). This suggests that adult 
Leydig cell number is regulated to some degree by AR signalling via Sertoli cells, 
but that androgens regulate Leydig cell function via cells other than Sertoli cells. 
In fact, steroidogenic gene expression in adult Leydig cells of SCARKOs was 





upregulated (e.g. Cyp11a1, 3β-HSD1 and Cyp17a1) which may suggest a 
compensatory mechanism to counteract for the 40% reduction in adult Leydig 
cells (De Gendt et al 2005). However, a more recent study that quantified adult 
Leydig cells in a SCARKO mouse model using the optical disector stereological 
method, revealed comparable numbers of adult Leydig cells between wild-type 
and SCARKO (O'Shaughnessy et al 2012). This difference may be a reflection of 
different stereological methods or different mouse strains, utilised between 
studies. In a transgenic mouse model of prematurely induced AR activation in 
Sertoli cells, the number of both fetal and adult Leydig cells was found to be 
reduced (Hazra et al 2013). Furthermore, adult Leydig cells displayed advanced 
maturation and increased androgen production per Leydig cell in order to 
maintain normal testosterone levels, while LH remained unchanged (Hazra et al 
2013). Thus, AR signalling via Sertoli cells appears to play an important role in 
adult Leydig cell development. 
 
1.12.2 Peritubular myoid cell androgen receptor knock out 
The peritubular myoid (PTM) cells lie in close proximity to Sertoli cells and are 
involved in AR signalling via Sertoli cells to mediate spermatogenesis. Knockout 
of AR in 40% of PTM cells (PTM-ARKO model) demonstrated that males were 
infertile and azoospermic with reduced Sertoli cell function (Welsh et al 2009). 
In relation to fetal Leydig cells, there was no evidence for abnormal 
steroidogenesis or protein expression, indicating that development of the fetal 
Leydig cell generation, occurs independent of androgen signalling via AR in PTM 
cells. Although the number of adult Leydig cells in PTMARKO mice was 
comparable to wild-type (Welsh et al 2009), Leydig cells displayed reduced 
function, evident by decreased mRNA for 3β-hsd6, and an increase in CYP17a1 
and evidence for compensated adult Leydig cell failure, evident by increased LH 
with normal intratesticular testosterone levels (Welsh et al 2009, 2012).  





1.13 Adult Leydig cell ablation/regeneration model 
Ethane dimethane sulphonate (EDS) is an alkylating sulphonic acid ester used to 
specifically ablate mature adult Leydig cells in rats, which results in a short 
period of sterility for 2-8 weeks while having few other toxicological or adverse 
effects (Bartlett et al 1986, Sharpe et al 1990, Teerds et al 1999). Following a 
single injection of 75mg/kg EDS, mature adult Leydig cells are ablated which 
results in the absence of testosterone production post-EDS, which returns to 
pre-injection levels after 3-7 weeks, coincident with redeveloping adult Leydig 
cells (Teerds et al 1999). Weight of the testes, seminal vesicles and prostate are 
reduced as a consequence of reduced testosterone production. Numbers of 
regenerating adult Leydig cells are restored to their pre-injection levels, after 
approximately 5-6 weeks post-EDS injection (Teerds and Rijintjes, 2007).  
EDS can exert its cytotoxic effect on other cell types e.g. the parenchymal cells of 
the adrenal cortex (Plecas et al 1997), but its main cytotoxic targets are mature 
adult Leydig cells. The counterpart in females to adult Leydig cells in males, are 
steroidogenic ovarian theca cells, however EDS did not affect the thecal cells 
(Smart et al 1990). Interestingly, EDS does not ablate progenitor/immature 
Leydig cells, as shown in studies in which EDS was administered to prepubertal 
rats (Kelce et al 1991). It is still unknown precisely how EDS specifically induces 
adult Leydig cell death but the biosynthesis of testosterone is inhibited as 
steroidogenic activity is severely reduced (Stocco and Clark 1996), which 
coincides with an increase in intracellular glutathione levels (Kelce and Zirkin 
1993). The majority of mature adult Leydig cells become apoptotic 24 hours 
post-EDS, evident by chromatin condensation and nuclear fragmentation, along 
with the presence of apoptotic proteins Fas and Fas-ligand, which cleave pro-
caspase3 into active-caspase 3, a known apoptotic marker (Taylor et al 1999, 
Kim et al 2000). EDS is an invaluable tool to investigate adult Leydig cell 
regeneration, as it recapitulates normal adult Leydig cell development. 
Furthermore, progenitor adult Leydig cells can be investigated in this model, 
prior to their differentiation into newly developing adult Leydig cells. 





1.14 Di (n-butyl) phthalate 
Di (n-butyl) phthalate (DBP) is a phthalate ester which has wide applications in 
plastics but is also used in some cosmetics and medications (Hu et al 2009, 
Martinez-Arguelles et al 2013). An earlier study that investigated the effects on 
the F1 generation of dams exposed to DBP in their diet, highlighted the 
significance of exposure during gestation, as opposed to adulthood. DBP-
exposed F1 male offspring exhibited abnormal testes and reproductive tract 
development along with decreased sperm production in adulthood (Wine et al 
1997). Thus, DBP disrupts fetal testis development and results in a variety of 
reproductive disorders (Albert and Jegou 2013), which can include; 
malformations of the epididymis, vas deferens, seminal vesicles or prostate 
(Mylchreest et al 1998), retained nipples (Foster, 2006), decreased AGD 
(Mylchreest et al 1998, van den Driesche et al 2012), hypospadias (Mylchreest 
et al 1998), cryptorchidism (McKinnell et al 2005). These hallmarks are a result 
of DBP-induced inhibition of fetal Leydig cell function e.g. testosterone and Insl3 
production.  
The primary mechanism via which DBP exerts its effects on fetal Leydig cells is 
still unclear but DBP exposure clearly inhibits a key player in the transport of 
cholesterol to initiate steroidogenesis, StAR (Clark et al 1995, Shultz et al 2001, 
Manna et al 2009, Papadopoulos and Miller 2012, van den Driesche et al 2012), 
as well as repression of steroidogenic genes encoding enzymes involved in the 
steroidogenic pathway e.g. Cyp11a1, 3β-hsd1, Cyp17a1 (Barlow et al 2003, 
Lehmann et al 2004, Thompson et al 2004, Plummer et al 2007, van den 
Driesche et al 2012, Desdoits-Lethimonier et al 2012). A large gene analysis 
study which investigated the effects of fetal rat exposure to different phthalates 
between e12-e19, showed that the most marked disruption involved DBP 
disruption of steroidogenic pathways and cholesterol transport (Liu et al 2005). 
As a consequence, fetal exposure to DBP significantly lowers intratesticular 
testosterone levels in the rat (Mylchreest et al 1999, Scott et al 2008, van den 
Driesche et al 2012). The number of fetal Leydig cells is unaltered by fetal DBP-
exposure, rather their cytoplasmic volume is reduced (van den Driesche et al 





2012). A study that compared steroidogenesis in the fetal testis and adrenal 
gland in the rat following fetal DBP exposure, showed that steroidogenic gene 
expression in the adrenal gland was unaltered whereas there was a rapid 
change in the fetal testis e.g. repressed transcription of StAR, Cyp11a1, Cyp17a1 
(Thompson et al 2005), thus demonstrating DBP-induced fetal Leydig cell 
dysfunction. An obvious hallmark of fetal DBP-exposure is the occurrence of 
large focal areas of fetal Leydig cell aggregates (Mahood et al 2005, Lin et al 
2008, van den Driesche et al 2012). Moreover, ectopic Sertoli cells form within 
these Leydig cell aggregates and manifest postnatally, as focal areas of 
dysgenesis containing malformed seminiferous tubules, Sertoli cell only tubules 
or tubules containing entrapped Leydig cells (Hutchinson et al 2008).  
Long term effects of fetal DBP exposure in rats were observed at 6, 12 and 18 
months of age, which included male reproductive tract abnormalities and 
Leydig cell dysgenesis (Barlow et al 2004). A recent study which investigated 
the effects of fetal DBP-exposure on adult rats, showed a reduction in testicular 
3β-HSD and17β-HSD enzymatic activity, associated with compensated adult 
Leydig cell failure (Giribabu et al 2012), indicating an altered/abnormal 
steroidogenic pathway throughout postnatal life as a result of fetal exposure to 
DBP. 
The purpose of exposing fetal rats to DBP during development and thus altering 
androgen production is to induce a TDS-like syndrome as evident in man, which 
similarly results in cryptorchidism, hypospadias, abnormal serum hormone 
levels and dysfunctional Leydig cells (Mylchreest et al 2002, Fisher et al 2003, 
Barlow and Foster 2003, Sharpe and Skakkebaek 2008). In cryptorchid 3-month 
old boys, FSH and LH levels were significantly increased compared to control 
infants (Suomi et al 2006), an abnormality also found in boys with hypospadias 
(Hsieh et al 2008, Wohlfahrt-Veje et al 2009). In a large clinical study 
investigating hormone levels in 357 infertile men, 18% were shown to have 
increased serum LH and 19% had lower testosterone levels, in comparison to 
318 fertile men, which is indicative of compensated adult Leydig cell failure 





(Andersson et al 2004). Thus, the use of DBP-induced testicular dysgenesis in 
rats provides an experimental model to investigate human TDS. 
1.15 Flutamide 
Flutamide is a synthetic non steroidal androgen receptor antagonist, specifically 
designed by pharmaceutical companies to competitively bind to AR and thereby 
block the action of testosterone and DHT (Peets et al 1974, Virtanen and 
Adamsson 2012). More specifically, flutamide can disrupt the N/C interaction of 
AR which prevents transcriptional activation of AR in target tissues. Flutamide 
is a useful tool to study androgen-dependent male reproductive development. 
Fetal exposure of flutamide in rats (e12-e21) resulted in reduced reproductive 
organ weights, reduced AGD, cryptorchidism, hypospadias and increased nipple 
retention, evident during postnatal life (McIntyre et al 2001). Perinatal 
exposure to flutamide in rats (e14-pnd 3) results in reduced reproductive organ 
weights, reduced AGD, cryptorchidism, hypospadias, penis malformation, and 
retained nipples (Miyata et al 2002). Furthermore, a long term effect of 
perinatal exposure to flutamide was evident during adulthood (pnd 60) from 
abnormal adult Leydig cell function i.e. significantly increased LH levels with 
normal testosterone levels (Miyata et al 2002). Administration of flutamide 
during gestational development in a porcine model demonstrated a long-term 
effect in adult boars with impaired Leydig cell responsiveness to LH and 
reduced testosterone (Kotula-Balak et al 2012). Fetal exposure to flutamide, at a 
dose of 100 mg/kg/day between e15-18 in the rat, inhibited masculinisation of 
the reproductive tract by blocking peripheral androgen action (Welsh et al 
2008, 2009). Postnatal exposure (pnd1-15) to flutamide reduced the number of 
Sertoli cells by 18% at pnd 25 and this reduction was exacerbated by prenatal 
DBP-exposure (Auharek et al 2010). Overall, while flutamide is a potent AR 
antagonist, it may have limited ability to antagonise the high intratesticular 
testosterone levels present in the fetal testis (Welsh et al 2008). 





1.16 Testosterone Proprionate 
Testosterone proprionate (TP) is an androgenic steroid which has previously 
been used to manipulate testosterone levels, as described below. Excess 
androgen exposure via TP during fetal development of rats, results in 
masculinised females, as evident from an increased AGD, absence of a vaginal 
opening, lack of nipples, masculinised external genitalia, and the presence of a 
prostate and seminal vesicles (Wolf et al 2002, Welsh et al 2008, 2010). In 
postnatal life, this resulted in anovulation and infertility (Wolf et al 2002). 
Increased masculinisation of the external genitalia in females was most likely 
due to increased circulating TP being converted to DHT. Increased exposure to 
TP during fetal life can also result in intrauterine growth retardation (IUGR) in 
rats (Wolf al 2002, 2004) and in humans (Carlsen et al 2006). The effect of fetal 
TP-exposure on male offspring was assessed in postnatal life in rats, and 
demonstrated a delayed onset of puberty and reduced testosterone plasma 
levels in adulthood (Dela Cruz and Pereira, 2012). 
1.17 Dihydrotestosterone 
Dihydrotestosterone (DHT), is a testosterone metabolite which is produced 
following testosterone conversion by 5α-reductase (type II). 5α-reductase (type 
I) is found in the skin and liver whereas type II is predominantly found in male 
reproductive tissues (Miller and Auchus, 2011). It is responsible for 
development of the prostate (Schultz and Wilson 1974, Imperato-McGinley et al 
1992), prevention of areola and nipple formation (Goldman et al 1976, Topper 
and Freeman 1980, Imperato-McGinley et al 1992), as well as determining the 
length of AGD (Imperato-McGinley et al 1985, 1986, Clark et al 1990, Bowman et 
al 2003, Welsh et al 2008). DHT binds to AR with a higher affinity than 
testosterone (Brinkmann, 2011). In humans, the vital role of DHT in 
masculinising external genitalia and the prostate was first highlighted in 1974 
(Imperato-McGinley et al 1974). Patients with a mutation in the gene coding for 
5α-reductase type II enzyme have a form of pseudohermaphroditism (normal 
differentiation of the Wolffian duct but defective external virilisation) (Wilson et 





al 1993, Verhoeven et al 2010). Lowering fetal DHT exposure levels in rats via 
finasteride, a 5α-reductase (type II) inhibitor (i.e. blocks the conversion of 
testosterone to DHT) results in permanent changes to AGD and nipple retention 
in males. This study also highlighted that DHT is not essential for differentiation 
of the Wolffian duct (Bowman et al 2003). A recent study that investigated the 
effect of exogenous fetal DHT-exposure in rats, demonstrated that 10mg/kg of 
DHT could masculinise females but could not advance or enhance male 
reproductive development, although a potential effect on Leydig cells was not 
examined (Dean et al 2012). 
1.18 Fetal/developmental programming 
The importance of the intrauterine environment in promoting lifelong health 
and/or disease risk is a relatively recent phenomenon, which began with the 
association between low birth weight and hypertension in adulthood (Barker et 
al 1993). Most human data of early life programming utilised fetal birth weight 
as an indication of intrauterine growth and development (Waterland and 
Michels 2007). It is becoming increasingly apparent that in terms of androgen 
exposure during fetal life, this can be measured by AGD throughout postnatal 
life (Eisenberg et al 2011, 2012). Furthermore, reduced AGD i.e. reduced fetal 
androgen action, is associated with increased risk of male reproductive 
disorders (Welsh et al 2008, Dean and Sharpe, 2013). 
1.19 Epigenetic changes 
The term 'epigenetics' was first coined by Conrad Waddington to describe the 
study of " interactions between genes and their products which bring phenotype 
into being" (Waddington, 1968). The term epigenetics refers to a mitotically and 
trans-generationally heritable alteration to the genetic make-up by altering 
gene expression without altering the DNA sequence (Berger et al 2009). Thus, 
the phenotype of daughter cells is altered without any change to the genotype, 
although this alteration is potentially reversible (Weaver et al 2005).  Epigenetic 
factors that can alter gene transcription include histone modifications, 





methylation of DNA and microRNAs (Bibikova et al 2008), which will be 
discussed below. These mechanisms interact with one another and abnormal 
activity of one or all of these mechanisms, can result in epigenetic diseases e.g. 
cancer. Together, these processes can determine when and where, various sets 
of genes are expressed in a tissue or cell (Zhang and Ho, 2011). 
Epigenetic modifications can occur through micro RNAs (miRNAs), which are a 
class of small non-coding RNAS which can bind to target mRNAs and suppress 
protein translation (Kong et al 2008). One miRNA can target several mRNAs, 
with each mRNA susceptible to negative influence by a variety of miRNAs. Thus 
extensive miRNA profiling in the future will open up the field of miRNAs in gene 
regulation. Epigenetic modifications can also occur via both methylation of DNA 
CpG dinucleotides and through histone modifications, in which the latter acts by 
remodelling chromatin to control gene expression (Warner and Ozanne, 2010). 
Thus, the organism can respond to its environment and change its gene 
expression accordingly, which has implications for fetal development in a 
perturbed intrauterine environment e.g. deficient androgen action. 
 
1.19.1 DNA methylation 
DNA methylation occurs at cytosines within cytosine-guanine dinucleotides 
(CpG) (the 'p' denotes a phosphate group) islands and converts cytosine to 5-
methylcytosine, and is generally associated with transcriptional silencing 
(Waterland and Michels 2007). A CpG island on one DNA strand always pairs 
with a CpG island on the complementary strand. To transfer epigenetic 
information during DNA replication, the newly synthesised DNA strands are 
unmethylated (hemimethylation). DNA methyltransferase 1 (DNMT1) 
maintenance methylase restores the pattern on the daughter DNA strand to that 
matching the parent DNA molecule (Waterland and Michels, 2007). This 
provides a mechanism for transferring epigenetic information in proliferating 
cells. DNMT3a and 3b generate new methylation patterns in quiescent cells 
during embryonic development (Siedlecki and Zielenkiewicz, 2006). CpG 





methylation in promoter regions of genes is associated with transcriptional 
silencing, potentially by affecting the binding of methylation-sensitive DNA-
binding proteins and interacting with histone modifications (Jaenisch and Bird 
2003). Site specific changes in DNA methylation are highly correlated with gene 
expression (Ehrlich 2003, Waterland and Michels 2007), thus CpG methylation 
studies can provide a read-out of epigenetic regulation.  
 
1.19.2 Histone modifications 
Transcriptional silencing is associated with methylated promoters, as described 
above; a process also associated with repressive histone markers (Tiwari et al 
2008), as discussed below. Chromatin is mainly composed of DNA wrapped 
around histones (H1, H2A, H3 and H4) in the nucleosome, which can be 
modified by acetylation, methylation, phosphorylation, sumoylation or 
ubiquitination (Matinez-Arguelles and Papadopoulos, 2010). 'Histone 
modifications' refer to modification/remodelling of the chromatin structure via 
histones, a process which can regulate gene transcription (Shen et al 2009) via 
transient or permanent reorganisation of chromatin (Kadonaga 1998, Kondo 
2009). Acetylation and methylation of histones are the best characterised of 
histone modifications. When histone lysine residues are acetylated, the charge 
attraction between DNA and histones weakens, thus decondensing the 
chromatin and in such manner, promotes gene transcription. Methylation of 
histone lysine residues can be activating or repressive e.g. methylation of 
H3K4me promotes an active chromatin structure leading to transcriptional 
activation. Conversely methylation of H3K27me for example, is known to be a 
repressive transcriptional mark (Zhang and Ho 2011). Thus transcriptional 
activation can occur via histone methylation e.g. of lysine 4 at histone 3 (H3K4) 
or transcriptional repression by methylation of lysine 27 at histone 3 (H3K27) 
(Lee et al 2005). Tri-methylation at lysine 27 of histone 3 (H3K27me3) is one 
such histone modification, the expression of which commonly acts as a 
repressive mark (Kirmizis et al 2004, Barski et al 2007, Sui et al 2012) by 





condensing the chromatin, thus impeding the binding of transcription factors to 
response elements in the promoter and thus preventing transcription (Li et al 
2007).   
Epigenetic changes can be meiotically and/or mitotically heritable, altering gene 
expression potential without altering the gene sequence (Wu and Morris, 2001), 
and can occur early during cell proliferation and development (Klein et al 2005). 
Of the histone modification marks, H3K27me3 and H3K9me3 demonstrate 
mitotic inheritance (Bernstein et al 2007, Margueron et al 2009). Epigenetic 
changes can also occur within the proximal promoter region of a gene 
(Bernstein et al 2006). This region in the promoter of Star was found to have 
reduced H3K27me3 upon StAR transcription, as induced by hCG injection in 
granulosa cells (Lee et al 2013). The proximal promoter region has also been 
shown to be important for StAR transcription in MA-10 cells (Hiroi et al 2004) 
and granulosa cells (Christenson et al 2001). In other recent studies 
investigating StAR regulation, its transcription was induced by hCG injection in 
granulosa cells (Lee et al 2013) or by 8-Br-cAMP in MA-10 cells (Hiroi et al 
2004) and in both cases, increased StAR transcription was associated with a 
reduction in H3K27me3 in the proximal promoter region of StAR.  
Histone methyltransferase (HMT) enzymes can modify specific lysine residues 
on core histones, in relation to H3, it can catalyse trimethylation of lysine 
residues on H3 (Zhang and Reinberg 2001, Lachner et al 2003). Lysine-specific 
demethylase 1 (LSD1) functions to remove transcriptionally repressive 
methylation marks from histone in favor of gene expression (Martinez-
Arguelles 2010). Knockdown of LSD1 results in decreased transcriptional 
activation of AR-driven genes (Metzger et al 2005). Thus, by relieving repressive 
histone marks, demethylases can control specific gene expression. 
Several studies have pointed to a role for polycomb-repressive complex 2 
(PRC2), which is comprised of histone methyltransferases e.g. enhancer of zeste 
(Ezh1/2), suppressor of zeste-12 (Suz12), and embryonic ectodermic 
development (Eed) (Cao et al 2002, Muller et al 2002, Shen et al 2008, 





Margueron et al 2008, 2009) and more recently a coregulator, 'Jarid2' (Shen et 
al 2009, Li et al 2010) as the main mediators of this process. More specifically, 
EZH2 catalyses the methylation of lysine 27 at histone 3 (H3K27me3) (Cao and 
Zhang 2004, Schuettengruber et al 2007). Overall, histone modifications in 
controlling gene regulation in postnatal life, warrants further investigation of 
'pre-programmed' progenitor cells during fetal development. 
1.20 Hypotheses  
The 'window of epigenetic reprogramming' is considered to occur in utero 
(Prins, 2008, Gluckman et al 2009, Thompson & Einstein 2010), and altering 
levels of androgen exposure during the MPW (Welsh et al 2008) can result in 
reproductive disorders manifesting in newborns and young men (Sharpe and 
Skakkebaek 2008). This may suggest that somatic testicular cells, altered by 
deficient androgen action, are epigenetically programmed during fetal 
development. Thus, the hypothesis underpinning this thesis, was that adult 
Leydig progenitor cells are present in the fetal testis and are susceptible to 
effects of altered androgen action/production, thus affecting their 
differentiation and functional development at puberty into normal functioning 
adult Leydig cells. As a consequence, adult Leydig cell function is altered, for 
example resulting in reduced testosterone production during adulthood. Lower 
testosterone levels in adulthood are associated with 'Western disorders', 
morbidity and mortality (Tivesten et al 2009, Traish et al 2011). The 
experimental work in this thesis aimed to investigate how fetal events, i.e. 
androgen exposure, can programme adult testosterone levels.  
To achieve this, adult Leydig cell development was first recapitulated via the 
EDS model, to characterise putative adult Leydig progenitor cells and assess 
whether COUP-TFII-expressing interstitial cells could differentiate into adult 
Leydig cells (Chapter 3). The next aim was to establish whether COUP-TFII+ 
interstitial cells might be fetal androgen targets i.e. express the AR (Chapter 3). 
To investigate whether the putative adult Leydig progenitor cells are androgen-
modulated, various AR knockout models including ubiquitous ARKO, Sertoli-cell 





specific ARKO and PTM-ARKO were analysed, in order to investigate whether 
this affected the number of adult Leydig progenitor cells and/or the function of 
adult Leydig cells (Chapter 4). This was also carried out in a DBP model to 
investigate whether lowered fetal testosterone levels affected the number of 
adult Leydig progenitor cells and/or the function of adult Leydig cells (Chapter 
4). The mRNA expression of adult Leydig cell specific genes in adulthood, after 
fetal exposure to DBP was also investigated (Chapter 4). Pregnant rats were 
exposed to various treatments to manipulate intratesticular androgen levels 
during fetal/postnatal development (Chapter 4). Finally, to investigate a 
mechanism of fetal 'programming' in DBP-exposed animals, ChIP analysis was 
undertaken to explore the hypothesis of altered StAR regulation via histone 
modifications i.e. increased histone repressor, H3K27me3 (Chapter 5).  
1.21 Aims 
To characterise adult Leydig progenitor cells in an adult Leydig cell 
ablation/regeneration model and throughout normal pubertal and adult Leydig 
cell development.  
To determine if adult Leydig progenitor cells are conserved across species in the 
fetal testis. 
To establish whether adult Leydig progenitor cells are androgen-modulated via 
several androgen receptor knockout models and altered testosterone 
production/action rodent models. 
To investigate potential 'gain of adult Leydig cell' function models. 
To investigate a mechanism of fetal 'programming' of adult Leydig progenitor 
cells, which may explain how fetal events programme adult testosterone levels.  





Chapter 2 General Materials and Methods 
2.1 Human fetal tissue collection 
Human fetal testes were obtained following termination of pregnancy. Women 
gave written consent according with UK national guidelines (Polkinghorne, 
1989) and the study was approved from the Local Research Ethics Committee. 
Medical/surgical termination was induced by treatment with mifepristone 
(200mg orally), followed by either misoprostol (Pharmacia, Surrey UK 200 mg 
every 3 h, per vaginam) or depending on weeks of gestation, vacuum aspiration 
under general anaesthetic. None of the terminations were for reasons of fetal 
abnormality. Gestational age was determined using ultrasound and confirmed 
by subsequent measurement of foot length in 2nd trimester samples examined. 
Micro-dissection of the testes from the fetal abdominal cavity was performed 
and samples were fixed in Bouin's for immunohistochemistry, as described 
below. 
2.2 Animal work 
All animal work was completed in the Biomedical Research Facility (BRF) Little 
France animal facility in accordance with the UK Home Office Animal 
Experimentation Scientific Procedures Act 1986, under project licences 
60/4564 and 60/4200. Wistar rats were purchased from Harlam UK and bred to 
generate stock within the BRF animal facility. William Mungal performed 
licensed procedures including treatments and day-to-day animal husbandry, 
while I performed licensed procedures under personal animal licence 
60/12997. 
 
2.2.1 Welfare conditions 
Animals were housed in the BRF animal facility in a room with fixed lighting for 
12h per day from 07:00 to 19:00. Humidity levels were maintained at 
approximately 55% while room temperature was kept between 20-25°C. Food 





and water were available ad libitum. Rats were housed in clear-sided cages, 
which contained solid bottoms covered in wood shavings for bedding.  
 
2.2.2 Time-matings 
Time-matings were used to allow calculation of gestational stages. For mating 
purposes, male and female rats were paired together in a grid-bottomed cage 
overnight, which was subsequently inspected for evidence of copulatory plugs 
which had fallen through the grid overnight.  This indicated successful mating 
and the gestational stage was immediately recorded as embryonic day (e), 0.5. 
The male was removed from the cage and pregnant female rats housed 
separately. Rats become sexually mature at approximately six weeks of age. 
Therefore, to ensure successful pregnancies, proven fertile male rats were used 
aged between 10 and 14 weeks of age. 
2.3 Treatments during pregnancy 
Androgens are required during fetal life for masculinisation and normal somatic 
cell development. Therefore, the purpose of the experiments described below 
was to manipulate fetal androgen exposure during development in order to 
investigate the effect on adult Leydig cell development. To address this, 
pregnant female rats were administered treatments during defined stages of 
pregnancy. In this manner, offspring could be assessed for abnormalities after 
indirect exposures during fetal development. The treatments used were: di-n-
butyl phthalate (DBP), testosterone proprionate (TP) or dihydrotestosterone 
(DHT). DBP was administered via oral gavage using a 15-16G blunt ended steel 
gavage cannula, 10-12cm in length (Medicut, Sherwood Medical Industries Ltd, 
UK) attached to a disposable plastic 1ml syringe. TP and DHT were 
administered by subcutaneous injection using a 25G, 0.5 x 16mm needle (BD 
Microlance) attached to a 1ml plastic syringe. To ensure correct dosing of the 
relevant chemical, rats were weighed directly prior to dosing. Treatments were 
administered between 09:00 and 11:00 for both consistency and to allow time 





to check the animals regularly for any sign of toxicity or discomfort during the 
rest of the day. 
 
2.3.1 Di (n-Butyl) phthalate 
Di (n-butyl) phthalate (DBP; Sigma) was administered via gavage to pregnant 
dams from e13.5-21.5, which encompasses the masculinisation programming 
window (MPW) (Welsh et al 2008, Macleod et al 2010), a period in which 
testosterone production is crucial for masculinisation. To investigate the effect 
that lowered fetal testosterone production has on adult Leydig cells and their 
progenitors, pregnant dams were gavaged daily with DBP at 500mg/kg 
maternal bodyweight. This dose has previously been shown to lower fetal 
testosterone by >70%, resulting in areas of focal dysgenesis at birth and 
adulthood, along with other reproductive tract abnormalities (Mylchreest et al 
1998, Foster et al 2001, Mahood et al 2005, Mahood et al 2006, Hutchison et al 
2008, van den Driesche et al 2012). DBP treatment did not cause any obvious 
adverse toxicological effects to the dams nor was there any increase in fetal 
mortality. DBP was diluted in corn oil (purchased from a supermarket) as per 
previous studies from our laboratory, e.g. to make up a dose of 500mg/kg dam 
bodyweight; 5ml DBP was made up to 10ml with corn oil and administered at 
1ml/kg maternal bodyweight. Treatments were freshly prepared and stored at 
room temperature in an airtight container. DBP-exposed fetuses were studied at 
the end of gestation (e21.5) or on postnatal days 6, 10, 25 or 90.  
 
2.3.2 Flutamide 
Flutamide (Sigma, Poole, UK) is a potent synthetic anti-androgenic compound 
which blocks the action of both testosterone and DHT by competitively binding 
to the androgen receptor. The purpose of exposing pups to flutamide 
postnatally was to investigate the modifying effects of androgen deprivation to 
adult Leydig progenitor cells during the postnatal period, prior to adult Leydig 
cell differentiation (~Pnd 15). To expose the pups via breast milk, flutamide was 





administered to nursing dams by oral gavage (100mg/kg maternal bodyweight) 
in 2.5% dimethylsulfoxide (DMSO; Sigma) in 1ml/kg corn oil (purchased from a 
supermarket) from pnd 1-15. In a separate series of studies, the postnatal 
flutamide treatment as described was combined with fetal DBP-exposure 
(Section 2.3.1) to investigate the cumulative effects of altered androgen 
exposure during pre- and postnatal life on adult Leydig progenitor cell 
development. Treatments were freshly prepared and stored at room 
temperature in an airtight container. 
 
2.3.3 Testosterone Proprionate 
As the purpose of administering the previous treatments was to decrease fetal 
androgen exposure, the aim of the next experiments were to increase the level 
of fetal or postnatal androgen exposure. The purpose of which, was to 
investigate potential effects to adult Leydig and/or their progenitor cells, 
potentially resulting in a "gain of adult Leydig cell function" model. Testosterone 
proprionate (TP; Sigma) is an androgenic steroid which has previously been 
used to manipulate testosterone levels (Wolf et al 2002, 2004, Welsh et al 2008, 
2010). TP was administered daily by subcutaneous injection to pregnant rats on 
e14.5-e21.5 at 20mg/kg maternal body weight, as in previous studies (Welsh et 
al 2008, 2010). In a separate series of experiments, newborn male rats were 
administered TP daily by subcutaneous injection from postnatal day 1-24, to 
investigate if increased postnatal TP affects the development of adult Leydig 
cells and/or their progenitor cells. TP was dissolved in corn oil (purchased from 
a supermarket) with treatments freshly prepared and stored at room 
temperature in an airtight container. 
 
2.3.4 Dihydrotestosterone 
As TP administration resulted in confounding factors, including fetal growth 
restriction and the potential aromatisation of TP to estradiol, this prompted the 
use of another model to potentially and effectively elevate intratesticular 





testosterone exposure. Dihydrotestosterone (DHT) has a higher affinity for the 
androgen receptor compared to testosterone and unlike the aforementioned, 
DHT cannot be aromatised into estradiol. To investigate whether increasing 
androgens during fetal development would affect adult Leydig cells and/or their 
progenitor cells, DHT was administered daily by subcutaneous injection to 
pregnant rats on e15.5-e21.5 at 10mg/kg maternal body weights. This dose was 
chosen as previous studies have shown administration of 10mg/kg induced a 
degree of female masculinisation (Dean et al 2012). DHT was dissolved in corn 
oil (purchased from a supermarket) with treatments freshly prepared and 
stored at room temperature in an airtight container.  
2.4 Inducible nitric oxide synthase knock out mouse model 
To investigate the effect that potentially increased fetal androgen exposure 
might have on adult Leydig progenitor cell development, the iNOS-/- mouse 
model was used. This model has previously been shown to have increased testis 
weight, increased Sertoli and adult Leydig cell number and increased AGD at all 
postnatal ages examined (Auharek et al 2011, 2012). As the administration of 
TP or DHT in the previous models used, as above, may not definitively increase 
intratesticular testosterone (ITT), the iNOS-/- model was chosen for its 
potentially increased endogenous ITT. Slides containing sections of wild-type 
control and iNOS-/- (from Prof. Luiz De Renato) were analysed. Briefly, wild type 
(C57BL/6) and iNOS-deficient mice (B6.129P2-Nos2tm1Lau/J) were purchased 
from the Jackson Laboratory. All animals were treated according to the Ethics 
Committee in animal experimentation from the Federal University of Minas 
Gerais, as described previously (Auharek et al 2011, 2012).  
 
2.5 Adult Leydig cell ablation/regeneration via ethane dimethane sulphonate  
Ethane dimethane sulphonate (EDS) is a toxic chemical used to specifically 
ablate mature adult Leydig cells in rats while having few other toxicological or 
adverse effects (Bartlett et al 1986, Sharpe et al 1990, Teerds et al 1999). One 





week after a single injection of 75mg/kg EDS, new adult Leydig cells begin to 
regenerate, with normal numbers restored after approximately 5-6 weeks post 
EDS injection. EDS (gift from Prof. Ian Morris) was used in this study as an 
ablation/regeneration model to recapitulate normal ALC development and to 
investigate the phenotype of the progenitor cells from which the ‘new’ adult 
Leydig cells differentiate. EDS was administered by a single i.p. injection to adult 
male Sprague Dawley rats at a dose of 75mg/kg/ml. Control animals received 
vehicle only (DMSO; Sigma). To dissolve the EDS in DMSO, the solution was 
heated for ten minutes. It was prepared fresh on the morning of injection and 
kept in an airtight container for use.  
2.6 Lineage-tracing of adult Leydig cells 
In order to demonstrate whether COUP-TFII+ adult Leydig progenitor cells could 
develop into adult Leydig cells, a model for adult Leydig lineage tracing was 
utilised, generated by Dr. Laura O'Hara and Prof. Lee Smith. Briefly, mice with 
Cre recombinase driven by the adipocyte protein (aP2) promoter were bred 
with a YFP reporter line which showed aP2 was restricted to Leydig cells 
(O'Hara et al, unpublished). The use of a YFP/GFP antibody allowed for 
visualisation of aP2 expression in adult Leydig cells and their progenitors in 
fetal life. More specifically, male congenic C57BL/6J mice hemizygous for an 
aP2-Cre transgene (He et al 2003) were mated to homozygous R26R-EYFP 
females (Srinivas et al 2001). An aP2-YFP (without Cre) was utilised as an 
appropriate control. 
2.7 Androgen receptor knockout mouse models  
Both the Sertoli cell androgen receptor knockout (SCARKO) and the androgen 
receptor knockout (ARKO) mouse model were generated by Karel de Gendt in 
Belgium, using cyclisation recombination (Cre) recombinase / loxP technology, 
as previously described (De Gendt et al 2005). Briefly, to generate Sertoli cell-
selective Androgen Receptor Knockout (SCARKO) mice, ARflox /+ female 
animals were crossed with anti-Müllerian hormone (AMH)-Cre+/+ male mice 





expressing Cre recombinase selectively in Sertoli cells. The complete Androgen 
Receptor Knockout (ARKO) mouse line was generated by crossing ARflox/AR+ 
female animals (129/Swiss) with phosphoglycerate kinase-1 (PGK)- Cre+/+ male 
animals, (C57BL/6) in which the Cre is expressed ubiquitously in cells. 
Peritubular myoid cell-specific AR knockout (PTM-ARKOs), were generated by 
mating male mice heterozygous for Cre recombinase under the control of a 
smooth muscle myosin heavy chain (MH; Xin et al 2002) promoter with female 
mice homozygous for a floxed AR (De Gendt et al 2004, Welsh et al 2009). Pgk1-
Cre without a floxed AR gene was used as an appropriate control in these mouse 
lines. A schematic representation is shown below (Figure 2.1). All animals were 
generated and maintained according to the UK Home Office guidelines for the 
Care and Use of Laboratory Animals and all experiments were approved by the 
Local Ethics Committees.  
 
Figure 2.1 Androgen Receptor knockout mouse models via Cre/loxP system. A 
specific promoter-driven Cre recombinase (scissors), targets loxP sites which flank 
the gene of interest, namely AR, in these studies. 






Postnatal animals were killed by inhalation of carbon dioxide (CO2) and 
subsequent cervical dislocation under schedule 1 of the animal (Scientific 
Procedures) Act 1986. Neonates from pregnant dams were killed by 
decapitation and placed in ice-cold 0.01M phosphate buffered saline (PBS; 
Sigma; section 2.16.3).  
 
2.8.1 Gross dissection 
Fetuses were removed from the deceased pregnant dam via standard gross 
dissection techniques. The dam was placed on her back and an incision to the 
abdomen allowed the uterus to be removed intact. Once each amniotic sac and 
umbilical cord was cut, measurements for each fetus were taken immediately 
prior to placing them in ice-cold PBS. This minimised tissue degradation 
occurring during transportation, prior to carrying out fine dissections (Section 
2.8.3). 
 
2.8.2 Anogenital distance 
The anogenital distance (AGD), refers to the measurement of the distance from 
the middle of the anus to the base of the genital tubercle. AGD is increased 
(nearly two-fold) in normal males compared to normal females in response to 
masculinisation and thus provides a read-out of androgen exposure during fetal 
life (Welsh et al 2008, Macleod et al 2010, Dean & Sharpe 2013).  Prior to any 
incision being made for tissue dissection, AGD was measured using electronic 
digital callipers with a resolution of 0.02mm (Faithfull Tools, Kent) which 
provided a measure of any increase/decrease in androgen exposure during fetal 
development. 
 





2.8.3 Fine dissection 
Bodyweight for each animal was measured using an electronic analytic balance 
(Handy H110, Sartorius) prior to decapitation. Each fetus was placed in a petri 
dish (Corning, UK) containing tissue paper soaked in PBS and placed under a 
binocular dissecting microscope (Leica, MZ6) which contained a trans-
illuminated stage. Extra lighting, when needed, was provided by external cold 
lights (Leica CLS 150x) to minimise any heat damage caused by the lights. 
Testes were trimmed using the bevelled edge of 27G needles (Monoject, sterile 
needles, 0.4mm x 12mm) attached to disposable plastic 1ml syringes. This 
allowed accurate removal of the fetal epididymis and efferent ducts, prior to 
weighing the testes for fixing or freezing. 
 
2.8.4 Postnatal tissue collection 
Postnatal tissue was collected in male rats on postnatal day 6, 10, 25, 75 and 90. 
Male rats were placed in a supine position for an incision to be made in their 
abdomen, to enable removal of the prostate and testes. The latter were obtained 
by pulling on the fat pad attached to the scrotal sac. Following tissue excision, 
the testes and prostate were weighed using an electronic analytic balance 
(Handy H110, Sartorius). Images of the dissected tissue were photographed 
using a D70 camera (Nikon, Surrey, UK) fitted with a Nikon AF Nikkor 24-120 
mm lens.  
2.9 Tissue preservation 
Following retrieval of tissue and their relevant measurements, samples were 
immediately either snap-frozen or stored in Bouin's solution to preserve the 
tissue for future use. 
 





2.9.1 Frozen tissue 
One testis per animal was cut in half and both halves were separately placed in a 
2ml eppendorf on dry-ice prior to being stored in the freezer at -80°C until 
required.  
 
2.9.2 Fixed tissue 
The isolated tissue was fixed in Bouin’s solution (see section 2.16.1) in an 
airtight container. For adult male rats, testes were left in Bouin’s solution for a 
total of 6 hours. Following the initial three hours, the partially fixed testis was 
halved using a razorblade and re-submerged in Bouin’s for a further three 
hours, to allow the solution to fully diffuse through the whole testis. Fetal testes 
were submerged in Bouin’s for two hours in an airtight container. Bouin's fixed 
tissue was then placed into 70% EtOH (ethanol) and processed by the histology 
team (SuRF, CRH, Edinburgh). Briefly, the tissue was processed through a series 
of graded alcohols for 17.5 hours in an automated Leica TP1050 tissue 
processor (Leica Microsystems, Milton Keynes, UK) and embedded into molten 
paraffin wax. Once the wax blocks containing the sample of interest had cooled 
and set, all samples were stored at room temperature for future use. 
2.10 Protein Expression  
2.10.1 Immunohistochemistry 
To detect protein expression in cells, antibodies against a specific protein of 
interest were detected by immunohistochemistry on Bouin’s fixed tissue, as 
outlined below. For immunohistochemistry undertaken on sections of animals 
exposed to treatments or otherwise, an appropriate age-matched control was 
also included in each experiment. Where possible, tissue sections from both 
control and treated animals were analysed on the same slide to allow for direct 
comparison. A sample size of at least five animals per experimental group, with 
at least two sections from the same animal, was included in each experiment, 
which ensured reproducibility of the results found. The protocols from 





sectioning to imaging for immunohistochemistry are outlined briefly, full details 
of which are given in sections 2.10.2-2.10.11. 
 Samples embedded in paraffin blocks were cut into 5µm sections using a 
microtome. 
 Sections were mounted onto labelled slides. 
 Slides containing sections of tissue were dewaxed and re-hydrated. 
 Tissue underwent antigen retrieval in a decloaking chamber. 
 Non-specific antigens were blocked. 
 Specific primary antibody was added and detected using an amplification 
system. 
 Protein of interest was visualised using a colour reaction (DAB).  
 Sections of tissue were covered with a glass coverslip using permafluor. 
 
2.10.2 Sectioning 
Parrafin wax blocks containing the tissue of interest were placed on ice for 10 
minutes to ensure that the wax was rigid to allow ease of sectioning at 5µm 
thickness using a microtome (Leica, model RM 212 5RT). The sections were 
then floated onto 30% industrial methylated spirits (IMS; Fischer Scientific) 
prior to being floated in a heated water bath (Lamb RA, model E/65) at 45-55°C 
to eliminate any creases in the section. Sections were teased apart using a thin 
brush and mounted onto a pre-labelled (slide labeller, Leica IPS) 
electrostatically charged glass slide (Leica Biosystems, Peterborough Limited). 
Slides were placed in a metal rack and left overnight in an incubator (Lamb RA, 
model E28.5) at 55°C, to allow the sections to adhere to the glass slide. Slides 
were then stored at room temperature until required. 





2.10.3 Dewaxing and rehydrating 
In order to remove paraffin wax from the section (dewaxing), slides were left in 
xylene for 5 minutes x2. Tissue was then rehydrated by immersion in 
decreasing concentrations of ethanol for 30 seconds each i.e. 100% ethanol (x2), 
95%, 80%, 70% and then rinsed in dH20. 
 
2.10.4 Antigen retrieval 
Bouin’s solution induces protein cross-linking to preserve the tissue integrity, 
which can often result in masking the protein/antigenic sites; thus cross-link 
removal was required for successful immuno detection. This was achieved by 
heat-induced antigen retrieval using a decloaking chamber/pressure cooker 
(Biocare Medical; CA, USA). Following rehydration, slides were immersed in a 
plastic holder which contained retrieval solution (25mls Citrate buffer pH6; 
section 1.14.6 and 225mls dH20). The holder was placed into the decloaking 
chamber (containing 500mls dH20) and the programme was run for 40 mins, 
which involved heating to 125°C followed by cooling to 90°C. Slides were rinsed 
in tris buffered saline (TBS; section 2.16.2) solution for 5 minutes. 
 
2.10.5 Blocking 
To prevent any non-specific binding of primary/secondary antibodies or 
detection agents to any molecules other than the protein of interest, slides were 
submerged in hydrogen peroxide (30mls; BDH) and methanol (270mls; Fischer 
Chemical) for 30 minutes on a rocker at room temperature. Slides were then 
washed with TBS for 5 minutes x2. Excess TBS was carefully dried from around 
the section with tissue paper. Blocking serum (Diagnostic; Scotland) was then 
added to the tissue section to block any potential remaining non-specific 
binding sites. Blocking serum was chosen from the species in which the 
secondary antibody was raised and was diluted 1:4 in TBS containing 5% 
bovine serum albumin (BSA; Sigma). Slides were incubated in a humidity 
chamber at room temperature for 30 mins. To further prevent any non-specific 





background staining, slides were washed for 5 minutes x2 between each step 
with TBS, on a rocker at 40-50 rpm at room temperature. 
 
2.10.6 Primary antibody 
Each primary antibody was initially optimised for all animals and ages used in 
this thesis. The primary antibody was diluted in blocking serum at its optimal 
concentration, carefully placed on the section and evenly distributed. For a 
negative control, sections were incubated with blocking serum only, in place of a 
primary antibody. The general conditions used for a sample of primary 
antibodies in this thesis are listed below (Table 2.1). All primary antibodies 
used for protein detection on sections were incubated overnight in a humidity 
chamber at 4°C.  
Table 2.1 Antibodies and Dilutions for Immunohistochemistry 
Primary Antibody Species Raised Dilution Manufacturer 
SMA Mouse 1:3,000 Santa Cruz 
COUP-TFII Mouse 1:100 Sigma 
3B-HSD Goat 1:500 Santa Cruz 
 
2.10.7 Secondary antibodies 
Slides were washed in TBS (5 minutes x2) to remove any unbound primary 
antibody. A biotin labelled (biotinylated) secondary antibody was then added to 
amplify the localisation of the primary antibody. Secondary antibodies were 
raised against a species-specific sequence on the primary antibody. Also, the 
secondary antibodies were raised in the same species as the blocking serum 
used. The biotinylated secondary antibody was diluted 1:500 in blocking serum 
and incubated on slides in a humidity chamber at room temperature for 30 
minutes. 





Table 2.2 Secondary antibodies used for Immunohistochemistry 
Target Antigen Species Host Species Supplier 
Rabbit Mouse Dako 
Rabbit Goat Dako 
 
2.10.8 Antigen Detection 
In order to amplify the biotinylated secondary antibody signal, slides were 
incubated with streptavidin/horseradish peroxidase (Strep HRP; Vector) 
diluted 1:500 in TBS for 30 minutes in a humidity chamber at room 
temperature. To localise the primary antibody, slides were incubated with 3,3’-
diaminobenzidine (liquid DAB+; DAKO) which was diluted in its own buffer 
according to manufacturer's instructions: 1 drop/ml buffer, immediately prior 
to use. A brown colour ensued following successful reaction to the specific 
antigenic sites of interest, as monitored under a microscope (Axiostar plus; 
Zeiss) after approximately 5 minutes. The reaction was quenched by immersing 
the slides in water, followed by TBS for 5 minutes to wash off any excess 
unbound DAB. A schematic representation of the reaction is shown in Figure 
2.2. 
 
2.10.9 Double/Triple immunohistochemistry 
For detection of more than one antigen at a time, instead of using Strep-HRP to 
amplify the signal, Streptavidin Alkaline phosphatase (Strep-AP; Sigma) was 
used. Following TBS washes, the chromagen used to detect the primary 
antibody was commercial fast blue/red (Diagnostics Biosystems, Pleasanton, 
CA) diluted in its own buffer as per manufacturers’ instructions. Slides were 
washed in TBS to remove any excess chromagen and underwent heat-induced 
antigen retrieval for a second time. This involved bringing retrieval solution 
(450mls water and 50 mls citrate pH6.0) to boiling point (4 minutes) and then 





immersing the slides in a plastic rack within a plastic container. A lid was placed 
on loosely and slides were left in the boiling retrieval solution for 2.5 minutes 
and left to cool for a further 20 minutes. Blocking serum was then placed on the 
sections prior to the subsequent primary antibody. The process was repeated 
until the final primary antibody detection stage where Strep-HRP was added for 
30 minutes at room temperature followed by a TBS wash (5 minutes x 2) and 




Figure 2.2 Schematic representation of localising the protein of interest. 
Proteins/antigens are expressed in cells which specific primary antibodies can bind 
to. A biotin-labelled secondary antibody specifically binds to the primary antibody 
and streptavidin-HRP then binds to the biotin label forming a complex. Addition of a 
chromagen substrate (Fast Red/Blue/DAB) reacts with the complex and releases a 
colour, allowing the protein of interest to be localised. 
 





2.10.10 Dehydration and mounting 
As ‘fast blue/red’ is soluble in alcohol, placing the slides through alcohol 
dehydration would remove the staining from the sections. For this reason 
following immunostaining, slides were immediately mounted using glass 
coverslips (Surgipath; Leica Biosystems) with an aqueous mounting medium, 




Localised target proteins of interest in tissue sections were examined using a 
Provis microscope (Olympus Optical, London, UK) and images were captured 
using an attached digital camera (Canon DS126161). Captured images were 
compiled using Adobe Photoshop 5.0 (Adobe Systems Inc, Mountain View, CA). 
 
2.11 Image analysis 
To analyse immunostained sections, slides were visualised using a Zeiss Axio-
Imager microscope (CarlZeiss Ltd., Welwyn Garden City, UK) fitted with a 
Hitachi HVC20 camera (Hitachi Denshi Europe, Leeds, UK) and a Prior 
automatic stage (Prior Scientific Instruments Ltd., Cambridge, UK) and utilised 
Image-Pro Plus 7.0 with Stereologer Analyser Pro (Media Cybernetics, UK).   
 
2.11.1 Determination of numbers of adult Leydig cells and their progenitor cells 
Adult Leydig progenitor cells, stained with DAB+ (Section 2.10.8) were counted 
using standard stereological techniques in order to determine whether specific 
treatments, or otherwise, altered the number of these cells per testis. Oil 
immersion was used to examine slides under the microscope using a Leitz x100 
objective fitted to a Zeiss Axio-Imager microscope (CarlZeiss Ltd; Welwyn 
Garden City, UK) fitted with a HVC20 camera (Hitachi Denshi Europe, Leeds, 
UK). This allowed the immunostaining to be visualised on screen using Image-





Pro 7.0 with Stereologer plug-in software (MagWorldwide; Wokingham, UK). 
The software generated a grid which was placed over the testis section and 
produced, at least 150, random fields of testicular cross-sections for each animal 
to be analysed. Points (crosses) falling over cell nuclei of interest were scored 
i.e. when the centre of a cross fell over a COUP-TFII+ interstitial cell. Cells which 
fell under the edge of the cross were excluded, ensuring consistency of the 
results. This data was expressed as a percentage of the total points counted and 
values were converted to absolute nuclear volumes per testis by multiplying by 
testis weight, which is equivalent to volume, as shrinkage is minimal. 
 
2.11.2 Determination of the mean nuclear volume for counted cells 
For each cell type quantified, the mean nuclear volume was determined, which 
allowed the conversion of nuclear cell volumes per testis to be expressed as the 
absolute number of cells per testis. Oil immersion was used to examine slides 
under the microscope and image analysis was carried out, as described above 
(Section 2.11.1), in which random fields were generated in the testis section. 
Fields containing cells of interest for each sample, group and age were 
measured. To measure the nuclear cell volume, the centre of each cell was 
selected which automatically generated three diameter measurements (µm) to 
trisect the cell. At each point on the cell of interest, where the line met the cell 
edge, a score was made and the nuclear volume was calculated by the software 
(Figure 2.3). The nuclear volume for at least 150 cell nuclei (e.g. in adult testes) 
was taken in order to have an accurate representation of the mean nuclear 
volume of each cell type. As I performed the scoring for cell counting and 
nuclear volume measurements for all studies in this thesis, it ensured that 
measurement errors were consistent. 





     
Number of cells = Absolute nuclear volume/testis (mg) x 1000                                             
(millions)         mean nuclear volume (µm3)  
Note: The fraction is multiplied by 109 to convert mg to µm3 (assuming specific gravity 
= 1) and divided by 106 because the result is expressed in terms of millions of cells.  
Figure 2.3 Schematic representation of the method for measuring nuclear cell 
volume and the formula used to calculate the absolute number of cells/testis. 
2.12 Immunofluorescence 
Fluorescent immunohistochemistry (immunofluorescence) is often more 
sensitive than colorimetric immunohistochemistry and thus proteins of interest 
are better visualised. To investigate whether different proteins of interest (each 
with a different colour of fluorophore attached) are present within the same 
cell, immunofluorescence was carried out to clearly visualise when fluorescent 
colours combine, i.e. co-localisation of proteins within a cell type. For the 
purpose of this thesis, any co-localisation is shown in yellow, as a result of green 
and red fluorophores combining. The protocols from sectioning to addition of 
primary antibodies, were similar to that described above for colorimetric 
immunohistochemistry (Section 2.10), and are outlined below. 
 Samples embedded in paraffin blocks were cut into 5µm sections using a 
microtome. 
 Sections were mounted onto labelled slides. 
 Slides containing sections of tissue were dewaxed and re-hydrated. 
 Tissue underwent antigen retrieval in a decloaking chamber. 





 Non-specific antigens were blocked via hydrogen peroxide in methanol. 
 Primary antibody one was added followed by peroxidase-conjugated 
secondary antibody. 
 Specific protein of interest was detected using a fluorescent tyramide 
amplification system. 
 Tissue underwent antigen retrieval in microwave. 
 Non-specific antigens were blocked via hydrogen peroxide in TBS-Tween 
 Primary antibody two was added followed by peroxidase-conjugated 
secondary antibody 
 Specific protein of interest was detected via fluorescent tyramide 
amplification system. 
 A nuclear counterstain, DAPI was added to section. 
 Sections of tissue were covered with a glass coverslip using permafluor. 
 
2.12.1 Blocking 
The conditions for blocking are identical to those outlined in section 2.10.5. For 
the majority of fluorescent immunohistochemistry used in this thesis, normal 
chicken serum was used as blocking serum to ensure cross-reactivity did not 
occur. 
 
2.12.2 Primary antibody 
Each primary antibody was initially optimised for all animals and ages used in 
this thesis. The primary antibody was diluted in blocking serum at its optimal 
concentration, carefully placed on the section and evenly distributed. For a 
negative control, sections were incubated with blocking peptide where available 
or blocking serum only, in place of a primary antibody. General conditions used 





for primary antibodies in this thesis are listed below (Table 2.4). All primary 
antibodies used for protein detection on sections were incubated overnight in a 
humidity chamber at 4°C. 
2.12.3 Secondary antibody 
The secondary antibodies used are summarised below (Table 2.3). Instead of 
using a biotin labelled secondary as in colorimetric immunohistochemistry, 
peroxidase (HRP) labelled secondary antibodies were used for fluorescence 
immunohistochemistry. The peroxidase labelled secondary antibody was 
diluted 1:200 in blocking serum and incubated on the tissue section in a 
humidity chamber at room temperature for 30 minutes. 
Table 2.3 Secondary antibodies for Immunofluorescence 
Target Antigen Species Host Species Supplier 
Chicken Rabbit Santa Cruz 
Chicken Goat Santa Cruz 
Chicken Mouse Santa Cruz 
 
2.12.4 Antigen detection 
In order to visualise the peroxidase labelled secondary antibody signal, slides 
were incubated with green, red or blue fluorescent dye using the ‘Tyramide 
Signal Amplification’ (TSA; PerkinElmer, MA, USA) system. This was diluted in 
its own buffer according to manufacturers’ instructions: 1:50, immediately prior 
to use and left to incubate on sections for 10 minutes in a humidity chamber at 
room temperature. The reaction was quenched by immersing the slides in TBS 
(5 minutes x2) in a covered dark container to prevent any photo bleaching 
occurring.  
 





2.12.5 Counterstaining and mounting 
Following TBS washes, the sections were counterstained with 4’,6- Diamidino-
2-Phenylindole, Dihydrochloride (DAPI; Sigma) which is a nuclear-specific dye. 
This was useful both to check the integrity of the section and also for orientation 
when visualising the section with the confocal microscope. DAPI was diluted 
1:500 in TBS and left to incubate for 10 minutes. Unbound/excess DAPI was 
washed off with TBS for 5 minutes and slides were mounted using glass 
coverslips (VWR, international, UK) with an aqueous mounting medium, 
Permafluor (Thermo scientific). Slides were covered in tinfoil to prevent photo-
bleaching occurring and stored at 4°C for subsequent imaging. 
 
2.12.6 Double/triple/quadruple immunofluorescence 
For co-localisation studies i.e. detection of more than one antigen, following 
initial tyramide detection, slides were washed in TBS (5 minutes x 2) and citrate 
retrieved (see section (2.10.4) to remove the previous tyramide dye. Slides were 
then blocked with hydrogen peroxide (30mls) in TBS-Tween (270mls) to block 
any endogenous peroxide. Slides were further blocked in serum for 30 minutes 
in a humidity chamber at room temperature, followed by incubation with the 
subsequent primary antibody and left overnight at 4°C. The protocol was 
continued as above for peroxidase labelled secondary antibodies and washed 
with TBS between steps. Each primary antibody was visualised with a separate 
fluorescent colour of tyramide. Slides were counterstained and mounted 
(Section 2.12.5). 
 
2.12.7 Fluorescent microscopy and imaging 
Localised/co-localised protein(s) of interest were visualised and imaged using a 
Zeiss LSM 710 Confocal Microscope (Carl Zeiss Ltd, Hertfordshire, UK) and Zen 
software (Carl Zeiss Ltd, 2009). Captured images were compiled using Adobe 
Photoshop 5.0 (Adobe Systems Inc, Mountain View, CA). 
 





Table 2.4 Antibodies and dilutions used for Immunofluorescence 
Primary  Species    Dilution Manufacturer Secondary Detection 
SMA Mouse 1:10,000 Santa Cruz C1 α M2 Tyr-Cy5 
COUP-TFII Mouse 1:1,000 Perseus Proteomics C α M Fluorescein 
3B-HSD Rabbit 1:8,000 Santa Cruz C α G3 Tyr-Cy3 
INSl3 Rabbit 1:500 Santa Cruz C α R4 Tyr-Cy3 
GATA4 Mouse 1:500 Santa Cruz C α M Tyr-Cy3 
CD31 Goat 1:500 Santa Cruz R α G Tyr-Cy3 
H3 Rabbit 1:5,000 Abcam C α R Tyr-Cy3 
H3K27me3 Rabbit 1:5,000 Active Motif C α R Tyr-Cy3 
H3K4me3 Rabbit 1:5,000 Active Motif C α R Tyr-Cy3 
PCNA Rabbit 1:500 Santa Cruz C α R Tyr-Cy3 
CD146 Rabbit 1:500 Abcam C α R Tyr-Cy3 
CD68 Mouse 1:1000 AbD Serotec R α M Tyr-Cy3 
AR Rabbit 1:200 Abcam G α R Tyr-Cy3 
SF1 Rabbit 1:200 Santa Cruz G α R Tyr-Cy3 
CD34 Goat 1:500 Santa Cruz R α G Tyr-Cy3 
S100A4 Rabbit 1:100 Dako C α R Tyr-Cy3 
LHR Rabbit 1:200 Santa Cruz G α R Tyr-Cy3 
MafB Rabbit 1:400 Abcam C α R Tyr-Cy3 
StAR Rabbit 1:500 Affinity BioReagents C α R Tyr-Cy3 
GFP Rabbit 1:1,500 Abcam C α R Fluorescein 
C1: Chicken; M2: Mouse; G3: Goat; R4: Rabbit sera. 





2.13 RNA analysis 
To investigate gene expression in tissues of interest, firstly RNA was extracted, 
followed by cDNA synthesis (PCR) and lastly qRT-PCR to investigate mRNA 
expression levels of any gene of interest. These procedures are detailed below. 
 
2.13.1 RNA extraction 
Tissue was retrieved from storage in the -80°C freezer and left to thaw for 10 
minutes on ice. RNA was isolated from the tissue of interest (adult rat testis) 
using the RNeasy Mini extraction kit (Qiagen, Crawley, UK), according to 
manufacturers' instructions. This entailed excising 30mg of frozen testis tissue 
from the centre of the testis and submerging in 600µl lysis buffer (β-
mercaptoethanol (Sigma) in RLT buffer (Qiagen; 1:100) in a 2ml eppendorf 
containing a 5mm diameter stainless steel bead for homogenisation. 
Homogenisation was carried out using a tissue lyser (Qiagen) for 5 minutes in 
total (2.5 minutes in opposite positions) at 25 Hz, which served to disrupt the 
tissue and thus release RNA. Samples were centrifuged ('eppendorf' centrifuge 
5424) for 3 minutes, 70% ethanol (600µl) was added to the supernatant and 
manually mixed by pipetting to promote binding of RNA to the RNeasy 
membrane. This mixture was transferred into supplied RNeasy mini columns 
and centrifuged for 15 secs at 10,000 rpm. Flow-through was discarded and 
RW1 buffer (350µl) was added and samples centrifuged for 15 seconds at 
10,000rpm to wash the spin column. Any genomic DNA contamination was 
removed using the supplied RNase-free DNase on-column digestion kit (10µl 
DNase in 70µl RDD buffer), incubated for 15 minutes at room temperature. RW1 
buffer (350µl) was added before samples were centrifuged for 15 seconds at 
10,000rpm. RPE buffer (500µl) was added and samples centrifuged for 15 
seconds at 10,000 rpm and flow-through discarded. A second 500µl of RPE 
buffer was added and samples centrifuged for longer (2 minutes at 10,000rpm) 
in order to dry the membrane to eliminate ethanol carry-over when eluting 
RNA. Using a new 2ml collection tube (Qiagen) to further eliminate ethanol and 
RPE buffer carry-over, samples were centrifuged at full speed (14,000 rpm) for 





1 minute. Lastly, to elute the RNA, the column was gently placed into a 1.5ml 
collection tube and 30µl of RNase-free water was pipetted directly onto the 
column membrane and incubated for 5 minutes at room temperature. Samples 
were then centrifuged for 1 minute at 10,000 rpm to collect the extracted RNA 
which was then placed on ice for immediate RNA quantification and quality 
check.  
 
2.13.2 RNA quantification 
To correct for varying amounts of RNA collected between samples, the 
concentration and quality of RNA was measured using a Nanodrop-1000 
spectrophotometer (Nanodrop Technologies, Delaware, USA). The ratio of 
absorbance at 260 and 280 nm is used as a measure of purity in RNA 
extractions. A ratio of ~2.0 is generally accepted as “pure” for RNA, a ratio <2.0 
may indicate a contamination in the sample e.g. the presence of proteins. Thus 
for the studies herein, only samples with an absorbance ratio of ~2.0 were used.  
 
2.13.3 Reverse transcription 
RNA was converted to cDNA via reverse transcriptase polymerase chain 
reaction (RT-PCR) using a ROX vilo kit (Invitrogen). The master mix for each 
reaction is listed below (Table 2.5). Control tubes were also included (master 
mix + water and another tube: water + sample). Once the reagents were added 
together into a labelled 0.2ml sterile thin walled PCR tube (Continental Lab 
Products, Oxford, UK), these were placed in a thermocycler (DNA Engine 
Thermal Cycler) for cycling on the following VILO programme (Table 2.5). 









Table 2.5 Reagents and thermocycling programme for cDNA 
Stock 1 reaction (20µl tube) 
5x Vilo Reaction Mix 4µl 
10x Superscript enzyme Mix 0.25µl 
RNA 100ng/µl 1µl 
RNase free water 14.75µl 






2.13.4 Primer and probe design 
In order to design primers and probes for Taqman PCR, the Universal Probe 
Library assay design centre was utilised (www.universalprobelibrary.com; 
Roche). This system designs specific primers for any gene of interest and 
assigns the best matched probe. Forward and reverse primers (MWG Biotech, 
London, UK) were reconstituted in nuclease free H20 and diluted to 20µM (20µl 
primer in 80µl H20). Aliquoting the primers reduced the likelihood of stock 
contamination. The primer sequences and the assigned probe number for each 









Table 2.6 Primer sequences and assigned probe used for taqman PCR 
Gene Forward Primer Reverse Primer (Probe #) 
Sox9 CTGAAGGGCTACGACTGGAC TCTTGATGTGCGTTCTCTGG (63) 
Lhr CTGGAGAAGATGCACAGTGG CTGCAATTTGGTGGAAGAAATA (107) 
StAR TCACGTGGCTGCTCAGTATT GGGTCTGTGATAAGACTTGGTTG (83) 
CYP11a1 TCACATGCAGAATTTCCAGAAG AGGATGTAAACTGACTCCATGTTG (7) 
3β-hsd TCATCTGATTTTGAACAATTTAGC CTCCTGCTCCTGTCACCAG (105) 
CYP17a1 CATCCCCCACAAGGCTAAC TGTGTCCTTGGGGACAGTAAA (67) 
17β-hsd3 AATATGTCACGATTGGAGCTGA AAGGAATCAGGTTCAGAATTATCG (5) 
 
2.13.5 Taqman PCR 
Quantitative real-time/reverse transcriptase polymerase chain reaction (RT-
qPCR) was carried out using the ABI Prism 7900 Sequence detection system 
(Applied Biosystems). It operates by amplifying the target DNA sequence while 
quantifying the number of cycles it takes to do so. Taqman uses a fluorescent 
reporter molecule to detect the PCR product as it accumulates during cycles i.e. 
as the product increases, so too does the fluorescence emitted. Both forward 
and reverse primers were designed along with an assigned probe from the 
Universal Probe library (Roche). For studies utilising Taqman PCR in this thesis, 
the probe contained a reporter dye (6-carboxyfluorexcein: FAM) at the 5′ end 
and a non-fluorescent quencher (6-carboxy-tetramethyl-rhodamine: TAMRA) at 
the 3′ end, which held the probe in a non-fluorescent state. 






Figure 2.4 Fluorescent Reporter is suppressed by quencher present on probe 
 
During Taqman PCR, the probe anneals to the target gene cDNA of interest (if 
present in the sample), between the forward and reverse primers. Taq 
polymerase enzyme binds to the 5’ of the primer until it reaches the probe, 
which is then cleaved and releases the fluorescent FAM dye. With every cycle 
and PCR product formed, the reporter is thus cleaved from the probe and 
fluoresces. In this manner, the amount of PCR product is measured 
quantitatively by the level of fluorescence produced. 
 
Figure 2.5 Taq Polymerase cleaves probe to release fluorescent reporter 
 





To ensure accuracy of results, samples were run in triplicate on a 96 well 
MicroAmp optical reaction plate (Applied Biosystems). The expression level of 
the gene of interest was related to an internal control 18s, a ribosomal RNA, 
which was used as a reference for RNA variation between samples. Both 18s 
RNA and sample RNA were analysed in the same wells but with different 
fluorescent endpoints. Positive controls (e.g. adult testes; Ambion) along with 
negative controls (water only/master mix only) were included in all runs. All 
samples and reagents were kept on ice while preparing the Taqman plate. 
Master mix, primers and probes were vortexed prior to use, while 18s was 
gently inverted. For each sample, the following reaction was prepared (Table 
2.7) with 13.5ul pipetted into each well, along with 1.5ul cDNA. To cover the 
plate, an optical adhesive cover (Applied Biosystems) was evenly applied and 
the plate was loaded onto an ABI 7900 sequence detection system. To minimise 
any potential variations in gene analysis, potentially due to different ABI 
machines, plates were consistently loaded onto ABI 7900 machine no.3 for 
every Taqman run. 
Table 2.7 Reagents used for Taqman PCR 
Reaction Volume per well (15µl) 
Nuclease free H20 5.325µl 
Taqman Master mix 7.5µl 
Forward Primer (5' - 3') 0.15µl 
Reverse Primer (3' - 5') 0.15µl 
Universal Probe 0.15µl 
18s 0.225µl 
cDNA 1.5µl 





2.13.6 Analysis of results 
Taqman PCR results are represented on an amplification plot. This 
demonstrates the amount of fluorescence produced as a result of the PCR 
product formed (Section 2.13.5) and thus the amount of target gene expressed 
in the tissue of interest. The baseline (d) refers to basal fluorescence present in 
the reaction plate while background (c) refers to any background fluorescence. 
As the level of fluorescence increases, it is associated with an exponential 
increase of PCR product, referred to as the threshold. Therefore, the threshold 
line must be set in the exponential phase, rather than in the linear (b), plateau 
(a) or background (c). Once the fluorescence signal is detected above the 
threshold, this is termed the threshold cycle (Ct value). It is this 'Ct value' which 
demonstrates the required number of cycles for amplification of the PCR 
product, which is significantly above the background level (Figure 2.6). 
 
Figure 2.6 A Taqman real time quantitative PCR plot.  a=plateau phase; b= 
linear phase; c=background; d=baseline. Threshold is indicated in green. 
Amplification plot is representative of a successful taqman run from studies in 
this thesis. 





In order to analyse any expression changes in a gene between control and 
treated samples, this was achieved using the comparative Ct method. To 
calculate the ΔCt for each sample, the Ct value of the internal positive control 
gene was subtracted from the Ct of the target gene (e.g. StAR Ct-18S Ct= ΔCt).  
As the sample reactions were prepared in triplicates (to account for pipetting 
errors), this result was averaged and compared to a reference sample (e.g. 
control adult rat testes total RNA) to give the ΔΔCt. This was achieved by simply 
subtracting the ΔCt of the reference sample from the ΔCt of the target gene (e.g. 
ΔCt control-ΔCt StAR=ΔΔCt). To calculate the amplified target, the formula 2-ΔΔCt  
was applied. This is derived from an equation describing the exponential 
amplification of PCR; (Xn=Xo x (1+Ex)n) (Livak and Schmittgen, 2001) where 
Xn=number of target molecules at threshold level, n=cycle number, Xo=number 
of target molecules at the start, 1+Ex=efficiency of target amplification (should 
be equal between target and internal control). Using the formula 2-ΔΔCt  provides 
a measure of relative quantification i.e. an increase or decrease in mRNA 
expression between samples and controls.   
2.14 ChIP assay 
Chromatin immunoprecipitation (ChIP) assay allows the analysis of epigenetic 
modifications of a selected region on a gene, which in these studies, referred to 
histone modifications. The expression levels of a methylated histone at a specific 
location on a gene of interest were examined to determine whether there was a 
specific histone modification which would affect transcription. The protocol is 
outlined below. 
 Histones are cross-linked to DNA to isolate chromatin. 
 Chromatin is sonicated. 
 Chromatin fragments are immunoprecipitated with a specific antibody. 
 PCR is carried out to quantify the level of histone modification to the 
gene of interest. 






Testis samples were retrieved from the -80°C freezer and left to thaw on ice for 
10 mins. A small segment (150mg) was excised, weighed (Sartorius, Northern 
Balance) and placed in a petri dish (Corning) on ice. The segment was 
immediately sliced with a sharp blade  into 1mm fragments and re-suspended in 
10mls PBS containing protease inhibitor (PI; Roche Complete), diluted 1:50 e.g. 
200µl of PI was added to 9.8mls of PBS to re-suspend the sample. In order to 
cross-link histones to DNA, 270µl of 37% formaldehyde (Sigma) was added and 
left to incubate for 10 minutes rotating on a rocker at room temperature.  
Formaldehyde was used as it is a reversible cross-linker. To quench cross-
linking, 125µl of glycine (Sigma) was added, the sample was centrifuged 
('eppendorf' centrifuge 5415) at 5,000rpm for 10 minutes and the supernatant 
discarded. The pellet was washed twice using ice-cold PBS containing PI and 




Tissue was homogenised with 20 strokes of a probe homogeniser (T10 Basic 
Ultra-Turrax, IKA, Staufen, Germany). Lysis buffer (200µl; section 2.16.7) was 
added and the sample incubated for 20 minutes on ice. The sonicator 
(Bioruptor; Diagenode, Belgium) was cooled for 10 minutes by addition of ice 
and the temperature was carefully monitored using a thermometer. Once the ice 
melted, dropping the temperature to 1°C, the samples were sonicated on 'high' 
using alternating pulses at 30 seconds on/off. Samples were stored in a -20°C 
freezer before immunoprecipitation. To check whether the sonication 
successfully sheared the DNA into fragments of 200-1000bp, 200µl of sonicated 
supernatant was removed from a sample, 8µl of NaCl was added and the sample 
was incubated for 4 hours at 65°C to reverse cross-links. This was followed by 
purification of the DNA (Section 2.14.4), which then underwent electrophoresis 
(Section 2.14.6) to visualise the size of DNA fragments after sonication.  





2.14.3  Immunoprecipitation 
The sonicated supernatant was diluted ten-fold with ChIP dilution buffer 
(Section 2.16.9) and a portion of this (1%) was kept as the "input control", used 
to quantitate the amount of DNA present. The solution was then divided into 
three aliquots and pre-cleaned with 75ul of 'salmon sperm DNA/protein A 
agarose-50% slurry' (Millipore) for 30 minutes at 4°C to reduce any non-
specific background. To pellet the agarose, samples were then centrifuged for 1 
minute at 10,000rpm at 4°C ('eppendorf' centrifuge 5415R). The three aliquots 
of supernatant fraction were appropriately labelled and incubated overnight 
with either 1) 10µl of a specific primary antibody (to attach to modified histone 
of interest), 2) negative control (IgG; Abcam) or 3) positive control (unmodified 
H3; Abcam) and rotated at 4°C. To collect the antibody/histone complex, 60µl 
sperm DNA/protein A agarose-50% slurry was added to the samples and 
incubated for 4 hours at 4°C. Samples were centrifuged at 4°C for 2 minutes at 
1,000 rpm and the supernatant containing unbound, non-specific DNA was 
discarded. Samples were then washed on a rotating platform with 1ml of buffers 
in the following order: low salt, high salt, LiCl, TE and a final TE buffer wash (see 
section 2.16.10-2.16.13). Between washes, the samples were centrifuged at 4°C 
for 1 minute at 10,000 rpm. To elute the histone complex from the antibody, 
100µl elution buffer (section 2.16.14) was added to the pelleted protein A 
agarose/antibody/histone complex and incubated on rotation for 15 minutes at 
room temperature. Following 2 minutes of centrifugation, the supernatant 
fraction (eluate) was carefully transferred to another labelled tube and the 
elution step was repeated with the subsequent eluates combined. To reverse the 
histone-DNA crosslinks, 8ul 5M NaCl was added to the sample and input control 
and heated at 65°C overnight, followed by 10µl 0.5M EDTA, 20µl 1M Tris HCl 
and 1µl 20 mg/ml proteinase K, with incubation at 45°C for 60 minutes. 
 
 





2.14.4 DNA purification 
DNA was purified from the samples using the QIAquick PCR purification kit 
(Qiagen). To bind DNA, the sample was placed in a QIAquick column and 
centrifuged for 30 seconds with the flow-through discarded. To wash the 
sample, 750µl buffer PE (containing ethanol) was added to the column, and the 
sample centrifuged for 30 seconds with the flow-through subsequently 
discarded. To remove any residual wash buffer, the column was centrifuged in a 
new 2ml collection tube (Qiagen). To elute DNA, the column was placed in a new 
1.5ml eppendorf containing 50µl elution buffer (containing 10mM Tris HCl) 
which was carefully added to the centre of the column, and left for 5 minutes 
before being centrifuged for 1 minute at 5,000 rpm. The purified DNA was 
stored in a -20°C freezer for future use.  
 
2.14.5 PCR using SYBR green 
In order to amplify purified DNA bound to the immunoprecipitated histone, PCR 
was carried out using SYBR green (Brilliant III Ultra-Fast SYBR; Agilent 
Technologies). Fluorescent SYBR green dye binds to double-stranded DNA and 
fluoresces, i.e. at the end of the PCR cycle when the double-stranded DNA 
product is produced. As the temperature increases, the DNA product melts and 
releases the SYBR green fluorescent dye and this melting/dissociation can be 
visualised at the end of the PCR cycle as a 'melting curve'. As SYBR green has the 
disadvantage of non-specifically binding to any double stranded DNA, analysing 
a melt curve (Figure 2.7) is essential to check that only a single gene-specific 
amplicon (visualised as a single peak in the melt curve) was generated. This is 
advantageous for primer design as any non-specific amplification (visualised as 
multiple peaks) identified in the melt curve may indicate primer dimer or 
genomic DNA contamination. Using a reference dye provides a stable baseline to 
normalise the samples, as the fluorescence in the reference dye remains 
unchanged throughout the programme.  






Figure 2.7 Melt Curve Analysis. The left plot shows a unique melt peak, indicative of 
specific amplification while the right plot shows two clearly distinct melt peaks, 
indicative of non-specific amplification.  
  
To ensure accuracy of results, samples were run in triplicate on a 96 well 
MicroAmp optical reaction plate (Applied Biosystems). All samples and reagents 
were kept on ice while preparing the PCR plate. For each sample, the following 
reaction was prepared (Table 2.8) with 8µl reaction mix pipetted into each well, 
followed by 2µl purified DNA. To cover the plate, an optical adhesive cover 
(Applied Biosystems) was evenly applied and the plate was loaded onto an ABI 
7900 sequence detection system and run on the programme (Table 2.9). To 
minimise any potential variations in gene analysis due to different ABI 











Table 2.8 Reagents used for SYBR green PCR 
Reaction Volume per well (10µl) 
2x Brilliant III SYBR Mix 5 µl 
25mM Forward Primer 0.2 µl 
25mM Reverse Primer 0.2 µl 
Diluted (1:50) Reference Dye 0.15 µl 
Nuclease free water 2.45 µl 
DNA 2 µl 
 
Table 2.9 PCR programme used with SYBR green 
Cycle Duration Temperature 
1  3 mins 95° C 
40  
5 secs 95° C 
12 secs 60° C 
 
2.14.6 Electrophoresis 
To make a 2% agarose gel for electrophoresis, 4g agarose (Sigma) was added to 
200mls TBE buffer (Section 2.16.5) in a conical flask (Corning). To fully dissolve 
the agarose, the solution was heated in a microwave for 2 minutes. As DNA 
cannot be visualised in natural light, 7µl of coloured dye (GelRed; Biotium), 
which binds to DNA and fluoresces under UV light, was added to the solution. 
This was then gently poured into the tray and all bubbles promptly removed. A 
comb was placed into the solution to create a well, to load the samples into once 
the gel was set after 1 hour. TBE buffer (500mls) was poured into the tank in 





preparation for electrophoresis. To determine the molecular weight of the DNA 
fragments, 5µl of 500bp DNA ladder (Bioline) was pipetted into the first well in 
the gel. Prior to loading samples into the wells, 1 volume (5µl) of loading buffer 
(Bioline) was mixed with 5 volumes (30µl) purified DNA. The loading buffer 
contains glycerol, a dense reagent, which allowed the DNA sample to sink to the 
bottom of the well. The electrophoresis was run at 90V (Bio-Rad Powerpac 300) 
for 90 minutes. This was monitored regularly so that the DNA did not run off the 
bottom of the gel. 
 
2.14.7 Densitometry 
DNA was visualised on the gel using UV light (GeneFlash Transilluminator 
Syngene, Cambridge, UK) and an image was generated (model P91 Mitsubishi, 
Hertz, UK) for analysis. ImageJ (version 1.46h, National Institutes of Health, 
USA) software was used to analyse the density (intensity) of the DNA bands. 
2.15 Statistical analyses 
Values are expressed as means ±SEM, where appropriate. Differences between 
means were analysed using an unpaired two-tailed t-test for two groups or one 
way Analysis of Variance (ANOVA) (for 3 or more groups) followed by the 
Bonferroni post-hoc test. Where unequal variances occurred, data were log 
transformed prior to statistical analysis. The criteria for significance, as 
indicated by asterisks, was set at p≤0.05=*; p≤0.01=**; p≤0.001=***. All 
statistical analyses in this thesis were carried out using GraphPad Prism 5.0 
(version 5, GraphPad software Inc, San Diego, CA). 
2.16 Common Solutions 
2.16.1 Bouin's  
Bouin’s Solution is a well-established formaldehyde based fixative, which 
appears bright yellow in colour (purchased from Triangle Biomedical Sciences 
Ltd, Lancashire, UK) and works by forming cross links between protein and 
aldehydes to produce a stable structure and avoids damaging antigenic sites. 





2.16.2 Tris-Buffered Saline  
To make 0.5M of 10 l solution of TBS, the following were added together: 
Tris (Sigma) 60.5 g 
NaCl (Sigma) 87.6 g 
HCl (BDH) 300 mls 
dH20 Up to 10 l 
TBS solution was very carefully adjusted to pH 7.4 using concentrated HCl and stored 
as a stock solution at 4°C. When needed, 1x TBS was made by diluting 1 l of 10x TBS 
with 9 l of dH20 and stored at room temperature. 
 
2.16.3  Phosphate Buffered Saline (PBS) Solution  
One PBS tablet (Sigma) was dissolved in 1 l of dH20 
 
2.16.4  EDTA Buffer  0.5M  
EDTA (Sigma) 186.1g 
dH20 800ml 
The pH was adjusted as required, e.g. for pH 8.0, NaOH was added and made up to 1 l 
with dH20 
 
2.16.5  Tris-Borate-Edta (TBE) Buffer 
For 1 l of 5x stock solution, add: 
Tris  54g 
Boric Acid (Sigma) 27.5g 
0.5M EDTA pH 8 20mls 
Add dH20 to make 1L 
Dilute to 1x with dH20 prior to use 
 
 





2.16.6  Citrate Buffer 
For 2 l of Citrate buffer, add: 
Citric acid monohydrate (Sigma) 42.02 g 
1900 mls dH20 
The pH of citrate buffer was adjusted to pH6.0 using NaOH and stored as a stock 
solution at 4°C or used at 0.01M by dilution (1:10) in dH20. 
 
2.16.7  Lysis Buffer 
For 10 mls: 
1ml 10% SDS 
10mM EDTA (200µl of 0.5M) 
50mM Tris HCl pH8 (5ml 0.1M) 
 
2.16.8  Glycine 
For 2.5 M of a stock solution:  
93.8g Glycine (Sigma)  
500mls dH20 
 
2.16.9  ChIP Dilution Buffer   
1ml of 1% SDS 
1.1 ml of Triton X (Sigma) 
240ul of 0.5M EDTA (1.2mM) 
16.7mls of 0.1m Tris HCl pH 8.1 
3.34mls of 5M NaCl 









2.16.10 Low Salt Solution 
For 100mls, add: 
1ml SDS 
1ml Triton X 
400µl 0.5M EDTA 
20mls 0.1M Tris HCl pH 8.1 
3mls 5M NaCl 
 
2.16.11 High Salt Buffer 
1ml of 1% SDS 
1ml Triton-X 
400µl of 0.5M EDTA 
20mls of 0.1M Tris HCl pH 8.1 
10mls of 5M NaCl 
 
2.16.12 LiCl Buffer 
25mls of 1M LiCl 
1ml Igepal ca-630 (Sigma) 
1g deoxycholic acid (Sigma) 
200µl of 0.5M EDTA 
10mls of 0.1M Tris HCl pH 8.1 
 
2.16.13 TE Buffer for ChIP 
200µl of 0.5M EDTA 
10mls of 0.1M Tris HCl pH8 
 
2.16.14 Elution Buffer  (Make fresh on day of use) 
1ml 10% SDS 
840µg NaHCO3 
100mls dH20 




Chapter 3 Characterisation of Adult Leydig Progenitor Cells 
3.1 Introduction 
The importance of normal functioning adult Leydig cells, which only 'appear' at 
puberty, is reflected by the significance of normal testosterone levels and/or 
function for spermatogenesis and overall male health. When puberty 
commences, residing adult Leydig progenitor cells express the definitive 
steroidogenic cell-specific marker 3B-hydroxysteroid dehydrogenase (3β-HSD) 
(Baker et al 1999) from as early as postnatal day (Pnd) 12 in the rat (Ariyaratne 
et al 2000) and at pnd 7 in the mouse (Baker et al 1999). This marks their 
differentiation into adult-type Leydig cells (Mendis-Handagama and Ariyaratne, 
2001, Zirkin, 2010). However, the precise origin of adult Leydig progenitor cells 
remains a mystery. As all adult testicular cell types, excluding adult Leydig cells, 
are already present in the fetal testis, it seems a logical assumption that adult 
Leydig progenitor cells are also present and remain quiescent in the 
interstitium until their differentiation into Leydig cells at puberty. The vast 
majority of research on adult Leydig progenitor cells to date, is based on their 
differentiation into adult Leydig cells during puberty. However the studies 
described in this chapter aimed to investigate whether adult Leydig progenitor 
cells might be present from fetal life onwards.  
Currently, there is no unifying/defined marker for adult Leydig progenitor cells 
prior to them differentiating into adult Leydig cells. Regarding this fact, an 
earlier study which demonstrated that inducible knockout of COUP-TFII in pre-
pubertal male mice results in failure of adult Leydig cells to develop (Qin et al 
2008) promoted the hypothesis that COUP-TFII might represent a marker for 
adult Leydig progenitor cells. In order to test this hypothesis, the first aim was 
to investigate EDS-induced adult Leydig cell ablation/regeneration to 
characterise the 'progenitor' cells from which the adult Leydig cells regenerated. 
A second approach was also used via a lineage tracing mouse model, in order to 
determine whether adult Leydig cells arise from COUP-TFII+ cells. The overall 
purpose of using these experimental models was to investigate if COUP-TFII 




could represent a useful marker for adult Leydig progenitor cells, and if so, 
whether these cells were conserved across species in the fetal testis.  
3.2 Materials and Methods 
3.2.1 EDS injection 
Selective destruction of all mature Leydig cells in adult wistar rats (90-100d) 
was achieved by a single i.p. injection of ethane dimethane sulphonate (EDS) at 
a dose of 75mg/kg bodyweight in 2ml/kg DMSO:H20 1:3 v:v (Section 2.5). 
Control rats received vehicle only.   
 
3.2.2 Tissue collection  
EDS-injected male rats were randomly assigned into 4 groups (n=5/group) and 
each group was killed at a specific time point, namely at 1, 2, 3 or 5 wks post-
EDS, via inhalation of carbon dioxide followed by cervical dislocation. Prostate 
and testes were removed from the rats and weighed. One testis was frozen for 
subsequent RNA analysis (Section 2.13), while the other was fixed in Bouin's 
(Section 2.16.1) for subsequent protein analysis via immunohistochemistry 
(Section 2.12). Human fetal tissue was collected by Prof. R Anderson (Section 
2.1). Sections of human fetal testis from second trimester (14-18wks gestation) 
were analysed via immunohistochemistry (Section 2.12). 
 
3.2.3 Lineage-tracing of adult Leydig cells 
To investigate if COUP-TFII could be used as a marker of the adult Leydig 
progenitor cell population in fetal life, a transgenic Leydig cell lineage tracing 
mouse model, generated by Dr. Laura O'Hara and Prof. Lee Smith, was utilised 
(Section 2.6). Sections from ap2-Cre/YFP+ mouse testes in fetal life underwent 
double immunohistochemical staining (Section 2.12.6) using an antibody that 
detects YFP/GFP to localise YFP+ cells and a second antibody, COUP-TFII, to 
mark the adult Leydig progenitor cell population. For the purpose of co-




localisation studies in this chapter, the YFP/GFP antibody localising YFP+ cells, 
is shown in green and labelled GFP. 
 
3.2.4 RNA extraction and preparation of cDNA 
Total RNA was isolated from frozen adult testes of control and EDS-injected rats 
using the RNeasy kit (Qiagen Ltd), (Section 2.13.1). RNA quality and 
concentration were measured (Section 2.13.2) and cDNA was prepared using 
the ROX Vilo kit (Invitrogen) (Section 2.13.3). 
 
3.2.5 Taqman qRT-PCR 
Quantitative RT-PCR was performed to analyse the expression of the 
steroidogenic genes Lhr and 3β-HSD in adult testes of control and EDS-injected 
rats using the ABI Prism 7900 Sequence Detection System (Applied Biosystems) 
(Section 2.13.5). Values were normalised to a control adult testis (Ambion). 
Primers and probes designed by Roche are detailed below (Table 3.1).  
 
Table 3.1 Primers and probes used for mRNA analysis of testis extracts from EDS-
injected rats 
Gene Forward Primer Reverse Primer (# probe) 
3β-hsd TCATCTGATTTTGAACAATTTAGC CTCCTGCTCCTGTCACCAG (105) 
Lhr CTGGAGAAGATGCACAGTGG CTGCAATTTGGTGGAAGAAATA (107) 
 
3.2.6 Immunohistochemistry 
Bouins fixed tissue was cut into sections on a microtome, mounted on glass 
slides, dewaxed and rehydrated (Section 2.10). Triple fluorescence 
immunohistochemistry was used to distinguish between cell types (Section 
2.12.6) and to investigate protein co-localisation. For stereological analysis to be 
performed, the stereological software required images to be stained 




colorimetrically and not fluorescently. Therefore triple colorimetric 
immunohistochemisty was used, as described below. 
 
3.2.7 Colorimetric Immunohistochemistry 
In order to investigate both the expression and to quantify the volume per testis 
of COUP-TFII+ cells, testis sections were firstly stained with specific markers to 
distinguish between cell types. Staining for colorimetric immunohistochemistry 
was performed on postnatal mouse testes at day 2, 12, 20, 50 or 140 and also on 
adult control and EDS treated rats using antibodies listed below (Table 1.2). 
Leydig cells were identified as cells immunopositive for the steroidogenic 
enzyme 3-Beta-Hydroxysteroid Dehydrogenase (3β-HSD). COUP-TFII was used 
to identify both presumptive adult Leydig progenitor cells (COUP-TFII+/3β-
HSDneg) and also adult Leydig cells (COUP-TFII+/3β-HSD+). Smooth Muscle Actin 
(SMA) was used to distinguish peritubular myoid (PTM) cells from interstitial 
cells and also to define the seminiferous cords/tubules.  
 
3.2.8 Triple colorimetric immunohistochemistry 
Following rehydration, the slides containing the testis sections underwent heat 
induced antigen retrieval (Section 2.10.4). To block non-specific binding, 
sections were placed in 3% (v/v) H202 in methanol for 30 minutes and washed 
in tap water. Slides were washed in tris-buffered saline (TBS) (Section 2.16.2) 
for 5 minutes and incubated with normal rabbit serum (NRS), (Biosera, 
Ringmer, UK) (4:1 TBS to NRS with 5% bovine serum albumin (BSA) (Sigma, 
Poole, Dorset)) for 30 minutes. Sections were then incubated with primary 








Table 3.2 Primary antibodies used for colorimetric immunohistochemistry 
Primary 
Antibody 
Source Retrieval Species Dilution 
3β-HSD Santa Cruz Yes Goat 1:100 
SMA Santa Cruz Yes Mouse 1:3000 
COUP-TFII Perseus Proteomics Yes Mouse 1:100 
MafB Abcam Yes Rabbit 1:400 
 
Sections were washed in TBS (5 minutes x 2) and incubated for 30 minutes with 
rabbit anti-goat biotinylated secondary antibody, diluted 1:500 in NRS, followed 
by 5 min TBS washes. Slides were incubated with Streptavidin-AP (alkaline 
phosphatase) at 1:200 diluted in TBS for 30 minutes followed by a TBS wash. 
Detection was performed using commercial fast blue buffer. Reactions were 
stopped in TBS and slides underwent further antigen retrieval in a microwave 
with 0.01 M citrate (pH 6.0) buffer (Sigma) for 2.5 minutes on medium heat. 
These were left to cool for 20 minutes and rinsed in TBS. Sections were then 
blocked in NRS/TBS/BSA as before for 30 minutes before application of the 
primary antibody. The same protocol was then followed as before, with the 
exception that rabbit anti-mouse biotinylated secondary antibody, diluted at 
1:500 in NRS/TBS/BSA was used. Fast red buffer was used for detection of SMA. 
COUP-TFII was optimised and applied at 1:100 to testis sections from mice at 
pnd 2, 12, 20, 50 and 140.  Streptavidin-HRP (horseradish peroxidase) at 1:1000 
was used to detect RAM-biotinylated secondaries (1:500) in TBS. Detection of 
COUP-TFII+ cells was performed using 3,3-diaminobenzidine tetrahydrochloride 
(DAB) (Dako, UK) and stopped in TBS. Slides were mounted with Permafluor 
(Thermo Scientific, Fremont, CA). Two separate slides containing tissue from 
the same animal were included in each experiment to ensure consistency of the 
resultant staining. 




3.2.9 Quantification of cell types 
The volume of adult Leydig progenitor cells (COUP-TFII+/3β-HSDneg) and adult 
Leydig cells (COUP-TFII+/3β-HSD+) per testis was determined using 
stereological techniques involving point-counting methods (Section 2.11).  This 
used a Zeiss Axio-Imager microscope (CarlZeiss Ltd; Welwyn Garden City, UK) 
fitted with a Hitachi HVC20 camera (Hitachi Denshi Europe, Leeds, UK) and a Prior 
automatic stage (Prior Scientific Instruments Ltd., Cambridge, UK) and utilised 
Image-Pro Plus version 7.0 with Stereologer Analyser Pro (Media Cybernetics, UK).  
Although the optical dissector method (Wreford, 1995), which involves the 
recognition of cell types by their position and shape, is more definitive for cell 
counting, it could not be used in these studies. This was due to the fact that  
these studies involved staining for three proteins, via triple colorimetric 
immunohistochemistry, in order to distinguish between both adult Leydig 
progenitor cells (COUP-TFII+/3β-HSDneg) and adult Leydig cells (COUP-
TFII+/3β-HSD+) for their subsequent quantification.  
 
3.2.10 Triple immunofluorescence 
Testis sections from rat, mouse, marmoset and human underwent triple 
fluorescence immunohistochemistry. Antibody dilutions were optimised for 
fluorescence prior to experimentation. As above, Leydig cells were identified as 
cells immunopositive for the steroidogenic enzyme 3β-HSD, in their cytoplasm. 
COUP-TFII was used to localise both interstitial adult Leydig progenitor cells 
(COUP-TFII+/3β-HSDneg) and also adult Leydig cells (COUP-TFII+/3β-HSD+). 
Smooth Muscle Actin (SMA) was used to distinguish peritubular myoid (PTM) 
cells from interstitial cells and also to define the seminiferous cords/tubules. 
Other interstitial cell types were identified using the following markers; 
macrophages (CD68), pericytes (CD146), endothelial cells (CD31), fibroblasts 
(S100A4), and haematopoietic stem cells (CD34). Other factors known to be 
expressed by adult Leydig cells were also examined e.g. Insl3 and GATA4. 
Interstitial cells expressing COUP-TFII in their nucleus, but not expressing any 
of the other aforementioned cell-specific markers, are termed ‘adult Leydig 




progenitor cells’. Following citrate retrieval, slides were blocked in normal 
chicken serum (NChS) and incubated overnight at 4˚C with the primary 
antibody of interest (Table 3.3). After TBS washes, slides were incubated at 
room temperature for 30 minutes with peroxidase labelled secondary 
antibodies (1:200, section 2.12.3). Tyramide dye (Tyr-Cy5/Cy3) was used as a 
detector dye to localise the proteins of interest and diamidinophenylindole 
(DAPI) was used as a nuclear counterstain. For co-localisation studies, NChS 
was used as a block to prevent cross-reaction with mouse/goat antibodies and 
the protocol continued as before.  Slides were mounted with Permafluor 
(Thermo Scientific, Fremont, CA) prior to visualisation.  
 
3.2.11 Image capture 
Triple colorimetric or single immunohistochemistry images were captured 
using a Provis BX2 microscope (Olympus America Inc. Center Valley, PA, USA), 
that was fitted with a Canon DS126131 camera and EOS image capture software 
(Canon, Woodhatch, Surrey, UK). Fluorescent images were captured using a 
laser scanning confocal microscope (LSM) 710 Axiovert Observer Z1 (Carl Zeiss, 
AG, Germany). Images were compiled using Photoshop 5.0 (Adobe Systems Inc., 













Table 3.3 Primary antibodies used for immunofluorescence 
Primary Antibody Source Retrieval Species Dilution 
3β-HSD Santa Cruz Yes Goat 1:500 
SMA Santa Cruz Yes Mouse 1:6000 
COUP-TFII Perseus Proteomics Yes Mouse 1:1000 
SF1 Santa Cruz Yes Rabbit 1:200 
LHR Santa Cruz Yes Rabbit 1:200 
S100A4 Dako Yes Rabbit 1:1000 
CD34 Santa Cruz Yes Goat 1:500 
CD31 Santa Cruz Yes Goat 1:500 
CD146 Abcam Yes Rabbit 1:500 
CD68 AbD Serotec Yes Mouse 1:1000 
Insl3 Santa Cruz Yes Rabbit 1:500 
Gata4 Santa Cruz Yes Mouse 1:500 
GFP/YFP Abcam Yes Rabbit 1:1500 











3.3.1 Adult Leydig cell ablation/regeneration model 
Given the recent study illustrating the importance of COUP-TFII for adult Leydig 
cell differentiation (Qin et al 2008), the initial aim was to determine whether 
cells expressing COUP-TFII may be putative progenitors for adult Leydig cells.  
Using ethane dimethane sulphonate (EDS), to recapitulate normal adult Leydig 
cell differentiation in rats, is a well-established model (Bartlett et al 1986, 
Sharpe et al 1990, Teerds et al 1999, Ariyaratne et al 2003, O’Shaughnessy et al  
2008) in which the adult Leydig cell population is ablated, followed 
subsequently by regeneration to their initial population size. Firstly, to 
determine whether EDS had effectively ablated adult Leydig cells; tissue weight, 
plasma LH and testosterone levels, along with steroidogenic enzyme transcript 
levels were analysed at 1, 2, 3 or 5 wks post-EDS. These results demonstrated a 
significant reduction in both prostate and testis weight, (Figure 3.1), elevation of 
blood LH with a reduction in blood testosterone levels (Figure 3.2), and finally as a 
measure of Leydig cell function, expression of 3β-hsd and Lhr were found to be 
significantly decreased (Figure 3.2) post-EDS. These results are consistent with 
previous EDS studies (as above), indicating effective ablation of adult Leydig 
cells in this study. 





Figure 3.1 Prostate and testes weight post-EDS in rats. Representative image of 
prostate (top left; arrow) and testes (top right: arrowhead) is shown from a control 
animal. The weight of the prostate (bottom left) and testes (bottom right) is shown 
from both control and EDS-injected animals at specific timepoints post-EDS at 1, 2, 
3 or 5 weeks. Both prostate and testis weight were reduced following EDS injection. 
Values are mean ± SEM for control (n=8) and EDS (n=5). Data were analysed by one-
way ANOVA followed by Bonferroni post-hoc test; ***p<0.001, **p<0.01, in 
comparison with control animals.  
 





Figure 3.2 Plasma levels and Leydig cell gene expression post-EDS in rats. Change 
in plasma levels of LH (top left) and testosterone (top tight) and in gene expression 
of Lhr (bottom left) and 3b-hsd (bottom right) in testes from EDS-injected rats after 
1, 2, 3 or 5 wks. Values are means ± SEM for n=5-7 per group. Data were analysed 
using an unpaired t-test; ***p<0.001, ** p<0.01 in comparison with vehicle control 
group (time 0). 
 
3.3.2 Adult Leydig cells (3β-HSD+) differentiate from COUP-TFII+ cells 
Having validated the EDS model for successful adult Leydig cell ablation, the 
following experiments aimed to determine firstly, whether COUP-TFII+ cells 
were sensitive to EDS and secondly, whether the re-population of newly formed 
adult Leydig cells expressed COUP-TFII. Double immunofluorescence using 
COUP-TFII (putative adult Leydig progenitor cell marker) and 3β-HSD (to 
distinguish adult Leydig cells), was carried out on testis sections from control 
and EDS-injected adult rats. In adult control testes (vehicle injected animals 
(DMSO+H20)), the interstitium contained an abundance of COUP-TFII+ spindle-




shaped cells (arrow) while adult Leydig (3β-HSD+) cells expressed COUP-TFII in 
their nuclei (Figure 3.3; arrowhead). One week after EDS-induced adult Leydig 
cell ablation, there were no identifiable adult Leydig cells present while COUP-
TFII+ spindle-shaped cells were still present (Figure 3.3; arrow). Two weeks 
post-EDS, COUP-TFII+ interstitial cells acquired 3β-HSD in their cytoplasm, 
marking the regeneration of identifiable new Leydig (3β-HSD+) cells (Figure 3.3; 
arrowhead). The recovery of adult Leydig cells, close to their previous number 
pre-EDS, was evident at 3 weeks post-EDS, in which the majority contained a 
COUP-TFII+ nucleus (Figure 3.3; arrowhead). Adult Leydig progenitor cells 
(COUP-TFII+/3β-HSDneg) cells remained in the interstitium along with 
regenerating COUP-TFII+ adult Leydig cells (COUP-TFII+/3β-HSD+) throughout 
the regeneration period.  
 





Figure 3.3 Adult Leydig cell regeneration from COUP-TFII+ progenitor cells 
following EDS-induced ablation in the rat. In adult controls (upper left), adult Leydig 
progenitor cells are identified by their COUP-TFII nuclear staining (green; white 
arrow) while adult Leydig cells, which also express nuclear COUP-TFII, are stained 
with the cytoplasmic steroidogenic enzyme marker 3β-HSD (red; yellow 
arrowhead). One week post-EDS (upper right), Leydig cells are absent but COUP-
TFII+ Leydig progenitor cells (green nuclei) remain (white arrow). Two weeks post-
EDS (lower left), some spindle shaped COUP-TFII+ Leydig progenitor cells (yellow 
arrowhead) have begun to acquire 3β-HSD+ staining (red; yellow arrowheads), thus 
marking their onset into the adult LC lineage. Three weeks post-EDS (lower right) 
numerous adult Leydig cells have regenerated and continue to express COUP-TFII in 
their nuclei, as in controls. Insets show higher magnification of cells in transition 
from progenitor to adult Leydig cells. Dashed line depicts the outline of 
seminiferous tubules. Scale bars = 20μm or 10μm: bottom right image. 




3.3.3 Adult Leydig cells (Insl3+/3β-HSD+) differentiate from COUP-TFII+  cells 
In order to further examine whether COUP-TFII putative adult Leydig 
progenitor cells differentiated into adult Leydig cells, as indicated by the co-
expression of 3β-HSD two weeks post-EDS (Figure 3.3), a second marker for 
adult Leydig cells, Insl3 (Ivell et al 2013) was studied. Triple 
immunofluorescence using COUP-TFII (green) and adult Leydig cell markers; 
Insl3 (red) and 3β-HSD (blue), was carried out. Adult Leydig cells are evident in 
control testes (Figure 3.4; arrowheads). COUP-TFII is evident within the nuclei 
of adult Leydig cells (arrowhead) and putative adult Leydig progenitor cells 
(arrows). One week post-EDS, only COUP-TFII+ putative adult Leydig progenitor 
cells are present (arrow), which acquire both adult Leydig cell markers, 3B-HSD 
(blue) and Insl3 (red) after two weeks (Figure 3.4; arrowhead). Three weeks 
post-EDS, putative adult Leydig progenitor cells (COUP-TFII+; green) and adult 
Leydig cells expressing COUP-TFII are evident (Figure 3.4; arrowhead). These 
results demonstrated that adult Leydig cells (3β-HSD+ and Insl3+) express 
COUP-TFII in their nuclei, which may suggest their differentiation from COUP-
TFII+ putative adult Leydig progenitor cells. This prompted the question as to 
whether the number of COUP-TFII+ putative adult Leydig progenitor cells 
changed during adult Leydig cell regeneration post-EDS injection. 





Figure 3.4 Adult Leydig cells (3β-HSD+ and Insl3+) differentiate from COUP-TFII+ 
cells following EDS-induced ablation in the rat. In adult controls (top left), Leydig 
progenitor cells (COUP-TFII+: green; white arrow) are evident alongside adult Leydig 
cells (3β-HSD+: blue and Insl3+: red), which also express COUP-TFII in their nucleus. 
One week post-EDS (top right), Leydig cells are absent but COUP-TFII+ Leydig 
progenitor cells (green nuclei) remain (white arrow). Two weeks post-EDS (bottom 
left), some COUP-TFII+ Leydig progenitor cells have acquired 3β-HSD and Insl3 
staining (arrowhead), which marks the onset of adult Leydig cell regeneration. 
Three weeks post-EDS (bottom right) numerous adult Leydig cells (3β-HSD+ and 
Insl3+; arrowhead) have regenerated expressing COUP-TFII in their nuclei, as in 
controls. Insets show higher magnification views of cells in transition from 
progenitors to adult Leydig cells. * indicates the seminiferous tubules. Scale bars = 
20μm.  




3.3.4 Reduction in COUP-TFII+ adult Leydig progenitor cell number after EDS 
As adult Leydig cells appear to differentiate from COUP-TFII+ putative adult 
Leydig progenitor cells (COUP-TFII+/3β-HSDneg), it raised the question as to 
whether their number changed during adult Leydig cell regeneration. Staining 
with the proliferation marker PCNA (red) showed that a small proportion of 
COUP-TFII+ cells (green nuclei; arrow) were proliferating, as indicated by 
'yellow' co-localisation of COUP-TFII+ and PCNA+ cells, one week post-EDS 
(Figure 3.5). However, following quantification of the putative adult Leydig 
progenitor cells (COUP-TFII+/3β-HSDneg), their number declined significantly 
over the 5-week period of adult Leydig cell regeneration (Figure 3.5), consistent 
with some of these cells differentiating into adult Leydig cells. The number of 
adult Leydig cells increased in number during their regeneration, to near 
normal levels (Figure 3.5). 





Figure 3.5 Quantification of adult Leydig cells and their putative progenitors. Adult 
Leydig cells (COUP-TFII+/3β-HSD+) and putative adult Leydig progenitor cells (COUP-
TFII+/3β-HSDneg) were quantified at 1, 2 3 or 5 weeks post-EDS in the rat. Adult 
Leydig cells were ablated and recovered after 5 weeks to near normal levels as in 
control. Putative adult Leydig progenitor cells significantly declined in numbers at 5 
weeks post-EDS. Values are means ± SEM; n=5-7 per group; Data were analysed 
using an unpaired t-test; ***p<0.001, *p<0.05 in comparison with vehicle control 
group (time 0). Scale bars = 20μm. 
 
 




3.3.5 COUP-TFII+ adult Leydig progenitor cells do not express key interstitial cell 
markers 
To investigate any alternative interstitial cell source for regenerating adult 
Leydig cells, other than COUP-TFII+ cells, double immunofluorescence was 
carried out using COUP-TFII (putative adult Leydig progenitor cells; green) and 
a range of other testicular interstitial cell markers (red). These included 
macrophages (CD68), pericytes (CD146), endothelial cells (CD31), peritubular 
myoid cells (SMA), fibroblasts (S100A4), or hematopoietic stem cells (CD34). 
Other immature/mature Leydig cell markers were also studied including SF1, 
LHR, Insl3 and Gata4 to investigate their expression profile in the putative adult 
Leydig progenitor cells. The results showed that COUP-TFII+ putative adult 
Leydig progenitor cells (green) did not express any other interstitial marker as 
listed above (red), other than COUP-TFII (Figure 3.6). Furthermore these cells 
did not express the phenotypical adult Leydig cell markers 3β-HSD (Figure 3.3) 
or Insl3 (Figure 3.4). MafB was also examined as a potential marker of adult 
Leydig progenitor cells, as it has been implicated in fetal Leydig cell 
development (DeFalco et al 2011). However adult Leydig progenitor cells did 
not express MafB at 1 or 2 weeks post-EDS (Figure 3.7). Lastly, the adult Leydig 
cell marker GATA4 (red) was examined. This demonstrated that, 1-2 weeks 
after EDS treatment, a proportion of putative adult Leydig progenitor cells 
(COUP-TFII+; green), located within the interstitium or bordering the 
seminiferous tubules, co-expressed GATA4 (COUP-TFII+/GATA4+; yellow 
arrows) whereas these cells were only rarely evident in control testes (Figure 
3.8). Two and three weeks post-EDS, a proportion of COUP-TFII+ progenitor 
cells expressing GATA4, differentiated into adult Leydig cells, as indicated by 
expression of 3β-HSD (Figure 3.8; arrowheads). A summary of interstitial cell 
markers and immature/mature adult Leydig cell markers investigated for 
expression in COUP-TFII+ putative adult Leydig progenitor cells is shown below 
(Table 3.4). Other factors which are associated with fetal/adult Leydig cell 
differentiation/development e.g. LHX9 (Birk et al 2000, Mazaud et al 2002, Tang 
et al 2008), POD1 (Tamura et al 2001, Cui et al 2004, Bhandari et al 2011), LIFR 
(Ge et al 2006) and GPRC6A (Karsenty, 2012, Oury et al 2013), were also 




investigated, but excluded from this thesis due to the non-specificity of the 
antibodies used. 
 
Figure 3.6 Adult Leydig progenitor cells do not express any other interstitial cell 
markers one week-post EDS in the rat. Adult Leydig progenitor cells (COUP-TFII+; green 
nuclei) are negative for the following: SMA staining, found in PTM cells surrounding the 
seminiferous tubules and blood vessels (red); pericyte marker, CD146 (red), endothelial cell 
marker CD31 (red), macrophage marker CD68 (red), haematopoietic stem cell CD34 (red) 
(SMA:blue) and a fibroblast marker S100A4 (red). Note that in the bottom left image 
(CD34); nuclear counterstain DAPI is shown in blue. * depicts seminiferous tubules. Scale 
bars = 20µm and represent n=5.    





Figure 3.7 MafB expression is restricted to regenerating adult Leydig cells post-
EDS in the rat. In control adult rat testis (top left), MafB expression is 
minimal/absent in the interstitium. One week post-EDS injection, the testis was 
negative for MafB staining (top right). Two weeks post-EDS, when adult Leydig cells 
begin to regenerate, MafB (brown) expression was evident in the cytoplasm of 
Leydig cells, as based on morphology (bottom image). * depicts seminiferous 
tubules. Scale bar = 50µm. 





Figure 3.8 Expression of GATA4 in COUP-TFII+ putative adult Leydig progenitor 
cells is an early step in their differentiation into adult Leydig cells (ALC) in the rat. In 
adult controls (top left), GATA4 expression (red) is confined to the nuclei of Sertoli 
cells (asterisks) and 3β-HSD+ (blue) Leydig cells (white arrowheads). COUP-TFII-
expressing Leydig progenitor cells (green) are negative for GATA4. One week post-
EDS (top right), Leydig cells are absent, but GATA4 has been switched on in a 
proportion of putative adult Leydig progenitor cells (yellow arrows; co-expression of 
green and red in nuclei). Two weeks post-EDS (bottom left), some of the GATA4-
expressing interstitial cells have switched on 3β-HSD (blue) and by three weeks 
(bottom right), these cells have completed their differentiation into adult Leydig 
cells. Cells co-expressing GATA4, 3β-HSD and COUP-TFII are labelled with white 
arrows. Insets show higher magnification. For technical reasons with triple 
immunofluorescence, nuclear COUP-TFII is only evident in a proportion of ALC in 
these images, whereas it is more clearly evident in ALC of earlier images with 
double immunofluorescence.   




Table 3.4 Summary of interstitial and adult Leydig cell markers investigated post 
EDS injection in rats, and whether or not they were expressed in COUP-TFII+ 




3.3.6 Lineage tracing of adult Leydig cells  
To establish whether COUP-TFII could be used as a true marker of the adult 
Leydig progenitor population, a model for adult Leydig lineage tracing was 
utilised. Mice with Cre recombinase driven by the adipocyte protein (aP2) 
promoter were bred with a YFP reporter line which showed aP2 was restricted 
to Leydig cells, and YFP reporter mice without a Cre transgene did not express 
YFP (O'Hara et al, unpublished). For the purpose of co-localisation studies in 
this chapter, the YFP/GFP antibody used to detect YFP+ cells is labelled GFP, as 
indicated in green. During fetal life, ap2+/GFP+ cells co-localised with COUP-TFII 




in Leydig progenitor cells when examined at birth (Figure 3.9; top panel). 
Follow up analysis demonstrated that this fetally-induced YFP expression was 
restricted to adult Leydig cells in adulthood (Figure 3.9; bottom panel), 
confirming that COUP-TFII marks a progenitor population which later develop 
into adult Leydig cells. Therefore, the COUP-TFII+ interstitial cells will be termed 
'adult Leydig progenitor cells' for the remainder of this thesis.  However, it 
should be noted that it is unclear if all of the progenitor cells identified have the 
capacity to develop into adult Leydig cells, or only a sub-population. Moreover, 
the lineage tracing experiment also showed that some adult Leydig cells did not 
express GFP (Figure 3.9). This may indicate that some adult Leydig cells may 
have differentiated from cells other than COUP-TFII+ adult Leydig progenitor 
cells, which were present at birth. 






Figure 3.9 COUP-TFII marks adult Leydig progenitor cells as evident from 
transgenic lineage of adult Leydig cells in mice. At birth (e18.5; top row), the 
adipocyte protein 2 (aP2) Cre Recombinase induced GFP expression (white arrows) 
was coincident with COUP-TFII-expressing cells in the testis (yellow arrows). Merged 
image shows both COUP-TFII and GFP co-localisation (white arrowheads) in adult 
Leydig progenitor cells. Follow up analysis in adulthood (pnd 50; bottom panel), 
demonstrated that this fetally-induced GFP expression (white arrow) was restricted 
to 3β-HSD-expressing (yellow arrow) adult Leydig cells, as indicated by their co-
expression (merged image; white arrowhead). Asterisks indicate non-GFP+ adult 
Leydig cells. Scale bars = 20 μm. 
 
3.3.7 Expression of COUP-TFII during puberty and adulthood 
As the results (above) demonstrated that adult Leydig cells regenerate from 
COUP-TFII+ progenitor cells, the next aim was to study Leydig cell 
differentiation during normal development i.e. puberty. Triple 
immunofluorescence was used on rat testes to distinguish adult Leydig cells 
(3β-HSD; red), to identify peritubular myoid (PTM) cells and delineate 




seminiferous tubules via expression of smooth muscle actin (SMA; blue) and to 
investigate adult Leydig progenitor cells (COUP-TFII+; green). As with adult 
Leydig cell regeneration, these results demonstrated that COUP-TFII is 
expressed in two cell types; 1) spindle shaped interstitial cells in close proximity 
to the tubules and within the interstitium (green; arrows) and 2) adult Leydig 
cells (red; arrowheads) expressing nuclear staining of COUP-TFII  (COUP-
TFII+/3β-HSD+) (Figure 3.10).  During adulthood, COUP-TFII is expressed in 
most adult Leydig cells (arrowheads) while COUP-TFII+ interstitial cells 
(arrows) are also present (Figure 3.10). 
 
 
Figure 3.10 COUP-TFII+ is expressed in adult Leydig progenitor cells and adult 
Leydig cells in puberty and adulthood in the rat. At puberty, COUP-TFII+ (green; 
arrows) spindle shaped interstitial cells are present (left), along with COUP-TFII+ 
adult Leydig cells with cytoplasmic 3β-HSD (red; arrowheads). Similarly, in 
adulthood (pnd 90), both COUP-TFII+ interstitial cells and adult Leydig cells (COUP-
TFII+/3β-HSD+) are present. A counterstain was used to visualise nuclear staining 
(DAPI; orange). Asterisks depict seminiferous tubules. Scale bar = 20µm. 
 
 




Recapitulating normal adult Leydig cell development via EDS demonstrated that 
GATA4 was switched on in COUP-TFII+ adult Leydig progenitor cells (Figure 3.8) 
prior to adult Leydig cell differentiation. To investigate whether this occurs 
during normal adult Leydig cell development, a similar expression study was 
undertaken using triple immunofluorescence for GATA4 (red), 3β-HSD (blue) 
and COUP-TFII (green) in control rats throughout puberty. At the initiation of 
puberty (day 15), GATA4 expression was evident in a proportion of the COUP-
TFII+ adult Leydig progenitor cells (yellow arrows), and by pnd 25, these cells 
had begun to transform into adult Leydig (3β-HSD+) cells (white arrows) 
(Figure 3.11), which mimics the sequence of protein expression during adult 
Leydig cell regeneration, after EDS (Figure 3.8). 
 
 
Figure 3.11 GATA4 is expressed in COUP-TFII+ adult Leydig progenitor cells during 
normal pubertal development. At the start of normal puberty (Pnd15) in the rat, 
co-expression of GATA4 in COUP-TFII+ Leydig progenitor cells was common (yellow 
arrows) and by Pnd25 (bottom right) many of these cells had also begun to switch 
on 3β-HSD (white arrows). Insets show higher magnification to emphasise the 
cascade of protein expression changes in the Leydig progenitor cells during their 
differentiation into Leydig cells. Asterisks depict seminiferous tubules. Scale bars = 
10µm (left image) and 20µm (right image). 




3.3.8 Adult Leydig progenitor cells are present during fetal life 
From the earlier lineage tracing experiment, it was evident that COUP-TFII+ 
adult Leydig progenitor cells were present at birth (Figure 3.9). To further 
investigate the presence of these cells during fetal life, double 
immunofluorescence was carried out using COUP-TFII (green nuclear staining; 
adult Leydig progenitor cells) and 3β-HSD (red cytoplasmic staining; fetal 
Leydig cells) on control fetal testis sections from rats at e21.5.  From both the 
tiled and high magnification images (Figure 3.12), COUP-TFII+ (green) 
interstitial cells are clearly the most abundant cell type in the fetal testis. Fetal 
Leydig cells (red) were negative for COUP-TFII (Figure 3.12) at this age. To 
ensure this was not a species specific finding, triple immunofluorescence with 
COUP-TFII, 3β-HSD and SMA (to delineate seminiferous tubules) was carried 
out on sections from fetal human, marmoset and mice, all of which 
demonstrated the numerous presence of COUP-TFII+ adult Leydig progenitor 
cells (Figure 3.13).  
 
Figure 3.12 COUP-TFII+ cells are abundant in the fetal rat testis. Double 
immunofluorescence for COUP-TFII (green) and 3β-HSD (red) in fetal rat testis 
(e21.5). COUP-TFII is expressed in the interstitial cells (green; arrows) while fetal 
Leydig cells (red; arrowhead), are negative for COUP-TFII staining. Scale bars = 
100µm (tiled image; left) and 20 µm (right image). Images are representative of at 
least 3 control animals. 





Figure 3.13 Expression of COUP-TFII in fetal testes across species. COUP-TFII+ 
(green) Leydig progenitor cells (white arrow) are the most abundant cell type in the 
fetal testis of human (top left), marmoset (top right), rat (bottom left) and mouse 
(bottom right) where red = 3β-HSD (fetal Leydig cells; LC) and blue = smooth muscle 
actin, (asterisks indicate seminiferous tubules). The majority of fetal Leydig cells are 
negative for COUP-TFII. Human sample = 16 weeks gestation; marmoset = 15 weeks 
gestation; rat = e21.5; mouse = e18.5. Scale bars = 20 µm. 
   
   




3.3.9 Steroidogenic Factor-1 and LHR are not expressed in adult Leydig 
progenitor cells 
Steroidogenic factor-1 (SF1), is required during fetal life for two fundamental 
events 1) normal testis development and 2) differentiation and steroidogenic 
function of fetal Leydig cells. Given the hypothesis that COUP-TFII+ cells present 
during fetal life are the progenitors for adult Leydig cells, triple 
immunofluorescence was undertaken to investigate whether SF-1 was 
expressed in adult Leydig progenitor cells in the fetal testis. This was carried out 
using COUP-TFII (green; nuclear staining), SF1 (red; nuclear staining) and 3B-
HSD (blue; cytoplasmic staining). From the tiled and higher power images  
(Figure 3.14) in rat (top panel) and mouse (bottom panel), the expression of 
COUP-TFII (green) is localised to the interstitium while SF1 (red) is clearly 
localised to Sertoli cells (within the tubules; red) and fetal Leydig cells (blue).  It 
is clearly evident that the COUP-TFII+ adult Leydig progenitor cells do not 
express SF1. Furthermore, to investigate whether COUP-TFII adult Leydig 
progenitor cells express the luteinising hormone receptor (LHR), double 
immunofluorescence was carried out using COUP-TFII (green) and LHR (red), 
which demonstrated that COUP-TFII+ cells do not express LHR (Figure 3.15). 





Figure 3.14 COUP-TFII+ adult Leydig progenitor cells do not express SF1 in rodents. 
COUP-TFII+ (green) adult Leydig progenitor cells (white arrow) do not co-localise 
with SF1 (red; Sertoli and fetal Leydig cells), as shown in the fetal rat testis at e21.5 
(top; tiled image and zoom) and mouse at e18.5 (bottom; tiled image and zoom). 
The majority of fetal Leydig cells (3β-HSD+; blue cytoplasmic staining), are negative 
for COUP-TFII. Asterisks indicate seminiferous cords. Scale bars = 100 µm (tiled 
images; left panel) and 20 µm (right panel).   





Figure 3.15 COUP-TFII+ cells do not express LHR in rat testes at e21.5. COUP-TFII+ 
adult Leydig progenitor cells (green) do not express the cytoplasmic marker LHR 
(red). Scale bars = 100 µm (tiled image; left) and 20 µm (right image).   
 
3.3.10 MafB is not expressed in adult Leydig progenitor cells in the fetal testis 
A recent study reported that ‘MafB’ is involved in the differentiation of fetal 
Leydig cells (DeFalco et al 2011), however little is known about its involvement 
in adult Leydig cell differentiation. To investigate whether MafB was potentially 
expressed in the adult Leydig progenitor cells, single immunofluorescence using 
DAB to localise Mafb (brown; arrowheads) was carried out on mouse testes at 
e18.5. Based on morphology, MafB was found to be solely expressed in the 
cytoplasm of fetal Leydig cells (arrowheads; Figure 3.16), therefore co-
localisation studies of Mafb with interstitial COUP-TFII+ adult Leydig progenitor 
cells, was not further investigated. 





Figure 3.16 Expression of MafB in fetal Leydig cells. MafB (brown) staining is 
restricted to the cytoplasm of fetal Leydig cells (arrowheads) in the mouse testis at 
e18.5. Scale bar = 100 µm (tiled image; left) with a higher magnification image 
shown on the right. Images are representative of at least 3 control animals. 
 
3.3.11 Volume per testis of adult Leydig cells and their progenitors  
As COUP-TFII is expressed in adult Leydig progenitor cells, adult Leydig cells 
and some peritubular myoid (PTM) cells, the only method of specifically 
investigating the volume per testis of COUP-TFII+ adult Leydig progenitor cells 
was to use triple immunohistochemistry to distinguish between cell types 
followed by stereological analysis. COUP-TFII+ interstitial cells that did not 
express SMA (i.e. PTM cells) or 3β-HSD (i.e. fetal/adult Leydig cells), were 
quantified using established stereological techniques (Auharek et al 2010, van 
den Driesche et al 2012) (Section 2.11). The software for stereological analysis 
in these studies required colorimetric immunohistochemistry and not 
fluorescence. Thus, sections underwent triple colorimetric 
immunohistochemistry using 3β-HSD (blue; Leydig cells) and SMA (red; 
seminiferous tubule lining) and COUP-TFII (brown; adult Leydig progenitors). 
This was performed on wild-type mice throughout development e.g. just after 
birth (Pnd 2), pre-puberty (Pnd 12, 20) and during adulthood (Pnd 50 and 140). 
As in the previous immunofluorescence images above, the representative triple 




colorimetric images revealed an abundance of COUP-TFII+ (brown) interstitial 
cells after birth (Pnd 2) with fetal Leydig cells (blue) negative for COUP-TFII 
expression (Figure 3.17). Prior to puberty, (Pnd 12) COUP-TFII+ (brown; 
arrows) interstitial cells were present along with differentiating adult Leydig 
cells expressing cytoplasmic 3B-HSD (blue) and nuclear COUP-TFII 
(arrowheads).  Both adult Leydig progenitor cells (COUP-TFII+) and adult Leydig 
cells (COUP-TFII+/3β-HSD+) were also present at adulthood (pnd 90) (Figure 
3.17). 
 
Figure 3.17 COUP-TFII expression in mouse testis across development. Triple 
immunostaining for adult Leydig progenitor cells (COUP-TFII; brown), Leydig cells 
(3β-HSD; blue) and peritubular myoid cells (SMA; red). At e18.5, COUP-TFII+ cells are 
abundant in the interstitium, (arrow). Fetal Leydig cells are negative for COUP-TFII 
staining.  Pre-puberty (Pnd 12), differentiating adult Leydig cells (arrowhead) exhibit 
nuclear staining for COUP-TFII. Interstitial COUP-TFII+ cells are also present (arrow). 
During adulthood (Pnd 90), both adult Leydig progenitor cells (COUP-TFII+) and adult 
Leydig cells (COUP-TFII+/3β-HSD+) were also present. e18.5, pnd90 (x 20 
magnification; scale bars = 50µm), pnd 12 (x 40 magnification; scale bar = 20µm). 
Images are representative of at least 3 control animals per age.  
 
To determine the volume of adult Leydig progenitor cells (COUP-TFII+/3β-
HSDneg) and adult Leydig cells (COUP-TFII+/3β-HSD+) per testis, stereological 
analysis was performed on testis sections in mice after birth (Pnd 2), pre-
puberty (Pnd 12, 20) and into adulthood (Pnd 50 and 140). Numbers of adult 
Leydig progenitor cells increased steadily across development, as did adult 




Leydig cells (Figure 3.18). It has been well established that adult Leydig cells 
(3β-HSD+) increase in number following their differentiation at puberty, which 
these results firstly confirm and secondly add a new dimension to the current 
understanding, as the developing adult Leydig cells also expressed COUP-TFII+ 
in their nuclei (Figure 3.17, 3.18). The adult Leydig progenitor cells were also 
quantified at e15.5 and e17.5 in the rat, which demonstrated a significant 
increase in cell number during fetal development (Figure 3.19). 
 
 
Figure 3.18 Increase in adult Leydig progenitor and adult Leydig cell numbers 
across development in the mouse. Adult Leydig progenitor cells (COUP-TFII+/3β-
HSDneg) and adult Leydig cells (COUP-TFII+/3β-HSD+) were quantified throughout 
development in mice; after birth (pnd 2), pre-puberty (pnd 12, 20) and adulthood 
(pnd 50, and 140). Values are means ± SEM for n=7-10 wild-type mice at each age. 
Data were analysed by one-way ANOVA followed by Bonferroni post-hoc test; 
**p<0.01, ***p<0.001 in comparison with pnd 2 and pnd 12 for progenitor Leydig 
cells and adult Leydig cells, respectively. 





Figure 3.19 Increase in COUP-TFII+ adult Leydig progenitor cells during fetal 
development in the rat. Adult Leydig progenitor cells (COUP-TFII+/3β-HSDneg) were 
quantified during fetal rat development. Values are means ± SEM for e15.5 (n=4) 
and e21.5 (n=7). Data were analysed using an unpaired t-test. ***p<0.001 in 



















The principal aim of this chapter was to establish whether COUP-TFII marks the 
adult Leydig progenitor cell population and whether these cells were present in 
the fetal testis. The current findings demonstrate adult Leydig cells differentiate 
from a population of COUP-TFII+ interstitial cells evident from 1) an EDS-
induced adult Leydig cell ablation/regeneration rat model, 2) lineage tracing in 
a mouse model and 3) their differentiation into adult Leydig cells during normal 
puberty. Furthermore, the importance of COUP-TFII+ adult Leydig progenitor 
cells is highlighted by their abundant and conserved presence within the fetal 
testis.  
Using ethane dimethane sulphonate (EDS) to ablate the population of mature 
adult Leydig cells is a valuable and well-established model to investigate adult 
Leydig cell development. The present findings support previous studies in 
showing complete Leydig cell ablation and subsequent regeneration two to 
three weeks post-EDS. This was evident from 1) the decrease in testis and 
prostate weight as a result of decreased testosterone, 2) immediate reduction 
followed by a gradual increase in mRNA transcripts for 3β-HSD and Lhr as a 
consequence of regenerating adult Leydig cells, 3) elevation of LH blood levels 
which corresponded with a reduction in blood testosterone levels between 2 
and 3 weeks post-EDS, and 4) definitive 3β-HSD and Insl3 immunoexpression at 
2 weeks post EDS, when regenerating adult Leydig cells are first detectable 
(Morris & Jackson 1978, Kerr et al 1985, Molenaar et al 1985, Bartlett et al 1986, 
Edwards et al 1988, Sharpe et al 1986, 1990, Teerds et al 1999, Ariyaratne et al 
2003, O’Shaughnessy et al 2008). These results demonstrate that unlike the 
mature adult Leydig cells which are sensitive to EDS and thus ablated COUP-
TFII+ progenitor cells are resistant to such an insult. Furthermore, COUP-TFII+ 
interstitial cells acquire adult Leydig cell markers (3β-HSD and Insl3) two 
weeks post-EDS, suggesting their differentiation into adult Leydig cells, which is 
further supported by the significant reduction in the number of adult Leydig 
progenitor cells five weeks post-EDS. 




Previous studies which investigated the differentiation of adult Leydig cells 
during normal puberty or after EDS-induced ablation/regeneration, have 
suggested that adult Leydig cells arise from peritubular myoid cells/fibroblast 
cells (Haider et al 1995, Russell et al 1995, Landreh et al 2013), perivascular 
smooth muscle cells and pericytes (Davidoff et al 2004, 2009), macrophages 
(Clegg and Mcmillan 1965) or vascular endothelial cells (Russell et al 1995). 
Using COUP-TFII as a marker for adult Leydig progenitor cells during adult 
Leydig cell regeneration (post-EDS) and examining any co-expression of the 
aforementioned interstitial cells, demonstrated that COUP-TFII+ adult Leydig 
progenitor cells are a distinct population, located within the interstitium and in 
peritubular locations.  
A proportion of COUP-TFII+ adult Leydig progenitor cells were located close to 
the vasculature, which may fit with studies suggesting perivascular smooth 
muscle cells and pericytes are a source for regenerating adult Leydig cells 
(Haider and Servos 1998, Davidoff et al 2004). However, this seems unlikely as 
COUP-TFII+ adult Leydig progenitor cells did not express the pericyte marker 
CD146, nor an endothelial cell marker CD31, one week post-EDS injection. 
Recent studies have suggested peritubular myoid cells may be a potential 
source for regenerating Leydig cells (Ge and Hardy 2007, Teerds et al 2007, 
Landreh et al 2013), however neither interstitial COUP-TFII+ adult Leydig 
progenitor cells or regenerating adult Leydig cells (COUP-TFII+/3β-
HSD+/Insl3+) in the EDS model expressed the peritubular cell marker (SMA) in 
this study. However, the potential dedifferentiation of SMA+ PTM cells into adult 
Leydig cells, i.e. losing SMA expression but retaining COUP-TFII, is also a 
possibility.   
This study cannot rule out the possibility that some adult Leydig cells might 
differentiate from cells other than COUP-TFII+ adult Leydig progenitor cells, as 
mentioned above. This is evident from the lineage tracing studies in which not 
all of the adult Leydig cells expressed GFP in adulthood. One explanation is that 
some adult Leydig progenitor cells might have suppressed the recombination of 
the loxP sites. Alternatively, as aP2Cre/GFP expression was localised to the 




interstitium and peritubular layer, but not perivascular cells of the fetal testis, 
this may suggest that some adult Leydig cells could in fact, have differentiated 
from the perivascular layer, which fits with previous studies (Davidoff et al 
2004, 2009). Nonetheless, the precise source(s) for regenerating/differentiating 
adult Leydig cells remains unknown. All that can currently be agreed upon, is 
that Leydig cells arise from undifferentiated progenitor mesenchymal cells 
located “within the interstitium” (Habert et al 2001, Mendis-Handagama and 
Ariyaratne, 2001), which is consistent with interstitial COUP-TFII+ cells in this 
study. Furthermore, as the majority of both normal and regenerating adult 
Leydig cells expressed COUP-TFII, and adult Leydig cells were shown to arise 
from aP2Cre/GFP+ cells which co-localised with COUP-TFII in the fetal testis, 
this strongly suggests COUP-TFII marks a population of adult Leydig progenitor 
cells. However, it is unclear whether all COUP-TFII+ adult Leydig progenitor 
cells have the potential to differentiate into adult Leydig cells, or only a subset. 
Although COUP-TFII+ adult Leydig progenitor cells did not co-express any other 
Leydig cell markers e.g. 3β-HSD, Insl3, LHR, SF1, a proportion of the progenitor 
cells post-EDS did however express GATA4, a transcription factor involved in 
Leydig cell development in humans and rodents (Ketola et al 2000, 2002, Ge et 
al 2006, Thurisch et al 2009). The COUP-TFII+ interstitial cells expressing 
GATA4 were located both within the interstitium and bordering the 
seminiferous tubules. These cells (COUP-TFII+/GATA4+) differentiated into 
adult Leydig cells two-three weeks post-EDS, as evident by their expression of 
the cytoplasmic adult Leydig cell marker, 3β-HSD. An earlier study isolated 
interstitial “Leydig stem cells” from neonatal rats, which amongst other factors, 
expressed GATA4 and were capable of differentiating into steroidogenic cells 
(Ge et al 2006). In conjunction with the present findings, this points to a role for 
GATA4 in adult Leydig progenitor/stem cell differentiation but also strengthens 
the hypothesis, due to the co-expression of GATA4, that COUP-TFII marks a 
population of adult Leydig progenitor cells. These results also highlight the 
accuracy of the EDS model in recapitulating normal adult Leydig cell 
development as the differentiation pattern of GATA4 as an early differentiation 




marker of adult Leydig cells, was also evident during puberty, as shown from 
immunostaining at pnd 15 and pnd 25 in the rat. 
Deletion of COUP-TFII from pre-pubertal male mice prevented adult Leydig cell 
differentiation (Qin et al 2008), which potentially suggests the importance of 
COUP-TFII in this process. The current findings are in agreement with the 
previous authors, as evident from COUP-TFII expression in regenerating Leydig 
cells post-EDS and during normal development throughout puberty and 
adulthood. Quantification of adult Leydig progenitor cells throughout postnatal 
life in the mouse revealed a significant increase in cell number from fetal life, 
and more specifically between puberty (Pnd 12) to adulthood (Pnd 140). This 
indicates that there may not be a limiting number of these cells but rather a 
large progenitor pool. The number of adult Leydig cells (COUP-TFII+/3β-HSD+) 
increased 20-fold, which corresponds with earlier data (De Gendt et al 2005) 
demonstrating a 26-fold increase in adult Leydig cell number during the same 
time frame. The increase in COUP-TFII+ adult Leydig progenitor cells during 
puberty is also consistent with an earlier study, which quantified ‘mesenchymal, 
non-Leydig interstitial cells’ based on morphology (Mendis-Handagama and 
Ariyaratne, 2001).  
The study by Ge et al 2006, as previously discussed, showed that interstitial 
“Leydig stem cells” could be isolated from neonatal rats, which suggests that the 
adult Leydig progenitor cells are present during fetal life. The results of the 
present studies clearly demonstrate that COUP-TFII+ adult Leydig progenitor 
cells are abundant in fetal testes and conserved across species e.g. in human, 
marmoset, rat and mouse. These cells are a distinct population from fetal Leydig 
cells as they do not express the markers SF1 (Val et al 2003), MafB (deFalco et al 
2011) nor do they express LHR (Chen et al 2009), which is consistent with 
studies that investigated LHR expression on Leydig “stem” cells (Ariyaratne et al 
2000, Ge et al 2006, Teerds et al 2007). Quantification of adult Leydig 
progenitor cells during fetal development (e15.5 and e21.5) in the rat 
demonstrated that the number of these cells increased ~17-fold from e15.5 to 
e21.5 in control rats. This increase is coincident with increasing testosterone 




levels during fetal programming/development (Welsh et al 2008, van den 
Driesche et al 2012), which may potentially point to a role for androgens in the 
proliferation of these cells. This raised the question as to whether the COUP-
TFII+ adult Leydig progenitors express the androgen receptor (AR) i.e. are 
androgen responsive and might therefore be affected by altered levels of 
androgen, which the following chapter will address.  
Since Leydig cell number in adulthood is a key determinant of testosterone 
levels in blood, and their function is vital for normal spermatogenesis and 
overall male health, the differentiation of adult Leydig cells is of great 
importance. Given the fact that adult Leydig cells rarely proliferate (Teerds et al 
1989), it seems logical to assume that adult Leydig cells must develop from a 
pool of interstitial progenitor cells, which the present studies have identified. 
This chapter has demonstrated that adult Leydig progenitor cells express COUP-
TFII and are present in the fetal testis across species, where they later 
differentiate into adult Leydig cells at puberty. This has been shown during 
normal development and in an EDS-induced ablation/regeneration model to 
recapitulate normal development. Furthermore, adult Leydig cell lineage tracing 
demonstrated that aP2Cre/GFP+ cells co-expressed COUP-TFII+ in fetal life, and 
a proportion of these cells differentiated into adult Leydig cells. The number of 
COUP-TFII+ adult Leydig progenitor cells increased significantly between 
puberty and adulthood, in parallel with the number of differentiating adult 
Leydig cells. The next chapter will address if adult Leydig progenitor cells are 
responsive and/or affected by manipulating fetal androgens using various 
animal models in order to determine if this may explain how fetal events 
predetermine adult testosterone levels. 




Chapter 4 Androgen Regulation of Adult Leydig Progenitor Cells 
4.1 Introduction 
The previous chapter demonstrated that a population of COUP-TFII+ interstitial 
cells, present in the fetal testis, differentiate into COUP-TFII+ adult Leydig cells 
at puberty, and are thus taken to be adult Leydig progenitor cells. The 
experiments in this chapter aimed to investigate whether adult Leydig 
progenitor cells, present during fetal life, were androgen targets and might 
therefore be androgen-mediated. Various attempts to manipulate androgen 
levels/action in pre and post-natal life were undertaken to investigate whether 
altering fetal androgen action affects the number/function of adult Leydig cells 
via effects on their progenitors.  
Androgens are vital for normal testis descent, however, they do not appear to be 
necessary for normal testis formation and organisation, as evident from ARKO 
mice (O'Shaughnessy et al 2002, De Gendt et al 2005, Verhoeven et al 2010). As 
Sertoli cells do not express AR in fetal life, it is interesting that fetal androgen 
deficiency results in a reduction of final Sertoli cell number as shown in ARKO 
but not SCARKO mice (De Gendt et al 2004, Tan et al 2005, O’Shaughnessy et al 
2012). This suggests that androgen effects on Sertoli cells must be indirect, 
potentially via an AR+ cell within the fetal testis. Deletion of AR in PTM cells 
does not affect Sertoli cell number (PTMARKO mouse; Welsh et al 2009), which 
points to a role for another AR+ cell present in the fetal testis, potentially via 
COUP-TFII+ adult Leydig progenitor cells. Therefore, the first aim of this chapter 
was to investigate if adult Leydig progenitor cell number and thus adult Leydig 
cell function were affected by altered fetal androgen signalling via ubiquitous 
ARKO and cell-specific ARKO mouse models.  
Previous studies that investigated the ablation of AR signalling in Sertoli cells 
(SCARKO), reported a 40% reduction in adult Leydig cell number (DeGendt et al 
2005), although a more recent study reported a comparable number of the 
latter cells between control and SCARKO (O'Shaughnessy et al 2012). AR 




ablation in PTM cells (PTMARKO), resulted in altered adult Leydig cell function 
(Welsh et al 2009).  Ubiquitous knockout of AR (ARKO) results in a reduction in 
adult Leydig cell number (DeGendt et al 2005, O'Shaughnessy et al 2012). Thus, 
use of the ubiquitous ARKO or cell-specific mouse models were used to 
determine whether the adult Leydig progenitor cells were androgen-modulated 
and if alterations to the number of the progenitor cells might explain the altered 
number and/or function in adult Leydig cells.  
Primary hypogonadism in men (also called hypergonadotrophic hypogonadism) 
can occur as a result of testicular failure due to genetic disorders (e.g. Klinefelter 
syndrome) or adult Leydig cell dysfunction and is associated with low-normal 
testosterone and high levels of LH and FSH (Tajar et al 2010). Secondary 
hypogonadism (also called hypogonadotropic hypogonadism) can occur due to 
hypothalamic-pituitary failure (e.g. Kallmann's syndrome) and is associated 
with low levels of testosterone and normal-low levels of LH and FSH (Tajar et al 
2010). The main difference between primary and secondary hypogonadism is 
an increase or decrease in LH levels respectively. ARKO male mice are a useful 
model for human AIS individuals with primary hypogonadism, which manifests 
as compensated adult Leydig cell failure. This is evident from increased LH and 
low-normal testosterone levels in ARKO males (Yeh et al 2002, Matsumoto et al 
2003, Notini et al 2005, De Gendt et al 2005).  
DBP-induced lowering of fetal testosterone in rats has been used to model 
human testicular dysgenesis syndrome (TDS) (Mahood et al 2005, 2006, Sharpe 
& Skakkebaek 2008, van den Driesche et al 2012). These studies illustrate the 
importance of normal fetal androgen action and suggest that fetal androgen 
deficiency can cause life-long abnormalities of the male reproductive tract 
(Barlow and Foster 2003). Using DBP to lower fetal androgen levels provides a 
useful model for investigating whether fetal androgens affect adult Leydig 
progenitor cells and their development into normal functioning adult Leydig 
cells. 




The next aim of this chapter was to investigate whether postnatal androgens 
could regulate adult Leydig progenitor cell development. Flutamide, a potent AR 
antagonist, has previously been used to block androgen action prenatally 
(Imperato-McGinley et al 1992, McIntyre et al 2001, Welsh et al 2008) and 
postnatally (Auharek et al 2010, van den Driesche et al 2011) which disrupted 
testis function. Postnatal flutamide treatment of fetally DBP-exposed animals 
was also investigated to determine whether androgen action during the pre- or 
postnatal period was more important for adult Leydig progenitor cell 
development.  
Fetal TP or DHT exposure has previously been reported to masculinise female 
offspring, which was evident at birth and in adulthood (Wolf et al 2002, 2004, 
Welsh et al 2008, 2010, Dean et al 2012). This suggests that the elevation in fetal 
androgen exposure was sufficient to masculinise females. However, as TP was 
administered via injection into the pregnant dam, it passes via the placenta to 
the developing fetus and thus introduces the confounding factor of increased 
aromatisation of TP into oestradiol. Therefore, administration of the more 
potent and non-aromatisable androgen, dihydrotestosterone, (DHT) was also 
investigated. These treatments were initially chosen to investigate whether an 
increase in fetal androgen level/action might potentially affect adult Leydig 
progenitor cell development. 
However, as both the TP and DHT models may not effectively increase 
intratesticular testosterone levels by much, a third approach to potentially raise 
endogenous intratesticular testosterone was utilised. Inducible nitric oxide 
synthase (iNOS) is expressed constitutively in adult Leydig cells (and other 
testicular cells) and suppresses testosterone production (O'Bryan et al 2000, 
Lee and Cheng 2004) under normal physiological conditions in the testis 
(Ishikawa & Morris 2006). iNOS levels are increased in aging rats, which 
coincides with the suppression of testosterone production (Sokanovik et al 
2013). A recent study reported that in adult iNOS-/- mice, AGD was significantly 
increased in comparison with respective wild-type controls. Furthermore, adult 
iNOS-/- mice showed a 60% increase in testis weight, along with a 16% increase 




in the number of adult Leydig cells per testis, whereas body weight was 
unchanged (Auharek et al 2011). During puberty in iNOS-/- mice, the number of 
adult Leydig cells was significantly increased by 60% and 40% at pnd 10 and 15 
respectively. Coinciding with these time points examined, AGD was significantly 
increased in iNOS-/- mice. These results suggest that there was an effective 
increase in fetal androgen exposure, in comparison to wild-type controls 
(Auharek et al 2012). Thus, the iNOS-/- mouse was chosen as a potentially 
effective model to increase endogenous fetal intratesticular testosterone levels 
and thus investigate potential effects on adult Leydig progenitor cell 
development. 
This chapter aimed to answer three fundamental questions. Firstly are adult 
Leydig progenitor cells AR-modulated, especially in fetal life. Secondly, does 
altering fetal and/or postnatal androgen levels affect adult Leydig progenitor 
cell development and thus potentially adult Leydig cell function. Thirdly, is it 
possible that in a potential 'gain of adult Leydig cell function' model, the number 
of adult Leydig progenitor cells are increased as a consequence of increased 














4.2 Materials and Methods 
4.2.1 Generation of complete or cell-selective AR knockout (ARKO) mice  
Ubiquitous and cell-specific androgen receptor knockout models were 
generated as described in Chapter 2. Groups of 5-11 wild-type, ARKO, SCARKO 
and PTMARKO mouse models were analysed at pnd 2, 12, 20, 50 or 140 for 
experiments described in this chapter. 
 
4.2.2 Human fetal testis tissue 
Second trimester (14-18 weeks) human fetal testes were obtained following 
termination of pregnancy. Women gave consent in accordance with UK national 
guidelines (Polkinghorne 1989), and ethical approval was obtained from the 
Local Research Ethics Committee, as described previously (Mitchell et al 2013). 
 
4.2.3 Tissue collection 
To recover fetal samples (e21.5) for investigations in this thesis, control and 
treated pregnant dams were killed by inhalation of CO2 and subsequent cervical 
dislocation. Postnatal animals were sacrificed in the same manner, and 
dissected tissue was subsequently fixed in Bouins, as previously described in 
chapter 2. 
 
4.2.4 Di-n-butyl phthalate treatment 
To investigate whether reduced fetal testosterone levels affects the 
development of adult Leydig progenitor cells, time-mated pregnant rats were 
administered di-n butyl phthalate (DBP; Sigma-Aldrich Co. Ltd., Poole, Dorset, 
UK) at 500mg/kg/day by oral gavage in 1 ml/kg corn oil from e13.5-e21.5. 
Testosterone production commences at e15.5 in rats (Warren et al 1973, Habert 
and Picon 1984), therefore the treatments were initiated just prior to this time 
point. A dose of 500mg/kg/day was chosen as this treatment regime reduces 
fetal intratesticular testosterone by 40-80% during the treatment period (van 
den Driesche et al 2012). Groups of 6-8 vehicle- and DBP-exposed rats were 




killed at e21.5 or at postnatal (Pnd) days 6, 10, 15, 25 or 75 days (Chapter 2). 
Sections of control and DBP-exposed animals were then used for 
immunohistochemistry and stereology. 
 
4.2.5 DBP and/or postnatal flutamide treatment 
To investigate the modifying effects of androgen deprivation during the 
postnatal period prior to adult Leydig cell differentiation (~Pnd15), the AR 
antagonist ‘flutamide’ (Sigma-Aldrich) (DMSO; Sigma-Aldrich) was 
administered to nursing dams by oral gavage in 1ml/kg corn oil from Pnd1-
Pnd15. In some animals, prenatal DBP treatment (as above) was combined with 
postnatal flutamide treatment. DBP disrupts fetal testosterone production (van 
den Driesche et al 2012), while flutamide blocks the action of testosterone and 
DHT by competitively binding to the AR in target tissues (Welsh et al 2008, 
2010). Groups of 5-8 vehicle- and DBP and/or flutamide-exposed rats were 
killed in early puberty (Pnd25) when adult Leydig cells are differentiating, or in 
adulthood (Pnd90) and used for experiments described in this chapter. 
 
4.2.6 Hormone analyses 
Plasma LH and testosterone were measured using radioimmunoassays as 
previously published (van den Driesche et al 2012, Mitchell et al 2013) and were 
performed by Chris Mc Kinnell in our research group, to whom I am extremely 
grateful. All samples from each experiment were run in a single assay for each 
hormone and the within-assay coefficients of variation were <10%.  
 
4.2.7 Testosterone proprionate treatment  
To investigate the modifying effects of increased androgen levels during fetal 
development, pregnant rats were administered testosterone propionate (TP) at 
20 mg/kg/day maternal bodyweight from e14.5-e21.5 and fetuses were killed at 
either birth (e21.5) or adulthood (Pnd90). Previous studies have shown that 
such treatment is sufficient to masculinise the female offspring (Wolf et al 2002, 




Welsh et al 2008). To investigate the effects of TP during the postnatal period, 
prior to adult Leydig cell differentiation (~Pnd15), TP was administered by 
subcutaneous injection at 20 mg/kg/day every third day from pnd 1-24 as 
described previously (Welsh et al 2010). Male offspring from control and treated 
groups were examined at e21.5, pnd 25 and 90. 
 
4.2.8 Dihydrotestosterone treatment 
A second model to investigate the modifying effects of increased fetal androgen 
levels on male offspring via dihydrotestosterone (DHT) treatment to pregnant 
dams was used. Pregnant rats were administered either 10mg/kg DHT or corn 
oil (controls) via subcutaneous injection daily during fetal development (e15.5-
e21.5). A dose of 10mg/kg/day of DHT has previously been shown to 
masculinise females (Dean et al 2012), however the effect on adult Leydig cells 
or their progenitors was not investigated. Testis sections from control and DHT-
exposed animals were analysed at e21.5 and pnd 75. 
 
4.2.9 Inducible nitric oxide synthase (iNOS-/-) knockout model 
As exogenous TP/DHT treatment may not effectively increase intratesticular 
testosterone levels by much, a better model would be one in which endogenous 
ITT levels were raised. One potential model for this was the generation of an 
iNOS-/- mouse, as described in Chapter 2. The iNOS-/- mouse model was 
previously reported to exhibit significantly increased testis weight and AGD 
from puberty onwards (Auharek et al 2011, 2012), suggesting an increase in 
fetal androgen exposure. Thus, this model was used to investigate whether 




Triple immunofluorescence was carried out as described in chapters 2 and 3 on 
testis sections from human and rodents at varying ages, as described below. 




Antibodies, their dilution and visualisation method employed, are listed in table 
4.1. For co-localisation studies of different proteins in this chapter, normal 
chicken serum (NChS) was used as a blocking serum to prevent cross-reaction 
with mouse/rabbit/goat antibodies and the protocol was continued as detailed 
earlier (Chapter 2).  
Table 4.1 Primary and secondary antibodies used for immunofluorescence 
Primary Species Raised Dilution Secondary Visualisation 
Ki67 Mouse 1:200 C α M Tyr-Cy3 (Red) 
AR Rabbit 1:200 C α R Tyr-Cy3 (Red) 
COUP-TFII Mouse 1:1,000 C α M Fluorescein Green 
3B-HSD Goat 1:1,000 C α G Tyr-Cy5 (Blue) 
  
4.2.11 Triple colorimetric immunohistochemistry 
In order to quantify both the adult Leydig progenitor cells (COUP-TFII+/3β-
HSDneg) and fetal or adult Leydig cells (COUP-TFII+/3β-HSD+), colorimetric triple 
immunohistochemistry was carried out as described in chapters 2 and 3. 
Primary and secondary antibodies used are described in Table 4.2. 
 
Table 4.2 Primary and secondary antibodies used for triple immunohistochemistry 
Primary Species raised Dilution Secondary Visualisation 
SMA Mouse 1:3,000 R α M Fast Red 
COUP-TFII Mouse 1:100 R α M DAB 
3B-HSD Goat 1:100 R α G Fast Blue 
 




4.2.12 Quantification of adult Leydig progenitor and adult Leydig cell number 
Quantification of adult Leydig progenitor cells (COUP-TFII+/3β-HSDneg) and adult 
Leydig cells (COUP-TFII+/3β-HSD+) was carried out using stereological 























4.3.1 AR expression in COUP-TFII+ adult Leydig progenitor cells 
As androgens are essential for fetal masculinisation and COUP-TFII+ adult 
Leydig progenitor cells are increasing in number during this time (between 
e17.5-e21.5) (Chapter 3), the first experiment aimed to establish whether or not 
the COUP-TFII+ adult Leydig progenitor cells were in fact proliferating, using the 
proliferative marker, Ki67. This was carried out using triple 
immunofluorescence for COUP-TFII (green), Ki67 (red) and 3β-HSD (blue). A 
proportion of COUP-TFII+ adult Leydig progenitor cells co-expressed Ki67, 
which shows that these cells are proliferating (Figure 4.1). Therefore, the next 
aim was to determine whether the adult Leydig progenitor cells were androgen 
targets i.e. express the androgen receptor (AR), and thus whether androgens 
might modulate their proliferation. Triple immunofluorescence using COUP-TFII 
(green; adult Leydig progenitor cells), AR (red; interstitial cells) and 3β-HSD 
(blue; fetal Leydig cells) was carried out on sections from fetal rat (e21.5) and 
human (14 weeks) testis tissue. The tiled and higher power images (Figure 4.2), 
in rat and human fetal testis, showed that the majority of COUP-TFII+ (green) 
adult Leydig cell progenitors co-expressed AR (red), as depicted by the yellow 
nuclear co-staining (COUP-TFII+/AR+). A small proportion of fetal Leydig cells 
(blue) in the rat at e21.5 expressed AR, but none were found to express COUP-
TFII.  





Figure 4.1 Proliferation of COUP-TFII adult Leydig progenitor cells during fetal life 
in the rat.   A population of COUP-TFII+ (green) adult Leydig progenitor cells express 
Ki67 (red), as indicated by the yellow nuclear costaining (arrows) in both images at 
e21.5 in the rat. Ki67 is also evident in Sertoli cells within the seminiferous cords 
(cords denoted by an asterisk). Fetal Leydig cells (3β-HSD+; blue) are negative for 
COUP-TFII and Ki67. Scale bars = 20µm.  





Figure 4.2 Co-localisation of COUP-TFII and AR in human and rat fetal testis. In rat 
and human fetal testis, the majority of COUP-TFII+ (green) Leydig progenitor cells 
co-express the androgen receptor (AR; red). COUP-TFII and AR co-localisation is 
evident by yellow nuclear staining (arrowheads). The majority of fetal Leydig cells, 
(3β-HSD+;blue cytoplasmic staining: LC), are negative for COUP-TFII with a small 
proportion positive for AR. Note that fetal Leydig cells are not evident in the human 
sample shown (16 weeks gestation). Asterisks indicate seminiferous cords. Scale 
bars = 20 µm. 
  
4.3.2 Effect of AR knockout on adult Leydig progenitor cell development 
As COUP-TFII+ adult Leydig progenitor cells appear to be androgen targets 
(COUP-TFII+/AR+), the next aim was to investigate whether knockout of the AR 
in COUP-TFII+ adult Leydig progenitor cells would affect their development. 




Unfortunately, there is no way of specifically targeting the AR in the interstitial 
COUP-TFII+ adult Leydig progenitor cell population, given the fact that both 
these markers (COUP-TFII and AR) are also expressed in PTM cells. Therefore, 
the development of adult Leydig progenitor cells was investigated in complete 
AR knockout (ARKO) mice. Triple immunofluorescence for COUP-TFII (green), 
AR (red) and 3β-HSD (blue) was undertaken on mouse testis sections from 
control (PGK-Cre only) and ARKO, around birth (e18.5) and during puberty 
(Pnd 12, 20). COUP-TFII+ (green) adult Leydig progenitor cells co-expressed AR 
(red) in control animals, as evident from yellow nuclear interstitial cell staining 
(white arrow) in the tiled and higher magnification images of fetal (Figure 4.3) 
and pubertal (Figures 4.4) mouse testes. Androgen receptor (red) expression 
was absent within the testes of ARKOs (Figures 4.3; 4.4). Fetal Leydig cells (3β-
HSD; blue) were negative for AR and COUP-TFII (Figure 4.3). During adult 
Leydig cell development, adult Leydig cells (3β-HSD, blue) in wild-type mice 
expressed both COUP-TFII (green) and AR (red) staining (Figure 4.4).  





Figure 4.3 Ubiquitous knockout of AR in fetal mouse testis at e18.5. In the control 
(PGK-Cre only), fetal mouse testis (e18.5), COUP-TFII+ (green) adult Leydig progenitor 
cells co-express AR (red), as indicated by the yellow nuclear staining. AR staining in 
the ARKO mouse testis is absent while COUP-TFII+ adult Leydig progenitor cells 
(green; arrows) are present in the interstitium. Fetal Leydig cells (blue; arrowheads) 
are negative for AR and COUP-TFII. Scale bars in tiled image = 100 µm, higher 
magnification = 20 µm. 
 
 





Figure 4.4 Expression of AR in COUP-TFII+ adult Leydig progenitor cells in control 
and ARKO mice during puberty. Adult Leydig progenitor cells (COUP-TFII+/AR+/3β-
HSDneg) are present in the interstitium (arrows; yellow colocalisation). Note absence 
of AR staining in ARKO samples. Control samples are PGK-Cre only. Adult Leydig 
cells are shown in blue. Scale bars = 20 µm, bottom left image = 10 µm.  
 
4.3.3 Quantification of adult Leydig progenitor cells in ARKO mice 
The next aim was to quantify the number of adult Leydig progenitor cells 
(COUP-TFII+/3β-HSDneg) in ARKO mice, in comparison to their respective wild-
type controls throughout development; samples were therefore investigated at 
pnd 2, 12, 20, 50 and 140. Knockout of AR specifically in Sertoli cells (SCARKO) 
has been reported to affect the development of adult Leydig cells (De Gendt et al 
2005), while knockout of AR in PTM cells (PTMARKO) affects only their function 




(Welsh et al 2009). Therefore, knockout of AR in these specific cell-types was 
also investigated for any effect on the development of the COUP-TFII+ adult 
Leydig progenitor population. As in chapter 3, the use of colorimetric 
immunohistochemistry was undertaken in order for stereological analysis of 
three separate proteins to be undertaken i.e. COUP-TFII (brown), 3β-HSD (blue) 
and SMA (red) on testis sections from control and ubiquitous/cell specific ARKO 
mouse models throughout development. Representative images from wild-type 
control, SCARKO and ARKO mice after birth (Pnd 2), during puberty (Pnd 12) 
and in adulthood (Pnd 50) are shown below (Figure 4.5). 
Staining for SMA (a marker for differentiated PTM cells) in ARKO males at pnd 
2, was weakly expressed in comparison to controls (Figure 4.5; top). Also, from 
initial observations, it appeared that adult Leydig cell hyperplasia had occurred 
in the adult ARKO compared to controls; however the fact that testis weight was 
reduced by about 90% in ARKOs (Figure 4.6), and tubule diameter was also 
reduced, most likely explains this 'illusion'. Quantification of adult Leydig 
progenitor cells (COUP-TFII+/3β-HSDneg) after birth (pnd 2) demonstrated these 
cells were reduced in number following complete AR knockout (ARKO), while 
fetal Leydig cell number was unchanged (Figure 4.7). A reduction in adult 
Leydig progenitor cells (approximately 40%) was further evident through 
postnatal life into adulthood in ARKO males, in comparison to their respective 
wild-type controls (Figure 4.8). There was a parallel reduction in adult Leydig 
cell (COUP-TFII+/3β-HSD+) numbers in ARKO males, in comparison to wild-type 
controls (Figure 4.8). In contrast, cell-selective knockout of AR, as in SCARKO 
and PTMARKO models, had no significant effect on numbers of adult Leydig or 
their progenitor cells during development (Figure 4.8 and 4.9).  





Figure 4.5 Gross testis morphology and occurrence of adult Leydig cells and their 
progenitors across development in control, SCARKO and ARKO mice. Adult Leydig 
progenitor cells (COUP-TFII+/3β-HSDneg; arrows) are located in the interstitium 
throughout development. Leydig cells are shown in blue (3β-HSD+). Control samples 
are PGK-Cre only. Note weak SMA staining in PTM cells in ARKO mice at pnd 2. Scale 
bars = 20 µm (Pnd 2, 12) and 50 µm (Pnd 50).  




   
Figure 4.6 Effect of complete ARKO on adult mouse testis weight and size in 
comparison to wild-type controls. Means ± SEM for n=5-6. Data were analysed using 





Figure 4.7 Adult Leydig progenitor cell number is decreased in ARKO mice at pnd 
2. Adult Leydig progenitor cell (COUP-TFII+/3β-HSDneg) number was reduced in ARKO 
males, in comparison to wildtype controls, unlike in the SCARKO model in which cell 
number was unchanged. Fetal Leydig cell number was comparable across all 
knockout models. Means ± SEM for n=5. Data were analysed using an unpaired t-
test; *p<0.05, in comparison to wildtype controls. 
 
 





Figure 4.8 Change in COUP-TFII+ adult Leydig progenitor and adult Leydig cells 
across development in wild-type, SCARKO and ARKO mouse models Adult Leydig 
progenitor cells (COUP-TFII+/3β-HSDneg) were reduced in number at all ages in ARKO 
males, in comparison to wild-type controls. A parallel reduction in adult Leydig cell 
numbers (COUP-TFII+/3β-HSD+) was also evident in ARKOs, in comparison to 
controls. Means ± SEM for n=7-10 mice, at each age. Data were analysed using an 
unpaired t-test; *p<0.05, **p<0.01, ***p<0.001, in comparison with respective 
wild-type controls. 
 
Figure 4.9 Adult Leydig progenitor cell number is unchanged in adult mouse testes 
in AR cell-selective knockout in PTM cells (PTMARKO). Adult Leydig progenitor cells 
(COUP-TFII+/3β-HSDneg) were quantified during adulthood (Pnd 50 and 140). Means 
± SEM for n=7-11 mice. Data were analysed using an unpaired t-test and found to 
be not significant.   
 




4.3.4 Evidence for compensated adult Leydig cell failure in ARKO males 
To determine adult Leydig cell function in ARKO males, plasma levels of LH and 
testosterone were measured in adulthood, and compared with wild-type 
controls. This provided evidence for ‘compensated Leydig cell failure’ in ARKO 
males, as evident from the significantly increased LH and grossly distorted 
blood LH:testosterone ratio, in comparison to wild-type controls (Figure 4.10), 
comfirming previous findings (De Gendt et al 2005).  
 
Figure 4.10 Plasma hormone levels in adulthood in control and ARKO mice. Plasma 
hormone levels, as a measure of adult Leydig cell function, are shown for LH 
(increased) and testosterone (decreased) in ARKO adult mice, in comparison to 
wild-type controls, resulting in an abnormal LH:testosterone ratio. Means ± SEM for 
n=5. Data were analysed using an unpaired t-test; *p<0.05, **p<0.01. 
 
Given the significant reduction in number of adult Leydig cells and their 
progenitors throughout development in ARKO mice, plus the evidence for 
compensated adult Leydig cell failure in adulthood, it suggests that fetal 
androgen action plays a key role in adult Leydig progenitor cell development 
and normal adult Leydig cell function. However, the fact that AR is knocked out 
ubiquitously in this model plus the fact that all testes are cryptorchid, are 
potentially confounding factors. Therefore, the next aim was to investigate a 
model in which fetal intratesticular testosterone was selectively reduced, in 
order to investigate whether this would affect the development of adult Leydig 
and/or their progenitor cell population, as it appeared to do in the ARKO model. 




4.3.5 DBP-Induced reduction of fetal intratesticular testosterone production 
Exposure to DBP (500mg/kg/day) during fetal life (e13.5-e21.5) has been 
shown to lower fetal intratesticular testosterone by ~70% (van den Driesche et 
al 2012). Therefore, DBP treatment was used in this study to investigate the 
effect that lowered intratesticular testosterone might have on the development 
of adult Leydig cells and/or their progenitor cells across development. The 
timing of treatment and postnatal ages of analyses, are indicated in the 
schematic below (Figure 4.11).  
 
 
Figure 4.11 Schematic indicating the timing of fetal DBP exposure in rats. The 
time-points at which adult Leydig cells and their progenitors were investigated are 
marked by red crosses.   
 
DBP-exposed males had lower intratesticular testosterone (ITT) levels at e21.5, 
(Figure 4.12; top left). As before, colorimetric immunohistochemistry was 
carried out prior to stereological analysis on testis sections throughout 
development at e21.5, pnd 6, 10, 25, 75 and 90. Quantification of adult Leydig 
progenitor cells (COUP-TFII+/3β-HSDneg) indicated a ~40% reduction at e21.5 
in DBP-exposed animals in comparison to their respective (vehicle) controls 
(Figure 4.12; top right), a deficit which persisted throughout postnatal 
development into adulthood (Figure 4.12; middle left). DBP-exposed males 
showed a significant reduction in the number of developing adult Leydig cells at 
pnd 25 but this shortfall in adult Leydig cells was not evident in adulthood (Pnd 
90) (Figure 4.12; middle right). However, normal adult Leydig cell number does 
not necessarily reflect normal Leydig cell function (Welsh et al 2009), therefore 




to investigate adult Leydig cell function in DBP-exposed males, plasma LH and 
testosterone blood levels were measured in adulthood and compared with 
controls. Despite the presence of normal adult Leydig cell numbers, these 
findings suggest there is evidence for compensated adult Leydig cell failure, as 
evident from significantly increased LH and decreased testosterone levels, 
resulting in a distorted LH:testosterone ratio (Figure 4.12; bottom).  





Figure 4.12 DBP-induced lowering of fetal ITT reduces the number of adult Leydig 
progenitor cells and alters adult Leydig cell function. At the end of fetal life in rats 
(e21.5), ITT was significantly reduced, as was the number of adult Leydig progenitor cells 
(COUP-TFII+/3β-HSDneg) throughout postnatal development. Adult Leydig cell (COUP-
TFII+/3β-HSD+) number was unchanged, except at Pnd 25. During adulthood (Pnd 90), 
plasma levels of LH were significantly increased whereas testosterone levels were reduced, 
resulting in a distorted LH: testosterone ratio. Means ± SEM for n=6-8 (stereological 
analyses) and n=29-32 (hormone analyses). The results shown in the bar charts in the first 
and third rows were analysed by unpaired t-tests. Initially, unpaired t-tests were also used 
to compare cell numbers between DBP-treated and vehicle controls at different ages 
(graphs in second row; results not shown). However, to avoid multiple pairwise tests, the 
analyses were repeated using two-way ANOVAs. For adult Leydig progenitor cells (left 
graph), this showed significant differences between treatments (p<0.0001) and among ages 
(p<0.0001) and the interaction between ages and treatments was also significant 
(p=0.0115). Bonferroni post-hoc tests demonstrated that differences in cell numbers 
between DBP-treated and vehicle controls were significant at pnd 25 and 75, as shown in 
the figure. For adult Leydig cells (right graph), the overall difference between treatments 
was not significant (p=0.6729) but the two ages differered significantly (p<0.0001) and the 
interaction between ages and treatments was also significant (p=0.0447). Bonferroni post-
hoc tests showed no significant difference between treatments at either age. *p<0.05, 
**p<0.01, ***p<0.001. 




4.3.6 Effect of postnatal androgen action on adult Leydig progenitor cell 
development 
The number of adult Leydig progenitor cells increased during postnatal 
development, albeit to a far lesser degree in the absence of normal androgen 
level/action (Figure 4.8 and 4.12). This posed two questions, firstly, whether 
blockade of postnatal androgen action prior to puberty (pnd 1-15) via an AR 
antagonist flutamide, would affect adult Leydig cells and/or their progenitor cell 
development, as outlined in the schematic (Flutamide; Figure 4.13). Secondly, 
whether postnatal administration of flutamide to DBP-fetal-exposed rats would 
affect adult Leydig progenitor cell development compared to fetal DBP exposure 
alone, as outlined in the schematic (DBP+Flutamide; Figure 4.14).  
To perform stereological quantification in the various outlined treatment 
groups at Pnd25 and 90, triple colorimetric immunohistochemistry for COUP-
TFII, 3β-HSD and SMA was initially carried out, as before. Stereological 
quantification revealed that postnatal flutamide treatment only, significantly 
reduced the number of adult Leydig progenitor cells at pnd 25 (Figure 4.15; top 
left). There was a similar reduction in adulthood, but this just failed to reach 
statistical significance (Figure 4.15; top left). Adult Leydig cell number (Figure 
4.15; top right) and function (Figure 4.15; middle and bottom) were unaffected 
by postnatal flutamide treatment. 
 In contrast, postnatal administration of flutamide to DBP-exposed animals, 
resulted in comparable changes to the effects of DBP treatment alone, as shown 
earlier (Figure 4.12). Postnatal administration of flutamide to DBP-exposed 
animals, significantly reduced the number of adult Leydig progenitor cells at 
pnd 25 (Figure 4.15; top left), although in adulthood a similar reduction did not 
reach statistical significance (Figure 4.15; top right). The DBP+Flutamide 
experimental group showed evidence for compensated adult Leydig cell failure 
i.e. significantly increased LH and reduced testosterone with a distorted 
LH:testosterone ratio (Figure 4.15; bottom). These results suggest that fetal 
androgen action (e13.5-e21.5) is more important than postnatal androgen 




action (Pnd1-15), in affecting adult Leydig progenitor cell development and in 
influencing adult Leydig cell function. 
 
 
Figure 4.13 Schematic indicating the timing of postnatal flutamide treatment in 
rats. The time-points at which adult Leydig cells and their progenitors were 
investigated are marked by red crosses.    
 
 
Figure 4.14 Schematic indicating the timing of postnatal flutamide treatment in 
DBP-exposed rats. The time-points at which adult Leydig cells and their progenitors 
were investigated are marked by red crosses.   
 





Figure 4.15 Effect of prenatal exposure to DBP and/or postnatal exposure to 
flutamide on the development of adult Leydig progenitor cells in relation to adult 
Leydig cell function in rats. Adult Leydig progenitor cells were reduced in both 
experimental groups (Oil+Flut and DBP+Flut)  at pnd 25 but not in adulthood (Pnd 90). 
There was no change in the number of adult  Leydig progenitor cells in adulthood (Pnd 90). 
For adult Leydig cells, there was no change in their number between experimental groups 
at pnd 25 or adulthood (Pnd 90), in comparison to respective control animals. Plasma LH 
was increased in DBP+Flut group, in comparison to both Oil and Oil+Flut group. Plasma 
testosterone was reduced in comparison to both Oil and Oil+Flut group. This resulted in a 
distorted LH:T ratio, but only in the DBP+Flut group, not in the Oil+Flut group. Means ± SEM 
for n=5-8 (Pnd 25) or n=5-11 (adulthood) rats per group. Data were analysed using an 
unpaired t-test. **p<0.01, ***p<0.001. 




Effect of exogenous testosterone propionate exposure on adult Leydig 
progenitor cells 
The previous results in this chapter have shown that lowering fetal androgen 
level/action results in a reduction in number of adult Leydig progenitor cells 
and somehow affects their functional competence when they differentiate into 
adult Leydig cells. Therefore, the next aim was to investigate whether increasing 
fetal androgen levels would have the opposite effect on adult Leydig progenitor 
cell development resulting in a potential "gain of adult Leydig cell function". 
Given that testosterone propionate (TP) exposure during fetal life has been 
shown to increase testosterone levels and masculinise female offspring (Wolf et 
al 2002, Welsh et al 2008) and the fact that normal testosterone production 
commences at e15.5 in the rat (Warren et al 1972), this study investigated the 
administration of 20mg/kg/day of TP during fetal life from e14.5-e21.5 (Figure 
4.16). To investigate if postnatal administration of TP affected adult Leydig 
progenitor cell development, a second experimental group in which TP was 
administered postnatally (d1-25) was also investigated (Figure 4.18). The dose 
of TP used in this study can induce dystocia (Welsh et al 2008), so to prevent 
this, TP-exposed fetuses were caesarean-derived and cross-fostered to 
untreated/control dams, that had previously delivered within 6 hours. As 
before, testis sections underwent triple colorimetric immunohistochemistry for 
COUP-TFII, 3β-HSD and SMA, prior to stereological analyses.  
Fetal TP-exposure resulted in significantly increased numbers of adult Leydig 
progenitor cells, as evident in adulthood (Figure 4.17; bottom). However, this 
did not appear to stem from prenatal changes because, at birth, the number of 
adult Leydig progenitor cells was not increased, and if anything, was reduced 
(Figure 4.17; top). Postnatal TP administration did not affect the number of 
adult Leydig progenitor cells at pnd 25 or 90, although it did appear to 
significantly decrease the number of adult Leydig cells at pnd 25 only (Figure 
4.19; top). Although these experiments aimed to increase intratesticular 
testosterone (ITT) levels via TP exposure, it was evident that other confounding 
factors might have occurred as a result of this treatment. For example, 




testosterone can be aromatised into oestradiol, thus increasing levels of the 
latter, which could have resulting adverse effects on fetal growth. In fact, a 
significant reduction in testis weight was evident at birth (e21.5), which might 
indicate an oestrogenic effect (Bartholomeusz et al 1999) (Figure 4.17). Also, 
altered development of the hypothalamic-pituitary-gonadal (HPG) axis might 
have been affected due to TP administration, resulting in permanent changes to 
LH secretion and/or negative feedback control (Grober et al 1998, Micevych et 
al 2010). Bearing these factors in mind, it seemed apparent that the best way to 
investigate if increased ITT levels could increase adult Leydig progenitor cell 
numbers is via specifically elevating ITT and not altering peripheral levels 
greatly. Therefore, fetal administration of a non-aromatisable androgen, 




Figure 4.16 Schematic indicating the timing of fetal TP-exposure in rats.  The time-
points at which adult Leydig cells and their progenitors were investigated are 
marked by red crosses.  





Figure 4.17 Effect of fetal TP exposure (e14.5-e21.5) on adult Leydig progenitor 
cell numbers at e21.5 and pnd 90 in the rat. Fetal TP exposure caused a reduction in 
testis weight at e21.5 and an apparent increase in adult Leydig progenitor cells and 
testis weight during adulthood. Means ± SEM for n=5. Data were analysed using an 




Figure 4.18 Schematic indicating the timing of postnatal TP administration in rats.  
The time-points at which adult Leydig cells and their progenitors were investigated 
are marked by red crosses. 
 
 





Figure 4.19 Effect of postnatal TP administration (Pnd1-25) on adult Leydig 
progenitor cell numbers and testis weight at pnd 25 and 90 in the rat.  Postnatal TP 
administration did not affect the number of adult Leydig progenitor cells, in 
comparison with respective controls. Testis weight was reduced at pnd 25 and 90 
and delayed differentiation of adult Leydig cells. Means are ± SEM for n=5. Data 
were analysed using an unpaired t-test; **p<0.01, ***p<0.001. 
 
4.3.7 Effect of fetal DHT exposure on adult Leydig progenitor cells 
Dihydrotestosterone (DHT) was used in these experiments as, unlike TP, it 
cannot be aromatised into oestradiol, thus eliminating potentially confounding 
results via this pathway. Pregnant dams received a dose of 10mg/kg DHT as 
used in an earlier study in the lab (Dean et al 2012) between e15.5-e21.5 
(Figure 4.20), to investigate whether this might increase adult Leydig 
progenitor cell proliferation. This dose did not cause any toxic effects to the 
dams (this study and Dean et al 2012). The overall aim was to investigate 
whether increasing fetal androgen levels via exogenous DHT exposure, would 




affect adult Leydig progenitor cell development in male offspring, which were 
analysed after birth (e21.5) and in adulthood (Pnd 75). Females were included 
in this study as a control parameter of DHT exposure i.e. to determine whether 
DHT treatment had been correctly administered and was capable of 
masculinising females, as previously shown (Dean et al 2012). 
 
 
Figure 4.20 Schematic indicating the timing of fetal DHT-exposure in rats.  The 
time-points at which adult Leydig cells and their progenitors were investigated are 
marked by red crosses.  
 
Fetal DHT exposure had no effect on the number of adult Leydig progenitor cells 
or fetal Leydig cells at e21.5, whereas fetal TP-exposure (above) had reduced 
the number of both adult Leydig progenitor and fetal Leydig cells (Figure 4.21). 
Similarly, whereas DHT-exposed animals had comparable testes weight to wild-
type controls at birth (e21.5), testis weight was reduced in TP-exposed fetal 
animals (Figure 4.21). Analysis of DHT-exposed female offspring in adulthood 
(Pnd 90), indicated that fetal DHT exposure was successful in inducing 
masculinisation, as evident from an increased AGD (Figure 4.23), lack of a 
vaginal opening and absence of nipples (Table 4.3). Furthermore, the presence 
of a rudimentary prostate gland was found in some females, or gross distension 
of the uterus (hydrometrocolpos) (Figure 4.22) (this study and Dean et al 2012), 
overall indicating that DHT treatment had been effective in masculinising 
female offspring. However, there was no evidence for an 'enhancing effect' on 
adult males, as neither AGD nor testis weight were increased, in comparison to 
their respective wild-type control animals (Figure 4.23). This experiment aimed 




to increase fetal intratesticular testosterone levels in males, in order to assess 
whether this could potentially increase the number of adult Leydig progenitor 
cells. However, it appeared that fetal DHT administration, in this study, was not 
sufficient in effectively increasing fetal androgen exposure in males, although 
this was not formally checked. Thus, adult Leydig progenitor cell number was 
not evaluated as it seemed apparent that exogenous fetal TP/DHT 
administration would not effectively elevate ITT levels enough to provide a true 
model of "gain of adult Leydig cell function". A better model of the 
aforementioned, would be one in which endogenous ITT levels might potentially 
be increased, which is discussed in the next section.  
 
Figure 4.21 Comparative effects of fetal exposure to TP or DHT, on fetal rats 
before birth (e21.5). Following fetal TP exposure (e14.5-21.5), the number of adult 
Leydig progenitor cells, fetal Leydig cells and testis weight were reduced before 
birth, in comparison to wild-type controls. Fetal DHT-exposed animals (e15.5-
e21.5), were comparable to wild-type controls at birth. Means ± SEM for n=5-9. 
Data were analysed using an unpaired t-test; ***p< 0.001 **p<0.01. Data for TP-











Table 4.3 External masculinisation in adult females following fetal DHT exposure. 
External masculinisation parameter DHT 10 mg/kg 
Vaginal Opening Absent 9/11 
Nipples Absent 11/11 
 
 
Figure 4.22 Fetal DHT exposure causes female masculinisation and 
hydrometrocolpos in the rat. Following DHT exposure during fetal life (e15.5-
e21.5), females were examined during adulthood (Pnd75), to investigate whether 
DHT could induce masculinisation. A rudimentary prostate is evident (left image; 
yellow arrow). Increased fluid in the uterine horn (hydrometrocolpos) is also shown 
(right image; yellow arrowhead), as a result of fetal DHT exposure. 
 
 





Figure 4.23 Effect of fetal DHT exposure in rats on AGD of fetal offspring before 
birth and AGD and testis weight in adulthood. Fetal DHT exposure (10mg/kg/day 
between e15.5-21.5) did not increase male AGD after birth (e21.5), or in adulthood 
(Pnd 90), in comparison with wild-type controls. Testis weight was  unchanged in 
adulthood following fetal DHT exposure. Female AGD was increased in adulthood, 
in comparison to wild-type controls. Means ± SEM for n=5-11. Data were analysed 
using an unpaired t-test; *p<0.05.  
 
4.3.8 Effect of iNOS knockout on adult Leydig progenitor cells 
The iNOS-/- mouse model has previously been shown to exhibit a 60% increase 
in testis weight, along with a 16% increase in the number of adult Leydig cells 
per testis during adulthood, whereas body weight was unchanged (Auharek et 
al 2011). During the pubertal period in iNOS-/- mice, the number of developing 
adult Leydig cells was significantly increased by 60% and 40% at pnd 10 and 15 
respectively. Coinciding with this, a significant increase in AGD was reported in 
iNOS-/- mice at the same time-points, suggesting that there was an effective 
increase in fetal androgen exposure (at least peripherally), in comparison to 
wild-type controls (Auharek et al 2012). Given the increase in adult Leydig cell 
number in puberty and adulthood in iNOS-/- mice as previously described, and 
the fact that LH blood levels appeared to be lower in the face of normal 
testosterone levels in adult iNOS-/- mice (Lue et al 2003), the evidence suggested 
that iNOS-/- mice might potentially have increased fetal ITT levels and 
potentially depict a "gain of adult Leydig cell function" model. Thus, adult Leydig 
progenitor cell number (COUP-TFII+/3β-HSDneg) was investigated at birth 




(e18.5), pre-puberty (Pnd 10, 15) and adulthood (Pnd 70). There was an 
increase in adult Leydig progenitor cells at pnd 10, 15 and 70, but not at e18.5, 
in comparison with wild-type controls (Figure 4.24). The number of adult 
Leydig cells did not differ between iNOS-/- and their respective wild-type 
controls (Figure 4.24). 
 
 
Figure 4.24 Effect of iNOS-/- on adult Leydig cells and their progenitors throughout 
development in the mouse. Testis weight and adult Leydig progenitor cell number 
were increased at pnd 10, 15 and 70, in comparison with wild-type controls. There 
was no difference in the number of adult Leydig cells between iNOS-/- and wild-type 
controls, at any age studied. Means ± SEM for n=4-10. Data were analysed using an 
unpaired t-test; *p<0.05, **p<0.01, ***p<0.001 in comparison with respective wild-
type controls. 





This chapter has established that COUP-TFII+ adult Leydig progenitor cells, 
present in the fetal testis, are androgen targets, as shown by their expression of 
AR in human and rodents. Deficient fetal androgen exposure via experimental 
reduction of androgen production/action primarily in fetal life in rodents (via 
transgenic and chemical manipulations), resulted in corresponding reductions 
in progenitor cell numbers which was accompanied by compensated adult 
Leydig cell failure.  
Previous studies have shown that AR is expressed in the fetal rat testis in non-
steroidogenic interstitial and peritubular myoid (PTM) cells from e17.5 to e21.5 
(Majdic et al 1995) and at 10 weeks in the human (Sajjad et al 2004). In 
postnatal life, (Pnd 5), AR expression was localised again to non-steroidogenic 
interstitial cells and PTM cells in the rat (Majdic et al 1995). The authors suggest 
these cells may represent adult Leydig progenitor cells, and that extensive 
morphological and marker analysis was needed to investigate this further 
(Eacker and Braun 2007). The current findings agree with the previous 
observations and demonstrate that the majority of COUP-TFII+ adult Leydig 
progenitor cells express AR in fetal human and rodent testes. COUP-
TFII+/AR+/3β-HSDneg adult Leydig progenitor cells are also present in the 
interstitium during postnatal life where they appear to differentiate into adult 
Leydig cells (COUP-TFII+/AR+/3β-HSD+) around puberty in the rat.  
To assess the role of androgens in adult Leydig progenitor cell development, the 
most direct approach would be to knock out AR specifically in the COUP-TFII+ 
adult Leydig progenitor cell population. However, this was not feasible as firstly 
the only known markers for these cells (from the studies in this thesis), are AR 
and COUP-TFII and, secondly, COUP-TFII is expressed not only in the progenitor 
cells, but also in PTM cells, and initially in fetal Leydig cells (van den Driesche et 
al 2012). It would have been useful to investigate the aP2-Cre;ARflox/flox  mouse 
model as a specific way of targetting AR on adult Leydig progenitor cells, 
however tissue for this model was not available at the time these studies were 
undertaken. Therefore, the ubiquitous ARKO mouse model (De Gendt et al 




2005), was used to investigate any effect that non-functioning AR in adult 
Leydig progenitor cells might have on their development and on adult Leydig 
cell development/function. The use of other cell selective ARKO models, Sertoli 
cell (SC)-ARKO (De Gendt et al 2005) and a peritubular myoid (PTM)-ARKO 
(Welsh et al 2009) were also included in this study to evaluate any effect 
androgen signalling via these cells may have on adult Leydig progenitor 
development. Quantification of adult Leydig progenitor cells (COUP-TFII+/3β-
HSDneg) in ARKO mice, revealed a significant reduction after birth (Pnd 2) and a 
40% deficit in number throughout postnatal life, in comparison to respective 
wild-type controls. This reduction was paralleled by a reduction in adult Leydig 
cell number throughout development in ARKOs. This finding is in agreement 
with previous studies that investigated the role of androgen signalling in adult 
Leydig cell development. ARKO mice were reported to exhibit an 83% reduction 
in adult Leydig cell number throughout postnatal development (De Gendt et al 
2005), and in adulthood, adult Leydig cells were reduced by 60% 
(O'Shaughnessy et al 2002, 2012). The fact that adult Leydig progenitor cells 
were also reduced in parallel adds a new dimension to the aforementioned 
studies. Fetal Leydig cell number was comparable in control, ARKO and SCARKO 
models at pnd 2, consistent with the fact that fetal Leydig cell development and 
function is androgen-independent (O'Shaughnessy et al 2002).  
However, the fact that AR is knocked out ubiquitously in the ARKO model plus 
the fact that all testes are cryptorchid, are all potentially confounding factors. 
Therefore, a model in which fetal intratesticular testosterone was selectively 
reduced, via DBP, was investigated to determine whether this would affect the 
development of adult Leydig and/or their progenitor cells, as it appeared to do 
so in the ARKO model. Fetal DBP-exposure reduced intratesticular testosterone 
levels in the rat by 40-80% (Mylchreest et al 1999, 2000, 2002, Scott et al 2007, 
van den Driesche et al 2012) and in this study. DBP was chosen as the prenatal 
'anti-androgen' instead of flutamide (Imperato McGinley et al 1992, Welsh et al 
2008, 2010), because it is the most direct way of reducing androgen action on 
the progenitor cells by reducing fetal intratesticular testosterone levels, rather 




than trying to block androgen action, as is the case with flutamide. Treatment 
with the latter may simply not be enough to block the actions of the already high 
intratesticular testosterone levels present during fetal development. DBP-
exposure resulted in a significant reduction (40%) in adult Leydig progenitor 
cell number at the end of gestation and throughout postnatal development into 
adulthood. The fact that knockout/inactivation of the AR in mice resulted in a 
similar magnitude of reduction in numbers of adult Leydig progenitor cells 
across development, led to the conclusion that this may have resulted from 
deficient androgen action. The reduction in adult Leydig cell number in ARKOs, 
could potentially reflect the lower number of adult Leydig progenitor cells 
present. However, a similar deficit in adult Leydig cell numbers was not found in 
DBP-exposed males (in which androgen level/action was only reduced in fetal 
life). One explanation is that knockout of AR in other cell types e.g. Sertoli or 
PTM cells might have contributed to the reduction in adult Leydig cell number, 
as reduced adult Leydig cell numbers were reported in SCARKO mice (De Gendt 
et al 2005) and abnormal adult Leydig cell differentiation, in PTM-ARKO mice 
(Welsh et al 2009). In this regard, there was no significant difference in the 
number of adult Leydig progenitor cells in SCARKO and PTMARKO models in 
the present study, in comparison to wild-type controls.  
The main findings in this chapter demonstrate that fetal androgen deficiency 
(ARKO and DBP-exposed males) results in a deficit in adult Leydig progenitor 
cell number and compensated adult Leydig cell failure, i.e. normal/reduced 
blood testosterone in the face of elevated LH, and thus an altered 
LH:testosterone ratio, in comparison with wild-type controls. This finding is in 
agreement with earlier studies of ARKO males, in which LH serum levels were 
significantly increased while testosterone levels were decreased/normal (Yeh et 
al 2002, Matusumoto et al 2003, Notini et al 2005, De Gendt et al 2005). In 
humans, it has been suggested that fetal androgen deficiency can result in adult 
Leydig cell dysfunction and thus 'primary hypogonadism' (Tajar er al 2010, 
Andersson et al 2004). Patients with symptoms in adulthood symptomatic of 
TDS, commonly display abnormal/compensated adult Leydig cell failure, as 




evident from increased LH and decreased testosterone (Joensen et al 2008, 
Lardone et al 2012). For example, Increased LH levels and low-normal 
testosterone levels appear to be a common finding in infertile men (Glass & 
Vigersky 1980, Stanwell-Smith et al 1985, Andersson et al 2004), indicative of 
compensated Leydig cell failure. In long-term follow up studies of males with 
disorders of sexual development (DSD), analysis of their serum hormone levels 
demonstrated an increase in LH and FSH with low-normal testosterone, again 
indicative of compensated adult Leydig cell failure (Kojima et al 2009, van der 
Zwan et al 2013). This phenotype is comparable to the ARKO and DBP models 
presented in this study, potentially as a result of lowered fetal androgen action.   
Overall, this suggests the importance of normal androgen signalling during fetal 
life for the development (numerically and functionally) of adult Leydig 
progenitors when they differentiate into adult Leydig cells. In a large clinical 
study of idiopathic infertile men, on average, LH was increased by 19% and 
testosterone serum levels were reduced by 18%, in comparison to fertile men 
(Andersson et al 2004). The authors suggested that adult Leydig cell 
dysfunction might have resulted from testicular dysgenesis during fetal 
development, which the results in this study provide evidence for. In fact a 
subgroup of the infertile men who had a history of cryptorchidism, had lower 
sperm concentration and an even poorer Leydig cell function, as reflected by an 
increased LH:testosterone ratio, in comparison with the fertile men without a 
history of cryptorchidism (Andersson et al 2004). In line with this, a shortened 
AGD in newborn males is associated with cryptorchidism and hypospadias, 
which highlights the role of fetal androgen action in these disorders (Eisenberg 
et al 2012, Jain & Singal 2013, Dean & Sharpe 2013). Newborns who present 
with cryptorchidism or hypospadias, potentially as a result of testicular 
dysgenesis, have a higher risk for other TDS conditions to manifest during 
postnatal life, e.g. adult Leydig cell dysfunction (Toppari et al 2010).  
The findings presented in this study demonstrate that a deficiency in fetal 
androgen level/action results in adult Leydig cell dysfunction in adulthood in 
rats. However, there could be other interpretations for these findings, such as, 




that fetal androgen deficiency could have induced other changes which could 
secondarily lead to altered adult Leydig function. As sex steroids can regulate 
the expression of GnRH neurons involved in normal signalling in the HPG axis 
(Garcia-Galiano et al 2012), it might seem plausible that the reduction in fetal 
androgens could have altered sensitivity of the HPG axis, involved in the 
androgen negative feedback pathway. This could then affect the number of adult 
Leydig progenitor cells. However, this seems unlikely as LH is not a key 
mediator of testis function during fetal life (Scott et al 2009, O'Shaughnessy and 
Fowler 2011), thus cannot be responsible for the clear reduction in adult Leydig 
progenitor cell number in the rodent models used in these studies. 
The present findings show that the number of adult Leydig progenitor cells 
increases substantially during postnatal life, prior to and during puberty, 
consistent with an increase in 'mesenchymal, non-Leydig interstitial cells' 
(Mendis-Handagama et al 2001). This prompted the investigation into whether 
or not these cells were affected by altering androgen levels/action during 
different periods of potential susceptibility i.e. fetal or postnatal life. Flutamide 
treatment prior to puberty in the rat (Pnd 1-15), resulted in a reduction of the 
number of adult Leydig progenitor cells at pnd 25, in comparison with wild-type 
controls. These findings are consistent with a recent study which highlighted 
the importance of postnatal androgens on Leydig progenitor cell proliferation 
(Guo et al 2013). In the latter study, a GnRH antagonist (NalGlu), was used to 
block LH stimulation of androgen production at pnd 14 in the rat, and resulted 
in a reduction (83%) of 'adult Leydig progenitor cells'. In the present study, 
postnatal flutamide treatment of fetally DBP-exposed animals, resulted in a 
significant reduction in adult Leydig progenitor cell numbers. While it appeared 
a similar reduction was evident in adult Leydig cells, this did not reach 
statistical significance, perhaps due to a smaller sample size in this group. In 
terms of adult Leydig cell function, postnatal flutamide treatment of fetally DBP-
exposed animals resulted in compensated adult Leydig cell failure, which was 
comparable to that found in DBP-exposed animals in the absence of postnatal 




flutamide treatment. This highlights that androgen deficiency in the fetal period, 
but not in the postnatal period, results in adult Leydig cell dysfunction.  
Previous studies have reported that fetal TP exposure resulted in masculinised 
female offspring (Wolf et al 2002, Welsh et al 2008), which suggests that 
exogenous fetal TP administration increases fetal androgen exposure during 
fetal life, although whether this extends to increasing intratesticular androgen 
levels in fetal males is unlikely based on an earlier study (Scott et al 2007). 
Nevertheless, it prompted the use of this model in order to investigate whether 
or not adult Leydig progenitor cells were affected by increased fetal exposure to 
TP. Furthermore, effects on adult Leydig progenitor cells were also investigated 
following postnatal TP treatment, to determine whether or not a potential 
increase in postnatal testosterone levels could 'advance' the development of 
adult Leydig progenitor cells. Fetal exposure to TP appeared to increase the 
number of adult Leydig progenitor cells at birth, and there was a tendency for 
the same change in adulthood, whereas there was no comparable effect 
following postnatal TP treatment. However, upon examination across 
development, the reduced testis size and fetal growth restriction following fetal 
TP exposure, similar to that found in previous studies (Wolf et al 2002, 2004, 
Welsh et al 2008), suggested that TP treatment of pregnant dams might have 
introduced confounding factors. Any results obtained from these experimental 
groups could not be confidently attributed as due to an androgenic response, as 
such effects could also have been due to potential aromatisation of excess TP 
into oestradiol.  
As dihydrotestosterone (DHT) is a more potent and non-aromatisable androgen, 
it was administered to pregnant dams, instead of TP. Fetal DHT exposure 
resulted in masculinisation of female offspring, as evident by an absence of 
nipples, absence of a vaginal opening and the presence of a vestigial prostate. 
However, in terms of enhancing male reproductive parameters, there was no 
affect evident on reproductive organ size in DHT-exposed males, in comparison 
with controls. Both AGD and the number of adult Leydig progenitor cells were 
comparable to controls at e21.5. This is in agreement with other studies that 




failed to find an increase in male reproductive development following fetal 
exposure to androgens (Wolf et al 2008, Welsh et al 2008, Dean et al 2012). A 
higher dose of 20 mg/kg of DHT was also administered to pregnant dams during 
these studies, which neither enhanced nor advanced any reproductive organ 
size or AGD in male offspring examined in adulthood. Although DHT has a 
higher affinity than testosterone for AR, it seems likely that intratesticular 
testosterone levels are already high enough to induce maximal androgen effects 
locally, and thus cannot be added to, although this was not formally checked. 
However, it seemed apparent that exogenous TP/DHT exposure, in this study, 
could not effectively demonstrate a gain of function (in terms of adult Leydig 
progenitor cells numbers and or adult Leydig cell function) due to exogenous 
androgen exposure. Therefore, a more convincing model would be one in which 
endogenous ITT levels might potentially be increased, namely the iNOS-/- 
mouse.  
Previous studies of the iNOS-/- mouse model reported a 40% and 16% increase 
in adult Leydig cell number at puberty and adulthood respectively, and 
increased AGD at both ages (Auharek et al 2011, 2012). Increased AGD suggests 
an increase in fetal androgen exposure which might in turn reflect elevated 
intratesticular testosterone levels (Welsh et al 2008, Auharek et al 2011, 2012). 
The current findings show that the number of adult Leydig progenitor cells in 
fetal life (at e18.5) of iNOS-/- mice, is comparable to their respective wild-type 
controls. In fact, it is only in postnatal life, that an increase in adult Leydig 
progenitor cells is evident (Pnd 10, 15 and 70). This is in contrast to the earlier 
studies described herein, which demonstrated that androgen action in the pre-
pubertal period is less important (than fetal life) for altering adult Leydig cell 
function. In adult iNOS-/- males, plasma levels of testosterone are normal whilst 
LH levels are decreased (Lue et al 2003), which suggests that lower LH is 
required to stimulate testosterone production in this model. Unfortunately, 
plasma levels of LH and testosterone for the iNOS-/- model, in which the present 
studies were undertaken, were unavailable from our collaborators. Also there 
was no difference in adult Leydig cell number in iNOS-/- mice, at any age 




examined, in comparison to control animals, which is contrast to earlier studies 
(Auharek et al 2011, 2012). This can potentially be explained by the difference 
in stereological techniques employed, as the previous study identified adult 
Leydig cells by morphology, unlike the present study. The previous study also 
reported that the size of individual adult Leydig cells was significantly reduced, 
thus suggesting that iNOS is important for steroidogenic cell function (Auharek 
et al 2011), so it may not be an effective gain of function model. In any case, vital 
data from the iNOS-/- model in this study are missing, e.g. the measurement of 
fetal intratesticular testosterone and adult hormone measurements (e.g. 
testosterone and LH), which could determine whether this model exhibits a true 
"gain of adult Leydig cell function." Without this key data, any effect on adult 
Leydig progenitor cell development, as a result of potentially increased 
intratesticular levels, can only be deemed as speculation. 
Smooth muscle actin (SMA) is a marker for differentiated peritubular myoid 
cells, which envelop Sertoli and germ cells and delineate the seminiferous 
cords/tubules, but also stain blood vessels. An interesting observation from 
these studies was that, compared with control testes at pnd 2, ARKO-males 
exhibited reduced SMA staining in the PTM cells, whereas this was normally 
present in the blood vessels of the same sample, indicating it was not due to any 
technical error. Testosterone has been shown to induce peritubular cell 
differentiation (Schlatt et al 1993) in prepubertal monkeys which suggests that 
androgens play a role in the differentiation of peritubular cells. Weak SMA 
staining in PTM cells in ARKOs at pnd 2, suggests there might be a delay in their 
differentiation, presumably due to the absence of fetal androgen signalling in 
ARKO males. A similar reduction in SMA expression in PTM cells was noted at 
e17.5 in Tfm mice with an inactivated AR (Merlet et al 2007). In relation to adult 
Leydig progenitor cells, the absence of AR signalling might affect/compromise 
their differentiation into adult Leydig cells.  Compared to control mice in which 
the number of adult Leydig cells increased between pnd12 and 20, coincident 
with adult Leydig cell differentiation, this increase appeared to be delayed in 
ARKO males and occurred between pnd 20 and 50. One potential explanation is 




that abnormal androgen signalling compromises the differentiation of adult 
Leydig progenitor cells into adult Leydig cells (Ivell et al 2013). 
A recent study that investigated adult Leydig cell function in DBP-exposed rats, 
using Insl3 as a marker, reported a disruption of normal adult Leydig cell 
development, as evident from a prolonged period of adult Leydig cell 
differentiation (Ivell et al 2013). This is similar to the current findings, which 
show that DBP-exposed rats exhibit a significant reduction in adult Leydig cell 
number at Pnd 25, but reach normal numbers in adulthood. Thus, 
differentiation of adult Leydig progenitor cells in DBP-exposed males between 
d15-25 appears somewhat delayed, in comparison to the controls. This 
potentially reflects a prolonged/delayed differentiation period of adult Leydig 
progenitor cells into adult Leydig cells.  
An earlier study reported that in adult ARKO males, there was no difference in 
the number of adult Leydig cells, in comparison to control animals (Notini et al 
2005). However, as there is no indication of how or if adult Leydig cell 
quantification was carried out, this might simply be a misleading observation 
made by the authors, due to the smaller diameter of the seminiferous tubules 
(which the authors had highlighted). Initial observations, within the present 
study, of adult Leydig cell hyperplasia in ARKOs were dismissed,, once adult 
Leydig cells were quantified (as above), which highlights the importance of cell 
quantification for accurate results (O'Shaughnessy et al 2002). 
The present findings in this chapter provide new insight into a potential role for 
androgens in regulating adult Leydig progenitor cell development numerically 
and their functional capability when they differentiate into adult Leydig cells, as 
evident from the ARKO and DBP rodent models investigated. In humans, 
infertile men with a history of cryptorchidism, exhibit compensated adult 
Leydig cell failure i.e. low-normal testosterone levels and high luteinising 
hormone to maintain a normal testosterone level (Andersson et al 2004). The 
authors suggest that compensated adult Leydig cell failure is a symptom of TDS, 
which is believed to have a common fetal origin, namely due to fetal androgen 




deficits (Skakkebaek et al 2001, Sharpe & Skakkebaek 2008). The results in this 
study provide direct evidence for this and suggest that fetal androgen deficiency 
affects the adult Leydig progenitor cells. Precisely how fetal events can 
predetermine adult testosterone levels has thus far not been elucidated, 
however, a potential mechanism using the DBP rat model to mimic human TDS, 
is investigated in the next chapter. 




Chapter 5 Fetal Programming of Adult Leydig Progenitor Cells 
5.1 Introduction 
The main findings from the previous chapter demonstrated that fetal androgen 
deficits, led to a reduction in the number of adult Leydig progenitor cells, and 
resulted in adult Leydig cell dysfunction. This chapter aimed to investigate the 
potential mechanisms how this might have occurred, by analysing expression of 
genes involved in the steroidogenic pathway in adulthood and investigating an 
epigenetic change to explain one potential mechanism involved. 
The previous chapter demonstrated that fetal DBP-exposure reduced 
testosterone production during fetal life, and in adulthood this resulted in 
‘compensated Leydig cell failure’. The exact mechanism via which DBP exerts its 
effects on fetal Leydig cells is unknown but DBP exposure clearly inhibits the 
rate limiting step in steroidogenesis, StAR (Clark et al 1995, Manna et al 2009, 
Papadopoulos and Miller 2012, van den Driesche et al 2012), as well as enzymes 
involved further downstream in the steroidogenic pathway (Schultz et al 2001, 
Barlow et al 2003, Lehmann et al 2004, Thompson et al 2004, Liu et al 2005, 
Plummer et al 2007, van den Driesche et al 2012). A recent study which used 
DBP (500mg/kg) to lower fetal testosterone levels showed that in adulhood, the 
levels of testicular 3β-HSD and 17β-HSD enzymatic activity were reduced, which 
was associated with compensated adult Leydig cell failure (Giribabu et al 2012). 
This indicates an altered/abnormal steroidogenic pathway, which will be 
investigated in this chapter. 
Epigenetic changes can be meiotically and/or mitotically heritable, altering gene 
expression potential without altering the gene sequence (Wu and Morris 2001), 
and can occur early during cell proliferation and development (Klein et al 2005). 
The proximal promoter region in StAR was found to have reduced H3K27me3 
upon StAR transcription, as induced by hCG injection in granulosa cells (Lee et al 
2013). This specific region has also been shown to be important for StAR 




transcription in MA-10 cells (Hiroi et al 2004) and granulosa cells (Christenson 
et al 2001) and will be investigated in this chapter.  
Transcription of StAR is crucial for regulating steroidogenesis. Epigenetic 
factors can alter gene transcription including methylation of DNA, microRNAs 
and histone modifications (Bibikova et al 2008). The latter refers to 
modifications to chromatin structure, which is composed mainly of DNA 
wrapped around histones. Histone modifications cause chromatin remodelling 
which controls gene transcription (Kadonaga 1998, Shen et al 2009). 
Transcriptional activation can occur via histone methylation e.g. of lysine 4 at 
histone 3 (H3K4) or transcriptional repression by methylation of lysine 27 at 
histone 3 (H3K27) (Lee et al 2005). Tri-methylation at lysine 27 of histone 3 
(H3K27me3) is one such histone modification, the expression of which 
commonly acts as a repressive mark (Kirmizis et al 2004, Barski et al 2007, Sui 
et al 2012) by condensing the chromatin, thus impeding the binding of 
transcription factors to response elements in the promoter and thus preventing 
transcription (Li et al 2007). These studies prompted the investigation into the 
hypothesis that compensated adult Leydig cell failure is ‘programmed’ in DBP-
exposed animals by increasing histone methylation in adult Leydig progenitor 











5.2 Materials and Methods 
5.2.1 RNA extraction and RT-PCR 
Briefly, total RNA was isolated from frozen testes from control and DBP-
exposed rats followed by RNA extraction and cDNA synthesis (Chapter 2). 
5.2.2 Quantitative gene expression analysis using Taqman PCR  
Quantitative PCR was performed for genes listen in Table 5.1 using primers and 
probes listed in Table 5.1 and an ABI Prism 7900 HT Sequence Detection System 
(Applied Biosystems; California, USA). This was run using optimised standard 
conditions and taqman probes (Chapter 2). 
 
Table 5.1 Primers and probes used for gene expression analysis. 
Gene Forward Primer Reverse Primer (Probe No.) 
Sox9 CTGAAGGGCTACGACTGGAC TCTTGATGTGCGTTCTCTGG (63) 
LHR CTGGAGAAGATGCACAGTGG CTGCAATTTGGTGGAAGAAATA (107) 
StAR TCACGTGGCTGCTCAGTATT GGGTCTGTGATAAGACTTGGTTG (83) 
CYP11a1 TCACATGCAGAATTTCCAGAAG AGGATGTAAACTGACTCCATGTTG (7) 
3β-HSD TCATCTGATTTTGAACAATTTAGC CTCCTGCTCCTGTCACCAG (105)  
CYP17a1 CATCCCCCACAAGGCTAAC TGTGTCCTTGGGGACAGTAAA (67) 
17β-HSD3 AATATGTCACGATTGGAGCTGA AAGGAATCAGGTTCAGAATTATCG (5) 
 
5.2.3 ChIP assay 
In order to isolate DNA which contained the histone of interest for this study, 
chromatin immunoprecipitation (ChIP) was carried out, which used whole rat 
testis DNA. Detailed methods are found in Chapter 2. All methods used to 
perform ChIP were initially validated as this was a novel technique in our 
research lab. The schematic illustrates the method employed (Figure 5.1). 
Briefly, DNA was cross linked to histones using formaldehyde. The DNA-histone 




complex was then broken into smaller fragments via sonication. An antibody 
against the histone of interest, H3K27me3, was used to isolate the chromatin 
fragments to which H3K27me3 had attached. The cross-links were then 
reversed and the ‘released’ DNA was separated by protease digestion and 
purified. Purified DNA was then quantified via PCR, as described below.  
 
Figure 5.1 Schematic of the methodology of a ChIP assay  
 
5.2.4 Primer design and validation 
Primers were specifically designed for the proximal promoter region (85bp 
upstream) of StAR, (Table 5.2; 167bp) using the websites 'UCSC Genome 
Bioinformatics' (http://genome.ucsc.edu/) and 'primer3' http://primer3.ut.ee/.  
Primers were purchased from Eurofins, MWG Operon (Germany) and validated 
using a standard curve (Figure 5.2). Slopes in the range of -3.10 to -3.60 are 
considered acceptable for real-time PCR. The slope of the standard curve in this 
study was -3.19, which correlates to a high amplification efficiency of the PCR 




reaction. A melt curve step was included to determine the specificity of the 
primers designed (Chapter 2) which demonstrated their high specificity for this 
study (Figure 5.2). PCR reaction was carried out as described in chapter 2. 
 




Figure 5.2 Standard curve (left) and melt curve analysis (right) of primers used 
 
5.2.5 Gel electrophoresis and densitometry 
As further validation of the findings from the ChIP assay, PCR products 
underwent gel electrophoresis, followed by densitometric analysis using 
'ImageJ' (Chapter 2). DNA bands from control animals are shown at the top 
adjacent to green labels and on the same gel, DNA bands from DBP-exposed 
animals are shown next to blue labels, as shown in a representative sample 
(Figure 5.3).  The software in 'ImageJ' computed the level of intensity of all the 
bands and this was compared to the input control. 
StAR AGGCAATCATTCCATCCTTG GCTCCCAGGGATTTGTTCTT 





Figure 5.3 Densitometric analysis of purified DNA after ChIP 
 
5.2.6 Immunofluorescence 
Double/triple immunofluorescence was carried out in order to determine 
whether the results obtained from the ChIP experiments, could also be 
demonstrated by antibody detection via immunofluorescence. A detailed 
protocol is provided in chapter 2. The primary antibodies used in these 








Table 5.3 Antibody dilutions and detections used for immunofluorescence 
Primary Species 
Raised  
Dilution  Manufacturer  Visualisation  
COUP-TFII  Mouse  1:1,000  Perseus 
Proteomics Inc  
Fluorescein 
(Green) 
3β-HSD Goat  1:1,000 Santa Cruz Tyr-Cy3 (Red) 
H3 Rabbit 1:5,000 Abcam Tyr-Cy3 (Red) 
H3K27me3 Rabbit 1:5,000 Active Motif Tyr-Cy3 (Red) 

















5.3.1 Steroidogenic gene analysis in adulthood following fetal DBP-exposure 
DBP-exposed animals had reduced fetal and adult testosterone levels, which 
alongside elevated blood LH levels, indicated 'compensated adult Leydig cell 
failure', as shown in the previous chapter. To further investigate adult Leydig cell 
function, specific genes involved in the steroidogenic pathway to produce 
testosterone were analysed. As fetal exposure to DBP can result in 
cryptorchidism and thus affect testicular cellular composition, in particular loss 
of germ cells (and their mRNA), the expression of each gene in each testis sample 
was expressed relative to the expression of Sox9, a specific Sertoli cell marker. 
This was chosen as an appropriate control as the number of Sertoli cells is 
unchanged in adulthood between scrotal or cryptorchid testes of DBP-exposed 
animals (Hutchison et al 2008). The Leydig-cell specific genes examined included 
Lhr, StAR, Cyp11a1, 3β-hsd, Cyp17a1, and 17β-hsd3 which all contribute to the end 
product, testosterone. There was a significant reduction in StAR and 3β-HSD 
mRNA expression in adulthood following fetal DBP exposure, without any 
significant effects evident for other steroidogenic genes examined (Figure 5.4). 
The next aim was to investigate the protein expression of both StAR and 3β-HSD. 





Figure 5.4 Effect of prenatal DBP exposure in rats on adult Leydig cell function as 
monitored by expression of Leydig cell-specific genes in the steroidogenic 
pathway. Values are relative mRNA levels as determined by quantitative PCR. 
The testosterone synthesis cascade is shown in the panel at the top, starting 
with the LH receptor (Lhr) and finishing with 17β-hydroxysteroid 
dehydrogenase type 3 (17β-hsd3). Values are Means ± SEM for n=11-12 rats in 
each control and DBP-exposure group. Data were analysed using an unpaired t-
test; *p<0.05, **p<0.01 in comparison with control (vehicle) animals. 




5.3.2 Expression of StAR in adulthood following fetal DBP exposure 
As StAR and 3β-HSD mRNA levels were decreased in DBP-exposed animals 
(Figure 5.4), the next experiment investigated the protein expression between 
control and DBP-exposed adult rats. Triple immunofluorescence was carried out 
using COUP-TFII (green), StAR (red) and 3β-HSD (blue) in adult testes of control 
and DBP-exposed rats. Both StAR and 3β-HSD were expressed in the cytoplasm 
of adult Leydig cells (arrowhead) with some Leydig cells expressing COUP-TFII in 
their nuclei in control and DBP-exposed animals (Figure 5.5). COUP-TFII+/3β-
HSDneg/StARneg adult Leydig progenitor cells (arrow) were also present in the 
interstitium in both groups (Figure 5.5). Overall, from the immunohistochemistry 
experiments, there was not a convincing or consistent difference in 3β-HSD or 
StAR protein expression in adult Leydig cells, which may be as a result of the 
subtle alteration/reduction in their gene expression (Figure 5.4). Although either 
change might theoretically lead to reduced steroidogenic output, StAR is one of 
the factors involved in cholesterol transport into the mitochondria (Fan & 
Papadopoulos 2013), which is rate-limiting for steroidogenesis (Miller & Bose 
2011), so this change was considered the most significant. Given the 
reduced StAR expression found in DBP-exposed animals in this study, this 
prompted its further investigation to potentially explain how StAR transcription 
is repressed, as a result of fetal androgen deficiency. 
 





Figure 5.5 COUP-TFII+ adult Leydig cells express StAR and 3β-HSD in adult control 
and DBP-exposed rats. COUP-TFII+ (green) adult Leydig cells express StAR (red) and 
3β-HSD (blue) in adulthood in both groups (arrowhead). COUP-TFII+/3β-
HSDneg/StARneg adult Leydig progenitor cells are also evident (arrow). Scale bar =20 
µm.  
5.3.3  Increased Histone 3 methylation in the proximal promoter region of StAR 
These experiments aimed to investigate the hypothesis that a histone 
modification may result in repression of StAR transcription, as shown above 
(Figure 5.4). Specific primers for the proximal promoter region of StAR were 
designed and validated, as described earlier (Figure 5.2). This region is 
important for regulation of StAR (Sandhoff et al 1998, Silverman et al 1999, 
LaVoie et al 2005, Lee et al 2013) and is shown in the schematic (Figure 5.6). 
Chromatin immunoprecipitation (ChIP) was used to isolate the repressive 
histone, H3K27me3, prior to PCR being undertaken using primers specific to the 
proximal promoter region of StAR. This demonstrated a significant increase in 
the level of H3K27me3 within the promoter region of StAR in DBP-exposed 
animals, compared with controls (Figure 5.6). Gel electrophoresis of the PCR 
products was undertaken, which firstly indicated the presence of a single PCR 
product (as expected from the earlier primer validation) and, secondly, allowed 
for densitometric analysis, as in a recent study (Jia et al 2013). The findings 
from the ChIP assay were confirmed by densitometric analysis (Figure 5.6), thus 




demonstrating increased levels of H3K27me3 in the StAR promoter region of 
DBP-exposed rats, compared with controls (Figure 5.6). Therefore, the next aim 
was to examine the immunoexpression of H3K27me3 in DBP-exposed animals 
compared with controls, to investigate if this histone modification was evident 
during fetal life and continued through to adulthood. 
 
Figure 5.6 Increased methylation of histone 3 at lysine 27 (H3K27me3) in the 
proximal promoter of StAR in DBP-exposed rats.  The schematic shows the region 
of the StAR promoter which was targeted during adulthood; 85bp upstream of the 
transcription start site, and amplified by PCR using primers as outlined (167bp in 
length). Levels of H3K27me3 were increased at the proximal promoter of StAR, as 
analyzed by ChIP and densitometric analysis of PCR products. Normal rabbit IgG was 
used as a negative control. Data were calculated using the percentage total genomic 
input method and shown as an average value (bottom left graph). The input DNA Ct 
value (i.e. DNA which did not undergo immunoprecipitation) was used to normalize 
the ChIP data in place of typical house-keeping gene values used to normalize real-
time PCR (RT-PCR) reactions. The average threshold cycle (Ct) for triplicate assays 
was used in all subsequent calculations. Values are Means ± SEM for n=3. Data were 
analysed using an unpaired t-test; **p<0.01, compared to (control) vehicle value.  




5.3.4 Increased H3K27me3 in adult Leydig progenitor cells of DBP-exposed rats 
in fetal life 
As fetally DBP-exposed animals in adulthood exhibit altered steroidogenesis, 
potentially as a result of increased histone repressor H3K27me3 at StAR, this 
posed the question as to whether this alteration was present in adult Leydig 
progenitor cells, during fetal life and manifested in adulthood in dysfunctional 
adult Leydig cells after their differentiation. To investigate this hypothesis, 
double immunofluorescence was carried out using an antibody against the 
repressive histone of interest (H3K27me3; red), and a marker of the adult 
Leydig progenitor cells (COUP-TFII+; green) in the rat at e21.5. In the control 
fetal testis, there was minimal H3K27me3 expression in the interstitium at this 
antibody dilution, whereas there was expression in the nuclei of adult Leydig 
progenitor cells in DBP-exposed animals, indicated by the yellow nuclear co-
staining (yellow arrows) which is more apparent in the higher magnification 
image (Figure 5.7). Expression of H3K27me3 in Sertoli cells seemed to be more 
strongly expressed in DBP-exposed animals as compared with control animals, 
however this finding was not further investigated within this study (Figure 5.7).  
To ensure these findings were representative of increased methylation of 
histone 3 (H3) and not an increase in expression of the histone itself, single 
immunofluorescence was carried out on the same control and DBP-exposed 
animals using an antibody against H3. The immunohistochemistry experiments 
demonstrated clearly that there was no change in the expression of H3 between 
control and DBP-exposed animals at e21.5 in the rat (Figure 5.8). 
 
 





Figure 5.7 Increase in repressive H3K27me3 in adult Leydig progenitor cells of 
DBP-exposed rats at e21.5.  A proportion of COUP-TFII+ adult Leydig progenitor 
cells co-express COUP-TFII (green) and H3K27me3 (red) in their nuclei (yellow 
arrows) in DBP-exposed rats at e21.5 (middle and zoom on right). In controls (left), 
H3K27me3 was absent from adult Leydig progenitor cells, at this antibody dilution 
and detected only in Sertoli cells. Scale bars = 20 µm 
 
 
Figure 5.8 Expression of histone 3 at e21.5 in control and DBP-exposed rats. 
Histone 3 (red) is comparable in the testes of control (left) and DBP-exposed (right) 
rats at e21.5. Scale bars = 20µm. 
 




5.3.5 Increased H3K27me3 in adult Leydig cells of DBP-exposed animals in 
postnatal Life 
As the adult Leydig progenitor cells in DBP-exposed animals expressed 
increased levels of H3K27me3 compared with controls during fetal life, the next 
experiment aimed to investigate whether this was evident during puberty and 
adulthood when Leydig cells have differentiated.  Double immunofluorescence 
was carried out using H3K27me3 (green) and 3β-HSD (red) on pnd25 and 
pnd90 testes from control and DBP-exposed rats. DAPI (blue) was used as a 
nuclear counterstain. These findings demonstrated that at puberty (top right) 
and in adulthood (bottom right), adult Leydig cells (3β-HSD+; red cytoplasm) 
clearly expressed higher levels of H3K27me3 (green nuclei; arrows) in DBP-
exposed rats compared with their age-matched controls (left panels) (Figure 
5.9). 
 





Figure 5.9 Increase in repressive H3K27me3 in adult Leydig cells of DBP-exposed 
rats. During puberty (Pnd25) and in adulthood (Pnd 90), adult Leydig cells (3β-HSD+; 
red cytoplasmic staining) in DBP-exposed rats expressed higher levels of H3K27me3 
in their nuclei (green; white arrow) compared to their age-matched controls in 
which it was minimal/absent (left panels), at this antibody dilution. Scale bars = 20 
µm.  
 
As before, to ensure these findings were representative of increased 
methylation of histone 3 (H3) and not an increase in expression of the histone 
itself, single immunofluorescence was carried out on the same control and DBP-
exposed animals using an antibody against H3. The level of H3 was comparable 
between control and DBP-treated animals at pnd25 and 90 in the rat (Figure 
5.10). 
 





Figure 5.10 Expression of histone 3 in the testis of pnd 25 and pnd 90 rats.  Histone 
3 (red) is comparable in the testes of control (left) and DBP-exposed (right) rats at 
pnd 25 (top panel) and pnd 90 (bottom panel). Scale bars=20µm. 
 
5.3.6 H3k4me3 is absent in DBP-exposed animals in adulthood 
Promoters of genes marked only with H3K27me3 are "stably repressed" 
(Bernstein et al 2007, Mikkelsen et al 2007) while with H3K4me3 are termed 
'active' (Lee et al 2006). Therefore to confirm that the histone modifications in 
the interstitial area were indicative of transcriptional repressive marks, and not 
active (H3K4me3) in DBP-exposed animals, double immunofluorescence was 
carried out using COUP-TFII (green) and H3K4me3 (red) on adult rat testes 
from control and DBP-exposed animals. Staining for H3K4me3 in COUP-TFII+ 
adult Leydig progenitor cells and in the interstitial area itself was minimal in 
control and absent in DBP-exposed animals in adulthood (Figure 5.11). This fits 
with the above findings (Figure 5.9) that an increase only in H3K27me3, in DBP-
exposed animals, provides evidence for transcriptional repression. 




   
Figure 5.11 Absence of H3K4me3 staining in the interstitium of DBP-exposed rats. 
H3K4me3 (red), a marker of active gene transcription is absent in COUP-TFII+ adult 
Leydig progenitor cells (green; arrows) and the interstitial area of DBP-exposed 
adult rats while is minimal in the interstitium of controls. Expression of H3K4me3 is 



















This chapter aimed to investigate a mechanism to potentially explain how adult 
Leydig cell dysfunction occurs as a result of fetal androgen deficiency. Following 
DBP-exposure to lower fetal testosterone, adult rats showed evidence for 
‘compensated Leydig cell failure’ i.e. low testosterone with increased LH, as in 
the previous chapter. This chapter demonstrates how this might occur via 
altered Leydig-cell specific gene expression in the steroidogenic pathway, as 
shown by reduced 3β-HSD and StAR expression. More specifically, histone 
modifications (increased tri-methylation of lysine 27 at histone 3 (H3K27me3) 
at the proximal promoter region of StAR, represses its transcription resulting in 
altered steroidogenesis and lowered testosterone in adulthood. The adult 
Leydig progenitor cells expressed increased H3K27me3 during fetal life, as did 
adult Leydig cells in DBP-exposed animals during postnatal life, compared with 
controls. Thus the epigenetic changes (programmed histone modifications) to 
adult Leydig progenitor cells may potentially affect adult Leydig cell function via 
their differentiation from 'programmed' progenitor cells.  
Leydig cell-specific genes in the steroidogenic pathway were investigated in 
adulthood following fetal testosterone reduction (DBP-exposure). As some DBP-
exposed animals were cryptorchid, this meant that Leydig cell mRNA may be 
over-represented due to the depletion of germ cells in cryptorchid testes. 
However, as Sertoli cell number is unchanged between control and DBP-
exposed animals (scrotal or cryptorchid testes) (Hutchinson et al 2008), this 
provided a control parameter i.e. the use of a Sertoli cell marker (Sox9), to 
control for target gene expression. The mRNA expression of StAR and 3β-HSD 
were significantly reduced in DBP-exposed animals as compared with controls, 
while there was no significant change to the expression of Lhr, Cyp11a1, Cyp-
17a1 or 17β-HSD3. A more recent study that investigated the effects in 
adulthood after fetal DBP-exposure demonstrated 'compensated Leydig cell 
failure', (evident from decreased testosterone and increased LH levels) and a 
reduction in the enzymatic activity of 3β-HSD and 17β-HSD (Giribabu et al 
2012), which suggests reduced steroidogenesis. However, the authors did not 




examine mRNA expression levels of steroidogenic genes, as in the present study. 
Given the significant reduction in the rate-limiting step of steroidogenesis, StAR, 
which is crucial for transportation of the steroid hormone precursor cholesterol, 
to the inner mitochondrial membrane (Manna et al 2009, Papadopoulos and 
Miller 2012), it was chosen for further investigation in the present study.  
To investigate whether histone modifications were one potential mechanism for 
StAR repression, a ChIP assay followed by quantitative PCR was carried out, and 
these results were further confirmed by densitometric analysis of the purified 
DNA after gel electrophoresis. The proximal promoter region contains crucial 
factors for regulating StAR, including transcription factors and histone 
modifications (Sugawara et al 1997, Silverman et al 1999, Christenson et al 
2001, Hiroi et al 2004, Lee et al 2013) which is conserved across species (Manna 
et al 2009), demonstrating its importance in transcriptional regulation. These 
experiments demonstrated increased tri-methylation of lysine 27 at histone 3 
(H3K27me3) in the proximal promoter region of StAR in DBP-exposed animals, 
in comparison with control animals. This suggests that histone modifications to 
StAR in DBP-exposed animals might be one potential mechanism via which StAR 
expression is repressed, which could result in reduced steroidogenesis.  
In a recent study investigating the mechanisms involved in down-regulation of 
inhibin a (Meldi et al 2012) after the normal LH surge during ovulation 
(Woodruff et al 1989), the authors demonstrated an increase in repressive 
H3K27me3 and H3K9me3 in the proximal promoter of inhibin a which 
corresponded with its repression.  This demonstrates a role for H3K27me3 in 
gene regulation and repression. More relevantly in relation to the StAR gene, 
there are limited studies to date on histone modifications regulating its 
transcription, with the majority of research based on female tissue. One such 
study investigated StAR regulation in granulosa cells (Christenson et al 2001) 
which is normally activated by the mid-cycle LH surge (Kiriakidou et al 1996), 
which the authors found, amongst other factors, occurred as a result of 
increased acetylation of histone 3 (H3) in the proximal promoter of StAR 
(Christenson et al 2001). In other recent studies investigating StAR regulation, 




its transcription was induced by hCG injection in granulosa cells (Lee et al 2013) 
or by exposure of MA-10 cells to 8-Br-cAMP (Hiroi et al 2004), and in both cases, 
increased StAR transcription was associated with a reduction in H3K27me3 in 
the proximal promoter region of StAR. Combining the previous studies with the 
current findings in this thesis, suggests that histone modifications, mainly an 
increase in H3K27me3 at the proximal promoter region plays a key role in 
regulation of the StAR gene resulting in its repression. This would explain the 
reduction in StAR transcription in DBP-exposed animals, when compared with 
controls. 
Methylation marks, particularly H3K27me3, have been suggested to stably 
function as a true epigenetic signal (Trojer and Reinberg 2006) as it is inherited 
by daughter cells after cell division (Hansen et al 2008, Margueron et al 2009, 
Walker et al 2011). In DBP-exposed animals, the increased immunoexpression 
of repressive H3K27me3 in adult Leydig cells (coinciding with an absence of 
activating H3K4me3) in adulthood and in their progenitors during fetal life, 
suggests that adult Leydig cells may have 'inherited' the programmed 
H3K27me3-induced modification of the StAR promoter from their progenitor 
cells, despite the huge proliferative changes that occur in the progenitor cells 
pre- and post-natally.  
These findings also suggest an altered responsiveness of the StAR gene, as its 
mRNA expression is usually positively regulated by LH, and normally induces 
increased mRNA expression levels (Clark et al 1995, Lee et al 2013). In contrast, 
in DBP-exposed animals which had significantly increased LH blood levels 
(previous chapter) and normal Lhr expression (this chapter), a decrease rather 
than an increase, in StAR mRNA expression was found. This could be explained 
by the increased H3K27me3 altering its regulation/responsiveness. 
Histone modifications to the distal region of the StAR promoter were not 
investigated in this study, mainly due to technical issues in validating the 
primers designed for this region. This seems irrelevant given the significance of 
the proximal promoter region in StAR regulation, as above, but also previous 




studies have shown that the distal promoter may not be as important for 
regulation of StAR, at least in relation to histone modifications (Hiroi et al 2004, 
Lee et al 2013). Furthermore, the distribution of H3K27me3 in 512 genes in the 
mouse was localised close to the transcription start site (Boyer et al 2006), 
which highlights a role for H3K27me3 in transcriptional regulation at the 
proximal promoter region.  
To further investigate the mechanism of StAR repression via increased 
H3K27me3, it would be interesting to examine precisely how trimethylation of 
Lysine 27 on histone 3 (H3K27me3) is mediated. Several studies have shown 
that the polycomb-repressive complex 2 (PRC2) plays a role, which is comprised 
of histone methyltransferases including enhancer of zeste (Ezh1/2) (Margueron 
et al 2008, 2009, Cao et al 2002, Muller et al 2002, Shen et al 2008) catalysing 
the methylation of H3K27 (Cao and Zhang 2004, Schuettengruber et al 2007). It 
could thus be insightful to investigate whether StAR transcription could be 
increased in DBP-exposed animals with the administration of a specific histone 
methyltransferase inhibitor to prevent trimethylation of lysine 27 at histone 3 
(H3K27me3) e.g. adenosine dialdehyde (Adox) or 3-deazaneplanocin A 
(DZNep), as previously shown (Miranda et al 2009). Lysine-specific 
demethylase (LSD1) removes repressive lysine-methylation in favour of gene 
transcription, as shown by LSD knockdown resulting in a decrease in 
transcriptional activation of the androgen receptor gene (Metzger et al 2005). 
Specific demethylases of H3K27 include UTX and JMJD3 (Agger et al 2007, De 
Santa et al 2007, Lan et al 2007 and Lee et al 2007) which may prove useful for 
future investigations into removing histone repression of gene transcription. 
This study is the first, to my knowledge, to investigate histone modifications to 
the proximal promoter of StAR in testis tissue and highlights their importance in 
altering the chromatin structure of promoters to impede/assist gene 
transcription. The findings in this thesis fit with the hypothesis that 
disorders/abnormalities such as adult Leydig cell dysfunction in the human 
(Andersson et al 2004, Eisenberg et al 2012) have a common fetal cause (Sharpe 
and Skakkebaek et al 2008). Importantly, these studies add a new layer to the 




current understanding of fetal programming by potentially providing one 
mechanism of how compensated adult Leydig cell failure can be programmed as 
the result of histone methylation at the proximal promoter of StAR. Although 
there are other factors, epigenetic or otherwise, which might be involved in this 
process, these findings demonstrate one way in which fetal androgen deficits 
can adversely programme adult Leydig cell dysfunction via their progenitor 
cells. 




Chapter 6 Final Discussion 
The experimental work in this thesis mainly stemmed from the TDS hypothesis, 
which suggests that common male reproductive disorders of newborn boys and 
young men, have a common fetal origin, namely fetal androgen deficiency 
(Skakkebaek et al 2001). Elucidating how this occurs, might help to address the 
topical issue of hypogonadism in aging men, which is associated with 'Western 
disorders', morbidity and mortality (Tivesten et al 2009, Traish et al 2011). Data 
from human and experimental animal studies have established that androgen 
exposure can programme adult testosterone levels, particularly if exposure 
occurs within the masculinisation programming window (Welsh et al 2008, 
Dean & Sharpe 2013). But the mechanism for how this occurs, has been 
unknown, as adult Leydig cells do not differentiate until puberty. Thus, the main 
hypothesis underpinning this thesis, was that fetal androgen deficiency can 
programme adult testosterone levels, via effects on adult Leydig progenitor 
cells, which are present in the fetal testis. Consequently, the main aims were 
firstly to identify/characterise adult Leydig progenitor cells in an adult Leydig 
cell ablation/regeneration model and throughout normal pubertal and adult 
Leydig cell development. Secondly, to determine if adult Leydig progenitor cells 
are conserved across species in the fetal testis. Thirdly, to establish whether 
adult Leydig progenitor cells are androgen-modulated via several androgen 
receptor knockout models and altered testosterone production/action rodent 
models. Fourthly, to investigate potential 'gain of function' models (in terms of 
adult Leydig progenitor numbers and/or adult Leydig cell function). Finally, to 
investigate a mechanism of fetal 'programming' of adult Leydig progenitor cells, 
which may explain how fetal events programme adult testosterone levels/ 
Leydig cell function. 
The presence of adult Leydig stem/progenitor cells in the fetal testis has long 
been a source of intrigue for researchers, as a common marker for these cells 
has not been identified. More recent studies have identified and isolated cells at 
pnd7/8 in the mouse, which expressed PDGFRα, GATA4, LIFR, c-KIT and were 
capable of differentiating into steroidogenic cells in the presence of 




differentiation-inducing medium in vitro, and in an adult Leydig regeneration 
model in vivo (Ge et al 2006, Landreh et al 2013). However, these studies did 
not examine whether the 'Leydig stem/progenitor cells' were present during 
fetal life, which this study addresses. The current findings demonstrated that 
COUP-TFII+ adult Leydig progenitor cells, present in the fetal testis, differentiate 
into adult Leydig cells during puberty. This was also evident in the EDS model 
which recapitulates normal adult Leydig cell development via adult Leydig cell 
ablation/regeneration. Similar to the aforementioned published studies, COUP-
TFII+ adult Leydig progenitor cells expressed GATA4 during their differentiation 
into adult Leydig cells during puberty and in the EDS model. Furthermore, 
COUP-TFII+ adult Leydig progenitor cells express AR, and these non-
steroidogenic COUP-TFII+/AR+ cells were shown to be conserved across species 
in the fetal testis (Chapter 3).  
An interesting study, following on from the identification of these cells, would 
be to establish which other factors regulate adult Leydig cell differentiation. 
Some of the key players include LIFR, c-KIT and PDGFRα, which have been 
reported to mark putative 'Leydig stem cells' (Ge et al 2006, Landreh et al 
2013). Various attempts by me, to localise LIFR in the rat testis failed, most 
likely due to the non-specificity of the antibody used. Future experiments are 
therefore needed to investigate whether COUP-TFII+ adult Leydig progenitor 
cells express LIFR. A more recent study demonstrated that PDGFRα+ cells 
isolated from pnd 8 rat testis, which belong to the peritubular myoid cell (PTC) 
lineage, expressed pluripotency markers and also expressed genes encoding 
steroidogenic enzymes in vitro (Landreh et al 2013). The present study also 
investigated PDGFRα expression in COUP-TFII+ adult Leydig progenitor cells, in 
fetal life (e21.5) and during adult Leydig cell development one week post-EDS in 
the rat, which yielded equivocal results. Some, but not all, COUP-TFII+ adult 
Leydig progenitor cells appeared to express PDGFRα, but there was large 
variation in PDGFRα expression between samples. Pre-absorption of the 
PDGFRα antibody used in this study, demonstrated that the antibody was 
specific, even though apparent non-specific interstitial background staining, was 




still evident in samples. Given the fact that the previous studies have isolated 
PDGFRα+ 'adult Leydig stem cells' just prior to or during the onset of puberty in 
the mouse at pnd 7/8, this may suggest that PDGFRα is increased in expression 
specifically during this time, in comparison to fetal life. It is interesting therefore 
to speculate that the majority of COUP-TFII+ adult Leydig progenitor cells only 
begin to express PDGFRα just prior to the onset of puberty. In line with this, it 
might also be possible that more COUP-TFII+ adult Leydig progenitor cells 
expressed PDGFRα immediately post-EDS, as PDGFRα expression was only 
examined one week post-EDS, in this study. In line with this, an earlier study 
investigating gene expression post-EDS, demonstrated that mRNA levels of 
pdgfrα increased dramatically and transiently one day post-EDS (O'Shaughnessy 
et al 2008). Future experiments to investigate PDGFRα expression using 
different PDGFRα antibodies and different time-points are needed to fully 
elucidate the role of PDGFRα in adult Leydig cell development. 
The precise structure or ligand regulation of COUP-TFII has not yet been 
elucidated. A previous study investigated the conformational status of COUP-
TFII and described it as having an 'autorepressed conformation', as the 
activation binding sites are inaccessible due to its folded conformation (Kruse et 
al 2008). Retinoic acid, a vitamin A metabolite, can alter this conformational 
state thus promoting COUP-TFII to recruit co-activators and increase its 
transcriptional activity (Kruse et al 2008). This is intriguing as retinoic acid has 
been reported to play a role in adult Leydig cell development, as described 
below. Male offspring of pregnant dams who were fed a vitamin A deficient diet, 
were reported to have reduced testosterone production by fetal Leydig cells 
(Livera et al 2004). This study showed that during fetal Leydig cell 
differentiation, retinoic acid negatively regulated steroidogenesis, potentially 
via down regulation of Cyp17a1, as demonstrated in cultured cells from fetal rat 
testes (Livera et al 2004). The role for retinoic acid in negatively regulating 
steroidogenesis during fetal Leydig cell differentiation (Livera et al 2004) 
appears somewhat similar to COUP-TFII, which has also been proposed to 
negatively regulate steroidogenesis in differentiating fetal Leydig cells (van den 




Driesche et al 2012). Of the six retinoic acid receptors, NR2B1 in particular is 
expressed in adult Leydig cells (Boulogne et al 1999). Taking the latter fact into 
account and the role for retinoic acid in altering the conformational state of 
COUP-TFII (Kruse et al 2008), might suggest that retinoic acid could potentially 
play a role in the onset of differentiation of adult Leydig progenitor cells via 
effects on COUP-TFII. The precise role and interplay between these factors 
postnatally, regarding adult Leydig progenitor cells differentiation, would be an 
interesting path to investigate.  
Androgen effects might be mediated in part by the control of retinoic acid 
concentrations (Eacker et al 2007, O'Shaughnessy et al 2007). In the latter 
study, androgen regulated genes were investigated in a large study comparing 
transcript levels between control and ARKO mice. Interestingly, 50% of 
downregulated ‘androgen genes’ in ARKOs, were associated with vitamin A 
metabolism, amongst other factors (O'Shaughnessy et al 2007). Upregulation of 
these genes by testosterone administration to hpg mice confirmed their 
regulation by androgen (O'Shaughnessy et al 2007). This study suggests a link 
between androgen action and retinoic acid action (Eacker et al 2007, 
O'Shaughnessy et al 2007). Even more interesting is that these genes were not 
identified in SCARKO mice, which suggests that Sertoli cells are not the main 
target cells for androgen stimulated upregulation of genes involved in vitamin A 
metabolism. It is tempting to speculate that this could occur via adult Leydig 
progenitor cells, as AR is still functioning in the latter cells in SCARKOs. This 
might further tie together retinoic acid and COUP-TFII+ adult Leydig progenitor 
cells, in regulating adult Leydig cell development. 
Insulin-like growth factor 1 (IGF1) enters the testis via the systemic 
bloodstream and is also produced within the testis by both Sertoli and Leydig 
cells, under the control of gonadotrophins (Smith and Walker 2014). Its 
receptor (IGF1R) is found on Leydig, Sertoli, PTM and germ cells (Yagci and Zik 
2006, Froment et al 2007), and also in progenitor and immature Leydig cells 
(Hu et al 2010). Administration of a specific inhibitor of IGF1R 
(picropodophyllin), resulted in a blockage of the anti-apoptotic effect of IGF1, 




during Leydig cell development, which highlights the role of IGF1 in Leydig cell 
survival (Colon et al 2007). IGF-1 treatment of cultured rat Leydig cells in vitro 
from pubertal and adult animals demonstrated an increase in intracellular 
steroidogenesis and testosterone production, with a greater response from the 
pubertal cells than adult, suggesting a role for IGF-1 in Leydig cell maturation 
(Gelber et al 1992). IGF-null mice exhibit a reduction in adult Leydig cell 
number, a reduction in the proliferative labelling index of progenitor and 
immature adult Leydig cells, and potentially as a consequence, an 80% 
reduction in serum testosterone levels, in comparison to wild-type controls 
(Baker et al 1996, Wang et al 2003, Hu et al 2010). The deficit in proliferative 
labelling index in progenitor and immature Leydig cells could be rescued by 
recombinant IGF-1 (Hu et al 2010). Interestingly, this deficit in proliferative 
capacity was not evident in 'stem' Leydig cells, in which proliferation was 
comparable to controls. This might suggest that during postnatal life, IGF1 is 
required for the postnatal proliferation of adult Leydig progenitor cells. The 
expression of IGF1 was not examined in this study, but it would be worthwhile 
to investigate whether COUP-TFII+ adult Leydig progenitor cells begin to 
express IGF during their proliferation in puberty. Also, IGF-II has previously 
been shown to regulate steroidogenesis in rat Leydig cells (Colon et al 2005). 
Whether or not IGFII can increase adult Leydig progenitor cell proliferation, via 
IGFR, would also be worth investigating.  
Desert hedgehog (Dhh)-null mice exhibit a failure of adult Leydig cell 
development (Clark et al 2000), which highlights a role for Dhh in adult Leydig 
cell development. Sonic, a hedgehog family member, acts via a common pathway 
to Dhh (Jenkins, 2009), and has been reported to regulate the expression of 
COUP-TFII in neurons (Krishnan et al 1997). Thus, it could be plausible that Dhh 
could act on COUP-TFII in the testis, to regulate differentiation of the COUP-
TFII+ adult Leydig progenitor cells into adult Leydig cells (Qin et al 2008). This 
merits further investigation in future experiments.  
Previous studies have reported an important role of thyroid hormone 
(thyrotrophin) in adult Leydig cell development (Rijntjes et al 2009, 2010). An 




isoform of thyroid hormone receptor (TRα1), was found abundantly expressed 
in unidentified spindle shaped interstitial cells in the developing mouse testis 
(Pnd 0-5) and in adult testis (Pnd 63) (Buzzard et al 2000). It would therefore 
be interesting to investigate whether TRα1 is expressed in COUP-TFII+ adult 
Leydig progenitor cells in which thyrotrophin could bind to and potentially play 
a role in their differentiation into adult Leydig cells. 
Studies that investigated adult Leydig cell development in ARKO males have 
demonstrated that androgens are required for adult Leydig cell development, as 
evident from the 80% reduction in cell number (De Gendt et al 2005, 
O'Shaughnessy et al 2002, 2012). Quantification of adult Leydig cell number in 
the ARKO mouse, confirmed the previous findings, and demonstrated that in the 
complete absence of androgen action, adult Leydig cells were significantly 
reduced by ~70% (Chapter 3). Furthermore, the current findings have added a 
new dimension to previous understanding, in that adult Leydig progenitor cells 
were also reduced in number as a result of ablating androgen action. Fetal 
exposure to DBP, results in a reduction in testosterone production (Mylchreest 
et al 2000, Fisher et al 2003, van den Driesche et al 2012), which the present 
data confirmed. Similar to ARKOs, fetal androgen deficiency via DBP-exposure, 
resulted in a ~40% reduction in adult Leydig progenitor cell number 
throughout development. There was evidence for compensated adult Leydig cell 
failure in both ARKO and DBP-exposed animals, which highlights the 
importance of androgen action during fetal development, rather than postnatal, 
for adult Leydig cell function (Chapter 4).  
Several attempts were made in this study, to investigate whether or not 
exogenous fetal androgen exposure could potentially increase intratesticular 
testosterone levels during fetal development and thus provide a "gain of 
function" model (in terms of adult Leydig progenitor cells numbers and or adult 
Leydig cell function) (Chapter 4). Fetal androgen exposure (TP/DHT), did not 
appear to have any enhancing effect on the number of adult Leydig progenitor 
cells, potentially due to the fact that intratesticular androgens are already high 
enough in the fetal testis to induce maximal androgen effects locally, and thus 




cannot be added to. Lack of key data in the iNOS-/- model from collaborators, 
hindered any interpretation of the findings thus far. An earlier iNOS-/- study, 
reported that adult Leydig cell cytoplasmic volume was reduced (Auharek et al 
2012), which suggests that steroidogenesis is affected by knockout of iNOS-/-. In 
fact, preliminary data from our collaborators have reported that steroidogenic 
genes (e.g. StAR) are downregulated in iNOS-/- mice, which taken together, might 
suggest that this is not a good model for the purpose of the studies described in 
this thesis. Irrespective of this, measurement of adult hormone levels, are 
crucial before any interpretation can be made regarding adult Leydig cell 
function in the iNOS-/- mouse.  
Fetal DBP-exposure resulted in compensated adult Leydig cell failure (Chapter 
4), and a reduction in StAR expression, potentially due to increased expression 
of histone repressor H3K27me3 in the proximal promoter region (Chapter 5). 
Adult Leydig progenitor cells at e21.5 and adult Leydig cells in adulthood, both 
expressed increased H3K27me3 expression, in comparison with wild-type 
controls (Chapter 5). What further ties these two cell types together, is the fact 
that H3K27me3 is inherited by daughter cells after cell division (Hansen et al 
2008, Margueron et al 2009, Walker et al 2011). It would be interesting to 
investigate whether other genes involved in steroidogenesis e.g. 3β-HSD, also 
displayed increased repressive histone methylation, as 3β-HSD mRNA levels 
were also decreased following fetal DBP exposure in this study (Chapter 5).  
To confirm that the increased repressive H3K27me3 mark in DBP exposed 
animals was not simply a DBP effect, but rather a result of fetal androgen 
deficiency, immunolocalisation of H3K27me3 in adult ARKOs would have been 
useful. In fact, this experiment was carried out during the completion of this 
thesis and demonstrated increased H3K27me3 expression in adult Leydig cells 
in ARKOs. This demonstrates that increased repressive histone methylation in 
adult Leydig cells, is evident in both fetal androgen deficient models (ARKO and 
DBP-exposed), which potentially provides a mechanism for how fetal events can 
result in adult Leydig cell dysfunction. 




The next logical step to advance the previous findings, would be to establish 
how the androgen-driven epigenetic change in adult Leydig progenitor cells is 
mediated e.g. trimethylation of H3K27. The histone methyltransferase enhancer 
of zeste (Ezh1/2) has been reported to catalyse the methylation of H3K27 (Cao 
and Zhang 2004, Schuettengruber et al 2007), which would be worth 
investigating. Another demethylase, namely Tet1, has been shown to be a 
regulator of H3K27me3 (Sui et al 2012). Preliminary studies within the lab 
indicate that COUP-TFII+ adult Leydig progenitor cells also express Tet1 at e21.5 
in the rat. Furthermore, a microarray analysis would also prove beneficial to 
compare the expression profiles of adult Leydig cell progenitors from control 
and DBP-exposed fetuses, which might reveal androgen target genes and/or 
identify potential new markers of adult Leydig progenitor cells. This would 
require the development of methods for the isolation of a highly enriched 
population of the adult Leydig progenitor cells. 
DBP treatment to lower fetal androgen production was administered to animals 
during fetal life, particularly between e15.5-e21.5, which encompassed the 
MPW (Welsh et al 2008), and resulted in adult Leydig cell dysfunction (Chapter 
4). It would be interesting to investigate whether DBP-exposure prior to or after 
the MPW, results in compensated adult Leydig cell failure, in order to determine 
the importance of this fetal period in determining long-term function of adult 
Leydig cells. Preliminary studies within the lab following the completion of this 
thesis, have demonstrated that fetal DBP-induced androgen suppression only 
within the MPW, causes compensated adult Leydig cell failure in adulthood. It 
might also be worth investigating whether lower doses of DBP exposure, which 
would result in a more subtle reduction of fetal testosterone production, might 
also affect adult Leydig progenitor cell number and adult Leydig cell function.  
Transplantation of COUP-TFII+ adult Leydig progenitor cells into DBP-exposed 
animals prior to puberty would be an intriguing experiment to investigate 
whether this could rescue adult Leydig dysfunction via differentiation from the 
transplanted cells. Of course, problematic issues would need to be addressed 
first, i.e. specific COUP-TFII+ adult Leydig progenitor cell isolation, along with 




the potential rejection of the transplanted cells in the animal. Perhaps isolation 
of adult Leydig progenitor cells could be successfully achieved during fetal life, 
as this is when the cells are most plentiful in the testis.  
An earlier clinical study that investigated male infertilty, reported that a portion 
of infertile men who had a previous history of cryptorchidism, were associated 
with poorer adult Leydig cell dysfunction and a lower sperm quality, in 
comparison to those without a history of cryptorchidism (Andersson et al 
2004). More recently, a study from close collaborators (in press), has reported 
that in a large-scale investigation of male fertility in 3,000 young men from the 
normal population, 15% of those who had low sperm counts, also exhibited 
compensated adult Leydig cell failure, which is consistent with the data 
presented in this thesis and the previous study (Andersson et al 2004). This 
strengthens the hypothesis that adult Leydig cell dysfunction is associated with 
other TDS disorders, as a result of fetal androgen deficiency (Figure 6.1).  
 
Figure 6.1 Fetal androgen deficiency results in adult Leydig cell dysfunction, as 
shown in the rat. Red shading depicts the period of reduced fetal androgen exposure (via 
DBP). Blue spindle-shaped cells represent adult Leydig stem/progenitor cells present during 
fetal and postnatal life. Larger round cells represent adult Leydig cells during their stages of 
differentiation into adult Leydig cells. Yellow cells represent the seperate generation of 
fetal Leydig cells. (Adapted from Martinez-Arguelles et al 2013). 
 
The current findings add a new dimension to the substantial body of evidence in 
that fetal androgen deficiency leads to a range of adverse changes in 
reproductive function and disorders in boys/men (Sharpe and Shakkebaek 
2008, Dean & Sharpe 2013). It also has wider health implications in relation to 
the aging related decline in testosterone levels (Travison et al 2007, Tajar et al 







Abdou, H. S., G. Villeneuve, et al. (2013). "The calcium signaling pathway regulates 
leydig cell steroidogenesis through a transcriptional cascade involving the nuclear 
receptor NR4A1 and the steroidogenic acute regulatory protein." Endocrinology 
154(1): 511-520. 
  
Abel, M. H., P. J. Baker, et al. (2008). "Spermatogenesis and sertoli cell activity in mice 
lacking sertoli cell receptors for follicle-stimulating hormone and androgen." 
Endocrinology 149(7): 3279-3285. 
  
Abel, M. H., A. N. Wootton, et al. (2000). "The effect of a null mutation in the follicle-
stimulating hormone receptor gene on mouse reproduction." Endocrinology 141(5): 
1795-1803. 
 
Acerini, C. L., H. L. Miles, et al. (2009). "The descriptive epidemiology of congenital and 
acquired cryptorchidism in a UK infant cohort." Arch Dis Child 94(11): 868-872. 
 
Adamovic, T. and A. Nordenskjold (2012). "The CAG repeat polymorphism in the 
androgen receptor gene modifies the risk for hypospadias in Caucasians." BMC Med 
Genet 13: 109. 
 
Adams, M. L., E. R. Meyer, et al. (1994). "Effects of nitric oxide-related agents on rat 
testicular function." J Pharmacol Exp Ther 269(1): 230-237. 
 
Agger, K., P. A. Cloos, et al. (2007). "UTX and JMJD3 are histone H3K27 demethylases 
involved in HOX gene regulation and development." Nature 449(7163): 731-734. 
 
Aiken, C. E. and S. E. Ozanne (2013). "Transgenerational developmental programming." 
Hum Reprod Update. 
 
Aitken, R.J. (2013). Falling sperm counts twenty years on: where are we now? Asian J. 
Androl. 15, 204–207. 
Albert, O. and B. Jegou (2013). "A critical assessment of the endocrine susceptibility of 
the human testis to phthalates from fetal life to adulthood." Hum Reprod Update. 
  
Amann, R. P. and D. N. Veeramachaneni (2007). "Cryptorchidism in common eutherian 
mammals." Reproduction 133(3): 541-561. 
  
Andersen, A. G., T. K. Jensen, et al. (2000). "High frequency of sub-optimal semen quality 
in an unselected population of young men." Hum Reprod 15(2): 366-372. 
 
Andersson, A. M., T. K. Jensen, et al. (2007). "Secular decline in male testosterone and 
sex hormone binding globulin serum levels in Danish population surveys." J Clin 
Endocrinol Metab 92(12): 4696-4705. 
 
Andersson, A. M., N. Jorgensen, et al. (2004). "Impaired Leydig cell function in infertile 
men: a study of 357 idiopathic infertile men and 318 proven fertile controls." J Clin 





Antony, F. F., M. M. Aruldhas, et al. (1995). "Inhibition of Leydig cell activity in vivo and 
in vitro in hypothyroid rats." J Endocrinol 144(2): 293-300. 
 
Arakane, F., S. R. King, et al. (1997). "Phosphorylation of steroidogenic acute regulatory 
protein (StAR) modulates its steroidogenic activity." J Biol Chem 272(51): 32656-
32662. 
  
Ariyaratne, H. B. and S. Chamindrani Mendis-Handagama (2000). "Changes in the testis 
interstitium of Sprague Dawley rats from birth to sexual maturity." Biol Reprod 62(3): 
680-690. 
  
Ariyoshi, N., Y. C. Kim, et al. (1998). "Characterisation of the rat Star gene that encodes 
the predominant 3.5-kilobase pair mRNA. ACTH stimulation of adrenal steroids in vivo 
precedes elevation of Star mRNA and protein." J Biol Chem 273(13): 7610-7619. 
  
Atanassova, N. N., M. Walker, et al. (2005). "Evidence that androgens and oestrogens, as 
well as follicle-stimulating hormone, can alter Sertoli cell number in the neonatal rat." J 
Endocrinol 184(1): 107-117. 
  
Auharek, S. A., G. F. Avelar, et al. (2011). "Sertoli cell numbers and spermatogenic 
efficiency are increased in inducible nitric oxide synthase mutant mice." Int J Androl 
34(6 Pt 2): e621-629. 
  
Auharek, S. A., L. R. de Franca, et al. (2010). "Prenatal plus postnatal exposure to Di(n-
Butyl) phthalate and/or flutamide markedly reduces final sertoli cell number in the 
rat." Endocrinology 151(6): 2868-2875. 
  
Auharek, S. A., N. L. Lara, et al. (2012). "Effects of inducible nitric oxide synthase (iNOS) 
deficiency in mice on Sertoli cell proliferation and perinatal testis development." Int J 
Androl 35(5): 741-751. 
  
Avallet, O., M. Vigier, et al. (1987). "Transforming growth factor beta inhibits Leydig cell 
functions." Biochem Biophys Res Commun 146(2): 575-581. 
  
Baker, J., M. P. Hardy, et al. (1996). "Effects of an Igf1 gene null mutation on mouse 
reproduction." Mol Endocrinol 10(7): 903-918. 
  
Baker, P. J., H. Johnston, et al. (2003). "Differentiation of adult-type Leydig cells occurs 
in gonadotrophin-deficient mice." Reprod Biol Endocrinol 1: 4. 
   
Baker, P. J. and P. J. O'Shaughnessy (2001). "Role of gonadotrophins in regulating 
numbers of Leydig and Sertoli cells during fetal and postnatal development in mice." 
Reproduction 122(2): 227-234. 
  
Baker, P. J., P. Pakarinen, et al. (2003). "Failure of normal Leydig cell development in 
follicle-stimulating hormone (FSH) receptor-deficient mice, but not FSHbeta-deficient 
mice: role for constitutive FSH receptor activity." Endocrinology 144(1): 138-145. 
  
Baker, P. J., J. A. Sha, et al. (1999). "Expression of 3beta-hydroxysteroid dehydrogenase 






Barker, D. J., S. P. Bagby, et al. (2006). "Mechanisms of disease: in utero programming in 
the pathogenesis of hypertension." Nat Clin Pract Nephrol 2(12): 700-707. 
  
Barker, D. J., C. N. Martyn, et al. (1993). "Growth in utero and serum cholesterol 
concentrations in adult life." BMJ 307(6918): 1524-1527. 
   
Barlow, N. J. and P. M. Foster (2003). "Pathogenesis of male reproductive tract lesions 
from gestation through adulthood following in utero exposure to Di(n-butyl) 
phthalate." Toxicol Pathol 31(4): 397-410. 
 
Barlow, N. J., B. S. McIntyre, et al. (2004). "Male reproductive tract lesions at 6, 12, and 
18 months of age following in utero exposure to di(n-butyl) phthalate." Toxicol Pathol 
32(1): 79-90. 
  
Barlow, N. J., S. L. Phillips, et al. (2003). "Quantitative changes in gene expression in 
fetal rat testes following exposure to di(n-butyl) phthalate." Toxicol Sci 73(2): 431-441. 
 
Barski, A., S. Cuddapah, et al. (2007). "High-resolution profiling of histone methylations 
in the human genome." Cell 129(4): 823-837. 
  
Barsoum, I. B., N. C. Bingham, et al. (2009). "Activation of the Hedgehog pathway in the 
mouse fetal ovary leads to ectopic appearance of fetal Leydig cells and female 
pseudohermaphroditism." Dev Biol 329(1): 96-103. 
  
Barsoum, I. B., J. Kaur, et al. (2013). "Dynamic changes in fetal Leydig cell populations 
influence adult Leydig cell populations in mice." FASEB J 27(7): 2657-2666. 
  
Bartholomeusz, R. K., N. W. Bruce, et al. (1999). "Embryo survival, and fetal and 
placental growth following elevation of maternal estradiol blood concentrations in the 
rat." Biol Reprod 61(1): 46-50. 
 
Basciani, S., S. Mariani, et al. (2002). "Expression of platelet-derived growth factor-A 
(PDGF-A), PDGF-B, and PDGF receptor-alpha and -beta during human testicular 
development and disease." J Clin Endocrinol Metab 87(5): 2310-2319. 
 
Basciani, S., S. Mariani, et al. (2010). "Role of platelet-derived growth factors in the 
testis." Endocr Rev 31(6): 916-939. 
  
Baulieu, E. E. (1997). "Neurosteroids: of the nervous system, by the nervous system, for 
the nervous system." Recent Prog Horm Res 52: 1-32. 
  
Berg, J. M. (1989). "DNA binding specificity of steroid receptors." Cell 57(7): 1065-
1068. 
  
Berger, S. L., T. Kouzarides, et al. (2009). "An operational definition of epigenetics." 
Genes Dev 23(7): 781-783. 
 








Bernstein, B. E., T. S. Mikkelsen, et al. (2006). "A bivalent chromatin structure marks 
key developmental genes in embryonic stem cells." Cell 125(2): 315-326. 
  
Berta, P., J. R. Hawkins, et al. (1990). "Genetic evidence equating SRY and the testis-
determining factor." Nature 348(6300): 448-450. 
 
Berthold, A.A. 1849. “Transplantation der Hoden. Arch Anat. Physiol u wiss. Med 16: 42-
46.  
Bhandari, R. K., I. Sadler-Riggleman, et al. (2011). "Basic helix-loop-helix transcription 
factor TCF21 is a downstream target of the male sex determining gene SRY." PLoS One 
6(5): e19935. 
 
Bibikova, M., L. C. Laurent, et al. (2008). "Unraveling epigenetic regulation in embryonic 
stem cells." Cell Stem Cell 2(2): 123-134. 
  
Bielinska, M., A. Seehra, et al. (2007). "GATA-4 is required for sex steroidogenic cell 
development in the fetal mouse." Dev Dyn 236(1): 203-213. 
 
Birk, O. S., D. E. Casiano, et al. (2000). "The LIM homeobox gene Lhx9 is essential for 
mouse gonad formation." Nature 403(6772): 909-913. 
 
Bitgood, M. J., L. Shen, et al. (1996). "Sertoli cell signaling by Desert hedgehog regulates 
the male germline." Curr Biol 6(3): 298-304. 
 
Blount, B. C., M. J. Silva, et al. (2000). "Levels of seven urinary phthalate metabolites in a 
human reference population." Environ Health Perspect 108(10): 979-982. 
  
Bobjer, J., M. Katrinaki, et al. (2013). "Negative association between testosterone 
concentration and inflammatory markers in young men: a nested cross-sectional 
study." PLoS One 8(4): e61466. 
  
Boisen, K. A., M. Chellakooty, et al. (2005). "Hypospadias in a cohort of 1072 Danish 
newborn boys: prevalence and relationship to placental weight, anthropometrical 
measurements at birth, and reproductive hormone levels at three months of age." J Clin 
Endocrinol Metab 90(7): 4041-4046. 
  
Boisen, K. A., M. Kaleva, et al. (2004). "Difference in prevalence of congenital 
cryptorchidism in infants between two Nordic countries." Lancet 363(9417): 1264-
1269. 
 
Bouin, P. & Ancel, P. (1903) The role of the interstitial cells of the embryonic testis. 
Comptes rendus des Séances de la Société de Biology et de Ses Filiales, 55, 1682–1684. 
  
Bolden, J. E., M. J. Peart, et al. (2006). "Anticancer activities of histone deacetylase 
inhibitors." Nat Rev Drug Discov 5(9): 769-784. 
  
Bose, H. S., V. R. Lingappa, et al. (2002). "Rapid regulation of steroidogenesis by 






Bose, H. S., T. Sugawara, et al. (1996). "The pathophysiology and genetics of congenital 
lipoid adrenal hyperplasia." N Engl J Med 335(25): 1870-1878. 
  
Boukari, K., M. L. Ciampi, et al. (2007). "Human fetal testis: source of estrogen and 
target of estrogen action." Hum Reprod 22(7): 1885-1892. 
  
Boulogne, B., C. Levacher, et al. (1999). "Retinoic acid receptors and retinoid X 
receptors in the rat testis during fetal and postnatal development: immunolocalization 
and implication in the control of the number of gonocytes." Biol Reprod 61(6): 1548-
1557. 
  
Boulogne, B., R. Olaso, et al. (1999). "Apoptosis and mitosis in gonocytes of the rat testis 
during foetal and neonatal development." Int J Androl 22(6): 356-365. 
 
Bowman, C. J., N. J. Barlow, et al. (2003). "Effects of in utero exposure to finasteride on 
androgen-dependent reproductive development in the male rat." Toxicol Sci 74(2): 
393-406. 
 
Boyer, L. A., K. Plath, et al. (2006). "Polycomb complexes repress developmental 
regulators in murine embryonic stem cells." Nature 441(7091): 349-353. 
  
Bray, F., L. Richiardi, et al. (2006). "Trends in testicular cancer incidence and mortality 
in 22 European countries: continuing increases in incidence and declines in mortality." 
Int J Cancer 118(12): 3099-3111. 
  
Bremner, W. J., M. R. Millar, et al. (1994). "Immunohistochemical localization of 
androgen receptors in the rat testis: evidence for stage-dependent expression and 
regulation by androgens." Endocrinology 135(3): 1227-1234. 
 
Brennan, J., C. Tilmann, et al. (2003). "Pdgfr-alpha mediates testis cord organization and 
fetal Leydig cell development in the XY gonad." Genes Dev 17(6): 800-810. 
 
Brinkmann, A. O. (2001). "Molecular basis of androgen insensitivity." Mol Cell 
Endocrinol 179(1-2): 105-109. 
  
Brinkmann, A. O. (2011). "Molecular mechanisms of androgen action--a historical 
perspective." Methods Mol Biol 776: 3-24. 
  
Brinkmann, A. O., P. W. Faber, et al. (1989). "The human androgen receptor: domain 
structure, genomic organization and regulation of expression." J Steroid Biochem 34(1-
6): 307-310. 
 
Brock, B. J. and M. R. Waterman (1999). "Biochemical differences between rat and 
human cytochrome P450c17 support the different steroidogenic needs of these two 
species." Biochemistry 38(5): 1598-1606. 
  
Brodie, A., S. Inkster, et al. (2001). "Aromatase expression in the human male." Mol Cell 








Brown, C. J., S. J. Goss, et al. (1989). "Androgen receptor locus on the human X 
chromosome: regional localization to Xq11-12 and description of a DNA 
polymorphism." Am J Hum Genet 44(2): 264-269. 
 
Brown-Séquard, C.E. 1889. Expérience démonstrant la puissance dynamogénique chez 
l'homme d'un liquide extrait de testicules d'animaux. Arch de Physiol Norm et Path . 21: 
651-658 
Budefeld, T., D. Jezek, et al. (2009). "Initiation of steroidogenesis precedes expression of 
cholesterologenic enzymes in the fetal mouse testes." Anat Histol Embryol 38(6): 461-
466. 
  
Buehr, M., S. Gu, et al. (1993). "Mesonephric contribution to testis differentiation in the 
fetal mouse." Development 117(1): 273-281. 
 
Bullejos, M. and P. Koopman (2001). "Spatially dynamic expression of Sry in mouse 
genital ridges." Dev Dyn 221(2): 201-205. 
  
Buzzard, J. J., J. R. Morrison, et al. (2000). "Developmental expression of thyroid 
hormone receptors in the rat testis." Biol Reprod 62(3): 664-669. 
  
Byskov, A. G. (1986). "Differentiation of mammalian embryonic gonad." Physiol Rev 
66(1): 71-117. 
  
Canto, P., D. Soderlund, et al. (2004). "Mutations in the desert hedgehog (DHH) gene in 
patients with 46,XY complete pure gonadal dysgenesis." J Clin Endocrinol Metab 89(9): 
4480-4483. 
  
Canto, P., F. Vilchis, et al. (2005). "A heterozygous mutation in the desert hedgehog gene 
in patients with mixed gonadal dysgenesis." Mol Hum Reprod 11(11): 833-836. 
  
Cao, R., L. Wang, et al. (2002). "Role of histone H3 lysine 27 methylation in Polycomb-
group silencing." Science 298(5595): 1039-1043. 
  
Cao, R. and Y. Zhang (2004). "The functions of E(Z)/EZH2-mediated methylation of 
lysine 27 in histone H3." Curr Opin Genet Dev 14(2): 155-164. 
  
Carlsen, E., A. Giwercman, et al. (1992). "Evidence for decreasing quality of semen 
during past 50 years." BMJ 305(6854): 609-613. 
  
Carlsen, E., A. Giwercman, et al. (1995). "Declining semen quality and increasing 
incidence of testicular cancer: is there a common cause?" Environ Health Perspect 103 
Suppl 7: 137-139. 
  
Carlsen, S. M., G. Jacobsen, et al. (2006). "Maternal testosterone levels during pregnancy 
are associated with offspring size at birth." Eur J Endocrinol 155(2): 365-370. 
  
Caron, K. M., S. C. Soo, et al. (1997). "Targeted disruption of the mouse gene encoding 
steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal 







Castro-Magana, M., M. Angulo, et al. (1988). "Hypothalamic-pituitary gonadal axis in 
boys with primary hypothyroidism and macroorchidism." J Pediatr 112(3): 397-402. 
 
Cavaco, J. E., S. S. Laurentino, et al. (2009). "Estrogen receptors alpha and beta in human 
testis: both isoforms are expressed." Syst Biol Reprod Med 55(4): 137-144. 
 
Cederroth, C. R., O. Schaad, et al. (2007). "Estrogen receptor alpha is a major 
contributor to estrogen-mediated fetal testis dysgenesis and cryptorchidism." 
Endocrinology 148(11): 5507-5519. 
  
Chaffin, C. L. and C. A. Vandevoort (2013). "Follicle growth, ovulation, and luteal 
formation in primates and rodents: a comparative perspective." Exp Biol Med 
(Maywood) 238(5): 539-548. 
  
Chamness, S. L., D. D. Ricker, et al. (1995). "The effect of androgen on nitric oxide 
synthase in the male reproductive tract of the rat." Fertil Steril 63(5): 1101-1107. 
  
Chemes, H. E., R. A. Rey, et al. (2008). "Physiological androgen insensitivity of the fetal, 
neonatal, and early infantile testis is explained by the ontogeny of the androgen 
receptor expression in Sertoli cells." J Clin Endocrinol Metab 93(11): 4408-4412. 
  
Chen, H., R. S. Ge, et al. (2009). "Leydig cells: From stem cells to aging." Mol Cell 
Endocrinol 306(1-2): 9-16. 
  
Chen, H., E. Stanley, et al. (2010). "Stem Leydig cells: from fetal to aged animals." Birth 
Defects Res C Embryo Today 90(4): 272-283. 
  
Chen, J. J., Y. Lukyanenko, et al. (2002). "25-hydroxycholesterol is produced by 
testicular macrophages during the early postnatal period and influences differentiation 
of Leydig cells in vitro." Biol Reprod 66(5): 1336-1341. 
  
Chen, W. Y., E. C. Bailey, et al. (1997). "Reactivation of silenced, virally transduced genes 
by inhibitors of histone deacetylase." Proc Natl Acad Sci U S A 94(11): 5798-5803. 
  
Cheng, C. Y. and D. D. Mruk (2010). "A local autocrine axis in the testes that regulates 
spermatogenesis." Nat Rev Endocrinol 6(7): 380-395. 
  
Cheng, J., S. C. Watkins, et al. (2007). "Testosterone activates mitogen-activated protein 
kinase via Src kinase and the epidermal growth factor receptor in sertoli cells." 
Endocrinology 148(5): 2066-2074. 
  
Christenson, L. K., R. L. Stouffer, et al. (2001). "Quantitative analysis of the hormone-
induced hyperacetylation of histone H3 associated with the steroidogenic acute 
regulatory protein gene promoter." J Biol Chem 276(29): 27392-27399. 
  
Christenson, L. K. and J. F. Strauss, 3rd (2001). "Steroidogenic acute regulatory protein: 
an update on its regulation and mechanism of action." Arch Med Res 32(6): 576-586. 
  
Clark, A. M., K. K. Garland, et al. (2000). "Desert hedgehog (Dhh) gene is required in the 
mouse testis for formation of adult-type Leydig cells and normal development of 






Clark, B. J., S. C. Soo, et al. (1995). "Hormonal and developmental regulation of the 
steroidogenic acute regulatory protein." Mol Endocrinol 9(10): 1346-1355. 
 
Clark, B. J., J. Wells, et al. (1994). "The purification, cloning, and expression of a novel 
luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor 
cells. Characterization of the steroidogenic acute regulatory protein (StAR)." J Biol 
Chem 269(45): 28314-28322. 
 
Clark, R. L., J. M. Antonello, et al. (1990). "External genitalia abnormalities in male rats 
exposed in utero to finasteride, a 5 alpha-reductase inhibitor." Teratology 42(1): 91-
100. 
 
Coffey, D.S. (1988) Androgen action and the sex accessory tissues. In: Knobil E, Neill 
(eds) The physiology of reproduction. J. Raven Press, New York pp 1081-1119 
Colon, E., K. V. Svechnikov, et al. (2005). "Stimulation of steroidogenesis in immature 
rat Leydig cells evoked by interleukin-1alpha is potentiated by growth hormone and 
insulin-like growth factors." Endocrinology 146(1): 221-230. 
 
Combes, A. N., D. Wilhelm, et al. (2009). "Endothelial cell migration directs testis cord 
formation." Dev Biol 326(1): 112-120. 
  
Cooke, B. A. (1999). "Signal transduction involving cyclic AMP-dependent and cyclic 
AMP-independent mechanisms in the control of steroidogenesis." Mol Cell Endocrinol 
151(1-2): 25-35. 
 
Cooke BA 1996. Transduction of the luteinizing hormone signal within the Leydig cell. 
In: The Leydig cell. Payne AH, Hardy MP, Russell LD (eds), Cache River Press, Vienna, IL. 
pp 352-366 
Cool, J., F. D. Carmona, et al. (2008). "Peritubular myoid cells are not the migrating 
population required for testis cord formation in the XY gonad." Sex Dev 2(3): 128-133. 
  
Cool, J., T. J. DeFalco, et al. (2011). "Vascular-mesenchymal cross-talk through Vegf and 
Pdgf drives organ patterning." Proc Natl Acad Sci U S A 108(1): 167-172. 
  
Cui, S., A. Ross, et al. (2004). "Disrupted gonadogenesis and male-to-female sex reversal 
in Pod1 knockout mice." Development 131(16): 4095-4105. 
  
Davidoff, M. S., R. Middendorff, et al. (2004). "Progenitor cells of the testosterone-
producing Leydig cells revealed." J Cell Biol 167(5): 935-944. 
  
Davidoff, M. S., R. Middendorff, et al. (2009). "The neuroendocrine Leydig cells and their 
stem cell progenitors, the pericytes." Adv Anat Embryol Cell Biol 205: 1-107. 
  
De Gendt, K., N. Atanassova, et al. (2005). "Development and function of the adult 
generation of Leydig cells in mice with Sertoli cell-selective or total ablation of the 








De Gendt, K., J. V. Swinnen, et al. (2004). "A Sertoli cell-selective knockout of the 
androgen receptor causes spermatogenic arrest in meiosis." Proc Natl Acad Sci U S A 
101(5): 1327-1332. 
 
de Kretser, D. M. (2004). "Editorial: Is spermatogenic damage associated with Leydig 
cell dysfunction?" J Clin Endocrinol Metab 89(7): 3158-3160. 
  
de Ronde, W., H. A. Pols, et al. (2003). "The importance of oestrogens in males." Clin 
Endocrinol (Oxf) 58(5): 529-542. 
  
De Santa, F., M. G. Totaro, et al. (2007). "The histone H3 lysine-27 demethylase Jmjd3 
links inflammation to inhibition of polycomb-mediated gene silencing." Cell 130(6): 
1083-1094. 
  
Dean, A. and R. M. Sharpe (2013). "Clinical review: Anogenital distance or digit length 
ratio as measures of fetal androgen exposure: relationship to male reproductive 
development and its disorders." J Clin Endocrinol Metab 98(6): 2230-2238. 
  
Dean, A., L. B. Smith, et al. (2012). "The effect of dihydrotestosterone exposure during 
or prior to the masculinization programming window on reproductive development in 
male and female rats." Int J Androl 35(3): 330-339. 
  
Defalco, T., A. Saraswathula, et al. (2013). "Testosterone levels influence mouse fetal 
Leydig cell progenitors through notch signaling." Biol Reprod 88(4): 91. 
  
DeFalco, T., S. Takahashi, et al. (2011). "Two distinct origins for Leydig cell progenitors 
in the fetal testis." Dev Biol 352(1): 14-26. 
  
Dela Cruz, C. and O. C. Pereira (2012). "Prenatal testosterone supplementation alters 
puberty onset, aggressive behavior, and partner preference in adult male rats." J 
Physiol Sci 62(2): 123-131. 
  
Denolet, E., K. De Gendt, et al. (2006). "The effect of a sertoli cell-selective knockout of 
the androgen receptor on testicular gene expression in prepubertal mice." Mol 
Endocrinol 20(2): 321-334. 
  
Desdoits-Lethimonier, C., O. Albert, et al. (2012). "Human testis steroidogenesis is 
inhibited by phthalates." Hum Reprod 27(5): 1451-1459. 
  
Dharia, S., A. Slane, et al. (2004). "Colocalization of P450c17 and cytochrome b5 in 
androgen-synthesizing tissues of the human." Biol Reprod 71(1): 83-88. 
  
Dierich, A., M. R. Sairam, et al. (1998). "Impairing follicle-stimulating hormone (FSH) 
signaling in vivo: targeted disruption of the FSH receptor leads to aberrant 
gametogenesis and hormonal imbalance." Proc Natl Acad Sci U S A 95(23): 13612-
13617. 
  
Ding, H., X. Wu, et al. (2000). "The mouse Pdgfc gene: dynamic expression in embryonic 







Dong, L., S. A. Jelinsky, et al. (2007). "Gene expression during development of fetal and 
adult Leydig cells." Ann N Y Acad Sci 1120: 16-35. 
 
Drake, A. J., S. van den Driesche, et al. (2009). "Glucocorticoids amplify dibutyl 
phthalate-induced disruption of testosterone production and male reproductive 
development." Endocrinology 150(11): 5055-5064. 
  
Eacker, S. M., J. E. Shima, et al. (2007). "Transcriptional profiling of androgen receptor 
(AR) mutants suggests instructive and permissive roles of AR signaling in germ cell 
development." Mol Endocrinol 21(4): 895-907. 
 
Eacker SM, Braun RE. Androgen Receptor in Leydig Cell Function and Development. In: 
Payne AH, Hardy MP, editors. The Leydig Cell in Health and Disease. Totowa, New 
Jersey: Humana Press; 2007. p. 345-62 
Eggers, S. and A. Sinclair (2012). "Mammalian sex determination-insights from humans 
and mice." Chromosome Res 20(1): 215-238. 
  
Eguchi, Y., K. Arishima, et al. (1978). "Development of the fetal pituitary-testicular 
system based on the observation of Leydig cells in encephalectomized, 
hypophysectomized and control fetal rats." Anat Rec 190(3): 679-686. 
  
Ehrlich, M. (2003). "Expression of various genes is controlled by DNA methylation 
during mammalian development." J Cell Biochem 88(5): 899-910. 
  
Eisenberg, M. L., M. H. Hsieh, et al. (2011). "The relationship between anogenital 
distance, fatherhood, and fertility in adult men." PLoS One 6(5): e18973. 
 
Eisenberg, M. L., T. K. Jensen, et al. (2012). "The relationship between anogenital 
distance and reproductive hormone levels in adult men." J Urol 187(2): 594-598. 
  
El-Gehani, F., M. Tena-Sempere, et al. (1998). "Vasoactive intestinal peptide is an 
important endocrine regulatory factor of fetal rat testicular steroidogenesis." 
Endocrinology 139(4): 1474-1480. 
 
Escalante-Alcalde, D. and Merchant-Larios, H. (1992). “Somatic and germ cell 
interactions during histogenetic aggregation of mouse fetal testes.” Exp Cell Res 
198:150-158. 
  
Fan, J. and V. Papadopoulos (2013). "Evolutionary origin of the mitochondrial 
cholesterol transport machinery reveals a universal mechanism of steroid hormone 
biosynthesis in animals." PLoS One 8(10): e76701. 
  
Fang, Y., A. E. Fliss, et al. (1996). "Hsp90 regulates androgen receptor hormone binding 
affinity in vivo." J Biol Chem 271(45): 28697-28702. 
 
Fecteau, K.A., Mrkonjich, L., et al (2006). “Detection of platelet-derived growth factor-









Ferrara, D., N. Hallmark, et al. (2006). "Acute and long-term effects of in utero exposure 
of rats to di(n-butyl) phthalate on testicular germ cell development and proliferation." 
Endocrinology 147(11): 5352-5362. 
  
Finkelstein, J. S., H. Lee, et al. (2013). "Gonadal steroids and body composition, strength, 
and sexual function in men." N Engl J Med 369(11): 1011-1022. 
  
Fisher, J. S. (2004). "Environmental anti-androgens and male reproductive health: focus 
on phthalates and testicular dysgenesis syndrome." Reproduction 127(3): 305-315. 
 
Fisher, J. S., S. Macpherson, et al. (2003). "Human 'testicular dysgenesis syndrome': a 
possible model using in-utero exposure of the rat to dibutyl phthalate." Hum Reprod 
18(7): 1383-1394. 
 
Fluck, C. E., W. L. Miller, et al. (2003). "The 17, 20-lyase activity of cytochrome p450c17 
from human fetal testis favors the delta5 steroidogenic pathway." J Clin Endocrinol 
Metab 88(8): 3762-3766. 
  
Foresta, C., D. Zuccarello, et al. (2008). "Role of hormones, genes, and environment in 
human cryptorchidism." Endocr Rev 29(5): 560-580. 
  
Foster, P. M. (2006). "Disruption of reproductive development in male rat offspring 
following in utero exposure to phthalate esters." Int J Androl 29(1): 140-147; 
discussion 181-145. 
 
Foster, P. M. and M. W. Harris (2005). "Changes in androgen-mediated reproductive 
development in male rat offspring following exposure to a single oral dose of flutamide 
at different gestational ages." Toxicol Sci 85(2): 1024-1032. 
  
Foster, P. M., E. Mylchreest, et al. (2001). "Effects of phthalate esters on the developing 
reproductive tract of male rats." Hum Reprod Update 7(3): 231-235. 
  
Froment, P., M. Vigier, et al. (2007). "Inactivation of the IGF-I receptor gene in primary 
Sertoli cells highlights the autocrine effects of IGF-I." J Endocrinol 194(3): 557-568. 
  
Fynn-Thompson, E., H. Cheng, et al. (2003). "Inhibition of steroidogenesis in Leydig 
cells by Mullerian-inhibiting substance." Mol Cell Endocrinol 211(1-2): 99-104. 
  
Galdiero, M., P. Vitale, et al. (2013). "The 17beta-hydroxysteroid dehydrogenase type 3 
deficiency: a case report of an 18-year patient and review of the literature." Minerva 
Endocrinol 38(1): 113-122. 
  
Gallegos, A. M., B. P. Atshaves, et al. (2001). "Gene structure, intracellular localization, 
and functional roles of sterol carrier protein-2." Prog Lipid Res 40(6): 498-563. 
  
Garcia-Galiano, D., L. Pinilla, et al. (2012). "Sex steroids and the control of the Kiss1 









Gaytan, F., C. Bellido, et al. (1994). "Effects of macrophage depletion at different times 
after treatment with ethylene dimethane sulfonate (EDS) on the regeneration of Leydig 
cells in the adult rat." J Androl 15(6): 558-564. 
 
Gaytan, F., C. Bellido, et al. (1994). "Selective depletion of testicular macrophages and 
prevention of Leydig cell repopulation after treatment with ethylene dimethane 
sulfonate in rats." J Reprod Fertil 101(1): 175-182. 
 
Ge, R. S., Q. Dong, et al. (2005). "Gene expression in rat leydig cells during development 
from the progenitor to adult stage: a cluster analysis." Biol Reprod 72(6): 1405-1415. 
  
Ge, R. S., Q. A. Dong, et al. (2006). "In search of rat stem Leydig cells: Identification, 
isolation, and lineage-specific development." Proc Natl Acad Sci USA 103(8): 2719-
2724. 
 
Ge, R., and Hardy, M. (2007). Regulation of Leydig Cells During Pubertal Development. 
In The Leydig Cell in Health and Disease, A. Payne, and M. Hardy, eds. (Humana Press), 
pp. 55–70. 
 
Gehring, U. and G. M. Tomkins (1974). "Characterization of a hormone receptor defect 
in the androgen-insensitivity mutant." Cell 3(1): 59-64. 
  
Gelber, S. J., M. P. Hardy, et al. (1992). "Effects of insulin-like growth factor-I on 
androgen production by highly purified pubertal and adult rat Leydig cells." J Androl 
13(2): 125-130. 
 
Gerendai, I., Z. Csaba, et al. (1995). "Involvement of a direct neural mechanism in the 
control of gonadal functions." J Steroid Biochem Mol Biol 53(1-6): 299-305. 
  
Ghali, S. A., B. Gottlieb, et al. (2003). "The use of androgen receptor amino/carboxyl-
terminal interaction assays to investigate androgen receptor gene mutations in subjects 
with varying degrees of androgen insensitivity." J Clin Endocrinol Metab 88(5): 2185-
2193. 
  
Giagulli, V. A. and A. Vermeulen (1988). "Leydig cell function in infertile men with 
idiopathic oligospermic infertility." J Clin Endocrinol Metab 66(1): 62-67. 
  
Giribabu, N., S. B. Sainath, et al. (2012). "Prenatal di-n-butyl phthalate exposure alters 
reproductive functions at adulthood in male rats." Environ Toxicol. 
  
Giwercman, A. (1995). "Declining semen quality and increasing incidence of 
abnormalities in male reproductive organs--fact or fiction?" Hum Reprod 10 Suppl 1: 
158-164. 
  
Glass, A. R. and R. A. Vigersky (1980). "Leydig cell function in idiopathic oligospermia." 
Fertil Steril 34(2): 144-148. 
  
Gluckman, P. D., M. A. Hanson, et al. (2009). "Epigenetic mechanisms that underpin 







Gnessi, L., S. Basciani, et al. (2000). "Leydig cell loss and spermatogenic arrest in 
platelet-derived growth factor (PDGF)-A-deficient mice." J Cell Biol 149(5): 1019-1026. 
  
Gnessi, L., A. Emidi, et al. (1995). "Testicular development involves the spatiotemporal 
control of PDGFs and PDGF receptors gene expression and action." J Cell Biol 131(4): 
1105-1121. 
  
Gnessi, L., A. Fabbri, et al. (1997). "Gonadal peptides as mediators of development and 
functional control of the testis: an integrated system with hormones and local 
environment." Endocr Rev 18(4): 541-609. 
 
Goldman, A. S., B. Shapiro, et al. (1976). "Role of testosterone and its metabolites in the 
differentiation of the mammary gland in rats." Endocrinology 99(6): 1490-1495. 
 
Gordon, C. T., T. Y. Tan, et al. (2009). "Long-range regulation at the SOX9 locus in 
development and disease." J Med Genet 46(10): 649-656. 
 
Gottlieb, B., Beitel, L., Trifiro, M. Androgen Insensitivity Syndrome. Gene Reviews. 
Pagon RA, Adam MP, Bird TD, et al., editors. Seattle (WA): University of Washington. 
Seattle; 1993-2014. 
 
Gould, M. L., P. R. Hurst, et al. (2007). "The effects of oestrogen receptors alpha and beta 
on testicular cell number and steroidogenesis in mice." Reproduction 134(2): 271-279. 
  
Gray, L. E., J. Ostby, et al. (2001). "Effects of environmental antiandrogens on 
reproductive development in experimental animals." Hum Reprod Update 7(3): 248-
264. 
 
Greene, R. R., Burrill, M. W., and Ivy, A. C. (1939). Experimental intersexuality. The effect 
of antenatal androgens on sexual development of female rats. Am. J. Anat. 65,415–469 
Grinspon, R. P. and R. A. Rey (2010). "Anti-mullerian hormone and sertoli cell function 
in paediatric male hypogonadism." Horm Res Paediatr 73(2): 81-92. 
  
Griswold, S. L. and R. R. Behringer (2009). "Fetal Leydig cell origin and development." 
Sex Dev 3(1): 1-15. 
  
Grober, M. S., G. M. Winterstein, et al. (1998). "The effects of estradiol on gonadotropin-
releasing hormone neurons in the developing mouse brain." Gen Comp Endocrinol 
112(3): 356-363. 
  
Gubbay, J., J. Collignon, et al. (1990). "A gene mapping to the sex-determining region of 
the mouse Y chromosome is a member of a novel family of embryonically expressed 
genes." Nature 346(6281): 245-250. 
  
Gubbay, J., N. Vivian, et al. (1992). "Inverted repeat structure of the Sry locus in mice." 
Proc Natl Acad Sci U S A 89(17): 7953-7957. 
  
Guo, J. J., X. Ma, et al. (2013). "Effects of luteinizing hormone and androgen on the 







Ha, T. Y., H. S. Kim, et al. (2004). "Expression of constitutive endothelial, neuronal and 
inducible nitric oxide synthase in the testis and epididymis of horse." J Vet Med Sci 
66(4): 351-356. 
 
Haberland, M. E. and J. A. Reynolds (1973). "Self-association of cholesterol in aqueous 
solution." Proc Natl Acad Sci U S A 70(8): 2313-2316. 
  
Habert, R., H. Lejeune, et al. (2001). "Origin, differentiation and regulation of fetal and 
adult Leydig cells." Mol Cell Endocrinol 179(1-2): 47-74. 
  
Habert, R. and R. Picon (1982). "Control of testicular steroidogenesis in foetal rat: effect 
of decapitation on testosterone and plasma luteinizing hormone-like activity." Acta 
Endocrinol (Copenh) 99(3): 466-473. 
  
Habert, R. and R. Picon (1984). "Testosterone, dihydrotestosterone and estradiol-17 
beta levels in maternal and fetal plasma and in fetal testes in the rat." J Steroid Biochem 
21(2): 193-198. 
  
Haider, S. G. (2004). "Cell biology of Leydig cells in the testis." Int Rev Cytol 233: 181-
241. 
  
Hales, D. B. (2002). "Testicular macrophage modulation of Leydig cell steroidogenesis." 
J Reprod Immunol 57(1-2): 3-18. 
  
Hallmark, N., M. Walker, et al. (2007). "Effects of monobutyl and di(n-butyl) phthalate 
in vitro on steroidogenesis and Leydig cell aggregation in fetal testis explants from the 
rat: comparison with effects in vivo in the fetal rat and neonatal marmoset and in vitro 
in the human." Environ Health Perspect 115(3): 390-396. 
  
Handa, R. J. and M. J. Weiser (2013). "Gonadal steroid hormones and the hypothalamo-
pituitary-adrenal axis." Front Neuroendocrinol. 
  
Hansen, K. H., A. P. Bracken, et al. (2008). "A model for transmission of the H3K27me3 
epigenetic mark." Nat Cell Biol 10(12): 1291-1300. 
  
Hardy, M. P., B. R. Zirkin, et al. (1989). "Kinetic studies on the development of the adult 
population of Leydig cells in testes of the pubertal rat." Endocrinology 124(2): 762-
770. 
  
Hasegawa, T., L. Zhao, et al. (2000). "Developmental roles of the steroidogenic acute 
regulatory protein (StAR) as revealed by StAR knockout mice." Mol Endocrinol 14(9): 
1462-1471. 
 
Hatano, O., A. Takakusu, et al. (1996). "Identical origin of adrenal cortex and gonad 
revealed by expression profiles of Ad4BP/SF-1." Genes Cells 1(7): 663-671. 
  
Hauet, T., Z. X. Yao, et al. (2005). "Peripheral-type benzodiazepine receptor-mediated 
action of steroidogenic acute regulatory protein on cholesterol entry into leydig cell 







Hawkins, J. R., A. Taylor, et al. (1992). "Evidence for increased prevalence of SRY 
mutations in XY females with complete rather than partial gonadal dysgenesis." Am J 
Hum Genet 51(5): 979-984. 
  
Hazra, R., M. Jimenez, et al. (2013). "Sertoli cell androgen receptor expression regulates 
temporal fetal and adult Leydig cell differentiation, function, and population size." 
Endocrinology 154(9): 3410-3422. 
  
He, W., Y. Barak, et al. (2003). "Adipose-specific peroxisome proliferator-activated 
receptor gamma knockout causes insulin resistance in fat and liver but not in muscle." 
Proc Natl Acad Sci U S A 100(26): 15712-15717. 
 
Hilton, D. J. (1992). "LIF: lots of interesting functions." Trends Biochem Sci 17(2): 72-
76. 
 
Hiort, O., P. M. Holterhus, et al. (1998). "Physiology and pathophysiology of androgen 
action." Baillieres Clin Endocrinol Metab 12(1): 115-132. 
  
Hiroi, H., L. K. Christenson, et al. (2004). "Temporal and spatial changes in transcription 
factor binding and histone modifications at the steroidogenic acute regulatory protein 
(stAR) locus associated with stAR transcription." Mol Endocrinol 18(4): 791-806. 
  
Ho, S. M. and W. Y. Tang (2007). "Techniques used in studies of epigenome 
dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult 
diseases." Reprod Toxicol 23(3): 267-282. 
 
Holdcraft, R. W. and R. E. Braun (2004). "Androgen receptor function is required in 
Sertoli cells for the terminal differentiation of haploid spermatids." Development 
131(2): 459-467. 
  
Hsieh, M. H., B. N. Breyer, et al. (2008). "Associations among hypospadias, 
cryptorchidism, anogenital distance, and endocrine disruption." Curr Urol Rep 9(2): 
137-142. 
  
Hu, G. X., Q. Q. Lian, et al. (2009). "Phthalate-induced testicular dysgenesis syndrome: 
Leydig cell influence." Trends Endocrinol Metab 20(3): 139-145. 
  
Hu, G. X., H. Lin, et al. (2010). "Deletion of the Igf1 gene: suppressive effects on adult 
Leydig cell development." J Androl 31(4): 379-387. 
  
Huang, P. C., P. L. Kuo, et al. (2009). "Association between prenatal exposure to 
phthalates and the health of newborns." Environ Int 35(1): 14-20. 
  
Hughes, I. A., J. D. Davies, et al. (2012). "Androgen insensitivity syndrome." Lancet 
380(9851): 1419-1428. 
 
Hughes, I. A., R. Werner, et al. (2012). "Androgen insensitivity syndrome." Semin 
Reprod Med 30(5): 432-442. 
  
Hutchison, G. R., H. M. Scott, et al. (2008). "Sertoli cell development and function in an 





Huhtaniemi, I. (1996) Ontogeny of the luteinizing hormone action in the male. In: The 
Leydig cell. Payne AH, Hardy MP, Russell LD (eds), Cache River Press, Vienna, IL. pp 
365-382 
Hutson, J. M., B. R. Southwell, et al. (2013). "The regulation of testicular descent and the 
effects of cryptorchidism." Endocr Rev 34(5): 725-752. 
  
Imperato-McGinley, J., Z. Binienda, et al. (1985). "The development of a male 
pseudohermaphroditic rat using an inhibitor of the enzyme 5 alpha-reductase." 
Endocrinology 116(2): 807-812. 
 
Imperato-McGinley, J., Z. Binienda, et al. (1986). "Nipple differentiation in fetal male 
rats treated with an inhibitor of the enzyme 5 alpha-reductase: definition of a selective 
role for dihydrotestosterone." Endocrinology 118(1): 132-137. 
 
Imperato-McGinley, J., L. Guerrero, et al. (1974). "Steroid 5alpha-reductase deficiency in 
man: an inherited form of male pseudohermaphroditism." Science 186(4170): 1213-
1215. 
  
Imperato-McGinley, J., R. S. Sanchez, et al. (1992). "Comparison of the effects of the 5 
alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and 
genital differentiation: dose-response studies." Endocrinology 131(3): 1149-1156. 
  
Imperato-McGinley, J. and Y. S. Zhu (2002). "Androgens and male physiology the 
syndrome of 5alpha-reductase-2 deficiency." Mol Cell Endocrinol 198(1-2): 51-59. 
  
Ingraham, H. A., Y. Hirokawa, et al. (2000). "Autocrine and paracrine Mullerian 
inhibiting substance hormone signaling in reproduction." Recent Prog Horm Res 55: 
53-67; discussion 67-58. 
  
Ishikawa, T. and P. L. Morris (2006). "Interleukin-1beta signals through a c-Jun N-
terminal kinase-dependent inducible nitric oxide synthase and nitric oxide production 
pathway in Sertoli epithelial cells." Endocrinology 147(11): 5424-5430. 
  
Ivell, R. and R. Anand-Ivell (2009). "Biology of insulin-like factor 3 in human 
reproduction." Hum Reprod Update 15(4): 463-476. 
  
Ivell, R. and R. A. Bathgate (2002). "Reproductive biology of the relaxin-like factor 
(RLF/INSL3)." Biol Reprod 67(3): 699-705. 
  
Ivell, R. and S. Hartung (2003). "The molecular basis of cryptorchidism." Mol Hum 
Reprod 9(4): 175-181. 
  
Ivell, R., K. Heng, et al. (2014). "Insulin-Like Factor 3 and the HPG Axis in the Male." 
Front Endocrinol (Lausanne) 5: 6. 
  
Ivell, R., K. Heng, et al. (2013). "Brief maternal exposure of rats to the xenobiotics 
dibutyl phthalate or diethylstilbestrol alters adult-type Leydig cell development in male 
offspring." Asian J Androl 15(2): 261-268. 
  
Ivell, R., J. D. Wade, et al. (2013). "INSL3 as a biomarker of Leydig cell functionality." 






Jaaskelainen, J., A. Deeb, et al. (2006). "Human androgen receptor gene ligand-binding-
domain mutations leading to disrupted interaction between the N- and C-terminal 
domains." J Mol Endocrinol 36(2): 361-368. 
  
Jaenisch, R. and A. Bird (2003). "Epigenetic regulation of gene expression: how the 
genome integrates intrinsic and environmental signals." Nat Genet 33 Suppl: 245-254. 
  
Jain, V. G. and A. K. Singal (2013). "Shorter anogenital distance correlates with 
undescended testis: a detailed genital anthropometric analysis in human newborns." 
Hum Reprod 28(9): 2343-2349. 
  
Jannini, E. A., A. Crescenzi, et al. (2000). "Ontogenetic pattern of thyroid hormone 
receptor expression in the human testis." J Clin Endocrinol Metab 85(9): 3453-3457. 
 
Jarazo-Dietrich, S., P. Jacobo, et al. (2012). "Up regulation of nitric oxide synthase-nitric 
oxide system in the testis of rats undergoing autoimmune orchitis." Immunobiology 
217(8): 778-787. 
 
Jenkins, D. (2009). "Hedgehog signalling: emerging evidence for non-canonical 
pathways." Cell Signal 21(7): 1023-1034. 
  
Jensen, T. K., N. Jorgensen, et al. (2004). "Association of in utero exposure to maternal 
smoking with reduced semen quality and testis size in adulthood: a cross-sectional 
study of 1,770 young men from the general population in five European countries." Am 
J Epidemiol 159(1): 49-58. 
  
Jia, Y., K. Takeda, et al. (2013). "Stepwise epigenetic and phenotypic alterations poise 
CD8+ T cells to mediate airway hyperresponsiveness and inflammation." J Immunol 
190(8): 4056-4065. 
  
Jiang, J., L. Ma, et al. (2007). "Study on developmental abnormalities in hypospadiac 
male rats induced by maternal exposure to di-n-butyl phthalate (DBP)." Toxicology 
232(3): 286-293. 
  
Joensen, U. N., N. Jorgensen, et al. (2008). "Testicular dysgenesis syndrome and Leydig 
cell function." Basic Clin Pharmacol Toxicol 102(2): 155-161. 
 
Johnston, H., P. J. Baker, et al. (2004). "Regulation of Sertoli cell number and activity by 
follicle-stimulating hormone and androgen during postnatal development in the 
mouse." Endocrinology 145(1): 318-329. 
  
Jones, M. E., W. C. Boon, et al. (2006). "Of mice and men: the evolving phenotype of 
aromatase deficiency." Trends Endocrinol Metab 17(2): 55-64. 
 
Jorgensen, N., C. Asklund, et al. (2006). "Coordinated European investigations of semen 
quality: results from studies of Scandinavian young men is a matter of concern." Int J 








Jorgensen, N., E. Carlsen, et al. (2002). "East-West gradient in semen quality in the 
Nordic-Baltic area: a study of men from the general population in Denmark, Norway, 
Estonia and Finland." Hum Reprod 17(8): 2199-2208. 
  
Josso, N., R. Rey, et al. (2012). "Testicular anti-Mullerian hormone: clinical applications 
in DSD." Semin Reprod Med 30(5): 364-373. 
  
Jost, A., S. Magre, et al. (1981). "Early stages of testicular differentiation in the rat." Hum 
Genet 58(1): 59-63. 
  
Jost, A., S. Perlman, et al. (1988). "Experimental control of the differentiation of Leydig 
cells in the rat fetal testis." Proc Natl Acad Sci U S A 85(21): 8094-8097. 
  
Kadonaga, J. T. (1998). "Eukaryotic transcription: an interlaced network of 
transcription factors and chromatin-modifying machines." Cell 92(3): 307-313. 
  
Karl, J. and B. Capel (1998). "Sertoli cells of the mouse testis originate from the 
coelomic epithelium." Dev Biol 203(2): 323-333. 
  
Karsenty, G. (2012). "The mutual dependence between bone and gonads." J Endocrinol 
213(2): 107-114. 
 
Kelce, W. R. and B. R. Zirkin (1993). "Mechanism by which ethane dimethanesulfonate 
kills adult rat Leydig cells: involvement of intracellular glutathione." Toxicol Appl 
Pharmacol 120(1): 80-88. 
  
Kelce, W. R., B. R. Zirkin, et al. (1991). "Immature rat Leydig cells are intrinsically less 
sensitive than adult Leydig cells to ethane dimethanesulfonate." Toxicol Appl 
Pharmacol 111(2): 189-200. 
  
Kerkhofs, S., S. Denayer, et al. (2009). "Androgen receptor knockout and knock-in 
mouse models." J Mol Endocrinol 42(1): 11-17. 
 
Ketola, I., M. Anttonen, et al. (2002). "Developmental expression and spermatogenic 
stage specificity of transcription factors GATA-1 and GATA-4 and their cofactors FOG-1 
and FOG-2 in the mouse testis." Eur J Endocrinol 147(3): 397-406. 
  
Ketola, I., V. Pentikainen, et al. (2000). "Expression of transcription factor GATA-4 
during human testicular development and disease." J Clin Endocrinol Metab 85(10): 
3925-3931. 
  
Ketola, I., N. Rahman, et al. (1999). "Expression and regulation of transcription factors 
GATA-4 and GATA-6 in developing mouse testis." Endocrinology 140(3): 1470-1480. 
   
Ketola, I., N. Rahman, et al. (1998). "Expression and regulation of transcription factors 
GATA-4 and GATA-6 in developing mouse testis." Endocrinology 140: 1470-1480. 
  
Khaw, K. T., M. Dowsett, et al. (2007). "Endogenous testosterone and mortality due to 
all causes, cardiovascular disease, and cancer in men: European prospective 
investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study." 





Khurana, M.L. and Pandey, K.N. (1993). “Receptor-mediated stimulatory effect of atrial 
natriuretic factor, brain natriuretic peptide, and C-type natriuretic peptide on 
testosterone prodicution in purified mouse Leydig cells: activation of cholesterol side-
chain cleavage enzyme. Endocrinology 133(5):2141-9. 
   
Kim, B. J., N. Takamoto, et al. (2009). "Chicken Ovalbumin Upstream Promoter-
Transcription Factor II (COUP-TFII) regulates growth and patterning of the postnatal 
mouse cerebellum." Dev Biol 326(2): 378-391. 
   
Kim, H. C., J. S. Byun, et al. (2007). "Expression of nitric oxide synthase isoforms in the 
testes of pigs." Anat Histol Embryol 36(2): 135-138.   
 
Kim, J. M., L. Luo, et al. (2000). "Caspase-3 activation is required for Leydig cell 
apoptosis induced by ethane dimethanesulfonate." Endocrinology 141(5): 1846-1853. 
   
Kimura, S., T. Matsumoto, et al. (2007). "Androgen receptor function in folliculogenesis 
and its clinical implication in premature ovarian failure." Trends Endocrinol Metab 
18(5): 183-189. 
   
King, P. J., L. Guasti, et al. (2008). "Hedgehog signalling in endocrine development and 
disease." J Endocrinol 198(3): 439-450. 
   
King, S. R. and H. A. LaVoi (2012). "Gonadal Transactivation of STARDI, CYP11A1 and 
HSD3B." Cell Biol Biochem 17: 824-846. 
  
King, S. R., P. R. Manna, et al. (2002). "An essential component in steroid synthesis, the 
steroidogenic acute regulatory protein, is expressed in discrete regions of the brain." J 
Neurosci 22(24): 10613-10620. 
   
Kiriakidou, M., J. M. McAllister, et al. (1996). "Expression of steroidogenic acute 
regulatory protein (StAR) in the human ovary." J Clin Endocrinol Metab 81(11): 4122-
4128. 
 
Kirilov, M., J. Clarkson, et al. (2013). "Dependence of fertility on kisspeptin-Gpr54 
signaling at the GnRH neuron." Nat Commun 4: 2492. 
   
Kirmizis, A., S. M. Bartley, et al. (2004). "Silencing of human polycomb target genes is 
associated with methylation of histone H3 Lys 27." Genes Dev 18(13): 1592-1605. 
   
Klein, G. (2005). "Epigenetics: surveillance team against cancer." Nature 434(7030): 
150. 
  
Klinghoffer, R. A., P. F. Mueting-Nelsen, et al. (2001). "The two PDGF receptors maintain 
conserved signaling in vivo despite divergent embryological functions." Mol Cell 7(2): 
343-354. 
   
Kohn, M. C., F. Parham, et al. (2000). "Human exposure estimates for phthalates." 
Environ Health Perspect 108(10): A440-442. 
  
Kojima, Y., K. Mizuno, et al. (2009). "Long-term physical, hormonal, and sexual outcome 





   
Kon, Y., Y. Namiki, et al. (2002). "Expression and distribution of inducible nitric oxide 
synthase in mouse testis." Jpn J Vet Res 50(2-3): 115-123. 
   
Kondo, T., T. Shono, et al. (2006). "Age-specific effect of phthalate ester on testicular 
development in rats." J Pediatr Surg 41(7): 1290-1293. 
   
Kondo, Y. (2009). "Epigenetic cross-talk between DNA methylation and histone 
modifications in human cancers." Yonsei Med J 50(4): 455-463. 
   
Kong, Y. W., I. G. Cannell, et al. (2008). "The mechanism of micro-RNA-mediated 
translation repression is determined by the promoter of the target gene." Proc Natl 
Acad Sci U S A 105(26): 8866-8871. 
 
Koopman, P. (2001). "Gonad development: signals for sex." Curr Biol 11(12): R481-483. 
   
Koopman, P., J. Gubbay, et al. (1991). "Male development of chromosomally female mice 
transgenic for Sry." Nature 351(6322): 117-121. 
   
Koritz, S. B. and A. M. Kumar (1970). "On the mechanism of action of the 
adrenocorticotrophic hormone. The stimulation of the activity of enzymes involved in 
pregnenolone synthesis." J Biol Chem 245(1): 152-159. 
  
Kotula-Balak, M., A. Hejmej, et al. (2012). "Prenatal and neonatal exposure to flutamide 
affects function of Leydig cells in adult boar." Domest Anim Endocrinol 42(3): 142-154. 
   
Kotula-Balak, M., A. Hejmej, et al. (2012). Hydroxysteroid Dehydrogenases – 
Localization, Function and Regulation in the Testis, Dehydrogenases, Prof. Rosa Angela 
Canuto (Ed.) 
 
Kouzarides, T. (2007). "Chromatin modifications and their function." Cell 128(4): 693-
705. 
  
Krishnan, V., G. Elberg, et al. (1997). "Identification of a novel sonic hedgehog response 
element in the chicken ovalbumin upstream promoter-transcription factor II 
promoter." Mol Endocrinol 11(10): 1458-1466. 
   
Kristensen, D. M., U. Hass, et al. (2011). "Intrauterine exposure to mild analgesics is a 
risk factor for development of male reproductive disorders in human and rat." Hum 
Reprod 26(1): 235-244. 
   
Kruse, S. W., K. Suino-Powell, et al. (2008). "Identification of COUP-TFII orphan nuclear 
receptor as a retinoic acid-activated receptor." PLoS Biol 6(9): e227. 
   
Lachner, M., R. J. O'Sullivan, et al. (2003). "An epigenetic road map for histone lysine 
methylation." J Cell Sci 116(Pt 11): 2117-2124. 
  
Lan, F., P. E. Bayliss, et al. (2007). "A histone H3 lysine 27 demethylase regulates animal 
posterior development." Nature 449(7163): 689-694. 






Landreh, L., J. B. Stukenborg, et al. (2013). "Phenotype and steroidogenic potential of 
PDGFRalpha-positive rat neonatal peritubular cells." Mol Cell Endocrinol 372(1-2): 96-
104. 
   
Lardone, M. C., A. Piottante, et al. (2012). "Histological and hormonal testicular function 
in azo/oligozoospermic infertile men." Andrologia. 
   
Latronico, A. C., J. Anasti, et al. (1996). "Brief report: testicular and ovarian resistance to 
luteinizing hormone caused by inactivating mutations of the luteinizing hormone-
receptor gene." N Engl J Med 334(8): 507-512. 
 
Latronico, A. C. and I. J. Arnhold (2012). "Inactivating mutations of the human 
luteinizing hormone receptor in both sexes." Semin Reprod Med 30(5): 382-386. 
   
Latronico, A. C. and I. J. Arnhold (2013). "Gonadotropin resistance." Endocr Dev 24: 25-
32. 
 
Laubach, V. E., E. G. Shesely, et al. (1995). "Mice lacking inducible nitric oxide synthase 
are not resistant to lipopolysaccharide-induced death." Proc Natl Acad Sci U S A 92(23): 
10688-10692. 
   
Laughlin, G. A., E. Barrett-Connor, et al. (2008). "Low serum testosterone and mortality 
in older men." J Clin Endocrinol Metab 93(1): 68-75. 
 
LaVoie, H. A. (2005). "Epigenetic control of ovarian function: the emerging role of 
histone modifications." Mol Cell Endocrinol 243(1-2): 12-18. 
 
Lee, D. Y., C. Teyssier, et al. (2005). "Role of protein methylation in regulation of 
transcription." Endocr Rev 26(2): 147-170. 
   
Lee, L., H. Asada, et al. (2013). "Changes in histone modification and DNA methylation of 
the StAR and Cyp19a1 promoter regions in granulosa cells undergoing luteinization 
during ovulation in rats." Endocrinology 154(1): 458-470. 
   
Lee, M. G., R. Villa, et al. (2007). "Demethylation of H3K27 regulates polycomb 
recruitment and H2A ubiquitination." Science 318(5849): 447-450. 
   
Lee, M. M., C. C. Seah, et al. (1999). "Mullerian-inhibiting substance type II receptor 
expression and function in purified rat Leydig cells." Endocrinology 140(6): 2819-
2827. 
   
Lee, N. P. and C. Y. Cheng (2004). "Nitric oxide/nitric oxide synthase, spermatogenesis, 
and tight junction dynamics." Biol Reprod 70(2): 267-276. 
   
Lee, T. I., R. G. Jenner, et al. (2006). "Control of developmental regulators by Polycomb 
in human embryonic stem cells." Cell 125(2): 301-313. 
   
Lei, Z. M., S. Mishra, et al. (2004). "Testicular phenotype in luteinizing hormone 
receptor knockout animals and the effect of testosterone replacement therapy." Biol 
Reprod 71(5): 1605-1613. 





Li, B., M. Carey, et al. (2007). "The role of chromatin during transcription." Cell 128(4): 
707-719. 
   
Li, G., R. Margueron, et al. (2010). "Jarid2 and PRC2, partners in regulating gene 
expression." Genes Dev 24(4): 368-380. 
   
Li, H., Z. Yao, et al. (2001). "Cholesterol binding at the cholesterol recognition/ 
interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine 
receptor and inhibition of steroidogenesis by an HIV TAT-CRAC peptide." Proc Natl 
Acad Sci U S A 98(3): 1267-1272. 
   
 
Li, X., A. Ponten, et al. (2000). "PDGF-C is a new protease-activated ligand for the PDGF 
alpha-receptor." Nat Cell Biol 2(5): 302-309. 
 
Li, L., Xie, X., et al. (2009). “The nuclear orphan receptor COUP-TFII plays an essential 
role in aipgenesis, glucose homeostasis, and energy metabolism.” Cell Metab 9(1):77-
87. 
   
Lim, P., M. Robson, et al. (2009). "Sertoli cell androgen receptor DNA binding domain is 
essential for the completion of spermatogenesis." Endocrinology 150(10): 4755-4765. 
   
Lin, D., T. Sugawara, et al. (1995). "Role of steroidogenic acute regulatory protein in 
adrenal and gonadal steroidogenesis." Science 267(5205): 1828-1831. 
   
Lin, F. J., J. Qin, et al. (2011). "Coup d'Etat: an orphan takes control." Endocr Rev 32(3): 
404-421. 
   
Lin, H., R. S. Ge, et al. (2008). "Involvement of testicular growth factors in fetal Leydig 
cell aggregation after exposure to phthalate in utero." Proc Natl Acad Sci U S A 105(20): 
7218-7222. 
   
Lin, T., D. Wang, et al. (1998). "Upregulation of human chorionic gonadotrophin-
induced steroidogenic acute regulatory protein by insulin-like growth factor-I in rat 
Leydig cells." Endocrine 8(1): 73-78. 
 
Lindzey, J., M. Grossmann, et al. (1993). "Regulation of the 5'-flanking region of the 
mouse androgen receptor gene by cAMP and androgen." Mol Endocrinol 7(12): 1530-
1540. 
   
Liu, J., M. B. Rone, et al. (2006). "Protein-protein interactions mediate mitochondrial 
cholesterol transport and steroid biosynthesis." J Biol Chem 281(50): 38879-38893. 
   
Liu, K., K. P. Lehmann, et al. (2005). "Gene expression profiling following in utero 
exposure to phthalate esters reveals new gene targets in the etiology of testicular 
dysgenesis." Biol Reprod 73(1): 180-192. 
   
Livera, G., C. Pairault, et al. (2004). "Retinoid-sensitive steps in steroidogenesis in fetal 
and neonatal rat testes: in vitro and in vivo studies." Biol Reprod 70(6): 1814-1821. 






Lording, D. W. and D. M. De Kretser (1972). "Comparative ultrastructural and 
histochemical studies of the interstitial cells of the rat testis during fetal and postnatal 
development." J Reprod Fertil 29(2): 261-269. 
  
Loss, E. S., A. P. Jacobus, et al. (2011). "Rapid signaling responses in Sertoli cell 
membranes induced by follicle stimulating hormone and testosterone: calcium inflow 
and electrophysiological changes." Life Sci 89(15-16): 577-583. 
   
Lue, Y., A. P. Sinha Hikim, et al. (2003). "Functional role of inducible nitric oxide 
synthase in the induction of male germ cell apoptosis, regulation of sperm number, and 
determination of testes size: evidence from null mutant mice." Endocrinology 144(7): 
3092-3100. 
   
Lukas-Croisier, C., C. Lasala, et al. (2003). "Follicle-stimulating hormone increases 
testicular Anti-Mullerian hormone (AMH) production through sertoli cell proliferation 
and a nonclassical cyclic adenosine 5'-monophosphate-mediated activation of the AMH 
Gene." Mol Endocrinol 17(4): 550-561. 
   
Lukyanenko, Y., J. J. Chen, et al. (2002). "Testosterone regulates 25-hydroxycholesterol 
production in testicular macrophages." Biol Reprod 67(5): 1435-1438. 
 
Lukyanenko, Y. O., A. M. Carpenter, et al. (2000). "Specificity of a new lipid mediator 
produced by testicular and peritoneal macrophages on steroidogenesis." Int J Androl 
23(5): 258-265. 
   
Lyng, F. M., G. R. Jones, et al. (2000). "Rapid androgen actions on calcium signaling in rat 
sertoli cells and two human prostatic cell lines: similar biphasic responses between 1 
picomolar and 100 nanomolar concentrations." Biol Reprod 63(3): 736-747. 
   
Lyon, M. F. and S. G. Hawkes (1970). "X-linked gene for testicular feminization in the 
mouse." Nature 227(5264): 1217-1219. 
  
Ma, X., Y. Dong, et al. (2004). "Targeted disruption of luteinizing hormone beta-subunit 
leads to hypogonadism, defects in gonadal steroidogenesis, and infertility." Proc Natl 
Acad Sci U S A 101(49): 17294-17299. 
   
MacLean, H. E., G. L. Warne, et al. (1995). "Defects of androgen receptor function: from 
sex reversal to motor neurone disease." Mol Cell Endocrinol 112(2): 133-141. 
   
Madden, J. D., P. C. Walsh, et al. (1975). "Clinical and endocrinologic characterization of 
a patients with the syndrome of incomplete testicular feminization." J Clin Endocrinol 
Metab 41(4): 751-760. 
   
Maddocks, S., T. B. Hargreave, et al. (1993). "Intratesticular hormone levels and the 
route of secretion of hormones from the testis of the rat, guinea pig, monkey and 
human." Int J Androl 16(4): 272-278. 
   
Mahood, I. K., N. Hallmark, et al. (2005). "Abnormal Leydig Cell aggregation in the fetal 
testis of rats exposed to di (n-butyl) phthalate and its possible role in testicular 
dysgenesis." Endocrinology 146(2): 613-623. 





Mahood, I. K., C. McKinnell, et al. (2006). "Cellular origins of testicular dysgenesis in rats 
exposed in utero to di(n-butyl) phthalate." Int J Androl 29(1): 148-154; discussion 181-
145. 
   
Majdic, G., M. R. Millar, et al. (1995). "Immunolocalisation of androgen receptor to 
interstitial cells in fetal rat testes and to mesenchymal and epithelial cells of associated 
ducts." J Endocrinol 147(2): 285-293. 
   
Malkin, C. J., P. J. Pugh, et al. (2004). "The effect of testosterone replacement on 
endogenous inflammatory cytokines and lipid profiles in hypogonadal men." J Clin 
Endocrinol Metab 89(7): 3313-3318. 
   
 
Manna, P. R., M. T. Dyson, et al. (2009). "Regulation of the steroidogenic acute 
regulatory protein gene expression: present and future perspectives." Mol Hum Reprod 
15(6): 321-333. 
   
Manna, P. R., P. Roy, et al. (2001). "Interaction of thyroid hormone and steroidogenic 
acute regulatory (StAR) protein in the regulation of murine Leydig cell 
steroidogenesis." J Steroid Biochem Mol Biol 76(1-5): 167-177.   
 
Manna, P. R., M. Tena-Sempere, et al. (1999). "Molecular mechanisms of thyroid 
hormone-stimulated steroidogenesis in mouse leydig tumor cells. Involvement of the 
steroidogenic acute regulatory (StAR) protein." J Biol Chem 274(9): 5909-5918. 
   
Maran, R. R., J. Arunakaran, et al. (2000). "T3 directly stimulates basal and modulates 
LH induced testosterone and oestradiol production by rat Leydig cells in vitro." Endocr 
J 47(4): 417-428. 
   
Maran, R. R., K. Ravichandran, et al. (2001). "Impact of neonatal hypothyroidism on 
Leydig cell number, plasma, and testicular interstitial fluid sex steroids concentration." 
Endocr Res 27(1-2): 119-141. 
   
Margueron, R., N. Justin, et al. (2009). "Role of the polycomb protein EED in the 
propagation of repressive histone marks." Nature 461(7265): 762-767. 
   
Margueron, R., G. Li, et al. (2008). "Ezh1 and Ezh2 maintain repressive chromatin 
through different mechanisms." Mol Cell 32(4): 503-518. 
   
Mariani, S., S. Basciani, et al. (2002). "PDGF and the testis." Trends Endocrinol Metab 
13(1): 11-17. 
   
Martin, L. J. and J. J. Tremblay (2010). "Nuclear receptors in Leydig cell gene expression 
and function." Biol Reprod 83(1): 3-14. 
 
Martineau, J., K. Nordqvist, et al. (1997). "Male-specific cell migration into the 
developing gonad." Curr Biol 7(12): 958-968. 
 
Martinez-Arguelles, D. B., E. Campioli, et al. (2013). "Fetal origin of endocrine 
dysfunction in the adult: the phthalate model." J Steroid Biochem Mol Biol 137: 5-17. 





Martinez-Arguelles, D. B., M. Culty, et al. (2009). "In utero exposure to di-(2-ethylhexyl) 
phthalate decreases mineralocorticoid receptor expression in the adult testis." 
Endocrinology 150(12): 5575-5585. 
   
Martinez-Arguelles, D. B. and V. Papadopoulos (2010). "Epigenetic regulation of the 
expression of genes involved in steroid hormone biosynthesis and action." Steroids 
75(7): 467-476. 
   
Matsumoto, A. M. and W. J. Bremner (1984). "Modulation of pulsatile gonadotropin 
secretion by testosterone in man." J Clin Endocrinol Metab 58(4): 609-614. 
   
Matsumoto, T., H. Shiina, et al. (2008). "Androgen receptor functions in male and female 
physiology." J Steroid Biochem Mol Biol 109(3-5): 236-241. 
 
Matsumoto, T., K. Takeyama, et al. (2003). "Androgen receptor functions from reverse 
genetic models." J Steroid Biochem Mol Biol 85(2-5): 95-99. 
   
Mazaud, S., E. Oreal, et al. (2002). "Lhx9 expression during gonadal morphogenesis as 
related to the state of cell differentiation." Gene Expr Patterns 2(3-4): 373-377. 
   
McFarland, K. C., R. Sprengel, et al. (1989). "Lutropin-choriogonadotropin receptor: an 
unusual member of the G protein-coupled receptor family." Science 245(4917): 494-
499. 
   
McGee, S. R. and P. Narayan (2013). "Precocious puberty and Leydig cell hyperplasia in 
male mice with a gain of function mutation in the LH receptor gene." Endocrinology 
154(10): 3900-3913. 
   
McIntyre, B. S., N. J. Barlow, et al. (2001). "Androgen-mediated development in male rat 
offspring exposed to flutamide in utero: permanence and correlation of early postnatal 
changes in anogenital distance and nipple retention with malformations in androgen-
dependent tissues." Toxicol Sci 62(2): 236-249. 
   
McKinnell, C., R. M. Sharpe, et al. (2005). "Expression of insulin-like factor 3 protein in 
the rat testis during fetal and postnatal development and in relation to cryptorchidism 
induced by in utero exposure to di (n-Butyl) phthalate." Endocrinology 146(10): 4536-
4544. 
   
McLachlan, R. I., L. O'Donnell, et al. (2002). "Identification of specific sites of hormonal 
regulation in spermatogenesis in rats, monkeys, and man." Recent Prog Horm Res 57: 
149-179. 
   
McLachlan, R. I., E. Rajpert-De Meyts, et al. (2007). "Histological evaluation of the 
human testis--approaches to optimizing the clinical value of the assessment: mini 
review." Hum Reprod 22(1): 2-16. 
   
McLaren, A. (1991). "Development of the mammalian gonad: the fate of the supporting 
cell lineage." Bioessays 13(4): 151-156. 







Meldi, K. M., G. A. Gaconnet, et al. (2012). "DNA methylation and histone modifications 
are associated with repression of the inhibin alpha promoter in the rat corpus luteum." 
Endocrinology 153(10): 4905-4917. 
   
Mendiola, J., R. W. Stahlhut, et al. (2011). "Shorter anogenital distance predicts poorer 
semen quality in young men in Rochester, New York." Environ Health Perspect 119(7): 
958-963. 
   
Mendis-Handagama, S. M. and H. B. Ariyaratne (2004). "Effects of thyroid hormones on 
Leydig cells in the postnatal testis." Histol Histopathol 19(3): 985-997.   
 
Mendis-Handagama, S. M. and H. B. Siril Ariyaratne (2005). "Leydig cells, thyroid 
hormones and steroidogenesis." Indian J Exp Biol 43(11): 939-962. 
   
Mendis-Handagama, S. M. L. C. and H. B. S. Ariyaratne (2001). "Differentiation of the 
adult Leydig cell population in the postnatal testis." Biol Reprod 65(3): 660-671. 
   
Mendonca, B. B., E. M. Costa, et al. (2010). "46,XY DSD due to impaired androgen 
production." Best Pract Res Clin Endocrinol Metab 24(2): 243-262. 
   
Merchant, H. (1975). "Rat gonadal and ovarioan organogenesis with and without germ 
cells. An ultrastructural study." Dev Biol 44(1): 1-21. 
 
Merchant-Larios, H. and N. Moreno-Mendoza (1998). "Mesonephric stromal cells 
differentiate into Leydig cells in the mouse fetal testis." Exp Cell Res 244(1): 230-238. 
 
Merchant-Larios, H., N. Moreno-Mendoza, et al. (1993). "The role of the mesonephros in 
cell differentiation and morphogenesis of the mouse fetal testis." Int J Dev Biol 37(3): 
407-415. 
   
Merlet, J., E. Moreau, et al. (2007). "Development of fetal testicular cells in androgen 
receptor deficient mice." Cell Cycle 6(18): 2258-2262. 
   
Metzger, E., M. Wissmann, et al. (2005). "LSD1 demethylates repressive histone marks 
to promote androgen-receptor-dependent transcription." Nature 437(7057): 436-439. 
   
Micevych, P., G. Bondar, et al. (2010). "Estrogen actions on neuroendocrine glia." 
Neuroendocrinology 91(3): 211-222. 
   
Migliaccio, A., G. Castoria, et al. (2000). "Steroid-induced androgen receptor-oestradiol 
receptor beta-Src complex triggers prostate cancer cell proliferation." EMBO J 19(20): 
5406-5417. 
   
Migrenne, S., C. Pairault, et al. (2001). "Luteinizing hormone-dependent activity and 
luteinizing hormone-independent differentiation of rat fetal Leydig cells." Mol Cell 
Endocrinol 172(1-2): 193-202. 
   
Mikkelsen, T. S., M. Ku, et al. (2007). "Genome-wide maps of chromatin state in 
pluripotent and lineage-committed cells." Nature 448(7153): 553-560. 






Miller, W. L. (1997). "Congenital lipoid adrenal hyperplasia: the human gene knockout 
for the steroidogenic acute regulatory protein." J Mol Endocrinol 19(3): 227-240. 
  
Miller, W. L. and H. S. Bose (2011). "Early steps in steroidogenesis: intracellular 
cholesterol trafficking." J Lipid Res 52(12): 2111-2135. 
   
Mindnich, R., G. Moller, et al. (2004). "The role of 17 beta-hydroxysteroid 
dehydrogenases." Mol Cell Endocrinol 218(1-2): 7-20. 
   
Miranda, T. B., C. C. Cortez, et al. (2009). "DZNep is a global histone methylation 
inhibitor that reactivates developmental genes not silenced by DNA methylation." Mol 
Cancer Ther 8(6): 1579-1588. 
   
Mitchell, R. T., G. Cowan, et al. (2008). "Germ cell differentiation in the marmoset 
(Callithrix jacchus) during fetal and neonatal life closely parallels that in the human." 
Hum Reprod 23(12): 2755-2765. 
   
Mitchell, R. T., P. T. Saunders, et al. (2010). "Xenografting of human fetal testis tissue: a 
new approach to study fetal testis development and germ cell differentiation." Hum 
Reprod 25(10): 2405-2414. 
   
Miyata, K., S. Yabushita, et al. (2002). "Effects of perinatal exposure to flutamide on sex 
hormones and androgen-dependent organs in F1 male rats." J Toxicol Sci 27(1): 19-33. 
 
Mooradian, A. D., J. E. Morley, et al. (1987). "Biological actions of androgens." Endocr 
Rev 8(1): 1-28. 
   
Morris, J. M. (1953). "The syndrome of testicular feminization in male 
pseudohermaphrodites." Am J Obstet Gynecol 65(6): 1192-1211. 
  
Muller, J., C. M. Hart, et al. (2002). "Histone methyltransferase activity of a Drosophila 
Polycomb group repressor complex." Cell 111(2): 197-208. 
   
Muraleedharan, V. and T. H. Jones (2010). "Testosterone and the metabolic syndrome." 
Ther Adv Endocrinol Metab 1(5): 207-223. 
   
Murashima, A., S. Miyagawa, et al. (2011). "Essential roles of androgen signaling in 
Wolffian duct stabilization and epididymal cell differentiation." Endocrinology 152(4): 
1640-1651. 
   
Murphy, L., I. A. Jeffcoate, et al. (1994). "Abnormal Leydig cell development at puberty 
in the androgen-resistant Tfm mouse." Endocrinology 135(4): 1372-1377. 
   
Mylchreest, E., R. C. Cattley, et al. (1998). "Male reproductive tract malformations in 
rats following gestational and lactational exposure to Di(n-butyl) phthalate: an 
antiandrogenic mechanism?" Toxicol Sci 43(1): 47-60. 
 
Mylchreest, E., M. Sar, et al. (1999). "Disruption of androgen-regulated male 
reproductive development by di(n-butyl) phthalate during late gestation in rats is 
different from flutamide." Toxicol Appl Pharmacol 156(2): 81-95. 





Mylchreest, E., D. G. Wallace, et al. (2000). "Dose-dependent alterations in androgen-
regulated male reproductive development in rats exposed to Di(n-butyl) phthalate 
during late gestation." Toxicol Sci 55(1): 143-151. 
   
Neaves, W. B., L. Johnson, et al. (1985). "Age-related change in numbers of other 
interstitial cells in testes of adult men: evidence bearing on the fate of Leydig cells lost 
with increasing age." Biol Reprod 33(1): 259-269. 
   
Neaves, W. B., L. Johnson, et al. (1984). "Leydig cell numbers, daily sperm production, 
and serum gonadotropin levels in aging men." J Clin Endocrinol Metab 59(4): 756-763. 
   
Nef, S. and L. F. Parada (2000). "Hormones in male sexual development." Genes Dev 
14(24): 3075-3086. 
 
Nel-Themaat, L., C. W. Jang, et al. (2011). "Sertoli cell behaviors in developing testis 
cords and postnatal seminiferous tubules of the mouse." Biol Reprod 84(2): 342-350. 
   
Nemoto, T., Y. Ohara-Nemoto, et al. (1994). "Dimerization characteristics of the DNA- 
and steroid-binding domains of the androgen receptor." J Steroid Biochem Mol Biol 
50(5-6): 225-233. 
 
Nemec, M., Kaufman, L., Stump, D.G., Lindstrom, P., Varsho, B.J,. Holson. J.F (2006). 
Significance, Reliability, and Interpretation of Developmental and Reproductive 
Toxicity Study Findings, Developmental Reproductive Toxicology: A Practical 
Approach. Informa Healthcare (2006) 
Nes, W. D., Y. O. Lukyanenko, et al. (2000). "Identification of the lipophilic factor 
produced by macrophages that stimulates steroidogenesis." Endocrinology 141(3): 
953-958. 
   
Nishino, K., K. Yamanouchi, et al. (2001). "Characterization of mesonephric cells that 
migrate into the XY gonad during testis differentiation." Exp Cell Res 267(2): 225-232. 
   
Nordkap, L., U. N. Joensen, et al. (2012). "Regional differences and temporal trends in 
male reproductive health disorders: semen quality may be a sensitive marker of 
environmental exposures." Mol Cell Endocrinol 355(2): 221-230. 
   
Normington, K. and D. W. Russell (1992). "Tissue distribution and kinetic 
characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct 
physiological functions." J Biol Chem 267(27): 19548-19554. 
   
Notini, A. J., R. A. Davey, et al. (2005). "Genomic actions of the androgen receptor are 
required for normal male sexual differentiation in a mouse model." J Mol Endocrinol 
35(3): 547-555. 
   
O'Bryan, M. K., S. Schlatt, et al. (2000). "Inducible nitric oxide synthase in the rat testis: 
evidence for potential roles in both normal function and inflammation-mediated 
infertility." Biol Reprod 63(5): 1285-1293. 








Ogilvie, K. and C. Rivier (1998). "The intracerebroventricular injection of interleukin-
1beta blunts the testosterone response to human chorionic gonadotropin: role of 
prostaglandin- and adrenergic-dependent pathways." Endocrinology 139(7): 3088-
3095. 
   
Ogilvie, K. M., K. Held Hales, et al. (1999). "The inhibitory effect of 
intracerebroventricularly injected interleukin 1beta on testosterone secretion in the 
rat: role of steroidogenic acute regulatory protein." Biol Reprod 60(2): 527-533. 
   
O'Hara, L. and L. B. Smith (2012). "Androgen receptor signalling in Vascular Endothelial 
cells is dispensable for spermatogenesis and male fertility." BMC Res Notes 5: 16. 
   
Orth, J. M. (1982). "Proliferation of Sertoli cells in fetal and postnatal rats: a quantitative 
autoradiographic study." Anat Rec 203(4): 485-492. 
 
O'Shaughnessy, P. J., P. Baker, et al. (1998). "Fetal development of Leydig cell activity in 
the mouse is independent of pituitary gonadotroph function." Endocrinology 139(3): 
1141-1146. 
   
O'Shaughnessy, P. J., P. J. Baker, et al. (2000). "Localization of 17beta-hydroxysteroid 
dehydrogenase/17-ketosteroid reductase isoform expression in the developing mouse 
testis--androstenedione is the major androgen secreted by fetal/neonatal leydig cells." 
Endocrinology 141(7): 2631-2637. 
   
O'Shaughnessy, P. J., P. J. Baker, et al. (2005). "Neuroendocrine regulation of Leydig cell 
development." Ann N Y Acad Sci 1061: 109-119. 
   
O'Shaughnessy, P. J., P. J. Baker, et al. (2006). "The foetal Leydig cell-- differentiation, 
function and regulation." Int J Androl 29(1): 90-95; discussion 105-108. 
 
O'Shaughnessy, P. J., P. J. Baker, et al. (2007). "Developmental changes in human fetal 
testicular cell numbers and messenger ribonucleic acid levels during the second 
trimester." J Clin Endocrinol Metab 92(12): 4792-4801. 
   
O'Shaughnessy, P. J. and P. A. Fowler (2011). "Endocrinology of the mammalian fetal 
testis." Reproduction 141(1): 37-46. 
 
O'Shaughnessy, P. J., H. Johnston, et al. (2002). "Failure of normal adult Leydig cell 
development in androgen-receptor-deficient mice." J Cell Sci 115(Pt 17): 3491-3496. 
   
O'Shaughnessy, P. J., A. Monteiro, et al. (2012). "Testicular development in mice lacking 
receptors for follicle stimulating hormone and androgen." PLoS One 7(4): e35136. 
   
O'Shaughnessy, P. J., I. D. Morris, et al. (2008). "Leydig cell re-generation and expression 
of cell signaling molecules in the germ cell-free testis." Reproduction 135(6): 851-858. 
   
O'Shaughnessy, P. J., I. D. Morris, et al. (2009). "Role of androgen and gonadotrophins in 
the development and function of the Sertoli cells and Leydig cells: data from mutant 
and genetically modified mice." Mol Cell Endocrinol 306(1-2): 2-8. 






O'Shaughnessy, P. J., G. Verhoeven, et al. (2010). "Direct action through the sertoli cells 
is essential for androgen stimulation of spermatogenesis." Endocrinology 151(5): 
2343-2348. 
   
O'Shaughnessy, P. J., L. Willerton, et al. (2002). "Changes in Leydig cell gene expression 
during development in the mouse." Biol Reprod 66(4): 966-975. 
   
Ostrer, H., H. Y. Huang, et al. (2007). "A cellular study of human testis development." Sex 
Dev 1(5): 286-292. 
   
Ottolenghi, C., E. Pelosi, et al. (2007). "Loss of Wnt4 and Foxl2 leads to female-to-male 
sex reversal extending to germ cells." Hum Mol Genet 16(23): 2795-2804. 
   
Papadopoulos, V. (1993). "Peripheral-type benzodiazepine/diazepam binding inhibitor 
receptor: biological role in steroidogenic cell function." Endocr Rev 14(2): 222-240. 
  
Papadopoulos, V. and W. L. Miller (2012). "Role of mitochondria in steroidogenesis." 
Best Pract Res Clin Endocrinol Metab 26(6): 771-790. 
   
Park, S. Y., M. Tong, et al. (2007). "Distinct roles for steroidogenic factor 1 and desert 
hedgehog pathways in fetal and adult Leydig cell development." Endocrinology 148(8): 
3704-3710. 
   
Paulozzi, L. J. (1999). "International trends in rates of hypospadias and 
cryptorchidism." Environ Health Perspect 107(4): 297-302. 
   
Payne A.H., O'Shaughnessy, P. (1996). Structure, function and regulation of 
steroidogenic enzymes in the Leydig cell. In: The Leydig cell. Payne AH, Hardy MP, 
Russell LD (eds), Cache River Press, Vienna, IL. pp260-285 
Payne, A. H. and D. B. Hales (2004). "Overview of steroidogenic enzymes in the pathway 
from cholesterol to active steroid hormones." Endocr Rev 25(6): 947-970. 
 
Peets, E. A., M. F. Henson, et al. (1974). "On the mechanism of the anti-androgenic action 
of flutamide (alpha-alpha-alpha-trifluoro-2-methyl-4'-nitro-m-propionotoluidide) in 
the rat." Endocrinology 94(2): 532-540. 
  
Pereira, F. A., Y. Qiu, et al. (1999). "The orphan nuclear receptor COUP-TFII is required 
for angiogenesis and heart development." Genes Dev 13(8): 1037-1049. 
   
Perheentupa, A., J. Makinen, et al. (2013). "A cohort effect on serum testosterone levels 
in Finnish men." Eur J Endocrinol 168(2): 227-233. 
   
Pierucci-Alves, F., A. M. Clark, et al. (2001). "A developmental study of the Desert 
hedgehog-null mouse testis." Biol Reprod 65(5): 1392-1402. 
   
Piprek, R. P. (2010). "Molecular and cellular machinery of gonadal differentiation in 
mammals." Int J Dev Biol 54(5): 779-786. 
   
Piquet-Pellorce, C., I. Dorval-Coiffec, et al. (2000). "Leukemia inhibitory factor 
expression and regulation within the testis." Endocrinology 141(3): 1136-1141. 





Plecas, B., A. Glavaski, et al. (1997). "Effects of ethane dimethanesulfonate on the 
structure of adult male rat adrenal cortex." Pharmacol Res 35(6): 541-546. 
   
Pomerantz, D. K. and V. Pitelka (1998). "Nitric oxide is a mediator of the inhibitory 
effect of activated macrophages on production of androgen by the Leydig cell of the 
mouse." Endocrinology 139(3): 922-931. 
   
Pratt, W. B. and D. O. Toft (1997). "Steroid receptor interactions with heat shock 
protein and immunophilin chaperones." Endocr Rev 18(3): 306-360. 
   
Prince, F. P. (1990). "Ultrastructural evidence of mature Leydig cells and Leydig cell 
regression in the neonatal human testis." Anat Rec 228(4): 405-417. 
   
Prince, F. P. (2001). "The triphasic nature of Leydig cell development in humans, and 
comments on nomenclature." J Endocrinol 168(2): 213-216. 
   
Prins, G. S. (2008). "Estrogen imprinting: when your epigenetic memories come back to 
haunt you." Endocrinology 149(12): 5919-5921. 
  
Qin, J., M. J. Tsai, et al. (2008). "Essential roles of COUP-TFII in Leydig cell differentiation 
and male fertility." PLoS One 3(9): e3285. 
   
Quigley, C. A., A. De Bellis, et al. (1995). "Androgen receptor defects: historical, clinical, 
and molecular perspectives." Endocr Rev 16(3): 271-321. 
 
Quigley, C. A., B. A. Evans, et al. (1992). "Complete androgen insensitivity due to 
deletion of exon C of the androgen receptor gene highlights the functional importance 
of the second zinc finger of the androgen receptor in vivo." Mol Endocrinol 6(7): 1103-
1112. 
   
Racine, C., R. Rey, et al. (1998). "Receptors for anti-mullerian hormone on Leydig cells 
are responsible for its effects on steroidogenesis and cell differentiation." Proc Natl 
Acad Sci U S A 95(2): 594-599. 
 
Rannikki, A.S., Zhang, F.P., et al. (1995). “Ontogeny of follicle-stimulating hormone 
receptor gene expression in the rat testis and ovary. Mol Cell Endocrinol 107(2):199-
208. 
   
Reddington, J. P., S. M. Perricone, et al. (2013). "Redistribution of H3K27me3 upon DNA 
hypomethylation results in de-repression of Polycomb target genes." Genome Biol 
14(3): R25. 
   
Rey, R., F. Mebarki, et al. (1994). "Anti-mullerian hormone in children with androgen 
insensitivity." J Clin Endocrinol Metab 79(4): 960-964. 
   
Rey, R. A. and R. P. Grinspon (2011). "Normal male sexual differentiation and aetiology 
of disorders of sex development." Best Pract Res Clin Endocrinol Metab 25(2): 221-238. 
   
Rey, R. A., R. P. Grinspon, et al. (2013). "Male hypogonadism: an extended classification 






Rey, R. A., M. Musse, et al. (2009). "Ontogeny of the androgen receptor expression in the 
fetal and postnatal testis: its relevance on Sertoli cell maturation and the onset of adult 
spermatogenesis." Microsc Res Tech 72(11): 787-795. 
   
Ricci, G., A. Catizone, et al. (2004). "Embryonic mouse testis development: role of 
platelet derived growth factor (PDGF-BB)." J Cell Physiol 200(3): 458-467. 
   
Richiardi, L., R. Bellocco, et al. (2004). "Testicular cancer incidence in eight northern 
European countries: secular and recent trends." Cancer Epidemiol Biomarkers Prev 
13(12): 2157-2166. 
   
Rijntjes, E., H. J. Swarts, et al. (2009). "Prenatal induced chronic dietary hypothyroidism 
delays but does not block adult-type Leydig cell development." Am J Physiol Endocrinol 
Metab 296(2): E305-314. 
   
Rijntjes, E., A. van Kesteren-Buiting, et al. (2010). "Chronic hypothyroidism only 
marginally affects adult-type Leydig cell regeneration after EDS administration." Int J 
Androl 33(1): e123-131. 
   
Rosen-Runge EC adn Anderson D 1959. The development of the interstitial cells in the 
testis of the albino rat. Acta Anat (Basel) 37: 125-137.  
Rosenberg, K. M. and G. F. Sherman (1974). "Testosterone induced pup-killing behavior 
in the ovariectomized female rat." Physiol Behav 13(5): 697-699. 
 
Rouiller-Fabre, V., S. Carmona, et al. (1998). "Effect of anti-Mullerian hormone on 
Sertoli and Leydig cell functions in fetal and immature rats." Endocrinology 139(3): 
1213-1220. 
   
Rouiller-Fabre, V., L. Lecref, et al. (1998). "Expression and effect of insulin-like growth 
factor I on rat fetal Leydig cell function and differentiation." Endocrinology 139(6): 
2926-2934. 
   
Rusovici, R., Y. Y. Hui, et al. (2005). "Epidermal growth factor-mediated inhibition of 
follicle-stimulating hormone-stimulated StAR gene expression in porcine granulosa 
cells is associated with reduced histone H3 acetylation." Biol Reprod 72(4): 862-871. 
   
Sajjad, Y., S. M. Quenby, et al. (2004). "Expression of androgen receptors in upper 
human fetal reproductive tract." Hum Reprod 19(7): 1659-1665. 
   
Salazar-Martinez, E., P. Romano-Riquer, et al. (2004). "Anogenital distance in human 
male and female newborns: a descriptive, cross-sectional study." Environ Health 3(1): 
8. 
   
Sandhoff, T. W., D. B. Hales, et al. (1998). "Transcriptional regulation of the rat 
steroidogenic acute regulatory protein gene by steroidogenic factor 1." Endocrinology 
139(12): 4820-4831. 
   
Sarraj, M. A., R. M. Escalona, et al. (2010). "Fetal testis dysgenesis and compromised 







Sathyanarayana, S., L. Beard, et al. (2010). "Measurement and correlates of ano-genital 
distance in healthy, newborn infants." Int J Androl 33(2): 317-323. 
   
Saunders, P. T., J. S. Fisher, et al. (1998). "Expression of oestrogen receptor beta (ER 
beta) occurs in multiple cell types, including some germ cells, in the rat testis." J 
Endocrinol 156(3): R13-17. 
   
Saunders, P. T., R. M. Sharpe, et al. (2001). "Differential expression of oestrogen 
receptor alpha and beta proteins in the testes and male reproductive system of human 
and non-human primates." Mol Hum Reprod 7(3): 227-236. 
   
Schlatt, S., G. F. Weinbauer, et al. (1993). "Appearance of alpha-smooth muscle actin in 
peritubular cells of monkey testes is induced by androgens, modulated by follicle-
stimulating hormone, and maintained after hormonal withdrawal." J Androl 14(5): 
340-350. 
   
Schmahl, J. and B. Capel (2003). "Cell proliferation is necessary for the determination of 
male fate in the gonad." Dev Biol 258(2): 264-276. 
   
Schmahl, J., E. M. Eicher, et al. (2000). "Sry induces cell proliferation in the mouse 
gonad." Development 127(1): 65-73. 
   
Schmahl, J., K. Rizzolo, et al. (2008). "The PDGF signaling pathway controls multiple 
steroid-producing lineages." Genes Dev 22(23): 3255-3267. 
 
Schoenmakers, E., G. Verrijdt, et al. (2000). "Differences in DNA binding characteristics 
of the androgen and glucocorticoid receptors can determine hormone-specific 
responses." J Biol Chem 275(16): 12290-12297. 
   
Schultz, F. M. and J. D. Wilson (1974). "Virilization of the Wolffian duct in the rat fetus 
by various androgens." Endocrinology 94(4): 979-986. 
 
Scott, H. M., G. R. Hutchison, et al. (2007). "Role of androgens in fetal testis development 
and dysgenesis." Endocrinology 148(5): 2027-2036. 
   
Scott, H. M., J. I. Mason, et al. (2009). "Steroidogenesis in the fetal testis and its 
susceptibility to disruption by exogenous compounds." Endocr Rev 30(7): 883-925. 
   
Sekido, R. and R. Lovell-Badge (2013). "Genetic control of testis development." Sex Dev 
7(1-3): 21-32. 
   
Selvage, D. J. and C. Rivier (2003). "Importance of the paraventricular nucleus of the 
hypothalamus as a component of a neural pathway between the brain and the testes 
that modulates testosterone secretion independently of the pituitary." Endocrinology 
144(2): 594-598. 
   
Seminara, S. B. (2006). "Mechanisms of Disease: the first kiss-a crucial role for 
kisspeptin-1 and its receptor, G-protein-coupled receptor 54, in puberty and 
reproduction." Nat Clin Pract Endocrinol Metab 2(6): 328-334. 






Seralini, G. and S. Moslemi (2001). "Aromatase inhibitors: past, present and future." Mol 
Cell Endocrinol 178(1-2): 117-131. 
   
Serrano, T., C. Chevrier, et al. (2013). "International geographic correlation study of the 
prevalence of disorders of male reproductive health." Hum Reprod 28(7): 1974-1986. 
   
Shah, M. N., S. S. Devesa, et al. (2007). "Trends in testicular germ cell tumours by ethnic 
group in the United States." Int J Androl 30(4): 206-213; discussion 213-204. 
   
Shalan, A. G., S. D. Bradshaw, et al. (2004). "Spermatogenesis and plasma testosterone 
levels in Western Australian burrowing desert frogs, Cyclorana platycephala, Cyclorana 
maini, and Neobatrachus sutor, during aestivation." Gen Comp Endocrinol 136(1): 90-
100. 
 
Shan, L., D. O. Hardy, et al. (1995). "Effects of luteinizing hormone (LH) and androgen 
on steady state levels of messenger ribonucleic acid for LH receptors, androgen 
receptors, and steroidogenic enzymes in rat Leydig cell progenitors in vivo." 
Endocrinology 136(4): 1686-1693. 
   
Shan, L. X., C. W. Bardin, et al. (1997). "Immunohistochemical analysis of androgen 
effects on androgen receptor expression in developing Leydig and Sertoli cells." 
Endocrinology 138(3): 1259-1266. 
   
Shan, L. X. and M. P. Hardy (1992). "Developmental changes in levels of luteinizing 
hormone receptor and androgen receptor in rat Leydig cells." Endocrinology 131(3): 
1107-1114. 
   
Shan, L. X., L. J. Zhu, et al. (1995). "Quantitative analysis of androgen receptor 
messenger ribonucleic acid in developing Leydig cells and Sertoli cells by in situ 
hybridization." Endocrinology 136(9): 3856-3862. 
   
Shang, Y., Myers, M., et al. (2002). "Formation of the androgen receptor transcription 
complex". Mol Cell 9;601-610. 
 
Shapiro, E., H. Huang, et al. (2005). "Immunolocalization of androgen receptor and 
estrogen receptors alpha and beta in human fetal testis and epididymis." J Urol 174(4 
Pt 2): 1695-1698; discussion 1698. 
   
Sharpe, R. M., H. M. Fraser, et al. (1981). "Sertoli-Leydig cell communication via an 
LHRH-like factor." Nature 290(5809): 785-787. 
   
Sharpe, R. M., S. Maddocks, et al. (1990). "Cell-cell interactions in the control of 
spermatogenesis as studied using Leydig cell destruction and testosterone 
replacement." Am J Anat 188(1): 3-20. 
   
Sharpe, R. M., C. McKinnell, et al. (2003). "Proliferation and functional maturation of 
Sertoli cells, and their relevance to disorders of testis function in adulthood." 
Reproduction 125(6): 769-784. 







Sharpe, R. M. and N. E. Skakkebaek (2008). "Testicular dysgenesis syndrome: 
mechanistic insights and potential new downstream effects." Fertil Steril 89(2 Suppl): 
e33-38. 
   
Shea-Eaton, W., T. W. Sandhoff, et al. (2002). "Transcriptional repression of the rat 
steroidogenic acute regulatory (StAR) protein gene by the AP-1 family member c-Fos." 
Mol Cell Endocrinol 188(1-2): 161-170. 
   
Shen, X., W. Kim, et al. (2009). "Jumonji modulates polycomb activity and self-renewal 
versus differentiation of stem cells." Cell 139(7): 1303-1314. 
   
Sherbet, D. P., M. Papari-Zareei, et al. (2007). "Cofactors, redox state, and directional 
preferences of hydroxysteroid dehydrogenases." Mol Cell Endocrinol 265-266: 83-88. 
   
Shultz, V. D., S. Phillips, et al. (2001). "Altered gene profiles in fetal rat testes after in 
utero exposure to di(n-butyl) phthalate." Toxicol Sci 64(2): 233-242. 
   
Siedlecki, P. and P. Zielenkiewicz (2006). "Mammalian DNA methyltransferases." Acta 
Biochim Pol 53(2): 245-256. 
   
Siegel, E. T., H. G. Kim, et al. (2013). "The molecular basis of impaired follicle-
stimulating hormone action: evidence from human mutations and mouse models." 
Reprod Sci 20(3): 211-233. 
   
Silverman, E., S. Eimerl, et al. (1999). "CCAAT enhancer-binding protein beta and GATA-
4 binding regions within the promoter of the steroidogenic acute regulatory protein 
(StAR) gene are required for transcription in rat ovarian cells." J Biol Chem 274(25): 
17987-17996. 
   
Simmons, R. A. (2009). "Developmental origins of adult disease." Pediatr Clin North Am 
56(3): 449-466, Table of Contents. 
   
Simpson, E. R. (1979). "Cholesterol side-chain cleavage, cytochrome P450, and the 
control of steroidogenesis." Mol Cell Endocrinol 13(3): 213-227. 
  
Simpson, E. R., C. Clyne, et al. (2002). "Aromatase--a brief overview." Annu Rev Physiol 
64: 93-127. 
   
Simpson, E. R. and M. R. Waterman (1988). "Regulation of the synthesis of 
steroidogenic enzymes in adrenal cortical cells by ACTH." Annu Rev Physiol 50: 427-
440. 
  
Sinclair, A. H., P. Berta, et al. (1990). "A gene from the human sex-determining region 
encodes a protein with homology to a conserved DNA-binding motif." Nature 
346(6281): 240-244. 
   
Skakkebaek, N. E. (2002). "Endocrine disrupters and testicular dysgenesis syndrome." 
Horm Res 57 Suppl 2: 43. 







Skakkebaek, N. E., E. Rajpert-De Meyts, et al. (2001). "Testicular dysgenesis syndrome: 
an increasingly common developmental disorder with environmental aspects." Hum 
Reprod 16(5): 972-978. 
   
Skinner, M. K., P. S. Tung, et al. (1985). "Cooperativity between Sertoli cells and 
testicular peritubular cells in the production and deposition of extracellular matrix 
components." J Cell Biol 100(6): 1941-1947. 
   
Smart, J. L., R. F. Massey, et al. (1990). "Growth and development of male and female 
rats treated with the Leydig cell cytotoxin ethane dimethane sulphonate during the 
suckling period." Food Chem Toxicol 28(2): 121-128. 
   
Smith, A. G., J. K. Heath, et al. (1988). "Inhibition of pluripotential embryonic stem cell 
differentiation by purified polypeptides." Nature 336(6200): 688-690. 
   
Smith, J. T. (2013). "Sex steroid regulation of kisspeptin circuits." Adv Exp Med Biol 
784: 275-295. 
   
Smith, J. T., D. K. Clifton, et al. (2006). "Regulation of the neuroendocrine reproductive 
axis by kisspeptin-GPR54 signaling." Reproduction 131(4): 623-630. 
 
Smith LB and Walker  WH. (2014) Hormone Signaling in the Testis. In Knobil and Neill’s 
Physiology of Reproduction (Fourth Edition) (In Press) 
Snyder, P. J. (2008). "Might testosterone actually reduce mortality?" J Clin Endocrinol 
Metab 93(1): 32-33. 
  
Sokanovic, S. J., A. Z. Baburski, et al. (2013). "The opposing roles of nitric oxide and 
cGMP in the age-associated decline in rat testicular steroidogenesis." Endocrinology 
154(10): 3914-3924. 
   
Srinivas, S., T. Watanabe, et al. (2001). "Cre reporter strains produced by targeted 
insertion of EYFP and ECFP into the ROSA26 locus." BMC Dev Biol 1: 4. 
   
Stanley, E., C. Y. Lin, et al. (2012). "Identification, proliferation, and differentiation of 
adult Leydig stem cells." Endocrinology 153(10): 5002-5010. 
   
Stanley, E. L., D. S. Johnston, et al. (2011). "Stem Leydig cell differentiation: gene 
expression during development of the adult rat population of Leydig cells." Biol Reprod 
85(6): 1161-1166. 
   
Stanwell-Smith, R., S. G. Thompson, et al. (1985). "Plasma concentrations of pituitary 
and testicular hormones of fertile and infertile men." Clin Reprod Fertil 3(1): 37-48. 
   
Stocco, D. M. (2001). "StAR protein and the regulation of steroid hormone 
biosynthesis." Annu Rev Physiol 63: 193-213. 
   
Stocco, D. M. (2001). "Tracking the role of a star in the sky of the new millennium." Mol 
Endocrinol 15(8): 1245-1254. 







Stocco, D. M. (2002). "Clinical disorders associated with abnormal cholesterol 
transport: mutations in the steroidogenic acute regulatory protein." Mol Cell 
Endocrinol 191(1): 19-25. 
   
Stocco, D. M. and B. J. Clark (1996). "Regulation of the acute production of steroids in 
steroidogenic cells." Endocr Rev 17(3): 221-244. 
  
Stocco, D. M. and T. C. Sodeman (1991). "The 30-kDa mitochondrial proteins induced by 
hormone stimulation in MA-10 mouse Leydig tumor cells are processed from larger 
precursors." J Biol Chem 266(29): 19731-19738. 
   
Strahl, B. D. and C. D. Allis (2000). "The language of covalent histone modifications." 
Nature 403(6765): 41-45. 
   
Strauss, L., J. Kallio, et al. (2009). "Increased exposure to estrogens disturbs maturation, 
steroidogenesis, and cholesterol homeostasis via estrogen receptor alpha in adult 
mouse Leydig cells." Endocrinology 150(6): 2865-2872. 
   
Sucov, H. M., E. Dyson, et al. (1994). "RXR alpha mutant mice establish a genetic basis 
for vitamin A signaling in heart morphogenesis." Genes Dev 8(9): 1007-1018. 
  
Sugawara, T., M. Kiriakidou, et al. (1997). "Regulation of expression of the steroidogenic 
acute regulatory protein (StAR) gene: a central role for steroidogenic factor 1." Steroids 
62(1): 5-9. 
   
Sugawara, T., M. Kiriakidou, et al. (1997). "Multiple steroidogenic factor 1 binding 
elements in the human steroidogenic acute regulatory protein gene 5'-flanking region 
are required for maximal promoter activity and cyclic AMP responsiveness." 
Biochemistry 36(23): 7249-7255. 
   
Sui, X., C. Price, et al. (2012). "Crosstalk Between DNA and Histones: Tet's New Role in 
Embryonic Stem Cells." Curr Genomics 13(8): 603-608. 
   
Suomi, A. M., K. M. Main, et al. (2006). "Hormonal changes in 3-month-old cryptorchid 
boys." J Clin Endocrinol Metab 91(3): 953-958. 
   
Svechnikov, K., L. Landreh, et al. (2010). "Origin, development and regulation of human 
Leydig cells." Horm Res Paediatr 73(2): 93-101. 
   
Svechnikov, K., J. B. Stukenborg, et al. (2014). "Similar causes of various reproductive 
disorders in early life." Asian J Androl 16(1): 50-59. 
   
Svingen, T. and P. Koopman (2013). "Building the mammalian testis: origins, 
differentiation, and assembly of the component cell populations." Genes Dev 27(22): 
2409-2426. 
   
Swan, S. H., E. P. Elkin, et al. (2000). "The question of declining sperm density revisited: 
an analysis of 101 studies published 1934-1996." Environ Health Perspect 108(10): 
961-966. 






Swan, S. H., K. M. Main, et al. (2005). "Decrease in anogenital distance among male 
infants with prenatal phthalate exposure." Environ Health Perspect 113(8): 1056-
1061. 
   
Swerdloff R. Hypothalamic-Pituitary-Testicular Axis, feedback loops. In: Robaire BCP, 
editor. Handbook of Andrology. The American Society of Andrology; 2010. pp. 2.1–2.4. 
 
Swigut, T. and J. Wysocka (2007). "H3K27 demethylases, at long last." Cell 131(1): 29-
32. 
   
Tajar, A., G. Forti, et al. (2010). "Characteristics of secondary, primary, and 
compensated hypogonadism in aging men: evidence from the European Male Ageing 
Study." J Clin Endocrinol Metab 95(4): 1810-1818. 
 
Takamoto, N., I. Kurihara, et al. (2005). "Haploinsufficiency of chicken ovalbumin 
upstream promoter transcription factor II in female reproduction." Mol Endocrinol 
19(9): 2299-2308. 
   
Tamura, M., Y. Kanno, et al. (2001). "Pod-1/Capsulin shows a sex- and stage-dependent 
expression pattern in the mouse gonad development and represses expression of 
Ad4BP/SF-1." Mech Dev 102(1-2): 135-144. 
   
Tan, K. A., K. De Gendt, et al. (2005). "The role of androgens in sertoli cell proliferation 
and functional maturation: studies in mice with total or Sertoli cell-selective ablation of 
the androgen receptor." Endocrinology 146(6): 2674-2683. 
   
Tang, H., J. Brennan, et al. (2008). "Notch signaling maintains Leydig progenitor cells in 
the mouse testis." Development 135(22): 3745-3753. 
 
Tang K, Lin FJ, Tsai SY, Tsai MJ. (2006). Role of chicken ovalbumin upstream promoter-
transcription factor I in the development of nervous system. In: Taneja R, editor. 
ed. Nuclear receptors in development: advances in developmental biology. Vol 
16 Philadelphia: Elsevier; 297–312. 
Tang, K., Xie, X., et al. (2010). “COUP-TFs regulate eye development by controlling 
factors essential for optic vesicle morphogenesis”. Development 137(5):725-34. 
Tapanainen, J. S., K. Aittomaki, et al. (1997). "Men homozygous for an inactivating 
mutation of the follicle-stimulating hormone (FSH) receptor gene present variable 
suppression of spermatogenesis and fertility." Nat Genet 15(2): 205-206. 
   
Taylor, M. F., M. de Boer-Brouwer, et al. (1999). "Leydig cell apoptosis after the 
administration of ethane dimethanesulfonate to the adult male rat is a Fas-mediated 
process." Endocrinology 140(8): 3797-3804. 
   
Teerds, K. J., M. de Boer-Brouwer, et al. (1999). "Identification of markers for precursor 
and leydig cell differentiation in the adult rat testis following ethane dimethyl 
sulphonate administration." Biol Reprod 60(6): 1437-1445. 
   
Teerds, K. J., D. G. De Rooij, et al. (1989). "Turnover time of Leydig cells and other 






Teerds and Rijintjes, 2007 Dynamics of Leydig cell regeneration after EDS In 
The Leydig Cell in Health and Disease, A. Payne, and M. Hardy, eds. (Humana Press), pp. 
91–110. 
Thankamony, A., N. Lek, et al. (2013). "Anogenital Distance and Penile Length in Infants 
with Hypospadias or Cryptorchidism: Comparison with Normative Data." Environ 
Health Perspect. 
   
Themmen, A. P. N. and I. T. Huhtaniemi (2000). "Mutations of gonadotropins and 
gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-
gonadal function." Endocr Rev 21(5): 551-583. 
   
Thompson, C. J., S. M. Ross, et al. (2005). "Differential steroidogenic gene expression in 
the fetal adrenal gland versus the testis and rapid and dynamic response of the fetal 
testis to di(n-butyl) phthalate." Biol Reprod 73(5): 908-917. 
   
Thompson, J., F. Saatcioglu, et al. (2001). "Disrupted amino- and carboxyl-terminal 
interactions of the androgen receptor are linked to androgen insensitivity." Mol 
Endocrinol 15(6): 923-935. 
   
Thompson, R. F. and F. H. Einstein (2010). "Epigenetic basis for fetal origins of age-
related disease." J Womens Health (Larchmt) 19(3): 581-587. 
 
Thuillier, R., Y. Wang, et al. (2003). "Prenatal exposure to estrogenic compounds alters 
the expression pattern of platelet-derived growth factor receptors alpha and beta in 
neonatal rat testis: identification of gonocytes as targets of estrogen exposure." Biol 
Reprod 68(3): 867-880. 
   
Thurisch, B., S. Y. Liang, et al. (2009). "Transgenic mice expressing small interfering 
RNA against Gata4 point to a crucial role of Gata4 in the heart and gonads." J Mol 
Endocrinol 43(4): 157-169. 
   
Tilley, W. D., M. Marcelli, et al. (1990). "Expression of the human androgen receptor 
gene utilizes a common promoter in diverse human tissues and cell lines." J Biol Chem 
265(23): 13776-13781. 
   
Tivesten, A., L. Vandenput, et al. (2009). "Low serum testosterone and estradiol predict 
mortality in elderly men." J Clin Endocrinol Metab 94(7): 2482-2488. 
   
Tiwari, V. K., K. M. McGarvey, et al. (2008). "PcG proteins, DNA methylation, and gene 
repression by chromatin looping." PLoS Biol 6(12): 2911-2927. 
   
Toloubeydokhti, T., Q. Pan, et al. (2008). "The expression and ovarian steroid regulation 
of endometrial micro-RNAs." Reprod Sci 15(10): 993-1001. 
   
Toppari, J. (2008). "Environmental endocrine disrupters." Sex Dev 2(4-5): 260-267. 
   
Toppari, J., M. Kaleva, et al. (2001). "Trends in the incidence of cryptorchidism and 
hypospadias, and methodological limitations of registry-based data." Hum Reprod 
Update 7(3): 282-286. 






Toppari, J., H. E. Virtanen, et al. (2010). "Cryptorchidism and hypospadias as a sign of 
testicular dysgenesis syndrome (TDS): environmental connection." Birth Defects Res A 
Clin Mol Teratol 88(10): 910-919. 
   
Topper, Y. J. and C. S. Freeman (1980). "Multiple hormone interactions in the 
developmental biology of the mammary gland." Physiol Rev 60(4): 1049-1106. 
  
Traish, A. M., M. M. Miner, et al. (2011). "Testosterone deficiency." Am J Med 124(7): 
578-587. 
  
Tran, P., X. K. Zhang, et al. (1992). "COUP orphan receptors are negative regulators of 
retinoic acid response pathways." Mol Cell Biol 12(10): 4666-4676. 
   
Travison, T. G., A. B. Araujo, et al. (2007). "The relative contributions of aging, health, 
and lifestyle factors to serum testosterone decline in men." J Clin Endocrinol Metab 
92(2): 549-555. 
   
Travison, T. G., A. B. Araujo, et al. (2007). "A population-level decline in serum 
testosterone levels in American men." J Clin Endocrinol Metab 92(1): 196-202. 
   
Trbovich, A. M., P. M. Sluss, et al. (2001). "Mullerian Inhibiting Substance lowers 
testosterone in luteinizing hormone-stimulated rodents." Proc Natl Acad Sci U S A 
98(6): 3393-3397. 
 
Tremblay, J. J. and R. S. Viger (2001). "GATA factors differentially activate multiple 
gonadal promoters through conserved GATA regulatory elements." Endocrinology 
142(3): 977-986. 
   
Trojer, P. and D. Reinberg (2006). "Histone lysine demethylases and their impact on 
epigenetics." Cell 125(2): 213-217. 
   
Tsai, M. Y., S. D. Yeh, et al. (2006). "Differential effects of spermatogenesis and fertility 
in mice lacking androgen receptor in individual testis cells." Proc Natl Acad Sci U S A 
103(50): 18975-18980. 
 
Tsai, S. Y. and M. J. Tsai (1997). "Chick ovalbumin upstream promoter-transcription 
factors (COUP-TFs): coming of age." Endocr Rev 18(2): 229-240. 
  
Tsujimura, A. (2013). "The Relationship between Testosterone Deficiency and Men's 
Health." World J Mens Health 31(2): 126-135. 
   
Tsujimura, A., Y. Miyagawa, et al. (2013). "Is low testosterone concentration a risk 
factor for metabolic syndrome in healthy middle-aged men?" Urology 82(4): 814-819. 
   
Tsujishita, Y. and J. H. Hurley (2000). "Structure and lipid transport mechanism of a 
StAR-related domain." Nat Struct Biol 7(5): 408-414. 
   
Turnbull, A. V. and C. Rivier (1997). "Inhibition of gonadotropin-induced testosterone 
secretion by the intracerebroventricular injection of interleukin-1 beta in the male rat." 
Endocrinology 138(3): 1008-1013. 





Tyagi, R. K., Y. Lavrovsky, et al. (2000). "Dynamics of intracellular movement and 
nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells." 
Mol Endocrinol 14(8): 1162-1174. 
   
Tyndall, V., M. Broyde, et al. (2012). "Effect of androgen treatment during foetal and/or 
neonatal life on ovarian function in prepubertal and adult rats." Reproduction 143(1): 
21-33. 
   
Uhlenhaut, N. H., S. Jakob, et al. (2009). "Somatic sex reprogramming of adult ovaries to 
testes by FOXL2 ablation." Cell 139(6): 1130-1142. 
   
Umehara, F., G. Tate, et al. (2000). "A novel mutation of desert hedgehog in a patient 
with 46,XY partial gonadal dysgenesis accompanied by minifascicular neuropathy." Am 
J Hum Genet 67(5): 1302-1305. 
   
Vahouny, G. V., R. Chanderbhan, et al. (1983). "Sterol carrier protein2. Identification of 
adrenal sterol carrier protein2 and site of action for mitochondrial cholesterol 
utilization." J Biol Chem 258(19): 11731-11737. 
   
Val, P., K. Jeays-Ward, et al. (2006). "Identification of a novel population of adrenal-like 
cells in the mammalian testis." Dev Biol 299(1): 250-256. 
   
Valladares, L. E. and A. H. Payne (1979). "Acute stimulation of aromatization in Leydig 
cells by human chorionic gonadotropin in vitro." Proc Natl Acad Sci U S A 76(9): 4460-
4463. 
   
Valladares, L. E. and A. H. Payne (1981). "Effects of hCG and cyclic AMP on 
aromatization in purified Leydig cells of immature and mature rats." Biol Reprod 25(4): 
752-758. 
  
van den Driesche, S., M. Walker, et al. (2012). "Proposed Role for COUP-TFII in 
Regulating Fetal Leydig Cell Steroidogenesis, Perturbation of Which Leads to 
Masculinization Disorders in Rodents." Plos One 7(5). 
   
van der Zwan, Y. G., N. Callens, et al. (2013). "Long-term outcomes in males with 
disorders of sex development." J Urol 190(3): 1038-1042. 
 
van Haren, L., K. J. Teerds, et al. (1992). "Sterol carrier protein 2 (non-specific lipid 
transfer protein) is localized in membranous fractions of Leydig cells and Sertoli cells 
but not in germ cells." Biochim Biophys Acta 1124(3): 288-296. 
   
van Noort, M., F. F. Rommerts, et al. (1988). "Regulation of sterol carrier protein2 
(SCP2) levels in the soluble fraction of rat Leydig cells. Kinetics and the possible role of 
calcium influx." Mol Cell Endocrinol 56(1-2): 133-140. 
   
Vanbillemont, G., B. Lapauw, et al. (2010). "Birth weight in relation to sex steroid status 
and body composition in young healthy male siblings." J Clin Endocrinol Metab 95(4): 
1587-1594. 
   
Verhoeven, G., J. Cailleau, et al. (1988). "Interleukin-1 stimulates steroidogenesis in 





Verhoeven, G., A. Willems, et al. (2010). "Androgens and spermatogenesis: lessons from 
transgenic mouse models." Philos Trans R Soc Lond B Biol Sci 365(1546): 1537-1556. 
   
Vickers, M. H. (2011). "Developmental programming of the metabolic syndrome - 
critical windows for intervention." World J Diabetes 2(9): 137-148. 
   
Vidal, V. P., M. C. Chaboissier, et al. (2001). "Sox9 induces testis development in XX 
transgenic mice." Nat Genet 28(3): 216-217. 
   
Virtanen, H. E. and A. Adamsson (2012). "Cryptorchidism and endocrine disrupting 
chemicals." Mol Cell Endocrinol 355(2): 208-220. 
   
Virtanen, H. E., E. Rajpert-De Meyts, et al. (2005). "Testicular dysgenesis syndrome and 
the development and occurrence of male reproductive disorders." Toxicol Appl 
Pharmacol 207(2 Suppl): 501-505. 
   
Vornberger, W., G. Prins, et al. (1994). "Androgen receptor distribution in rat testis: 
new implications for androgen regulation of spermatogenesis." Endocrinology 134(5): 
2307-2316. 
 
Waddington, C. H. (1968). "Towards a theoretical biology." Nature 218(5141): 525-
527. 
  
Walker, C. L. (2011). "Epigenomic reprogramming of the developing reproductive tract 
and disease susceptibility in adulthood." Birth Defects Res A Clin Mol Teratol 91(8): 
666-671. 
   
Walker, W. H. (2011). "Testosterone signaling and the regulation of spermatogenesis." 
Spermatogenesis 1(2): 116-120. 
   
Wang, C., G. Jackson, et al. (2011). "Low testosterone associated with obesity and the 
metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk 
in men with type 2 diabetes." Diabetes Care 34(7): 1669-1675. 
  
Wang, G. and M. P. Hardy (2004). "Development of leydig cells in the insulin-like growth 
factor-I (igf-I) knockout mouse: effects of igf-I replacement and gonadotropic 
stimulation." Biol Reprod 70(3): 632-639. 
   
Wang, G. M., P. J. O'Shaughnessy, et al. (2003). "Effects of insulin-like growth factor I on 
steroidogenic enzyme expression levels in mouse leydig cells." Endocrinology 144(11): 
5058-5064. 
 
Wang, L. H., S. Y. Tsai, et al. (1989). "COUP transcription factor is a member of the 
steroid receptor superfamily." Nature 340(6229): 163-166. 
   
Wang, X., L. P. Walsh, et al. (2000). "The role of arachidonic acid in steroidogenesis and 
steroidogenic acute regulatory (StAR) gene and protein expression." J Biol Chem 
275(26): 20204-20209. 







Ward, C. M., K. M. Barrow, et al. (2004). "Significant variations in differentiation 
properties between independent mouse ES cell lines cultured under defined 
conditions." Exp Cell Res 293(2): 229-238. 
   
Warner, M. J. and S. E. Ozanne (2010). "Mechanisms involved in the developmental 
programming of adulthood disease." Biochem J 427(3): 333-347. 
   
Warren, D. W., G. C. Haltmeyer, et al. (1972). "Synthesis and metabolism of testosterone 
in the fetal rat testis." Biol Reprod 7(1): 94-99. 
  
Warren, D. W., G. C. Haltmeyer, et al. (1973). "Testosterone in the fetal rat testis." Biol 
Reprod 8(5): 560-565. 
  
Wattenberg, L. W. (1958). "Microscopic histochemical demonstration of steroid-3 beta-
ol dehydrogenase in tissue sections." J Histochem Cytochem 6(4): 225-232. 
  
Weaver, I. C., F. A. Champagne, et al. (2005). "Reversal of maternal programming of 
stress responses in adult offspring through methyl supplementation: altering 
epigenetic marking later in life." J Neurosci 25(47): 11045-11054. 
   
Weissman, B. A., E. Niu, et al. (2005). "Paracrine modulation of androgen synthesis in 
rat leydig cells by nitric oxide." J Androl 26(3): 369-378. 
 
Weissman, B. A., C. M. Sottas, et al. (2007). "Testosterone production in mice lacking 
inducible nitric oxide synthase expression is sensitive to restraint stress." Am J Physiol 
Endocrinol Metab 292(2): E615-620. 
   
Welsh, M., L. Moffat, et al. (2012). "Androgen receptor signalling in peritubular myoid 
cells is essential for normal differentiation and function of adult Leydig cells." Int J 
Androl 35(1): 25-40. 
   
Welsh, M., P. T. Saunders, et al. (2009). "Androgen action via testicular peritubular 
myoid cells is essential for male fertility." FASEB J 23(12): 4218-4230. 
   
Welsh, M., P. T. Saunders, et al. (2008). "Identification in rats of a programming window 
for reproductive tract masculinization, disruption of which leads to hypospadias and 
cryptorchidism." J Clin Invest 118(4): 1479-1490. 
 
Werner, R., A. Kulle, et al. (2012). "Testosterone synthesis in patients with 17beta-
hydroxysteroid dehydrogenase 3 deficiency." Sex Dev 6(4): 161-168. 
 
Wilhelm, D. and P. Koopman (2006). "The makings of maleness: towards an integrated 
view of male sexual development." Nat Rev Genet 7(8): 620-631. 
   
Willems, A., K. De Gendt, et al. (2010). "Early effects of Sertoli cell-selective androgen 
receptor ablation on testicular gene expression." Int J Androl 33(3): 507-517. 
   
Wine, R. N., L. H. Li, et al. (1997). "Reproductive toxicity of di-n-butylphthalate in a 
continuous breeding protocol in Sprague-Dawley rats." Environ Health Perspect 
105(1): 102-107. 





Wohlfahrt-Veje, C., K. M. Main, et al. (2009). "Testicular dysgenesis syndrome: foetal 
origin of adult reproductive problems." Clin Endocrinol (Oxf) 71(4): 459-465. 
   
Wolf, C. J., A. Hotchkiss, et al. (2002). "Effects of prenatal testosterone propionate on the 
sexual development of male and female rats: a dose-response study." Toxicol Sci 65(1): 
71-86. 
   
Woodruff, T. K., J. D'Agostino, et al. (1989). "Decreased inhibin gene expression in 
preovulatory follicles requires primary gonadotropin surges." Endocrinology 124(5): 
2193-2199. 
   
Wreford, N. G. (1995). "Theory and practice of stereological techniques applied to the 
estimation of cell number and nuclear volume in the testis." Microsc Res Tech 32(5): 
423-436. 
   
Wright, L. S., J. Li, et al. (2003). "Gene expression in human neural stem cells: effects of 
leukemia inhibitory factor." J Neurochem 86(1): 179-195. 
   
Wu, C. and J. R. Morris (2001). "Genes, genetics, and epigenetics: a correspondence." 
Science 293(5532): 1103-1105. 
   
Wu, F. C., I. A. Swanston, et al. (1982). "Raised plasma oestrogens in infertile men with 
elevated levels of FSH." Clin Endocrinol (Oxf) 16(1): 39-47. 
   
Wu, F. C. W., A. Tajar, et al. (2008). "The Euopean Male Aging Study Group.  
Hypothalamic-Pituitary-Testicular Axis Disruptions in Older Men are differentially 
linked to age and modifiable risk factors: The European Male Aging Study." J Clin 
Endocrinol Metab 93: 2737-2745. 
  
Xu, Q., H. Y. Lin, et al. (2007). "Infertility with defective spermatogenesis and 
steroidogenesis in male mice lacking androgen receptor in Leydig cells." Endocrine 
32(1): 96-106. 
   
Yagci, A. and B. Zik (2006). "Immunohistochemical localization of insulin-like growth 
factor-I receptor (IGF-IR) in the developing and mature rat testes." Anat Histol Embryol 
35(5): 305-309. 
 
Yamazaki, T., Y. Yoshimatsu, et al. (2009). "COUP-TFII regulates the functions of Prox1 
in lymphatic endothelial cells through direct interaction." Genes Cells 14(3): 425-434. 
   
Yao, H. H., W. Whoriskey, et al. (2002). "Desert Hedgehog/Patched 1 signaling specifies 
fetal Leydig cell fate in testis organogenesis." Genes Dev 16(11): 1433-1440. 
   
Yeap, B. B., H. Alfonso, et al. (2012). "Reference Ranges and Determinants of 
Testosterone, Dihydrotestosterone, and Estradiol Levels Measured using Liquid 
Chromatography-Tandem Mass Spectrometry in a Population-Based Cohort of Older 
Men." J Clin Endocrinol Metab 97(11): 4030-4039. 
   
Yeap, B. B., S. A. P. Chubb, et al. (2009). "Lower serum testosterone is independently 
associated with insulin resistance in non-diabetic older men: the Health In Men Study." 





Yeh, S., M. Y. Tsai, et al. (2002). "Generation and characterization of androgen receptor 
knockout (ARKO) mice: an in vivo model for the study of androgen functions in 
selective tissues." Proc Natl Acad Sci U S A 99(21): 13498-13503. 
   
You, L. and M. Sar (1998). "Androgen receptor expression in the testes and 
epididymides of prenatal and postnatal Sprague-Dawley rats." Endocrine 9(3): 253-
261. 
   
You, L. R., F. J. Lin, et al. (2005). "Suppression of Notch signalling by the COUP-TFII 
transcription factor regulates vein identity." Nature 435(7038): 98-104. 
   
Young, J., R. Rey, et al. (1999). "Antimullerian hormone in patients with 
hypogonadotropic hypogonadism." J Clin Endocrinol Metab 84(8): 2696-2699. 
   
Young, M. D., T. A. Willson, et al. (2011). "ChIP-seq analysis reveals distinct H3K27me3 
profiles that correlate with transcriptional activity." Nucl Acids Res 39(17): 7415-7427. 
   
Zambrano, E., C. Guzman, et al. (2014). "Fetal programming of sexual development and 
reproductive function." Mol Cell Endocrinol 382(1): 538-549. 
   
Zhang, F. P., T. Pakarainen, et al. (2004). "Molecular characterization of postnatal 
development of testicular steroidogenesis in luteinizing hormone receptor knockout 
mice." Endocrinology 145(3): 1453-1463. 
   
Zhang, F. P., M. Poutanen, et al. (2001). "Normal prenatal but arrested postnatal sexual 
development of luteinizing hormone receptor knockout (LuRKO) mice." Mol Endocrinol 
15(1): 172-183. 
 
Zhang, Y., X. Jiang, et al. (2004). "Reproductive and developmental toxicity in F1 
Sprague-Dawley male rats exposed to di-n-butyl phthalate in utero and during lactation 
and determination of its NOAEL." Reprod Toxicol 18(5): 669-676. 
   
Zhang, Y. and D. Reinberg (2001). "Transcription regulation by histone methylation: 
interplay between different covalent modifications of the core histone tails." Genes Dev 
15(18): 2343-2360. 
  
Zhou, Q., R. Nie, et al. (2002). "Localization of androgen and estrogen receptors in adult 
male mouse reproductive tract." J Androl 23(6): 870-881. 
   
Zhou, Z. X., M. V. Lane, et al. (1995). "Specificity of ligand-dependent androgen receptor 
stabilization: receptor domain interactions influence ligand dissociation and receptor 
stability." Mol Endocrinol 9(2): 208-218. 
   
Zimmermann, S., G. Steding, et al. (1999). "Targeted disruption of the Insl3 gene causes 
bilateral cryptorchidism." Mol Endocrinol 13(5): 681-691. 
 
Zirkin, B. R. (2010). "Where do adult Leydig cells come from?" Biol Reprod 82(6): 1019-
1020. 
  
Zirkin, B. R. and H. Chen (2000). "Regulation of Leydig cell steroidogenic function 





Zirkin BR. Integration of the hypothalamus, pituitary and testis. In: Robaire BCP, 
editor. Handbook of Andrology. The American Society of Andrology; 2010. pp. 4.1–4.4 
Zirkin, B, Papadopoulos, V and Hardy, M. (2009). Leydig cell development and function. 
In: Infertility in the male. 4th ed. L. Lipshultz, Howards,S.,  Niederberger C, eds. 
Cambridge University press. pp 33-35. 
Zirkin, B. R. and J. L. Tenover (2012). "Aging and declining testosterone: past, present, 
and hopes for the future." J Androl 33(6): 1111-1118.   
 
